// Global userProfile variable
let userProfile = {
    "userProfile": {
        "name": "",
        "surname": "",
        "email": "",
        "password": "",
        "phone": ""
    },
    "patient_metrics": {},
    "medication_entry": {},
    "pre_existing_conditions": {},
    "diagnostics": {}
};

// Function to save user profile to localStorage
function saveUserProfile() {
    try {
        localStorage.setItem("userProfile", JSON.stringify(userProfile));
    } catch (e) {
        console.log("Could not save to localStorage:", e);
    }
}

// Function to load user profile from localStorage
function loadUserProfile() {
    try {
        const stored = localStorage.getItem("userProfile");
        if (stored) {
            userProfile = JSON.parse(stored);
        }
    } catch (e) {
        console.log("Could not load from localStorage:", e);
    }
}

// Load profile on page load
document.addEventListener('DOMContentLoaded', function() {
    loadUserProfile();
});

// Function to show the selected screen
function showScreen(screenId) {
  // Remove 'active' class from all screens
  document
    .querySelectorAll(".screen")
    .forEach((screen) => screen.classList.remove("active"));

  // Add 'active' class to the target screen
  const targetScreen = document.getElementById(screenId);
  if (targetScreen) {
    targetScreen.classList.add("active");

    // Close the mobile menu if on a small screen
    if (window.innerWidth <= 768) {
      toggleMenu();
    }
  }
}

function scrollToDiagnostics() {
  const target = document.getElementById("diagnostics-start");
  if (target) {
    target.scrollIntoView({ behavior: "smooth" });
  }
}










// Function to toggle the mobile menu
function toggleMenu() {
  const mobileNav = document.getElementById("mobileNav");
  mobileNav.style.display =
    mobileNav.style.display === "flex" ? "none" : "flex";
}

// Ensure mobileNav is hidden by default on larger screens when resizing
window.addEventListener("resize", () => {
  if (window.innerWidth > 768) {
    document.getElementById("mobileNav").style.display = "none";
  }
});



function calculateMetrics() {
  const weight = parseFloat(document.getElementById("weight").value);
  const weightUnit = document.getElementById("weight-unit").value;
  const height = parseFloat(document.getElementById("height").value);
  const heightUnit = document.getElementById("height-unit").value;
  const age = parseInt(document.getElementById("age").value);
  const sex = document.getElementById("sex").value;

  // Convert weight to kg if in lbs
  const weightInKg = weightUnit === "lbs" ? weight * 0.453592 : weight;

  // Convert height to meters if in cm or inches
  const heightInMeters = heightUnit === "cm" ? height / 100 : height * 0.0254;

  // BMI Calculation
  const bmi = (weightInKg / heightInMeters ** 2).toFixed(2);

  // BMR Calculation (Harris-Benedict Formula)
  let bmr;
  if (sex === "male") {
    bmr = (
      88.362 +
      13.397 * weightInKg +
      4.799 * heightInMeters * 100 -
      5.677 * age
    ).toFixed(2);
  } else if (sex === "female") {
    bmr = (
      447.593 +
      9.247 * weightInKg +
      3.098 * heightInMeters * 100 -
      4.33 * age
    ).toFixed(2);
  } else {
    bmr = "N/A"; // For "Other", BMR could be averaged or skipped.
  }

  // Display Results
  document.getElementById("bmi-result").innerText = bmi;
  document.getElementById("bmr-result").innerText = bmr;
}





document.querySelectorAll("input[type='radio']").forEach(radio => {
    radio.addEventListener("change", function () {
        let category = this.dataset.category;  // Example: "cardio"
        let question = this.dataset.question;  // Example: "blood_pressure"
        let value = this.value;                // Example: "High"

        // Ensure category exists
        if (!userProfile.diagnostics[category]) {
            userProfile.diagnostics[category] = {};
        }

        // Update userProfile with the selected value
        userProfile.diagnostics[category][question] = value;

        // Save updated profile
        saveUserProfile();
    });
});



document.querySelectorAll('input[type="radio"]').forEach((radio) => {
    radio.addEventListener('click', function () {
        if (this.checked) {
            if (this.getAttribute('data-clicked') === 'true') {
                this.checked = false; // Uncheck if already clicked
                this.removeAttribute('data-clicked');
            } else {
                this.setAttribute('data-clicked', 'true');
            }
        }
    });
});










document.querySelectorAll('.category-button, .diagnostic-button, .respiratory-button').forEach(button => {
    button.addEventListener('click', function() {
        // 🔹 Step 1: Remove 'active' class from all buttons
        document.querySelectorAll('.category-button, .diagnostic-button, .respiratory-button')
            .forEach(btn => btn.classList.remove('active'));

        // 🔹 Step 2: Add 'active' class to the clicked button
        this.classList.add('active');

        // 🔹 Step 3: Ensure Smooth Scrolling to the VERY Top
        setTimeout(() => {
            window.scrollTo({
                top: this.getBoundingClientRect().top + window.scrollY - 0, // No offset, aligns perfectly at top
                behavior: "smooth"
            });
        }, 50);
    });
});










document.querySelectorAll('.category-button').forEach(button => {
    button.addEventListener('click', function() {
        document.querySelectorAll('.category-button').forEach(btn => btn.classList.remove('active')); // Remove active class from others
        this.classList.add('active'); // Add active class to clicked button
    });
});














function toggleQuestions(questionnaireId) {
  const questionnaire = document.getElementById(questionnaireId);

  if (questionnaire) {
    const isHidden = questionnaire.classList.contains("hidden");

    // Hide all other questionnaires
    document.querySelectorAll(".question-container").forEach((container) => {
      container.classList.add("hidden");
      container.style.display = "none";
    });

    // Show or hide the clicked questionnaire
    if (isHidden) {
      questionnaire.classList.remove("hidden");
      questionnaire.style.display = "block";
    } else {
      questionnaire.classList.add("hidden");
      questionnaire.style.display = "none";
    }
  }
}









// General Blood Test Modal
function openGeneralBloodTestModal() {
  document.getElementById("generalBloodTestModal").style.display = "block";
}

function closeGeneralBloodTestModal() {
  document.getElementById("generalBloodTestModal").style.display = "none";
}

// Electrolytes Modal
function openElectrolytesInput() {
  document.getElementById("electrolytesModal").style.display = "block";
}

function closeElectrolytesInput() {
  document.getElementById("electrolytesModal").style.display = "none";
}








// Event listener to close modals by clicking outside
window.onclick = function (event) {
  const generalBloodTestModal = document.getElementById(
    "generalBloodTestModal"
  );
  const electrolytesModal = document.getElementById("electrolytesModal");
  if (event.target === generalBloodTestModal) {
    generalBloodTestModal.style.display = "none";
  } else if (event.target === electrolytesModal) {
    electrolytesModal.style.display = "none";
  }
};






















function openDialog(dialogId) {
    document.getElementById(dialogId).style.display = "block";
    document.querySelector(".dialog-overlay").style.display = "block"; // Show overlay
}

function closeDialog(dialogId) {
    document.getElementById(dialogId).style.display = "none";
    document.querySelector(".dialog-overlay").style.display = "none"; // Hide overlay
}








// Track selected conditions
const preExistingConditions = [];

// DOM Elements
const dialog = document.getElementById("conditions-dialog");
const openDialogButton = document.getElementById("open-conditions-dialog");
const closeDialogButton = document.getElementById("close-dialog");
const conditionInput = document.getElementById("condition-input");
const autocompleteList = document.getElementById("autocomplete-list");
const selectedConditionsList = document.getElementById("selected-conditions");

// Open dialog
openDialogButton.addEventListener("click", () => {
  dialog.classList.add("active");
});

// Close dialog
closeDialogButton.addEventListener("click", () => {
  dialog.classList.remove("active");
  console.log("Selected conditions:", preExistingConditions);
});

// Handle input for autocomplete
conditionInput.addEventListener("input", () => {
  const query = conditionInput.value.toLowerCase();
  autocompleteList.innerHTML = ""; // Clear previous suggestions

  if (query) {
    const suggestions = []; // ✅ DECLARE THIS

    // Gather matching conditions
    Object.entries(conditionsData).forEach(([category, conditions]) => {
      conditions
        .filter((condition) => condition.toLowerCase().includes(query))
        .forEach((condition) => suggestions.push(condition));
    });

    // Sort suggestions alphabetically
    suggestions.sort();

    // Display sorted suggestions
    suggestions.forEach((condition) => {
      const suggestionItem = document.createElement("li");
      suggestionItem.textContent = condition;

      // Add click event to select condition
      suggestionItem.addEventListener("click", () =>
        selectCondition(condition)
      );
      autocompleteList.appendChild(suggestionItem);
    });
  }
});

// Function to handle selecting a condition
function selectCondition(condition) {
  if (!preExistingConditions.includes(condition)) {
    preExistingConditions.push(condition);

    // Create and display selected condition
    const conditionItem = document.createElement("div");
    conditionItem.classList.add("condition-item");
    conditionItem.innerHTML = `
      <span>${condition}</span>
      <button class="delete-button">Remove</button>
    `;

    // Add delete functionality
    conditionItem
      .querySelector(".delete-button")
      .addEventListener("click", () => {
        const index = preExistingConditions.indexOf(condition);
        if (index > -1) preExistingConditions.splice(index, 1);
        conditionItem.remove();
      });

    selectedConditionsList.appendChild(conditionItem);
  }

  // Clear input and suggestions
  conditionInput.value = "";
  autocompleteList.innerHTML = "";
}

// ✅ Data for conditions
const conditionsData = {
  Cardiovascular: [
    "Hypertension (High Blood Pressure)",
    "Heart Disease (e.g., Coronary Artery Disease)",
    "Arrhythmias (Irregular Heartbeat)",
    "Congestive Heart Failure",
    "Stroke (History of Cerebrovascular Accidents)",
    "Peripheral Artery Disease"
  ],
  Respiratory: [
    "Asthma",
    "Chronic Obstructive Pulmonary Disease (COPD)",
    "Emphysema",
    "Pulmonary Fibrosis",
    "Sleep Apnea",
    "History of Tuberculosis"
  ],
  Metabolic: [
    "Diabetes (Type 1)",
    "Diabetes (Type 2)",
    "Thyroid Disorders (Hyperthyroidism or Hypothyroidism)",
    "Obesity",
    "Dyslipidemia (Abnormal cholesterol levels)",
    "Metabolic Syndrome"
  ],
  Gastrointestinal: [
    "Irritable Bowel Syndrome (IBS)",
    "Celiac Disease",
    "Crohn’s Disease",
    "Ulcerative Colitis",
    "Cirrhosis",
    "Hepatitis",
    "Gastroesophageal Reflux Disease (GERD)"
  ],
  Renal: [
    "Chronic Kidney Disease (CKD)",
    "Kidney Stones",
    "Urinary Tract Infections (Recurrent)"
  ],
  Neurological: [
    "Epilepsy",
    "Parkinson’s Disease",
    "Multiple Sclerosis (MS)",
    "Migraine",
    "History of Traumatic Brain Injury (TBI)"
  ],
  Immunological: [
    "Rheumatoid Arthritis",
    "Systemic Lupus Erythematosus (SLE)",
    "Psoriasis",
    "Ankylosing Spondylitis",
    "Immunodeficiency Disorders (e.g., HIV, Primary Immunodeficiency)",
    "Organ Transplant History (Immunosuppressive therapy)"
  ],
  Hematological: [
    "Anemia (Iron-deficiency, Sickle Cell, etc.)",
    "Thalassemia",
    "Clotting Disorders (e.g., Hemophilia)",
    "History of Deep Vein Thrombosis (DVT)"
  ],
  Oncology: [
    "Breast Cancer",
    "Lung Cancer",
    "Colon Cancer",
    "Prostate Cancer",
    "Leukemia or Lymphoma",
    "Skin Cancer (e.g., Melanoma)"
  ],
  Psychiatric: [
    "Depression",
    "Anxiety Disorders",
    "Bipolar Disorder",
    "Schizophrenia",
    "Post-Traumatic Stress Disorder (PTSD)"
  ],
  Infections: [
    "HIV/AIDS",
    "Hepatitis B or C",
    "Chronic Lyme Disease",
    "Recurrent Pneumonia or Infections"
  ],
  Musculoskeletal: [
    "Osteoarthritis",
    "Osteoporosis",
    "Fibromyalgia",
    "Gout"
  ]
};


// Function to open modal (registration or login)
function openModal(modalId) {
    document.getElementById(modalId).style.display = "block";
}

// Function to close modal (registration or login)
function closeModal(modalId) {
    document.getElementById(modalId).style.display = "none";
}





// ✅ Function to open a popup
function openPopup(popupId) {
  const popup = document.getElementById(popupId);
  const overlay = document.getElementById("popupOverlay");

  if (popup && overlay) {
    popup.style.display = "block";
    overlay.style.display = "block";
  }
}

// ✅ Function to close a specific popup
function closePopup(popupId) {
  const popup = document.getElementById(popupId);
  const overlay = document.getElementById("popupOverlay");

  if (popup) {
    popup.style.display = "none";
  }

  // Check if any other popups are still open
  const anyOpen = Array.from(document.querySelectorAll(".popup"))
    .some(el => el.style.display === "block");

  if (!anyOpen) {
    overlay.style.display = "none";
  }
}

// ✅ Function to close all popups (e.g. on overlay click)
function closeAllPopups() {
  document.querySelectorAll(".popup").forEach(p => p.style.display = "none");
  document.getElementById("popupOverlay").style.display = "none";
}





// Function to handle user registration
function registerUser(event) {
    event.preventDefault(); // Prevent form submission reload

    // Get user input values
    let name = document.getElementById('reg-name').value.trim();
    let surname = document.getElementById('reg-surname').value.trim();
    let email = document.getElementById('reg-email').value.trim();
    let confirmEmail = document.getElementById('reg-confirm-email').value.trim();
    let password = document.getElementById('reg-password').value;
    let confirmPassword = document.getElementById('reg-confirm-password').value;
    let phone = document.getElementById('reg-phone').value.trim();

    // Validation checks
    if (!name || !surname || !email || !confirmEmail || !phone || !password || !confirmPassword) {
        alert("Please fill in all fields.");
        return;
    }
    if (email !== confirmEmail) {
        alert("Emails do not match!");
        return;
    }
    if (password !== confirmPassword) {
        alert("Passwords do not match!");
        return;
    }

    // Check if the diagnostic JSON already exists in localStorage
    let existingData = localStorage.getItem("diagnosticData");
    let diagnosticData = existingData ? JSON.parse(existingData) : {};

    // If user profile section doesn't exist, create it
    if (!diagnosticData.user) {
        diagnosticData.user = {
            name: name,
            surname: surname,
            email: email,
            phone: phone,
            password: password // NOTE: Password is stored (consider hashing for security)
        };
    } else {
        // Only update missing values, keep existing ones
        diagnosticData.user.name = name || diagnosticData.user.name;
        diagnosticData.user.surname = surname || diagnosticData.user.surname;
        diagnosticData.user.email = email || diagnosticData.user.email;
        diagnosticData.user.phone = phone || diagnosticData.user.phone;
        diagnosticData.user.password = password || diagnosticData.user.password;
    }

    // Store updated JSON back into localStorage
    localStorage.setItem("diagnosticData", JSON.stringify(diagnosticData));

    // Update the Welcome Box with user details
    updateWelcomeMessage(diagnosticData.user.name, diagnosticData.user.surname, diagnosticData.user.email, diagnosticData.user.phone);

    // Hide Register & Login buttons
    document.querySelector('.auth-buttons').style.display = "none";

    // Close the registration modal
    closeModal('register-modal');
}







// Function to handle user login
function loginUser(event) {
    event.preventDefault(); // Prevent form submission reload

    let email = document.getElementById('login-email').value.trim();
    let password = document.getElementById('login-password').value;

    let storedData = localStorage.getItem("diagnosticData");

    if (storedData) {
        let userData = JSON.parse(storedData).user;

        // Check if email and password exist in localStorage
        if (userData && userData.email === email && userData.password === password) {
            // Store login state so it persists after refresh
            localStorage.setItem("loggedIn", "true");

            // Update the Welcome Box with user details
            updateWelcomeMessage(userData.name, userData.surname, userData.email, userData.phone);

            // Hide Register & Login buttons
            document.querySelector('.auth-buttons').style.display = "none";

            // Close the login modal
            closeModal('login-modal');
        } else {
            alert("Invalid email or password!");
        }
    } else {
        alert("No registered user found. Please register first.");
    }
}

// Ensure user stays logged in after page refresh
window.onload = function () {
    let isLoggedIn = localStorage.getItem("loggedIn");
    if (isLoggedIn) {
        initializeUserProfile(); // Reload user profile
    }
};



// Function to update Welcome Box after registration/login
function updateWelcomeMessage(name, surname, email, phone) {
    let welcomeBox = document.getElementById('welcome-box');
    let welcomeMessage = document.getElementById('welcome-message');

    // Display user info inside Welcome Box (Now includes phone)
    welcomeMessage.innerHTML = `Welcome, ${name} ${surname}<br>Email: ${email}<br>Phone: ${phone}`;
    welcomeBox.style.display = "block";

    // Show Update Profile & Logout buttons
    document.getElementById('update-profile-btn').style.display = "inline-block";
    document.getElementById('logout-btn').style.display = "inline-block";
}

// Function to logout user
function logoutUser() {
    localStorage.removeItem("diagnosticData");

    // Hide Welcome Box & Show Register/Login buttons
    document.getElementById('welcome-box').style.display = "none";
    document.querySelector('.auth-buttons').style.display = "flex";
}

// Function to check if user is already logged in when page loads
function initializeUserProfile() {
    let storedProfile = JSON.parse(localStorage.getItem("diagnosticData"));

    if (storedProfile && storedProfile.user) {
        updateWelcomeMessage(
            storedProfile.user.name,
            storedProfile.user.surname,
            storedProfile.user.email,
            storedProfile.user.phone
        );

        // Hide Register & Login buttons
        document.querySelector('.auth-buttons').style.display = "none";
    }
}

// Call initializeUserProfile on page load
window.onload = initializeUserProfile;















// Function to handle updating user profile
function updateProfile(event) {
    event.preventDefault(); // Prevent form submission reload

    // Get updated user input values
    let updatedName = document.getElementById('update-name').value.trim();
    let updatedSurname = document.getElementById('update-surname').value.trim();
    let updatedEmail = document.getElementById('update-email').value.trim();
    let updatedPhone = document.getElementById('update-phone').value.trim();

    // Retrieve existing profile data from localStorage
    let storedData = localStorage.getItem("diagnosticData");

    if (storedData) {
        let diagnosticData = JSON.parse(storedData);

        // Ensure 'user' object exists in JSON
        if (!diagnosticData.user) {
            diagnosticData.user = {};
        }

        // Update only changed values, keep existing ones
        diagnosticData.user.name = updatedName || diagnosticData.user.name || "";
        diagnosticData.user.surname = updatedSurname || diagnosticData.user.surname || "";
        diagnosticData.user.email = updatedEmail || diagnosticData.user.email || "";
        diagnosticData.user.phone = updatedPhone || diagnosticData.user.phone || "";

        // Save updated JSON back to localStorage
        localStorage.setItem("diagnosticData", JSON.stringify(diagnosticData));

        // Update the Welcome Box with new details
        updateWelcomeMessage(
            diagnosticData.user.name,
            diagnosticData.user.surname,
            diagnosticData.user.email,
            diagnosticData.user.phone
        );

        // Close the update profile modal
        closeModal('update-profile-modal');
    } else {
        alert("No user profile found. Please register first.");
    }
}














// Function to handle user login
function loginUser(event) {
    event.preventDefault(); // Prevent form submission reload

    let email = document.getElementById('login-email').value.trim();
    let password = document.getElementById('login-password').value;

    let storedData = localStorage.getItem("diagnosticData");

    if (storedData) {
        let diagnosticData = JSON.parse(storedData);

        // Ensure 'user' object exists
        if (!diagnosticData.user) {
            alert("No user profile found. Please register first.");
            return;
        }

        let userData = diagnosticData.user;

        // Ensure the password exists in localStorage
        if (!userData.password) {
            alert("Password not found. Please register again.");
            return;
        }

        // Check if email and password match stored data
        if (userData.email === email && userData.password === password) {
            // Store login state in localStorage to persist after refresh
            localStorage.setItem("loggedIn", "true");

            // Update the Welcome Box with user details
            updateWelcomeMessage(userData.name, userData.surname, userData.email, userData.phone);

            // Hide Register & Login buttons
            document.querySelector('.auth-buttons').style.display = "none";

            // Close the login modal
            closeModal('login-modal');
        } else {
            alert("Invalid email or password!");
        }
    } else {
        alert("No registered user found. Please register first.");
    }
}

// Ensure user stays logged in after page refresh
window.onload = function () {
    let isLoggedIn = localStorage.getItem("loggedIn");
    if (isLoggedIn) {
        initializeUserProfile(); // Reload user profile
    }
};




// Function to log out the user
function logoutUser() {
    // Remove stored user data from localStorage
    localStorage.removeItem("userProfile");

    // Hide the Welcome Box
    document.getElementById('welcome-box').style.display = "none";

    // Show Register & Login buttons again
    document.querySelector('.auth-buttons').style.display = "flex";
}









// Function to initialize the full user profile structure
function initializeUserProfile() {
    let storedProfile = JSON.parse(localStorage.getItem("userProfile"));

    if (!storedProfile) {
        let userProfile = {
            "userProfile": {
                "name": "",
                "surname": "",
                "email": "",
                "password": "",
                "phone": ""
            },
            "patient_metrics": {
                "sex": "",
                "weight": { "value": "", "unit": "" },
                "height": { "value": "", "unit": "" },
                "age": "",
                "bmi": "",
                "bmr": ""
            },
            "medication_entry": {}, // Stores medication intake
            "pre_existing_conditions": {}, // Stores known conditions
            "diagnostics": {
               "upper_respiratory": {
    "recent_infections": {
        "had_recent_infection": "",
        "infection_type": []
    },
    "allergies": {
        "has_allergies": "",
        "allergy_type": [],
        "causes_respiratory_symptoms": ""
    },
    "temperature": {
        "measured_temperature": "",
        "symptom_duration": ""
    },
    "runny_nose": {
        "symptom_duration": "",
        "discharge_color": "",
        "sneezing": ""
    },
    "sore_throat": {
        "symptom_duration": "",
        "tonsil_swelling": "",
        "difficulty_swallowing": ""
    },
    "chest_tightness": {
        "chest_pain": "",
        "pain_worsens_with_coughing": "",
        "tightness_pattern": ""
    },
    "ear_pain": {
        "pain_location": "",
        "pain_type": "",
        "ear_discharge": ""
    },
    "hearing_changes": {
        "hearing_loss_location": "",
        "ringing_symptoms": "",
        "hearing_consistency": ""
    }
},
                "baseline_health_assessment": {
    "general_blood_test": {
        "wbc_count": "",
        "rbc_count": "",
        "hemoglobin_level": "",
        "hematocrit_level": "",
        "platelet_count": ""
    },
    "electrolytes": {
        "sodium": "",
        "potassium": "",
        "calcium": "",
        "bicarbonate": ""
    }
},
                "lower_respiratory": {
    "persistent_cough": {
        "cough_duration": "",
        "cough_type": "",
        "cough_time": ""
    },
    "wheezing": {
        "wheezing_frequency": "",
        "wheezing_trigger": ""
    },
    "frequent_infections": {
        "had_frequent_infections": "",
        "require_antibiotics": "",
        "infection_duration": ""
    },
    "mucus_production": {
        "mucus_present": "",
        "mucus_color": ""
    },
    "rapid_breathing": {
        "breathing_frequency": "",
        "breathing_time": "",
        "breathing_trigger": ""
    },
    "chest_tightness": {
        "tightness_time": "",
        "tightness_symptoms": "",
        "tightness_frequency": ""
    },
    "shortness_of_breath": {
        "breathing_frequency": "",
        "breathing_activity": "",
        "breathing_additional_symptoms": ""
    },
    "oxygen_saturation": {
        "oxygen_saturation_level": ""
    },
    "chest_pain_deep_breaths": {
        "pain_deep_breath": "",
        "pain_type": "",
        "pain_intensity": "",
        "position_effect": ""
    },
    "difficulty_breathing_lying_down": {
        "shortness_lying_down": "",
        "shortness_sitting_up": "",
        "pillow_usage": "",
        "lying_breath_severity": "",
        "other_lying_symptoms": ""
    },
    "night_sweats": {
        "sweats_frequency": "",
        "sweats_symptoms": "",
        "sweats_sleep_quality": "",
        "sweats_intensity": "",
        "sweats_trigger": "",
        "sweats_impact": ""
    },
    "respiration_rate": {
        "respiration_rate_value": ""
    },
    "lung_capacity_test": {
        "lung_capacity_value": ""
    }
},
                "cardio": {
    "high_blood_pressure": {
        "diagnosed": "",
        "controlled_with_medication": ""
    },
    "calcium_dynamics": {
        "daily_calcium_intake": "",
        "bone_health_status": "",
        "calcium_symptoms": ""
    },
    "blood_pressure": {
        "systolic": "",
        "diastolic": "",
        "hdl": "",
        "ldl": "",
        "vldl": "",
        "glucose_level": "",
        "kidney_function": ""
    },
    "heart_rate": {
        "bpm": ""
    },
    "chest_pain": {
        "frequency": "",
        "pain_type": "",
        "pain_radiation": ""
    },
    "ecg_interpretation": {
        "ecg_findings": "",
        "ecg_image": ""
    },
    "heart_health_test": {
        "troponin_level": ""
    },
    "homocysteine_test": {
        "homocysteine_level": ""
    },
    "shortness_of_breath": {
        "frequency": "",
        "activity_trigger": "",
        "additional_symptoms": ""
    },
    "palpitations": {
        "frequency": "",
        "activity_trigger": ""
    },
    "clotting_inr": {
        "fibrinogen": "",
        "prothrombin_time": "",
        "factor_v": "",
        "factor_vii": "",
        "factor_x": ""
    },
    "edema": {
        "swelling_location": ""
    },
    "irregular_heartbeat": {
        "frequency": ""
    },
    "fainting_frequency": {
        "fainting_occurrence": ""
    },
    "cold_extremities": {
        "cold_extremities_present": ""
    },
    "heartburn": {
        "frequency": "",
        "worsens_lying_down": ""
    },
    "fatigue": {
        "frequency": "",
        "worse_after_activity": ""
    },
    "bnp_test": {
        "bnp_level": ""
    },
    "lipoprotein_a_test": {
        "lipoprotein_a_level": ""
    },
    "d_dimer_test": {
        "d_dimer_level": ""
    },
    "dizziness": {
        "frequency": "",
        "related_to_sudden_movement": ""
    },
    "sweating": {
        "excessive_sweating": "",
        "without_exertion": ""
    },
    "leg_pain": {
        "occurs_during": ""
    }
},
                "renal_diagnostics": {
    "glomerular_filtration": {
        "age": "",
        "creatinine": "",
        "gender": "",
        "race": "",
        "egfr_result": ""
    },
    "electrolytes": {
        "sodium": "",
        "potassium": "",
        "chloride": "",
        "electrolytes_result": ""
    },
    "acid_base_status": {
        "bicarbonate": "",
        "sodium": "",
        "chloride": "",
        "anion_gap_result": ""
    },
    "proteinuria": {
        "urinary_protein": "",
        "urinary_creatinine": "",
        "protein_creatinine_ratio": ""
    }
},
                "endocrine": {
    "fatigue": {
        "fatigue_frequency": ""
    },
    "thyroid_function": {
        "tsh_level": "",
        "t4_level": "",
        "t3_level": "",
        "thyroid_autoimmunity": {
            "autoimmune_history": "",
            "symptoms": "",
            "tpoab": "",
            "tgab": ""
        }
    },
    "adrenal_function": {
        "adrenal_test_history": "",
        "morning_cortisol": "",
        "acth_response": ""
    },
    "glucose_levels": {
        "blood_glucose": "",
        "urine_glucose": "",
        "spinal_fluid_glucose": ""
    },
    "weight_changes": {
        "experienced_changes": ""
    },
    "hormonal_dynamics": {
        "muscle_skin_changes": "",
        "estrogen": "",
        "testosterone": "",
        "progesterone": ""
    },
    "temperature_sensitivity": {
        "sensitivity": "",
        "basal_body_temp": ""
    },
    "increased_thirst": {
        "thirst_increase": "",
        "aldosterone": "",
        "vasopressin": ""
    },
    "hunger_regulation": {
        "hunger_increase": "",
        "leptin": "",
        "ghrelin": ""
    },
    "skin_changes": {
        "noticed_changes": ""
    },
    "hair_changes": {
        "experienced_changes": "",
        "ferritin": ""
    },
    "menstrual_irregularities": {
        "irregular_cycles": "",
        "cycle_length_variability": "",
        "period_duration": "",
        "pain_level": ""
    },
    "mood_changes": {
        "experienced_changes": ""
    },
    "concentration_issues": {
        "difficulty_concentrating": ""
    }
},
                "neural": {
    "headache": {
        "frequency": ""
    },
    "dizziness": {
        "frequency": "",
        "related_to_movement": "",
        "duration": "",
        "occurrence": "",
        "onset": "",
        "timing": "",
        "type": ""
    },
    "numbness": {
        "frequency": "",
        "location": "",
        "duration": "",
        "trigger": "",
        "additional_symptoms": ""
    },
    "tremors": {
        "frequency": "",
        "location": "",
        "timing": "",
        "duration": "",
        "additional_symptoms": ""
    },
    "seizures": {
        "frequency": "",
        "type": "",
        "duration": "",
        "triggers": "",
        "additional_symptoms": ""
    },
    "memory_loss": {
        "frequency": "",
        "type": "",
        "onset": "",
        "triggers": "",
        "additional_symptoms": ""
    },
    "memory_test": {
        "recall_rating": "",
        "recognition": "",
        "short_term_memory": "",
        "long_term_memory": "",
        "names_dates": "",
        "daily_forgetfulness": "",
        "memory_changes_over_time": ""
    },
    "balance_test": {
        "stand_on_one_foot": "",
        "tandem_walk": "",
        "dizziness_unsteadiness": "",
        "eyes_closed_balance": "",
        "difficulty_on_stairs": "",
        "history_of_falls": "",
        "uneven_surfaces": ""
    },
    "speech_difficulties": {
        "difficulty_speaking": "",
        "situational_difficulty": "",
        "type": "",
        "onset": "",
        "frequency": "",
        "severity": "",
        "additional_symptoms": "",
        "fatigue_impact": ""
    },
    "muscle_weakness": {
        "experienced": "",
        "location": "",
        "frequency": "",
        "onset": "",
        "severity": "",
        "fatigue_impact": "",
        "additional_symptoms": "",
        "medication_impact": ""
    },
    "vision_changes": {
        "experienced": "",
        "type": "",
        "onset": "",
        "frequency": "",
        "severity": "",
        "additional_symptoms": "",
        "specific_activities": "",
        "lighting_conditions": ""
    },
    "balance_issues": {
        "experienced": "",
        "timing": "",
        "frequency": "",
        "onset": "",
        "situational_triggers": "",
        "severity": "",
        "additional_symptoms": "",
        "history_of_falls": ""
    },
    "sensitivity_to_light_or_sound": {
        "experienced": "",
        "trigger_type": "",
        "frequency": "",
        "severity": "",
        "situational_worsening": "",
        "additional_symptoms": "",
        "protective_measures": "",
        "onset": ""
    }
},
                "gastrointestinal": {
    "abdominal_pain": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "type": ["Sharp", "Dull", "Cramping", "Burning"],
        "location": ["Upper abdomen", "Lower abdomen", "Right side", "Left side", "All over"],
        "triggers": ["After eating", "When hungry", "Physical activity", "Stress", "No specific triggers"],
        "duration": ["A few minutes", "A few hours", "All day", "Varies"],
        "severity": ["Mild", "Moderate", "Severe"],
        "associated_symptoms": ["Nausea", "Vomiting", "Bloating", "Diarrhea", "Constipation", "None"],
        "relief_factors": ["Rest", "Medication", "Eating", "Applying heat", "No relief"]
      }
    },
    "nausea_vomiting": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "vomiting_recent": ["Yes", "No"],
        "triggers": ["After eating", "Motion or travel", "Strong smells", "Medications", "No specific triggers"],
        "time_of_day": ["Morning", "Afternoon", "Evening", "Night", "No specific time"],
        "severity": ["Mild", "Moderate", "Severe"],
        "duration": ["A few minutes", "A few hours", "All day", "Varies"],
        "associated_symptoms": ["Dizziness", "Abdominal pain", "Headache", "Diarrhea", "None"],
        "relief_factors": ["Rest", "Medication", "Eating small meals", "Hydration", "No relief"]
      }
    },
    "diarrhea": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "blood_in_stool": ["Yes", "No"],
        "consistency": ["Watery", "Loose", "Mucous-like", "Variable"],
        "duration": ["A few hours", "A day", "Several days", "Varies"],
        "triggers": ["Certain foods", "Stress", "Medications", "No specific triggers"],
        "associated_symptoms": ["Nausea", "Abdominal cramps", "Fever", "Fatigue", "None"],
        "time_of_day": ["Morning", "Afternoon", "Evening", "Night", "No specific time"],
        "relief_factors": ["Hydration", "Rest", "Avoiding specific foods", "Medication", "No relief"]
      }
    },
    "constipation": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "straining": ["Yes", "No"],
        "stool_consistency": ["Hard", "Lumpy", "Pebble-like", "Normal"],
        "duration": ["A few days", "A week", "Several weeks", "Varies"],
        "triggers": ["Certain foods", "Lack of exercise", "Medications", "Stress", "No specific triggers"],
        "associated_symptoms": ["Bloating", "Abdominal pain", "Nausea", "Loss of appetite", "None"],
        "bowel_movement_frequency": ["Once a day", "Every other day", "Twice a week", "Once a week or less"],
        "relief_factors": ["Increased fiber intake", "Drinking more water", "Exercise", "Medication", "No relief"]
      }
    },
    "heartburn": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "worsens_after_eating": ["Yes", "No"],
        "time_of_day": ["Morning", "Afternoon", "Evening", "Night", "No specific time"],
        "severity": ["Mild", "Moderate", "Severe"],
        "triggers": ["Spicy foods", "Fatty foods", "Alcohol", "Caffeine", "No specific triggers"],
        "associated_symptoms": ["Acid taste in mouth", "Chest discomfort", "Bloating", "Difficulty swallowing", "None"],
        "relief_factors": ["Antacids", "Drinking water", "Avoiding certain foods", "Sitting upright", "No relief"],
        "duration": ["A few minutes", "A few hours", "All day", "Varies"]
      }
    },
    "bloating": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "time_of_day": ["Morning", "Afternoon", "Evening", "Night", "No specific time"],
        "triggers": ["After eating", "Certain foods", "Carbonated drinks", "Stress", "No specific triggers"],
        "duration": ["A few minutes", "A few hours", "All day", "Varies"],
        "severity": ["Mild", "Moderate", "Severe"],
        "associated_symptoms": ["Abdominal pain", "Gas", "Nausea", "Diarrhea", "Constipation", "None"],
        "relief_factors": ["Passing gas", "Medication", "Avoiding certain foods", "Drinking water", "No relief"]
      }
    },
    "changes_in_appetite": {
      "questions": {
        "change_type": ["Increased", "Decreased", "No Change"],
        "duration": ["A few days", "A few weeks", "A few months", "Ongoing"],
        "triggers": ["Stress", "Medications", "Physical activity level", "Illness or infection", "No specific triggers"],
        "frequency": ["Occasionally", "Frequently", "Constantly"],
        "associated_symptoms": ["Weight loss", "Weight gain", "Fatigue", "Nausea", "No other symptoms"],
        "eating_habits_impact": ["Eating more frequently", "Eating less frequently", "Skipping meals", "No impact"],
        "mental_health_factors": ["Yes", "No", "Not sure"]
      }
    },
    "blood_in_stool": {
      "questions": {
        "presence": ["Yes", "No"],
        "frequency": ["Once", "Occasionally", "Frequently", "Every time"],
        "color": ["Bright red", "Dark red", "Black or tarry", "Unknown"],
        "associated_symptoms": ["Abdominal pain", "Diarrhea", "Constipation", "Weight loss", "No other symptoms"],
        "stool_consistency": ["Loose", "Hard", "Normal", "Variable"],
        "triggers": ["After physical activity", "After eating certain foods", "After constipation", "No specific factors"],
        "recent_diet_medication_change": ["Yes, dietary changes", "Yes, medication changes", "No changes"]
      }
    },
    "indigestion": {
      "questions": {
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "time_of_day": ["Morning", "Afternoon", "Evening", "Night", "No specific time"],
        "triggers": ["After eating", "Spicy foods", "Fatty foods", "Alcohol", "No specific triggers"],
        "duration": ["A few minutes", "A few hours", "All day", "Varies"],
        "severity": ["Mild", "Moderate", "Severe"],
        "associated_symptoms": ["Heartburn", "Bloating", "Nausea", "Abdominal pain", "No other symptoms"],
        "relief_factors": ["Antacids", "Drinking water", "Avoiding certain foods", "Sitting upright", "No relief"]
      }
    },
    "difficulty_swallowing": {
      "questions": {
        "presence": ["Yes", "No"],
        "frequency": ["Rarely", "Occasionally", "Frequently", "Constantly"],
        "difficulty_with": ["Solids", "Liquids", "Both"],
        "associated_symptoms": ["Pain", "Coughing", "Choking", "Sensation of food stuck", "No other symptoms"],
        "triggers": ["Certain foods", "Eating too quickly", "Stress or anxiety", "No specific triggers"],
        "duration": ["A few days", "A few weeks", "A few months", "More than a year"],
        "relief_factors": ["Drinking water", "Eating slowly", "Avoiding certain foods", "No relief"]
      }
    }
  },
                "psychological_evaluation": {},
                "psychiatric_evaluation": {},
                "musculoskeletal_evaluation": {}
            }
        };

        // Store in localStorage
        localStorage.setItem("userProfile", JSON.stringify(userProfile));
    }
}

// Call the function to ensure user profile is initialized
initializeUserProfile();








function toggleCategory(categoryId) {
    // Hide all sections
    document.querySelectorAll('.diagnostic-section').forEach(section => {
        section.classList.add('hidden');
    });
    
    // Show the selected section
    document.getElementById(categoryId).classList.remove('hidden');
}




function toggleCategory(categoryId) {
    let section = document.getElementById(categoryId);
    
    if (section.classList.contains('hidden')) {
        // Hide all sections
        document.querySelectorAll('.diagnostic-section').forEach(sec => {
            sec.classList.add('hidden');
        });
        
        // Show the selected section
        section.classList.remove('hidden');
    } else {
        // Close the currently open section
        section.classList.add('hidden');
    }
}









function toggleAccordion(sectionId) {
    let panel = document.getElementById(sectionId);
    panel.style.display = (panel.style.display === "block") ? "none" : "block";
}






function displayBloodTypeInfo() {
    const bloodType = document.getElementById("blood-type").value;
    const rhFactor = document.getElementById("rh-factor").value;
    const resultBox = document.getElementById("blood-analysis-result");

    if (!bloodType && !rhFactor) {
        resultBox.innerHTML = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 ABO/Rh Blood Type Analysis:<br>`;
    const missing = [];

    if (bloodType && rhFactor) {
        result += `🩸 Blood Type ${bloodType} Rh${rhFactor === "Positive" ? "+" : "-"}.<br>`;

        // ✅ Compatibility Notes
        if (bloodType === "O" && rhFactor === "Negative") {
            result += "✅ Universal Blood Donor — O− can donate to all types.<br>";
        } else if (bloodType === "AB" && rhFactor === "Positive") {
            result += "✅ Universal Blood Recipient — AB+ can receive from all types.<br>";
        }

        // 🟡 Disease Risk Notes
        if (bloodType === "A") {
            result += "🟡 Slightly increased risk of gastric cancer and clotting.<br>";
        } else if (bloodType === "O") {
            result += "🟡 Lower clotting risk, but increased bleeding tendency.<br>";
        }

        // 🟡 Pregnancy Risk for Rh-
        if (rhFactor === "Negative") {
            result += "🟡 Rh-negative mothers may require Rh immunoglobulin during pregnancy.<br>";
        }
    } else {
        if (!bloodType) missing.push("Blood Type");
        if (!rhFactor) missing.push("Rh Factor");
    }

    if (missing.length > 0) {
        result += `<br>Missing: ${missing.join(", ")}`;
    }

    resultBox.innerHTML = result;

    // ✅ Update Welcome Box Automatically
    updateWelcomeBoxWithBloodType();
}












function updateWelcomeBox(userData) {
    if (userData) {
        document.getElementById("welcome-box").style.display = "block";
        document.getElementById("welcome-message").innerText = `Welcome, ${userData.name}`;

        // ✅ Update Blood Type & Rh Factor
        if (userData.bloodType) {
            document.getElementById("blood-type-value").innerText = userData.bloodType;
            document.getElementById("display-blood-type").style.display = "block";
        }

        if (userData.rhFactor) {
            document.getElementById("rh-factor-value").innerText = userData.rhFactor;
            document.getElementById("display-rh-factor").style.display = "block";
        }

        // ✅ Show Profile Update & Logout Buttons
        document.getElementById("update-profile-btn").style.display = "block";
        document.getElementById("logout-btn").style.display = "block";
    }
}











function analyzeRBC() {
    const hemoglobin = document.getElementById("hemoglobin2").value;
    const hematocrit = document.getElementById("hematocrit2").value;
    const mcv = document.getElementById("mcv2").value;
    const mch = document.getElementById("mch2").value;
    const mchc = document.getElementById("mchc2").value;
    const rdw = document.getElementById("rdw2").value;
    const resultDisplay = document.getElementById("rbcResult");

    const values = [hemoglobin, hematocrit, mcv, mch, mchc, rdw];
    const hasAny = values.some(v => v !== "");
    const missing = [];

    if (!hasAny) {
        resultDisplay.innerHTML = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 RBC Analysis:<br>`;

    // Hemoglobin
    if (hemoglobin !== "") {
        const val = parseFloat(hemoglobin);
        if (val < 13.5) {
            result += "🟡 Hemoglobin is low — may indicate anemia, iron deficiency, or chronic illness.<br>";
        } else if (val > 17.5) {
            result += "🔴 Hemoglobin is high — possible dehydration, chronic hypoxia, or polycythemia.<br>";
        } else {
            result += "✅ Hemoglobin is within normal range.<br>";
        }
    } else {
        missing.push("Hemoglobin");
    }

    // Hematocrit
    if (hematocrit !== "") {
        const val = parseFloat(hematocrit);
        if (val < 38) {
            result += "🟡 Hematocrit is low — may reflect anemia or fluid overload.<br>";
        } else if (val > 50) {
            result += "🔴 Hematocrit is high — possible hemoconcentration or excess red cells.<br>";
        } else {
            result += "✅ Hematocrit is within normal range.<br>";
        }
    } else {
        missing.push("Hematocrit");
    }

    // MCV
    if (mcv !== "") {
        const val = parseFloat(mcv);
        if (val < 80) {
            result += "🟡 MCV is low — microcytosis, often due to iron deficiency or thalassemia.<br>";
        } else if (val > 100) {
            result += "🔴 MCV is high — macrocytosis, possibly from B12 or folate deficiency.<br>";
        } else {
            result += "✅ MCV is within normal range.<br>";
        }
    } else {
        missing.push("MCV");
    }

    // MCH
    if (mch !== "") {
        const val = parseFloat(mch);
        if (val < 27) {
            result += "🟡 MCH is low — may suggest hypochromia, often from iron-deficiency anemia.<br>";
        } else if (val > 33) {
            result += "🔴 MCH is high — could indicate macrocytosis or altered hemoglobin levels.<br>";
        } else {
            result += "✅ MCH is within normal range.<br>";
        }
    } else {
        missing.push("MCH");
    }

    // MCHC
    if (mchc !== "") {
        const val = parseFloat(mchc);
        if (val < 32) {
            result += "🟡 MCHC is low — linked to hypochromic anemias. Iron studies recommended.<br>";
        } else if (val > 36) {
            result += "🔴 MCHC is high — could suggest spherocytosis or dehydration.<br>";
        } else {
            result += "✅ MCHC is within normal range.<br>";
        }
    } else {
        missing.push("MCHC");
    }

    // RDW
    if (rdw !== "") {
        const val = parseFloat(rdw);
        if (val > 14.5) {
            result += "🔴 RDW is high — anisocytosis. Check iron, B12, folate. Correlate with MCV.<br>";
        } else {
            result += "✅ RDW is within normal range.<br>";
        }
    } else {
        missing.push("RDW");
    }

    if (missing.length > 0) {
        result += `<br>Missing: ${missing.join(", ")}`;
    }

    resultDisplay.innerHTML = result;
}












function analyzeWBC1() {
    const neutrophils = document.getElementById("neutrophils").value;
    const lymphocytes = document.getElementById("lymphocytes").value;
    const eosinophils = document.getElementById("eosinophils").value;
    const monocytes = document.getElementById("monocytes").value;
    const basophils = document.getElementById("basophils").value;
    const resultDisplay = document.getElementById("wbcResult");

    const values = [neutrophils, lymphocytes, eosinophils, monocytes, basophils];
    const hasAny = values.some(v => v !== "");
    const missing = [];

    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 White Blood Cell Differential Analysis:\n`;

    // Neutrophils
    if (neutrophils !== "") {
        const val = parseFloat(neutrophils);
        if (val < 40) {
            result += "🟡 Neutrophils are low — may indicate viral infection, bone marrow suppression, or autoimmune activity.\n";
        } else if (val > 70) {
            result += "🔴 Neutrophils are high — suggests bacterial infection, inflammation, or stress.\n";
        } else {
            result += "✅ Neutrophils are within normal range.\n";
        }
    } else {
        missing.push("Neutrophils");
    }

    // Lymphocytes
    if (lymphocytes !== "") {
        const val = parseFloat(lymphocytes);
        if (val < 20) {
            result += "🔴 Lymphocytes are low — may reflect acute stress, steroid use, or immunosuppression.\n";
        } else if (val > 40) {
            result += "🔴 Lymphocytes are high — possible viral infection, autoimmune disease, or lymphoproliferative disorder.\n";
        } else {
            result += "✅ Lymphocytes are within normal range.\n";
        }
    } else {
        missing.push("Lymphocytes");
    }

    // Eosinophils
    if (eosinophils !== "") {
        const val = parseFloat(eosinophils);
        if (val < 1) {
            result += "🟡 Eosinophils are slightly low — usually not clinically significant.\n";
        } else if (val > 6) {
            result += "🔴 Eosinophils are high — may indicate allergy, parasite, or eosinophilic disorder.\n";
        } else {
            result += "✅ Eosinophils are within normal range.\n";
        }
    } else {
        missing.push("Eosinophils");
    }

    // Monocytes
    if (monocytes !== "") {
        const val = parseFloat(monocytes);
        if (val < 2) {
            result += "🟡 Monocytes are low — can reflect transient marrow suppression or steroid use.\n";
        } else if (val > 10) {
            result += "🔴 Monocytes are high — may indicate chronic infection, inflammation, or hematologic disease.\n";
        } else {
            result += "✅ Monocytes are within normal range.\n";
        }
    } else {
        missing.push("Monocytes");
    }

    // Basophils
    if (basophils !== "") {
        const val = parseFloat(basophils);
        if (val < 0.5) {
            result += "🟡 Basophils are low — generally not significant unless part of leukopenia.\n";
        } else if (val > 2) {
            result += "🔴 Basophils are high — may suggest allergy, inflammation, or hematologic issue.\n";
        } else {
            result += "✅ Basophils are within normal range.\n";
        }
    } else {
        missing.push("Basophils");
    }

    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultDisplay.innerText = result.trim();
}





function analyzePlatelets() {
    const mpv = document.getElementById("mpv2").value;
    const pdw = document.getElementById("pdw2").value;
    const resultDisplay = document.getElementById("plateletResult");

    const hasAny = [mpv, pdw].some(v => v !== "");
    const missing = [];

    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 Platelet Indices Analysis:\n`;

    // MPV
    if (mpv !== "") {
        const val = parseFloat(mpv);
        if (val < 7.5) {
            result += "🟡 MPV is low — may indicate bone marrow suppression or older, smaller platelets.\n";
        } else if (val > 11.5) {
            result += "🔴 MPV is high — suggests increased platelet turnover or destruction.\n";
        } else {
            result += "✅ MPV is within normal range.\n";
        }
    } else {
        missing.push("MPV");
    }

    // PDW
    if (pdw !== "") {
        const val = parseFloat(pdw);
        if (val < 9) {
            result += "🟡 PDW is low — indicates uniform platelet size, possibly suppressed marrow.\n";
        } else if (val > 17) {
            result += "🔴 PDW is high — increased size variation; may reflect activation or clotting disorder.\n";
        } else {
            result += "✅ PDW is within normal range.\n";
        }
    } else {
        missing.push("PDW");
    }

    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultDisplay.innerText = result.trim();
}











function analyzeInflammatoryMarkers() {
    const crp = parseFloat(document.getElementById("inflammatory1_crp").value);
    const hsCRP = parseFloat(document.getElementById("inflammatory1_hscrp").value);
    const saa = parseFloat(document.getElementById("inflammatory1_saa").value);
    const ferritin = parseFloat(document.getElementById("inflammatory1_ferritin").value);
    const fibrinogen = parseFloat(document.getElementById("inflammatory1_fibrinogen").value);
    const esr = parseFloat(document.getElementById("inflammatory1_esr").value);
    const wbc = parseFloat(document.getElementById("inflammatory1_wbc").value);
    const nlr = parseFloat(document.getElementById("inflammatory1_nlr").value);
    const tnf = parseFloat(document.getElementById("inflammatory1_tnf").value);

    const resultDisplay = document.getElementById("inflammatory-analysis-result");
    if (!resultDisplay) return;

    const values = [crp, hsCRP, saa, ferritin, fibrinogen, esr, wbc, nlr, tnf];
    const hasAny = values.some(val => !isNaN(val));
    const missing = [];

    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 Inflammatory Marker Analysis:\n`;

    if (!isNaN(crp)) {
        if (crp > 10) result += "🔴 CRP is high — active inflammation, often bacterial or autoimmune in origin.\n";
        else if (crp > 5) result += "🟡 CRP is mildly elevated — possible early infection or systemic stress.\n";
        else result += "✅ CRP is within normal range.\n";
    } else missing.push("CRP");

    if (!isNaN(hsCRP)) {
        if (hsCRP > 3) result += "🟡 hs-CRP is elevated — low-grade chronic inflammation, cardiovascular risk.\n";
        else result += "✅ hs-CRP is within normal range.\n";
    } else missing.push("hs-CRP");

    if (!isNaN(saa)) {
        if (saa > 10) result += "🟡 SAA is elevated — inflammation possibly due to infection, trauma, or immune activation.\n";
        else result += "✅ SAA is within normal range.\n";
    } else missing.push("SAA");

    if (!isNaN(ferritin)) {
        if (ferritin > 300) result += "🟡 Ferritin is high — may reflect inflammation, iron overload, or liver dysfunction.\n";
        else result += "✅ Ferritin is within normal range.\n";
    } else missing.push("Ferritin");

    if (!isNaN(fibrinogen)) {
        if (fibrinogen > 4.5) result += "🟡 Fibrinogen is elevated — possible inflammation or prothrombotic activity.\n";
        else result += "✅ Fibrinogen is within normal range.\n";
    } else missing.push("Fibrinogen");

    if (!isNaN(esr)) {
        if (esr > 20) result += "🟡 ESR is elevated — may indicate chronic inflammation or autoimmune process.\n";
        else result += "✅ ESR is within normal range.\n";
    } else missing.push("ESR");

    if (!isNaN(wbc)) {
        if (wbc < 4) result += "🟡 WBC is low — may indicate viral suppression or bone marrow dysfunction.\n";
        else if (wbc > 11) result += "🔴 WBC is high — indicates infection or inflammatory response.\n";
        else result += "✅ WBC is within normal range.\n";
    } else missing.push("WBC");

    if (!isNaN(nlr)) {
        if (nlr > 4) result += "🟡 NLR is elevated — suggests immune activation or inflammation.\n";
        else result += "✅ NLR is within normal range.\n";
    } else missing.push("NLR");

    if (!isNaN(tnf)) {
        if (tnf > 8) result += "🔴 TNF-α is elevated — indicates strong pro-inflammatory activity.\n";
        else result += "✅ TNF-α is within normal range.\n";
    } else missing.push("TNF-α");

    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultDisplay.innerText = result.trim();
}



















function analyzeCancerMarkers() {
    const psa = parseFloat(document.getElementById("cancer1_psa").value);
    const ca125 = parseFloat(document.getElementById("cancer1_ca125").value);
    const ca19_9 = parseFloat(document.getElementById("cancer1_ca19_9").value);
    const afp = parseFloat(document.getElementById("cancer1_afp").value);
    const cea = parseFloat(document.getElementById("cancer1_cea").value);
    const ldh = parseFloat(document.getElementById("cancer1_ldh").value);

    const resultEl = document.getElementById("cancer-analysis-result");
    if (!resultEl) return;

    const values = [psa, ca125, ca19_9, afp, cea, ldh];
    const hasAny = values.some(val => !isNaN(val));
    const missing = [];

    if (!hasAny) {
        resultEl.innerText = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 Cancer Marker Analysis:\n`;

    // PSA
    if (!isNaN(psa)) {
        if (psa > 10) {
            result += "🔴 PSA very high — prostate ultrasound and further urologic evaluation recommended.\n";
        } else if (psa > 4.0) {
            result += "🟡 PSA elevated — repeat in 3 months; consider further screening if symptomatic.\n";
        } else {
            result += "✅ PSA is within normal range.\n";
        }
    } else missing.push("PSA");

    // CA-125
    if (!isNaN(ca125)) {
        if (ca125 > 100) {
            result += "🔴 CA-125 very high — pelvic ultrasound and monitoring advised.\n";
        } else if (ca125 > 35) {
            result += "🟡 CA-125 elevated — consider follow-up and imaging if symptoms present.\n";
        } else {
            result += "✅ CA-125 is within normal range.\n";
        }
    } else missing.push("CA-125");

    // CA 19-9
    if (!isNaN(ca19_9)) {
        if (ca19_9 > 100) {
            result += "🔴 CA 19-9 very high — imaging and liver function tests recommended.\n";
        } else if (ca19_9 > 37) {
            result += "🟡 CA 19-9 elevated — monitor for abdominal symptoms.\n";
        } else {
            result += "✅ CA 19-9 is within normal range.\n";
        }
    } else missing.push("CA 19-9");

    // AFP
    if (!isNaN(afp)) {
        if (afp > 50) {
            result += "🔴 AFP very high — liver ultrasound and hepatitis panel suggested.\n";
        } else if (afp > 10) {
            result += "🟡 AFP elevated — follow-up imaging and monitoring advised.\n";
        } else {
            result += "✅ AFP is within normal range.\n";
        }
    } else missing.push("AFP");

    // CEA
    if (!isNaN(cea)) {
        if (cea > 10) {
            result += "🔴 CEA very high — colonoscopy and abdominal scan recommended.\n";
        } else if (cea > 5.0) {
            result += "🟡 CEA elevated — monitor GI symptoms and retest.\n";
        } else {
            result += "✅ CEA is within normal range.\n";
        }
    } else missing.push("CEA");

    // LDH
    if (!isNaN(ldh)) {
        if (ldh > 600) {
            result += "🔴 LDH very high — further testing to assess tissue damage or malignancy.\n";
        } else if (ldh > 280) {
            result += "🟡 LDH elevated — repeat test and assess systemic symptoms.\n";
        } else {
            result += "✅ LDH is within normal range.\n";
        }
    } else missing.push("LDH");

    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultEl.innerText = result.trim();
}






function analyzeInfectionMarkers() {
    const pct = document.getElementById("infection1_pcr");
    const neutrophils = document.getElementById("infection1_neutrophils");
    const lymphocytes = document.getElementById("infection1_lymphocytes");
    const hivStatus = document.getElementById("infection1_hiv");
    const hepatitisStatus = document.getElementById("infection1_hepatitis");
    const resultDisplay = document.getElementById("infection-analysis-result");

    if (!pct || !neutrophils || !lymphocytes || !hivStatus || !hepatitisStatus || !resultDisplay) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    const pctValue = parseFloat(pct.value);
    const neutrophilsValue = parseFloat(neutrophils.value);
    const lymphocytesValue = parseFloat(lymphocytes.value);
    const hiv = hivStatus.value;
    const hepatitis = hepatitisStatus.value;

    if (isNaN(pctValue) || isNaN(neutrophilsValue) || isNaN(lymphocytesValue)) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    let resultText = `🔬 Infection Marker Review:\n`;

    // Procalcitonin (PCT)
    if (pctValue > 2.0) {
        resultText += "🔴 Procalcitonin very high (>2.0 ng/mL) — likely SEVERE bacterial infection or sepsis. Immediate medical evaluation required.\n";
    } else if (pctValue > 0.5) {
        resultText += "🔴 Procalcitonin elevated (>0.5 ng/mL) — suggests bacterial infection. Consider initiating antibiotics based on clinical signs.\n";
    } else {
        resultText += "✅ Procalcitonin low (<0.5 ng/mL) — consistent with viral infection or non-bacterial inflammation. Antibiotics not indicated.\n";
    }

    // Neutrophil / Lymphocyte Pattern
    if (neutrophilsValue > 70 && lymphocytesValue < 20) {
        resultText += "🔴 Neutrophil-dominant profile — strong bacterial signal. Common in acute infections, abscesses, or pneumonia.\n";
    } else if (lymphocytesValue > 50 && neutrophilsValue < 40) {
        resultText += "🟡 Lymphocyte-dominant profile — consistent with viral or chronic infections (e.g., EBV, CMV, hepatitis).\n";
    } else {
        resultText += "✅ Balanced neutrophil/lymphocyte ratio — no dominant pattern. May suggest resolving or early-stage infection.\n";
    }

    // Immune Status Check — ⚠ exactly as you wrote
    if (hiv === "Positive") {
        resultText += "⚠ HIV status: Positive — immune suppression may alter WBC patterns. CD4 count and viral load recommended.\n";
    }
    if (hepatitis === "Positive") {
        resultText += "⚠ Hepatitis markers detected — consider ALT/AST, bilirubin, and liver function to assess inflammatory burden.\n";
    }

    resultDisplay.innerText = resultText.trim();
}






function analyzeClottingFactors() {
    const dDimer = parseFloat(document.getElementById("clotting1_dimer").value);
    const inr = parseFloat(document.getElementById("clotting1_inr").value);
    const pt = parseFloat(document.getElementById("clotting1_pt").value);
    const aptt = parseFloat(document.getElementById("clotting1_aptt").value);
    const platelets = parseFloat(document.getElementById("clotting1_platelets").value);

    const resultDisplay = document.getElementById("clotting-analysis-result");
    let resultText = `🔬 Clotting Factor Analysis:\n`;
    let missing = [];

    const hasAny = ![dDimer, inr, pt, aptt, platelets].every(val => isNaN(val));
    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    // D-Dimer
    if (!isNaN(dDimer)) {
        if (dDimer > 2.0) {
            resultText += "🔴 D-Dimer is critically elevated — possible DVT, PE, or DIC. Urgent imaging may be required.\n";
        } else if (dDimer > 0.5) {
            resultText += "🟡 D-Dimer is elevated — may indicate inflammation, surgery, or infection.\n";
        } else {
            resultText += "✅ D-Dimer is within normal range.\n";
        }
    } else {
        missing.push("D-Dimer");
    }

    // INR
    if (!isNaN(inr)) {
        if (inr > 3.5) {
            resultText += "🔴 INR is critically high — high bleeding risk. May require dose adjustment or vitamin K.\n";
        } else if (inr > 1.2) {
            resultText += "🟡 INR is elevated — slower clotting, possible liver or drug effect.\n";
        } else if (inr < 0.8) {
            resultText += "🟡 INR is low — may reflect hypercoagulability or dehydration.\n";
        } else {
            resultText += "✅ INR is within normal range.\n";
        }
    } else {
        missing.push("INR");
    }

    // PT
    if (!isNaN(pt)) {
        if (pt > 20) {
            resultText += "🔴 PT is severely prolonged — consider liver dysfunction or medication.\n";
        } else if (pt > 14) {
            resultText += "🟡 PT is mildly prolonged — possible vitamin K deficiency or hepatic issue.\n";
        } else if (pt < 10) {
            resultText += "🟡 PT is shortened — may suggest hypercoagulability.\n";
        } else {
            resultText += "✅ PT is within normal range.\n";
        }
    } else {
        missing.push("PT");
    }

    // aPTT
    if (!isNaN(aptt)) {
        if (aptt > 60) {
            resultText += "🔴 aPTT is critically prolonged — may indicate factor deficiency or anticoagulant effect.\n";
        } else if (aptt > 35) {
            resultText += "🟡 aPTT is moderately prolonged — check for meds or lab error.\n";
        } else {
            resultText += "✅ aPTT is within normal range.\n";
        }
    } else {
        missing.push("aPTT");
    }

    // Platelets
    if (!isNaN(platelets)) {
        if (platelets < 50) {
            resultText += "🔴 Platelets critically low — high bleeding risk. Requires urgent evaluation.\n";
        } else if (platelets < 150) {
            resultText += "🟡 Platelets are reduced — possible viral effect or marrow suppression.\n";
        } else if (platelets > 450) {
            resultText += "🟡 Platelets are elevated — may reflect inflammation or iron deficiency.\n";
        } else {
            resultText += "✅ Platelet count is within normal range.\n";
        }
    } else {
        missing.push("Platelets");
    }

    if (missing.length > 0) {
        resultText += `\nMissing: ${missing.join(", ")}`;
    }

    resultDisplay.innerText = resultText.trim();
}

















function analyzeLiverPanel() {
    const bilirubin = parseFloat(document.getElementById("liver_total_bilirubin").value);
    const alt = parseFloat(document.getElementById("liver_alt").value);
    const ast = parseFloat(document.getElementById("liver_ast").value);
    const alp = parseFloat(document.getElementById("liver_alp").value);
    const albumin = parseFloat(document.getElementById("liver_albumin").value);
    const hdl = parseFloat(document.getElementById("liver_hdl").value);
    const ldl = parseFloat(document.getElementById("liver_ldl").value);

    const resultDisplay = document.getElementById("liver-analysis-result");
    let resultText = `🔬 Liver Panel Analysis:\n`;
    let missing = [];

    const all = [bilirubin, alt, ast, alp, albumin, hdl, ldl];
    const hasAny = all.some(val => !isNaN(val));

    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    if (!isNaN(bilirubin)) {
        resultText += bilirubin > 1.2
            ? "🔴 Bilirubin is elevated — possible liver dysfunction or hemolysis.\n"
            : "✅ Bilirubin is within normal range.\n";
    } else missing.push("Bilirubin");

    if (!isNaN(alt)) {
        resultText += alt > 56
            ? "🔴 ALT is elevated — possible hepatitis or liver cell injury.\n"
            : "✅ ALT is within normal range.\n";
    } else missing.push("ALT");

    if (!isNaN(ast)) {
        resultText += ast > 40
            ? "🔴 AST is elevated — may indicate liver or muscle injury.\n"
            : "✅ AST is within normal range.\n";
    } else missing.push("AST");

    if (!isNaN(alp)) {
        resultText += alp > 147
            ? "🔴 ALP is elevated — possible bile obstruction or bone disorder.\n"
            : "✅ ALP is within normal range.\n";
    } else missing.push("ALP");

    if (!isNaN(albumin)) {
        if (albumin < 3.5) {
            resultText += "🔴 Albumin is low — may suggest liver disease or malnutrition.\n";
        } else if (albumin > 5.0) {
            resultText += "🟡 Albumin is slightly elevated — may be due to dehydration.\n";
        } else {
            resultText += "✅ Albumin is within normal range.\n";
        }
    } else missing.push("Albumin");

    if (!isNaN(hdl)) {
        resultText += hdl < 40
            ? "🔴 HDL is low — increases cardiovascular risk.\n"
            : "✅ HDL is within healthy range.\n";
    } else missing.push("HDL");

    if (!isNaN(ldl)) {
        resultText += ldl > 130
            ? "🔴 LDL is elevated — increases cardiovascular and liver burden.\n"
            : "✅ LDL is within healthy range.\n";
    } else missing.push("LDL");

    if (missing.length > 0) {
        resultText += `\nMissing: ${missing.join(", ")}`;
    }

    resultDisplay.innerText = resultText.trim();
}










function analyzeDiabetes() {
    const glucose = parseFloat(document.getElementById("glucose-level").value);
    const hba1c = parseFloat(document.getElementById("hba1c-level").value);
    const ogtt = parseFloat(document.getElementById("ogtt-level").value);
    const cPeptide = parseFloat(document.getElementById("c-peptide").value);
    const resultDisplay = document.getElementById("diabetes-analysis-result");

    const values = [glucose, hba1c, ogtt, cPeptide];
    const hasAny = values.some(val => !isNaN(val));
    let result = "🔬 Diabetes Panel Analysis:\n";
    let missing = [];

    if (!hasAny) {
        resultDisplay.innerText = "⛔ Enter at least one value.";
        return;
    }

    // Glucose
    if (!isNaN(glucose)) {
        if (glucose < 70) {
            result += "🔴 Fasting glucose is low — may cause fatigue, dizziness, or confusion. Check for insulin excess or adrenal insufficiency.\n";
        } else if (glucose < 100) {
            result += "✅ Fasting glucose is in the optimal range.\n";
        } else if (glucose < 126) {
            result += "🟡 Fasting glucose is elevated — prediabetic range. Recommend lifestyle changes and follow-up.\n";
        } else {
            result += "🔴 Fasting glucose is high — consistent with diabetes. Confirm with repeat or HbA1c.\n";
        }
    } else missing.push("Fasting Glucose");

    // HbA1c
    if (!isNaN(hba1c)) {
        if (hba1c < 4.5) {
            result += "🔴 HbA1c is very low — may indicate overtreatment or endocrine issues.\n";
        } else if (hba1c < 5.7) {
            result += "✅ HbA1c is normal — no evidence of long-term hyperglycemia.\n";
        } else if (hba1c < 6.5) {
            result += "🟡 HbA1c is prediabetic — monitor and improve glucose control.\n";
        } else {
            result += "🔴 HbA1c is high — diabetic range. Indicates chronic hyperglycemia.\n";
        }
    } else missing.push("HbA1c");

    // OGTT
    if (!isNaN(ogtt)) {
        if (ogtt < 140) {
            result += "✅ OGTT is normal — glucose tolerance preserved.\n";
        } else if (ogtt < 200) {
            result += "🟡 OGTT is elevated — prediabetic range. Suggest insulin sensitivity check.\n";
        } else {
            result += "🔴 OGTT is high — diabetic range. Recommend full metabolic workup.\n";
        }
    } else missing.push("OGTT");

    // C-Peptide
    if (!isNaN(cPeptide)) {
        if (cPeptide < 0.5) {
            result += "🔴 C-Peptide is very low — pancreatic failure. Consistent with Type 1 diabetes.\n";
        } else if (cPeptide <= 2.0) {
            result += "✅ C-Peptide is normal — endogenous insulin production adequate.\n";
        } else {
            result += "🔴 C-Peptide is elevated — insulin resistance. Common in early Type 2 diabetes.\n";
        }
    } else missing.push("C-Peptide");

    if (missing.length > 0) {
        result += "\nMissing: " + missing.join(", ");
    }

    resultDisplay.innerText = result.trim();
}

          
 









// ✅ Core Diagnostic Functions
function analyzeHematology() {
  const cbc = parseFloat(document.getElementById("cbc").value);
  const hemoglobin = parseFloat(document.getElementById("hemoglobin").value);
  const hematocrit = parseFloat(document.getElementById("hematocrit").value);
  const wbc = parseFloat(document.getElementById("wbc").value);
  const platelets = parseFloat(document.getElementById("platelets").value);
  const ddimer = parseFloat(document.getElementById("ddimer").value);
  const fibrinogen = parseFloat(document.getElementById("fibrinogen").value);
  const ferritin = parseFloat(document.getElementById("ferritin").value);
  const pt_inr = parseFloat(document.getElementById("pt_inr").value);
  const aptt = parseFloat(document.getElementById("aptt").value);

  const resultLabel = document.getElementById("hematology-result");
  let result = "🔬 Hematology Analysis\n";
  const lines = [];
  const missing = [];

  if (!isNaN(cbc)) {
    if (cbc < 4) lines.push("🔴 Low RBC — possible anemia or marrow suppression.");
    else if (cbc < 4.5) lines.push("🟡 Slightly low RBC — early anemia. Monitor.");
    else lines.push("✅ RBC normal.");
  } else missing.push("RBC");

  if (!isNaN(hemoglobin)) {
    if (hemoglobin < 12) lines.push("🔴 Low Hemoglobin — likely anemia. Fatigue risk.");
    else if (hemoglobin < 13) lines.push("🟡 Borderline Hemoglobin — monitor iron.");
    else lines.push("✅ Hemoglobin normal.");
  } else missing.push("Hemoglobin");

  if (!isNaN(hematocrit)) {
    if (hematocrit < 36) lines.push("🔴 Low Hematocrit — blood loss or overhydration.");
    else if (hematocrit < 38) lines.push("🟡 Borderline Hematocrit — monitor.");
    else lines.push("✅ Hematocrit normal.");
  } else missing.push("Hematocrit");

  if (!isNaN(wbc)) {
    if (wbc > 11) lines.push("🔴 High WBC — infection or inflammation.");
    else if (wbc < 4) lines.push("🔴 Low WBC — immune suppression.");
    else lines.push("✅ WBC normal.");
  } else missing.push("WBC");

  if (!isNaN(platelets)) {
    if (platelets < 150) lines.push("🔴 Low Platelets — bleeding risk.");
    else if (platelets > 450) lines.push("🔴 High Platelets — clot risk. Check inflammation.");
    else lines.push("✅ Platelets normal.");
  } else missing.push("Platelets");

  if (!isNaN(ddimer)) {
    if (ddimer > 0.5) lines.push("🔴 High D-Dimer — possible clot. Rule out DVT/PE.");
    else lines.push("✅ D-Dimer normal.");
  } else missing.push("D-Dimer");

  if (!isNaN(fibrinogen)) {
    if (fibrinogen > 400) lines.push("🟡 Elevated Fibrinogen — inflammation or clot risk.");
    else if (fibrinogen < 200) lines.push("🔴 Low Fibrinogen — impaired clotting.");
    else lines.push("✅ Fibrinogen normal.");
  } else missing.push("Fibrinogen");

  if (!isNaN(ferritin)) {
    if (ferritin < 15) lines.push("🔴 Low Ferritin — iron deficiency.");
    else if (ferritin < 30) lines.push("🟡 Borderline Ferritin — monitor iron stores.");
    else lines.push("✅ Ferritin normal.");
  } else missing.push("Ferritin");

  if (!isNaN(pt_inr)) {
    if (pt_inr > 1.5) lines.push("🔴 High PT/INR — clotting disorder risk.");
    else lines.push("✅ PT/INR normal.");
  } else missing.push("PT/INR");

  if (!isNaN(aptt)) {
    if (aptt > 35) lines.push("🔴 Prolonged aPTT — possible clotting defect.");
    else lines.push("✅ aPTT normal.");
  } else missing.push("aPTT");

  if (lines.length === 0) {
    resultLabel.innerText = "⛔ Enter at least one value.";
    return;
  }

  result += lines.join("\n");
  if (missing.length > 0) result += `\n\nMissing: ${missing.join(", ")}`;

  resultLabel.innerText = result.trim();
}

// ✅ Core UI toggle for question sections
function toggleQuestions(sectionId) {
  const allSections = document.querySelectorAll(".question-container");
  allSections.forEach(section => {
    if (section.id !== sectionId) {
      section.classList.add("hidden");
      section.style.display = "none";
    }
  });
  const targetSection = document.getElementById(sectionId);
  if (targetSection) {
    const isHidden = targetSection.classList.contains("hidden");
    if (isHidden) {
      targetSection.classList.remove("hidden");
      targetSection.style.display = "block";
    } else {
      targetSection.classList.add("hidden");
      targetSection.style.display = "none";
    }
  }
}

// ✅ Active button highlight and scroll-to-top
document.querySelectorAll('.category-button, .diagnostic-button, .respiratory-button').forEach(button => {
  button.addEventListener('click', function() {
    document.querySelectorAll('.category-button, .diagnostic-button, .respiratory-button').forEach(btn => btn.classList.remove('active'));
    this.classList.add('active');
    setTimeout(() => {
      window.scrollTo({
        top: this.getBoundingClientRect().top + window.scrollY,
        behavior: "smooth"
      });
    }, 50);
  });
});









function scrollToBaseline() {
  const baselineSection = document.querySelector(".baseline-health-section");
  if (baselineSection) {
    // Remove hidden class if it exists
    baselineSection.classList.remove("hidden");
    // Scroll into view
    baselineSection.scrollIntoView({ behavior: "smooth" });
  }
}






          
          
          
          
          
          
          

function analyzeCBC() {
    const wbc = parseFloat(document.getElementById("wbcCount").value);
    const rbc = parseFloat(document.getElementById("rbcCount").value);
    const hemoglobin = parseFloat(document.getElementById("hemoglobinLevel").value);
    const hematocrit = parseFloat(document.getElementById("hematocritLevel").value);
    const platelets = parseFloat(document.getElementById("plateletCount").value);
    const resultBox = document.getElementById("cbcResult");

    // Show ⛔ only if ALL fields are empty
    if (
        isNaN(wbc) &&
        isNaN(rbc) &&
        isNaN(hemoglobin) &&
        isNaN(hematocrit) &&
        isNaN(platelets)
    ) {
        resultBox.innerHTML = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 Complete Blood Count (CBC) Analysis:<br>`;
    const missing = [];

    // WBC — 4.0–11.0 x10^3/µL
    if (!isNaN(wbc)) {
        if (wbc < 4.0) {
            result += "🔴 WBC low — may indicate immune suppression, viral infection, or bone marrow dysfunction.<br>";
        } else if (wbc > 11.0) {
            result += "🔴 WBC high — likely infection, inflammation, or stress response.<br>";
        } else {
            result += "✅ WBC normal — immune system appears balanced.<br>";
        }
    } else {
        missing.push("WBC");
    }

    // RBC — 4.2–5.9 million/µL
    if (!isNaN(rbc)) {
        if (rbc < 4.2) {
            result += "🔴 RBC low — possible anemia, blood loss, or chronic disease.<br>";
        } else if (rbc > 5.9) {
            result += "🔴 RBC high — may indicate dehydration, hypoxia, or polycythemia.<br>";
        } else {
            result += "✅ RBC normal — oxygen transport appears adequate.<br>";
        }
    } else {
        missing.push("RBC");
    }

    // Hemoglobin — 13.5–17.5 g/dL (adult male range)
    if (!isNaN(hemoglobin)) {
        if (hemoglobin < 13.5) {
            result += "🔴 Hemoglobin low — may suggest anemia or chronic disease.<br>";
        } else if (hemoglobin > 17.5) {
            result += "🔴 Hemoglobin high — possible dehydration or chronic lung condition.<br>";
        } else {
            result += "✅ Hemoglobin normal — oxygen-carrying capacity is appropriate.<br>";
        }
    } else {
        missing.push("Hemoglobin");
    }

    // Hematocrit — 38–50%
    if (!isNaN(hematocrit)) {
        if (hematocrit < 38) {
            result += "🔴 Hematocrit low — suggests anemia or fluid overload.<br>";
        } else if (hematocrit > 50) {
            result += "🔴 Hematocrit high — may indicate dehydration or excessive red cell production.<br>";
        } else {
            result += "✅ Hematocrit normal — volume and red cell mass are balanced.<br>";
        }
    } else {
        missing.push("Hematocrit");
    }

    // Platelets — 150k–450k/µL
    if (!isNaN(platelets)) {
        if (platelets < 150000) {
            result += "🔴 Platelets low — risk of bleeding, may indicate viral suppression or marrow issue.<br>";
        } else if (platelets > 450000) {
            result += "🔴 Platelets high — risk of clotting or inflammation.<br>";
        } else {
            result += "✅ Platelet count normal — clotting capacity intact.<br>";
        }
    } else {
        missing.push("Platelets");
    }

    // Append missing values if any
    if (missing.length > 0) {
        result += `<br>Missing: ${missing.join(", ")}`;
    }

    resultBox.innerHTML = result;
}





function analyzeWBC2() {
  const neutro = parseFloat(document.getElementById('neutrophils2').value);
  const lymph = parseFloat(document.getElementById('lymphocytes2').value);
  const eos = parseFloat(document.getElementById('eosinophils2').value);
  const mono = parseFloat(document.getElementById('monocytes2').value);
  const baso = parseFloat(document.getElementById('basophils2').value);
  const wbcTotal = parseFloat(document.getElementById('wbc-total2').value);
  const resultEl = document.getElementById("wbcResult2");

  if (!resultEl) return;

  if (
    isNaN(neutro) &&
    isNaN(lymph) &&
    isNaN(eos) &&
    isNaN(mono) &&
    isNaN(baso) &&
    isNaN(wbcTotal)
  ) {
    resultEl.innerText = "⛔ Enter at least one value.";
    return;
  }

  let resultText = "🔬 White Blood Cell (WBC) Analysis:\n";
  const missing = [];

  // Total WBC
  if (!isNaN(wbcTotal)) {
    if (wbcTotal < 4) {
      resultText += "🔴 WBC total low — may indicate bone marrow suppression or vulnerability to infection.\n";
    } else if (wbcTotal > 11) {
      resultText += "🔴 WBC total high — suggests ongoing infection triggering immune response.\n";
    } else {
      resultText += "✅ WBC total within normal range.\n";
    }
  } else missing.push("Total WBC");

  // Neutrophils
  if (!isNaN(neutro)) {
    if (neutro < 40) {
      resultText += "🟡 Neutrophils low — common in viral infections or immune suppression.\n";
    } else if (neutro > 70) {
      resultText += "🔴 Neutrophils high — strong bacterial signal or immune overdrive.\n";
    } else {
      resultText += "✅ Neutrophils normal.\n";
    }
  } else missing.push("Neutrophils");

  // Lymphocytes
  if (!isNaN(lymph)) {
    if (lymph < 20) {
      resultText += "🟡 Lymphocytes low — stress, corticosteroids, or immune compromise.\n";
    } else if (lymph > 40) {
      resultText += "🔴 Lymphocytes high — consistent with viral infection or chronic stimulation.\n";
    } else {
      resultText += "✅ Lymphocytes normal.\n";
    }
  } else missing.push("Lymphocytes");

  // Monocytes
  if (!isNaN(mono)) {
    if (mono > 10) {
      resultText += "🔴 Monocytes high — may reflect chronic infection or recovery phase.\n";
    } else {
      resultText += "✅ Monocytes normal.\n";
    }
  } else missing.push("Monocytes");

  // Eosinophils
  if (!isNaN(eos)) {
    if (eos > 6) {
      resultText += "🔴 Eosinophils high — allergic response or parasitic infection likely.\n";
    } else {
      resultText += "✅ Eosinophils normal.\n";
    }
  } else missing.push("Eosinophils");

  // Basophils
  if (!isNaN(baso)) {
    if (baso > 1) {
      resultText += "🔴 Basophils high — linked to allergy, inflammation, or bone marrow overproduction.\n";
    } else {
      resultText += "✅ Basophils normal.\n";
    }
  } else missing.push("Basophils");

  // Missing data line
  if (missing.length > 0) {
    resultText += `\nMissing: ${missing.join(", ")}`;
  }

  resultEl.innerText = resultText;
  resultEl.style.fontWeight = "normal";
  resultEl.style.whiteSpace = "pre-line";
}





function analyzeInflammation() {
    const crp = parseFloat(document.getElementById("crp").value);
    const ferritin = parseFloat(document.getElementById("ferritin").value);
    const resultBox = document.getElementById("inflammationResult");

    if (isNaN(crp) && isNaN(ferritin)) {
        resultBox.innerHTML = "⛔ Enter at least one value.";
        return;
    }

    let result = `🔬 Inflammation Panel:\n`;
    const missing = [];

    // CRP — Normal < 1.0 mg/L
    if (!isNaN(crp)) {
        if (crp < 1) {
            result += "✅ CRP normal — no active inflammatory response.\n";
        } else if (crp <= 5) {
            result += "🟡 CRP mildly elevated — possible metabolic strain or recent mild infection.\n";
        } else if (crp <= 10) {
            result += "🔴 CRP moderately elevated — may reflect early infection or systemic stress.\n";
        } else {
            result += "🔴 CRP high — strong inflammatory signal likely triggered by infection or autoimmune flare.\n";
        }
    } else {
        missing.push("CRP");
    }

    // Ferritin — 30–400 ng/mL
    if (!isNaN(ferritin)) {
        if (ferritin < 30) {
            result += "🔴 Ferritin low — depleted iron stores, possibly from chronic blood loss or absorption issues.\n";
        } else if (ferritin > 400) {
            result += "🔴 Ferritin high — often reflects inflammation-driven iron sequestration or overload.\n";
        } else if (ferritin <= 50) {
            result += "🟡 Ferritin borderline — iron stores low-normal. Monitor in clinical context.\n";
        } else {
            result += "✅ Ferritin normal — iron storage appears sufficient.\n";
        }
    } else {
        missing.push("Ferritin");
    }

    // Missing line
    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultBox.innerText = result;
    resultBox.style.whiteSpace = "pre-line";
    resultBox.style.fontWeight = "normal";
}








function analyzeElectrolytes() {
  const sodium = parseFloat(document.getElementById("sodium").value);
  const potassium = parseFloat(document.getElementById("potassium").value);
  const calcium = parseFloat(document.getElementById("calcium").value);
  const bicarbonate = parseFloat(document.getElementById("bicarbonate").value);
  const magnesium = parseFloat(document.getElementById("magnesium").value);
  const resultBox = document.getElementById("result");

  if (!resultBox) return;

  if (
    isNaN(sodium) &&
    isNaN(potassium) &&
    isNaN(calcium) &&
    isNaN(bicarbonate) &&
    isNaN(magnesium)
  ) {
    resultBox.innerText = "⛔ Enter at least one value.";
    return;
  }

  let result = "🧪 Electrolyte Panel — 💧 Ca²⁺, K⁺ , Na⁺\n";
  const missing = [];

  // Sodium — 135–145 mmol/L
  if (!isNaN(sodium)) {
    if (sodium < 135) {
      result += "🔴 Sodium low — may reflect fluid overload or adrenal dysfunction.\n";
    } else if (sodium > 145) {
      result += "🔴 Sodium high — often due to dehydration or salt imbalance.\n";
    } else {
      result += "✅ Sodium normal.\n";
    }
  } else missing.push("Sodium");

  // Potassium — 3.5–5.0 mmol/L
  if (!isNaN(potassium)) {
    if (potassium < 3.5) {
      result += "🔴 Potassium low — risk of muscle weakness or arrhythmias.\n";
    } else if (potassium > 5.0) {
      result += "🔴 Potassium high — possible kidney issue or excess supplementation.\n";
    } else {
      result += "✅ Potassium normal.\n";
    }
  } else missing.push("Potassium");

  // Calcium — 8.5–10.5 mg/dL
  if (!isNaN(calcium)) {
    if (calcium < 8.5) {
      result += "🔴 Calcium low — may cause cramps or tingling.\n";
    } else if (calcium > 10.5) {
      result += "🔴 Calcium high — possible supplement excess or parathyroid issue.\n";
    } else {
      result += "✅ Calcium normal.\n";
    }
  } else missing.push("Calcium");

  // Bicarbonate — 22–28 mmol/L
  if (!isNaN(bicarbonate)) {
    if (bicarbonate < 22) {
      result += "🔴 Bicarbonate low — possible acidosis.\n";
    } else if (bicarbonate > 28) {
      result += "🔴 Bicarbonate high — suggests alkalosis.\n";
    } else {
      result += "✅ Bicarbonate normal.\n";
    }
  } else missing.push("Bicarbonate");

  // Magnesium — 1.7–2.2 mg/dL
  if (!isNaN(magnesium)) {
    if (magnesium < 1.7) {
      result += "🔴 Magnesium low — can cause tremors or muscle issues.\n";
    } else if (magnesium > 2.2) {
      result += "🔴 Magnesium high — check for renal causes.\n";
    } else {
      result += "✅ Magnesium normal.\n";
    }
  } else missing.push("Magnesium");

  if (missing.length > 0) {
    result += `\nMissing: ${missing.join(", ")}`;
  }

  resultBox.innerText = result;
  resultBox.style.whiteSpace = "pre-line";
  resultBox.style.fontWeight = "normal";
}














function handleTemperatureInput() {
    let temp = parseFloat(document.getElementById("temperatureInput").value);
    let durationSection = document.getElementById("durationSection");
    let analyzeButton = document.getElementById("analyzeFeverButton");

    // Reset everything if no valid temperature
    if (isNaN(temp)) {
        durationSection.classList.add("hidden");
        analyzeButton.classList.add("hidden");
        return;
    }

    // Show duration section only if temperature is entered
    durationSection.classList.remove("hidden");
}

function checkFeverReadiness() {
    let temp = document.getElementById("temperatureInput").value;
    let duration = document.querySelector('input[name="symptomDuration"]:checked');
    let analyzeButton = document.getElementById("analyzeFeverButton");

    // Show button only when both temperature & duration are provided
    if (temp && duration) {
        analyzeButton.classList.remove("hidden");
        analyzeButton.removeAttribute("disabled");
    } else {
        analyzeButton.classList.add("hidden");
        analyzeButton.setAttribute("disabled", true);
    }
}


function analyzeFever() {
  const temp = parseFloat(document.getElementById("temperatureInput").value);
  const duration = document.querySelector('input[name="symptomDuration"]:checked')?.value;
  const feverFeedback = document.getElementById("temperatureFeedback");

  if (isNaN(temp)) {
    feverFeedback.innerText = "";
    return;
  }

  let message = "🌡️ Temperature Analysis\n";
  message += `Temperature: ${temp}°C\n\n`; // <-- TWO line breaks

  if (temp >= 39) {
    message += "🔴 High fever detected.\n";

    if (duration === "1 Day") {
      message += "This may be a normal immune response. Stay hydrated and monitor symptoms.";
    } else if (duration === "2-3 Days") {
      message += "Persistent fever—this may be a bacterial or inflammatory issue.\nRecommended tests: CRP, WBC, Procalcitonin.";
    } else if (duration === "More than 3 days") {
      message += "Extended fever—further testing is recommended.\nCRP, ESR, and Ferritin can help identify chronic inflammation.";
    } else if (duration === "1 Week" || duration === "2 Weeks") {
      message += "Chronic fever — consider TB, endocarditis, autoimmune causes.\nAdd D-Dimer and Fibrinogen if clotting signs appear.";
    } else if (duration === "More than 2 Weeks") {
      message += "⚠️ Over 2 weeks of fever — full systemic evaluation needed.\nCRP, ESR, Ferritin, IL-6, WBC. Add D-Dimer/Fibrinogen if relevant.";
    }

  } else if (temp >= 38) {
    message += "🟠 Moderate fever.\n";

    if (duration === "1 Day") {
      message += "Likely early immune reaction. Monitor and hydrate.";
    } else if (duration === "2-3 Days") {
      message += "Could be bacterial. Suggested tests: Procalcitonin, WBC.";
    } else if (duration === "More than 3 days") {
      message += "Ongoing fever — CRP and ESR recommended.";
    } else if (duration === "1 Week" || duration === "2 Weeks") {
      message += "Prolonged fever — chronic inflammation suspected.\nTests: CRP, ESR, Ferritin, IL-6.";
    } else if (duration === "More than 2 Weeks") {
      message += "⚠️ Persistent fever — full immune/inflammatory panel advised.";
    }

  } else if (temp > 37) {
    message += "🟡 Slightly elevated temperature — may reflect early immune response.";
  } else if (temp >= 36) {
    message += "✅ Temperature is within normal range.";
  } else {
    message += "🟡 Below normal — may indicate metabolic or endocrine issues.";
  }

  feverFeedback.innerText = message;
  feverFeedback.style.whiteSpace = "pre-line"; // ensures \n works visually
}



function analyzeBP() {
    const systolic = parseInt(document.getElementById("systolic").value, 10);
    const diastolic = parseInt(document.getElementById("diastolic").value, 10);
    const pulse = parseInt(document.getElementById("pulse").value, 10);
    const bpResult = document.getElementById("bpResult");

    if (isNaN(systolic) || isNaN(diastolic) || isNaN(pulse)) {
        bpResult.innerHTML = "⛔ Please enter valid values for systolic, diastolic pressure, and pulse.";
        return;
    }

    let message = `🩺 Blood Pressure & Pulse Analysis<br>`;
    message += `Systolic: ${systolic} mmHg<br>`;
    message += `Diastolic: ${diastolic} mmHg<br>`;
    message += `Pulse: ${pulse} bpm<br><br>`;

    // --- Blood Pressure Evaluation ---
    if (systolic >= 90 && systolic <= 130 && diastolic >= 60 && diastolic <= 85) {
        message += "✅ Blood pressure is within optimal range — good vascular tone and perfusion. No immediate intervention needed.<br>";
    } 
    else if (
        (systolic >= 131 && systolic <= 139) ||
        (diastolic >= 86 && diastolic <= 89)
    ) {
        message += "🟡 Borderline elevated blood pressure — may indicate early vascular resistance or sympathetic overactivity. Lifestyle adjustment recommended: reduce sodium, improve sleep, and monitor.<br>";
    } 
    else if (systolic < 90 || diastolic < 60) {
        message += "🔴 Low blood pressure — may reduce perfusion to organs. Can cause fatigue, dizziness, or cold extremities. Causes include dehydration, adrenal dysfunction, or autonomic imbalance. Monitor in context of symptoms.<br>";
    } 
    else if (systolic >= 140 || diastolic >= 90) {
        message += "🔴 High blood pressure — sustained elevation increases risk of stroke, heart failure, and renal damage. Evaluate lifestyle, stress, renal function, and mineral intake (potassium, magnesium).<br>";
    }

    // --- Pulse Evaluation ---
    message += `<br>`; // Visual separator
    if (pulse >= 60 && pulse <= 90) {
        message += "✅ Resting pulse is within normal range — stable autonomic tone and cardiovascular balance.<br>";
    } 
    else if (pulse > 90 && pulse <= 100) {
        message += "🟡 Elevated pulse — may reflect stress, dehydration, anemia, or overtraining. Monitor HR variability and rest patterns.<br>";
    } 
    else if (pulse > 100) {
        message += "🔴 Tachycardia — elevated resting heart rate. May signal autonomic imbalance, infection, or cardiovascular strain. Evaluate hydration, thyroid status, and systemic inflammation.<br>";
    } 
    else if (pulse < 60) {
        message += "🔴 Bradycardia — if not athlete-related, may indicate vagal excess, electrolyte disturbance, or conduction delay. Assess for fatigue or syncope.<br>";
    }

    bpResult.innerHTML = message;
}










function evaluateOxygenSaturation() {
    const spo2 = parseFloat(document.getElementById("oxygenSaturation").value.trim());
    const result = document.getElementById("oxygen-result");

    if (isNaN(spo2) || spo2 <= 0) {
        result.innerHTML = "⛔ Please enter a valid Oxygen Saturation percentage.";
        return;
    }

    const paO2 = Math.round((spo2 - 30) * 2); // rough clinical estimate
    let resultMessage = `🫁 Oxygen Saturation Analysis<br>`;
    resultMessage += `SpO₂: ${spo2}% — Estimated PaO₂: ~${paO2} mmHg<br><br>`; // single break after data

    if (spo2 >= 95) {
        resultMessage += "✅ Normal oxygen saturation — lungs are effectively oxygenating blood. No intervention needed.";
    } 
    else if (spo2 >= 91 && spo2 < 95) {
        resultMessage += "🟡 Mild hypoxia — early reduction in blood oxygen. May occur with altitude, mild lung conditions, or early respiratory compromise. Monitor trends; consider checking ABG if symptoms (fatigue, breathlessness) present.";
    } 
    else if (spo2 >= 86 && spo2 < 91) {
        resultMessage += "🔴 Moderate hypoxia — indicates reduced oxygen delivery to tissues. May reflect lung disease, ventilation-perfusion mismatch, or airway compromise. Consider oxygen therapy and clinical assessment.";
    } 
    else {
        resultMessage += "🔴 Severe hypoxia — SpO₂ below 86%. Immediate intervention required. Risk of organ dysfunction, confusion, loss of consciousness. Urgent oxygen support and clinical stabilization needed.";
    }

    result.innerHTML = resultMessage;
}


function analyzeRespiration() {
  const rate = parseFloat(document.getElementById("respirationRate").value);
  const resultLabel = document.getElementById("respirationResult");

  if (isNaN(rate)) {
    resultLabel.innerText = "⛔ Enter at least one value.";
    return;
  }

  let output = "🫁 Respiration Analysis\n";

  if (rate >= 12 && rate <= 20) {
    output += `✅ Respiration Rate: ${rate} breaths/min — Normal range.`;
  } else if ((rate >= 10 && rate < 12) || (rate > 20 && rate <= 24)) {
    output += `🟡 Respiration Rate: ${rate} breaths/min — Slightly abnormal. Monitor closely.`;
  } else {
    output += `🔴 Respiration Rate: ${rate} breaths/min — Abnormal. Possible respiratory imbalance.`;
  }

  resultLabel.innerText = output;
}






function analyzeLungCapacity() {
  const capacity = parseFloat(document.getElementById("lungCapacity").value);
  const resultLabel = document.getElementById("lungCapacityResult");

  if (isNaN(capacity)) {
    resultLabel.innerText = "⛔ Enter at least one value.";
    return;
  }

  let output = "🫁 Lung Capacity Analysis\n";

  if (capacity >= 4.0 && capacity <= 6.0) {
    output += `✅ Lung Capacity: ${capacity} L — Normal range.`;
  } else if ((capacity >= 3.0 && capacity < 4.0) || (capacity > 6.0 && capacity <= 6.5)) {
    output += `🟡 Lung Capacity: ${capacity} L — Borderline value. May vary by age, sex, fitness.`;
  } else {
    output += `🔴 Lung Capacity: ${capacity} L — Abnormal. Reduced or excessive volume detected.`;
  }

  resultLabel.innerText = output;
}















function checkBloodPressure() {
    const systolicInput = document.getElementById('systolic1').value.trim();
    const diastolicInput = document.getElementById('diastolic1').value.trim();
    const additionalTestsSection = document.getElementById('additional-tests');

    const systolic = parseInt(systolicInput, 10);
    const diastolic = parseInt(diastolicInput, 10);

    if (!systolicInput || !diastolicInput || isNaN(systolic) || isNaN(diastolic)) {
        alert("⛔ Please enter valid blood pressure values.");
        return;
    }

    let message = "";

    if (systolic > 120 || diastolic > 80 || systolic < 90 || diastolic < 65) {
        additionalTestsSection.classList.remove('hidden');
        additionalTestsSection.style.display = "block";
        message = "🔴 Your blood pressure suggests further evaluation.";
    } else {
        additionalTestsSection.classList.add('hidden');
        additionalTestsSection.style.display = "none";
        message = "✅ Your blood pressure is within the normal range.";
    }

    alert(message);
}








function analyzeAdditionalTests() {
    const hdl = parseFloat(document.getElementById("hdl").value);
    const ldl = parseFloat(document.getElementById("ldl").value);
    const vldl = parseFloat(document.getElementById("vldl").value);
    const glucose = parseFloat(document.getElementById("glucoseTest").value);
    const kidneyFunction = parseFloat(document.getElementById("kidneyFunction").value);
    const resultBox = document.getElementById("additionalTestsResult");

    const missing = [];
    let result = "🧪 Lipids (Fats), Glucose & Renal Markers<br><br>";

    // HDL — Optimal ≥ 60 mg/dL
    if (!isNaN(hdl)) {
        if (hdl < 40) {
            result += "🔴 HDL low — increased risk of atherosclerosis. Improve with aerobic exercise, omega-3s, and reduction of refined carbs.<br>";
        } else if (hdl < 60) {
            result += "🟡 HDL borderline — not protective. Aim to increase via healthy fats and physical activity.<br>";
        } else {
            result += "✅ HDL optimal — offers cardiovascular protection.<br>";
        }
    } else {
        missing.push("HDL");
    }

    // LDL — Optimal < 100 mg/dL
    if (!isNaN(ldl)) {
        if (ldl > 160) {
            result += "🔴 LDL high — major risk factor for heart disease. Requires lifestyle change and possible lipid panel follow-up.<br>";
        } else if (ldl >= 100) {
            result += "🟡 LDL borderline — moderate risk. Improve with dietary adjustments, fiber, and physical activity.<br>";
        } else {
            result += "✅ LDL within target range — lower risk of plaque formation.<br>";
        }
    } else {
        missing.push("LDL");
    }

    // VLDL — Normal < 40 mg/dL
    if (!isNaN(vldl)) {
        if (vldl > 40) {
            result += "🔴 VLDL elevated — associated with high triglycerides. Often due to excess sugar intake, alcohol, or metabolic dysfunction.<br>";
        } else {
            result += "✅ VLDL within range — triglyceride transport appears stable.<br>";
        }
    } else {
        missing.push("VLDL");
    }

    // Glucose — Normal 70–99 mg/dL
    if (!isNaN(glucose)) {
        if (glucose < 70) {
            result += "🔴 Glucose low — hypoglycemia risk. May cause dizziness, sweating, or fainting. Eat balanced carbs with protein.<br>";
        } else if (glucose < 100) {
            result += "✅ Glucose normal — no evidence of glycemic dysregulation.<br>";
        } else if (glucose < 126) {
            result += "🟡 Glucose elevated — prediabetes range. Recommend HbA1c and dietary review.<br>";
        } else {
            result += "🔴 Glucose high — diabetes likely. Confirm with HbA1c and OGTT.<br>";
        }
    } else {
        missing.push("Glucose");
    }

    // GFR — Normal ≥ 90 mL/min (60–89 = mild loss)
    if (!isNaN(kidneyFunction)) {
        if (kidneyFunction < 60) {
            result += "🔴 GFR reduced — chronic kidney disease stage 3 or worse. Requires nephrology follow-up and hydration monitoring.<br>";
        } else if (kidneyFunction < 90) {
            result += "🟡 GFR mildly reduced — early kidney stress. Monitor hydration, blood pressure, and creatinine levels.<br>";
        } else {
            result += "✅ GFR normal — filtration function preserved.<br>";
        }
    } else {
        missing.push("GFR");
    }

    // Final missing list
    if (missing.length === 5) {
        result = "⛔ Enter at least one value.";
    } else if (missing.length > 0) {
        result += `<br><strong>Missing:</strong> ${missing.join(", ")}`;
    }

    resultBox.innerHTML = result;
}





function checkHeartRate() {
    let heartRate = document.getElementById("heartRate").value.trim();
    const result = document.getElementById("heart-rate-result");

    if (heartRate === "") {
        result.innerHTML = "⛔ Please enter your heart rate.";
        return;
    }

    heartRate = parseInt(heartRate, 10);

    let message = "💓 Heart Rate Analysis<br>";
    message += `Heart Rate: ${heartRate} bpm<br><br>`;

    if (heartRate >= 60 && heartRate <= 80) {
        message += "✅ Normal resting rate — balanced autonomic tone, good cardiovascular regulation.";
    } 
    else if (heartRate > 80 && heartRate <= 90) {
        message += "🟡 Slightly elevated — could be due to stress, caffeine, dehydration, or early autonomic imbalance. Monitor if persistent.";
    } 
    else if (heartRate < 60) {
        message += "🔴 Bradycardia — may reflect athletic conditioning, but also possible conduction delay or vagal excess. Evaluate if symptomatic (dizziness, fatigue).";
    } 
    else {
        message += "🔴 Tachycardia — elevated resting heart rate may signal overactivation, dehydration, anemia, or cardiovascular strain. Requires assessment if sustained.";
    }

    result.innerHTML = message;
}











function analyzeECG() {
    const pWave = parseFloat(document.getElementById("pWave").value);
    const prInterval = parseFloat(document.getElementById("prInterval").value);
    const qrsDuration = parseFloat(document.getElementById("qrsDuration").value);
    const qtInterval = parseFloat(document.getElementById("qtInterval").value);
    const rrInterval = parseFloat(document.getElementById("rrInterval").value);
    const stSegment = document.getElementById("stSegment").value.trim();
    const tWave = document.getElementById("tWave").value.trim();
    const qrsAxis = document.getElementById("qrsAxis").value.trim();
    const qtcInterval = parseFloat(document.getElementById("qtcInterval").value);

    const result = document.getElementById("ecgResult");
    let message = "🫀 ECG Interpretation<br><br>";
    let missing = [];
    let filled = false;

    // P Wave
    if (!isNaN(pWave)) {
        filled = true;
        message += `P Wave: ${pWave} sec — `;
        message += (pWave >= 0.06 && pWave <= 0.10) ?
            "✅ Normal atrial depolarization.<br><br>" :
            "🔴 Abnormal P wave — possible atrial enlargement or conduction delay.<br><br>";
    } else {
        missing.push("P Wave");
    }

    // PR Interval
    if (!isNaN(prInterval)) {
        filled = true;
        message += `PR Interval: ${prInterval} sec — `;
        message += (prInterval >= 0.12 && prInterval <= 0.20) ?
            "✅ Normal atrioventricular conduction.<br><br>" :
            "🔴 PR interval abnormal — may suggest AV block or preexcitation.<br><br>";
    } else {
        missing.push("PR Interval");
    }

    // QRS Duration
    if (!isNaN(qrsDuration)) {
        filled = true;
        message += `QRS Duration: ${qrsDuration} sec — `;
        message += (qrsDuration < 0.12) ?
            "✅ Normal ventricular depolarization.<br><br>" :
            "🔴 QRS prolonged — may indicate bundle branch block or ventricular origin.<br><br>";
    } else {
        missing.push("QRS Duration");
    }

    // QT Interval
    if (!isNaN(qtInterval)) {
        filled = true;
        message += `QT Interval: ${qtInterval} sec — `;
        message += (qtInterval >= 0.36 && qtInterval <= 0.44) ?
            "✅ QT duration within expected range.<br><br>" :
            "🔴 QT abnormal — consider electrolyte imbalance or risk of arrhythmia.<br><br>";
    } else {
        missing.push("QT Interval");
    }

    // RR Interval
    if (!isNaN(rrInterval)) {
        filled = true;
        message += `RR Interval: ${rrInterval} sec — Used for rate and rhythm assessment.<br><br>`;
    } else {
        missing.push("RR Interval");
    }

    // ST Segment
    if (stSegment) {
        filled = true;
        message += `ST Segment: ${stSegment} — Interpretation depends on deviation or elevation.<br><br>`;
    } else {
        missing.push("ST Segment");
    }

    // T Wave
    if (tWave) {
        filled = true;
        message += `T Wave: ${tWave} — Shape and polarity reflect repolarization status.<br><br>`;
    } else {
        missing.push("T Wave");
    }

    // QRS Axis
    if (qrsAxis) {
        filled = true;
        message += `QRS Axis: ${qrsAxis} — Used to detect axis deviation or chamber enlargement.<br><br>`;
    } else {
        missing.push("QRS Axis");
    }

    // QTc
    if (!isNaN(qtcInterval)) {
        filled = true;
        message += `QTc: ${qtcInterval} sec — `;
        message += (qtcInterval >= 0.36 && qtcInterval <= 0.46) ?
            "✅ Corrected QT within normal limits.<br><br>" :
            "🔴 Abnormal QTc — risk of arrhythmias (e.g., Long QT Syndrome).<br><br>";
    } else {
        missing.push("QTc");
    }

    // Final output
    if (!filled) {
        result.innerHTML = "⛔ Please enter at least one value.";
        return;
    }

    if (missing.length > 0) {
        message += `Missing: ${missing.join(", ")}`;
    }

    result.innerHTML = message;
}





// Function to preview ECG Image
function previewECGImage() {
    const fileInput = document.getElementById("ecgUpload");
    const previewContainer = document.getElementById("ecgPreviewContainer");
    const previewImage = document.getElementById("ecgPreview");

    const file = fileInput.files[0];

    if (file) {
        const reader = new FileReader();
        reader.onload = function (e) {
            previewImage.src = e.target.result;
            previewContainer.classList.remove("hidden");
        };
        reader.readAsDataURL(file);
    }
}

// Function to delete ECG Image
function deleteECGImage() {
    document.getElementById("ecgPreview").src = "data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs=";
    document.getElementById("ecgPreviewContainer").classList.add("hidden");
    document.getElementById("ecgUpload").value = "";
}






function evaluateTroponin() {
    const troponinInput = document.getElementById("troponinResult").value.trim();
    const troponin = parseFloat(troponinInput);
    const resultDisplay = document.getElementById("troponin-result");

    if (isNaN(troponin)) {
        resultDisplay.innerHTML = "⛔ Please enter a valid troponin level.";
        return;
    }

    let message = "🫀 Troponin Evaluation<br><br>";
    message += `Troponin: ${troponin} ng/L<br><br>`;

    if (troponin < 10) {
        message += "✅ Normal — no biochemical evidence of cardiac muscle damage.<br>Troponin is within the safe physiological range. No myocardial injury detected.";
    } 
    else if (troponin >= 10 && troponin < 45) {
        message += "🟡 Borderline elevation — may reflect early myocardial strain, minor cardiac stress (e.g., tachycardia, myocarditis, renal insufficiency), or post-procedure elevation.<br>Repeat testing in 3–6 hours is advised to track trend.";
    } 
    else {
        message += "🔴 Elevated — likely myocardial injury.<br>Values above 45 ng/L often indicate acute coronary syndrome (e.g., NSTEMI, STEMI) or myocardial inflammation.<br>Requires urgent cardiac evaluation and correlation with ECG and symptoms.";
    }

    resultDisplay.innerHTML = message;
}





function evaluateHomocysteine() {
    const input = document.getElementById("homocysteine-level").value.trim();
    const homocysteine = parseFloat(input);
    const result = document.getElementById("homocysteine-result");

    if (input === "") {
        result.innerHTML = "⛔ Please enter a value.";
        return;
    }

    let message = "🧬 Homocysteine Analysis<br>";
    message += `Homocysteine: ${homocysteine} µmol/L<br><br>`;

    if (homocysteine < 5.0) {
        message += "🔴 Too low — may indicate overmethylation, excess B12/folate, or oxidative stress. Check glutathione, SAMe, and methylation markers.";
    } 
    else if (homocysteine <= 15.0) {
        message += "✅ Normal range (5–15 µmol/L) — no action needed.";
    } 
    else if (homocysteine <= 30.0) {
        message += "🟡 Moderately elevated — may indicate B6, B9 (folate), or B12 deficiency, poor methylation, or early kidney stress. Consider checking methylation and renal markers.";
    } 
    else {
        message += "🔴 Severely elevated (>30 µmol/L) — may indicate kidney disease, B-vitamin deficiency, or genetic methylation disorder (e.g. MTHFR). Recommended tests: B6, B12, folate, creatinine, eGFR, methylmalonic acid.";
    }

    result.innerHTML = message;
}












function analyzeClotting() {
    const fibrinogen = parseFloat(document.getElementById("fibrinogen").value);
    const prothrombin = parseFloat(document.getElementById("prothrombin").value);
    const inr = parseFloat(document.getElementById("inr").value);
    const factorV = parseFloat(document.getElementById("factorV").value);
    const factorVII = parseFloat(document.getElementById("factorVII").value);
    const factorX = parseFloat(document.getElementById("factorX").value);
    const resultDisplay = document.getElementById("clottingResult");

    let result = "🧬 Clotting Function<br><br>";
    let missing = [];

    // Fibrinogen
    if (isNaN(fibrinogen)) {
        missing.push("Fibrinogen");
    } else if (fibrinogen < 200) {
        result += "🔴 Fibrinogen low — may signal liver dysfunction, DIC, or malnutrition. Check ALT/AST and D-Dimer to evaluate clotting cascade.<br>";
    } else if (fibrinogen > 400) {
        result += "🔴 Fibrinogen high — suggests systemic inflammation, infection, or thrombotic risk. Assess CRP, ESR, and lipid status.<br>";
    } else {
        result += "✅ Fibrinogen within range — clotting substrate level appears adequate.<br>";
    }

    // Prothrombin
    if (isNaN(prothrombin)) {
        missing.push("Prothrombin Time");
    } else if (prothrombin < 10) {
        result += "🟡 PT short — may indicate hypercoagulability. Evaluate Factor V Leiden and antiphospholipid antibodies if thrombosis suspected.<br>";
    } else if (prothrombin > 14) {
        result += "🔴 PT prolonged — may reflect vitamin K deficiency, liver dysfunction, or anticoagulant use. Check INR and vitamin K levels.<br>";
    } else {
        result += "✅ Prothrombin time normal — coagulation timing appears regulated.<br>";
    }

    // INR
    if (isNaN(inr)) {
        missing.push("INR");
    } else if (inr < 0.8) {
        result += "🟡 INR low — may indicate increased clotting tendency. Review thrombin activity and screen for inherited thrombophilia.<br>";
    } else if (inr > 1.2) {
        result += "🔴 INR elevated — may suggest anticoagulant therapy, vitamin K depletion, or hepatic dysfunction. Monitor closely if on warfarin.<br>";
    } else {
        result += "✅ INR within normal range — balanced coagulation status.<br>";
    }

    // Factor V
    if (isNaN(factorV)) {
        missing.push("Factor V");
    } else if (factorV < 50) {
        result += "🟡 Factor V low — may be due to liver disease or hereditary deficiency. Consider full clotting panel.<br>";
    } else if (factorV > 150) {
        result += "🔴 Factor V high — possible risk of thrombosis. Rule out Factor V Leiden mutation and assess D-Dimer.<br>";
    } else {
        result += "✅ Factor V within normal limits — functional procoagulant cofactor.<br>";
    }

    // Factor VII
    if (isNaN(factorVII)) {
        missing.push("Factor VII");
    } else if (factorVII < 50) {
        result += "🟡 Factor VII low — may impair clot initiation. Investigate vitamin K status and hepatic output.<br>";
    } else if (factorVII > 150) {
        result += "🔴 Factor VII elevated — may increase clot formation tendency. Assess cardiovascular and inflammatory status.<br>";
    } else {
        result += "✅ Factor VII within range — normal extrinsic pathway activity.<br>";
    }

    // Factor X
    if (isNaN(factorX)) {
        missing.push("Factor X");
    } else if (factorX < 50) {
        result += "🟡 Factor X low — risk of bleeding tendency. Often related to liver dysfunction or inherited deficiency. Review PT and aPTT.<br>";
    } else if (factorX > 150) {
        result += "🔴 Factor X elevated — may suggest increased thrombotic activity. Evaluate D-Dimer and perform thrombophilia screen.<br>";
    } else {
        result += "✅ Factor X normal — final common pathway activity appears intact.<br>";
    }

    if (missing.length === 6) {
        resultDisplay.innerHTML = "⛔ Please enter at least one value.";
    } else {
        if (missing.length > 0) {
            result += `<br>Missing: ${missing.join(", ")}`;
        }
        resultDisplay.innerHTML = result;
    }
}



function analyzeLipoproteinA() {
    const lpaInput = document.getElementById("lipoproteinALevel").value.trim();
    const lpa = parseFloat(lpaInput);
    const resultDisplay = document.getElementById("lipoprotein-a-result");

    if (isNaN(lpa)) {
        resultDisplay.innerHTML = "⛔ Please enter a valid Lipoprotein(a) level.";
        return;
    }

    let message = "🧬 Lipoprotein(a)<br><br>";
    message += `Lipoprotein(a): ${lpa} mg/dL<br>`;

    if (lpa < 30) {
        message += "✅ Normal — no elevated cardiovascular risk from Lp(a). Genetic atherogenic potential appears low.";
    } 
    else if (lpa >= 30 && lpa < 50) {
        message += "🟡 Mildly elevated — borderline atherogenic potential. May increase cardiovascular risk over time, especially if other risk factors are present. Monitor periodically.";
    } 
    else {
        message += "🔴 High Lp(a) — genetically driven lipoprotein elevation. Significantly increases atherosclerosis and thrombosis risk. Lifestyle optimization and specialist lipid evaluation recommended.";
    }

    resultDisplay.innerHTML = message;
}





function analyzeDDimer() {
    const dDimerInput = document.getElementById("dDimerLevel").value.trim();
    const dDimer = parseFloat(dDimerInput);
    const result = document.getElementById("d-dimer-result");

    if (isNaN(dDimer)) {
        result.innerHTML = "⛔ Please enter a valid D-Dimer level.";
        return;
    }

    let message = "🧬 D-Dimer<br><br>";
    message += `D-Dimer: ${dDimer} ng/mL<br>`;

    if (dDimer < 500) {
        message += "✅ Normal — low probability of active clot formation. No signs of thrombotic activity.";
    } 
    else if (dDimer >= 500 && dDimer < 1000) {
        message += "🟡 Mild elevation — may reflect inflammation, minor injury, or recent surgery. Repeat testing if clinical suspicion persists.";
    } 
    else {
        message += "🔴 High D-Dimer — likely clot breakdown activity. May indicate DVT, PE, or systemic infection. Imaging is recommended.";
    }

    result.innerHTML = message;
}





function calculateRenalEGFR() {
    const age = parseFloat(document.getElementById("renal-age").value);
    const creatinine = parseFloat(document.getElementById("renal-creatinine").value);
    const gender = document.getElementById("renal-gender").value;
    const race = document.getElementById("renal-race").value;
    const result = document.getElementById("renal-egfr-result");

    if (isNaN(age) || isNaN(creatinine)) {
        result.innerHTML = "⛔ Please enter all values.";
        return;
    }

    let egfr = (140 - age) * (1.23 / creatinine);
    if (gender === "female") egfr *= 0.85;
    if (race === "black") egfr *= 1.2;

    egfr = Math.round(egfr);

    let message = "🧬 Renal Function (eGFR)<br><br>";
    message += `Estimated GFR: ${egfr} mL/min<br>`;

    if (egfr >= 90) {
        message += "✅ Normal kidney function — filtration rate is healthy. No renal impairment detected.";
    } 
    else if (egfr >= 60 && egfr < 90) {
        message += "🟡 Mild decrease — early renal decline or age-related reduction. Monitor annually, especially if diabetic or hypertensive.";
    } 
    else if (egfr >= 30 && egfr < 60) {
        message += "🔴 Moderate impairment — stage 3 CKD. Reduced ability to filter waste. Monitor electrolytes, blood pressure, and consult nephrology.";
    } 
    else if (egfr >= 15 && egfr < 30) {
        message += "🔴 Severe impairment — stage 4 CKD. High risk of complications (anemia, acidosis, bone loss). Nephrology referral needed.";
    } 
    else {
        message += "🔴 Critical renal failure — stage 5 CKD (eGFR <15). Urgent nephrology care required. Dialysis or transplant planning advised.";
    }

    result.innerHTML = message;
}









function submitRenalElectrolytes() {
    const sodium = parseFloat(document.getElementById("renal-sodium").value);
    const potassium = parseFloat(document.getElementById("renal-potassium").value);
    const calcium = parseFloat(document.getElementById("renal-calcium").value);
    const result = document.getElementById("renal-electrolytes-result");

    if (isNaN(sodium) && isNaN(potassium) && isNaN(calcium)) {
        result.innerHTML = "⛔ Please enter at least one value.";
        return;
    }

    let resultText = "💧 Electrolyte Balance (Na⁺, K⁺, Ca²⁺)<br><br>";

    // Sodium
    if (!isNaN(sodium)) {
        if (sodium >= 135 && sodium <= 145) {
            resultText += `✅ Sodium (Na⁺): ${sodium} mmol/L — Normal (135–145). Sodium balance is maintained.<br>`;
        } else if ((sodium >= 133 && sodium < 135) || (sodium > 145 && sodium <= 147)) {
            resultText += `🟡 Sodium (Na⁺): ${sodium} mmol/L — Borderline. Slight deviation may result from hydration status. Monitor and retest if symptomatic.<br>`;
        } else if (sodium < 133) {
            resultText += `🔴 Sodium (Na⁺) low — Hyponatremia: ${sodium} mmol/L. May indicate fluid overload, adrenal issues, or SIADH. Risk of confusion or seizures if severe.<br>`;
        } else {
            resultText += `🔴 Sodium (Na⁺) high — Hypernatremia: ${sodium} mmol/L. Suggests dehydration or endocrine dysfunction. Can cause neurological effects.<br>`;
        }
    }

    // Potassium
    if (!isNaN(potassium)) {
        if (potassium >= 3.5 && potassium <= 5.0) {
            resultText += `✅ Potassium (K⁺): ${potassium} mmol/L — Normal (3.5–5.0). Stable for cardiac and neuromuscular function.<br>`;
        } else if ((potassium >= 3.3 && potassium < 3.5) || (potassium > 5.0 && potassium <= 5.2)) {
            resultText += `🟡 Potassium (K⁺): ${potassium} mmol/L — Borderline. Watch for muscle cramps or palpitations. Retest if persistent.<br>`;
        } else if (potassium < 3.3) {
            resultText += `🔴 Potassium (K⁺) low — Hypokalemia: ${potassium} mmol/L. Risk of arrhythmia, fatigue, or muscle weakness. May be caused by diuretics or poor intake.<br>`;
        } else {
            resultText += `🔴 Potassium (K⁺) high — Hyperkalemia: ${potassium} mmol/L. May signal renal dysfunction or tissue breakdown. Monitor ECG if critical.<br>`;
        }
    }

    // Calcium
    if (!isNaN(calcium)) {
        if (calcium >= 2.2 && calcium <= 2.6) {
            resultText += `✅ Calcium (Ca²⁺): ${calcium} mmol/L — Normal (2.2–2.6). Supports bone integrity and nerve signaling.<br>`;
        } else if ((calcium >= 2.1 && calcium < 2.2) || (calcium > 2.6 && calcium <= 2.7)) {
            resultText += `🟡 Calcium (Ca²⁺): ${calcium} mmol/L — Borderline. May reflect temporary metabolic shifts. Repeat if symptoms occur.<br>`;
        } else if (calcium < 2.1) {
            resultText += `🔴 Calcium (Ca²⁺) low — Hypocalcemia: ${calcium} mmol/L. May cause muscle spasms, numbness, or seizures. Check vitamin D and parathyroid levels.<br>`;
        } else {
            resultText += `🔴 Calcium (Ca²⁺) high — Hypercalcemia: ${calcium} mmol/L. Could result from overactive parathyroid or malignancy. Watch for fatigue and GI issues.<br>`;
        }
    }

    result.innerHTML = resultText;
}








function calculateRenalAnionGap() {
    const sodium = parseFloat(document.getElementById("renal-sodium-acid").value);
    const chloride = parseFloat(document.getElementById("renal-chloride-acid").value);
    const bicarbonate = parseFloat(document.getElementById("renal-bicarbonate").value);
    const result = document.getElementById("renal-anion-gap-result");

    if (isNaN(sodium) && isNaN(chloride) && isNaN(bicarbonate)) {
        result.innerHTML = "⛔ Please enter at least one value.";
        return;
    }

    if (isNaN(sodium) || isNaN(chloride) || isNaN(bicarbonate)) {
        result.innerHTML = "⛔ Please complete all three values to calculate the Anion Gap.";
        return;
    }

    const anionGap = sodium - (chloride + bicarbonate);
    let resultText = `💧 Anion Gap (Na⁺ - [Cl⁻ + HCO₃⁻])<br><br>`;
    resultText += `Anion Gap: ${anionGap.toFixed(1)} mmol/L — `;

    if (anionGap > 16) {
        resultText += "🔴 High — suggests unmeasured acid accumulation. Possible causes include lactic acidosis, DKA, renal failure, or toxic ingestion (e.g., methanol, ethylene glycol). Requires urgent investigation.<br>";
    } 
    else if (anionGap >= 8 && anionGap <= 16) {
        resultText += "✅ Normal — no signs of metabolic acid buildup. Acid–base balance is within expected range.<br>";
    } 
    else {
        resultText += "🟡 Low — uncommon. May indicate hypoalbuminemia, multiple myeloma, or lab error. Consider checking serum albumin and repeating test.<br>";
    }

    result.innerHTML = resultText;
}








function analyzeRenalUrinalysis() {
    const urinePH = parseFloat(document.getElementById("renal-ph").value);
    const specificGravity = parseFloat(document.getElementById("renal-specific-gravity").value);
    const result = document.getElementById("renal-urinalysis-result");

    if (isNaN(urinePH) && isNaN(specificGravity)) {
        result.innerHTML = "⛔ Please enter at least one value.";
        return;
    }

    if (isNaN(urinePH) || isNaN(specificGravity)) {
        result.innerHTML = "⛔ Please complete both fields to analyze urinalysis.";
        return;
    }

    let resultText = "💧 Urinalysis: pH & Specific Gravity<br><br>";

    // pH Analysis
    if (urinePH < 5.0) {
        resultText += "🔴 Urine pH < 5.0 — Strongly acidic. May indicate metabolic acidosis, dehydration, high-protein diet, or diabetic ketosis.<br>";
    } 
    else if (urinePH >= 5.0 && urinePH <= 7.0) {
        resultText += `✅ Urine pH: ${urinePH} — Normal range (5.0–7.0). Acid–base handling appears balanced.<br>`;
    } 
    else if (urinePH > 7.0 && urinePH <= 7.5) {
        resultText += "🟡 Urine pH 7.1–7.5 — Slightly alkaline. Possible causes include vegetarian diet, mild infection, or postprandial response.<br>";
    } 
    else {
        resultText += "🔴 Urine pH > 7.5 — Alkaline. May signal UTI, risk of struvite stones, or metabolic alkalosis.<br>";
    }

    // Specific Gravity Analysis
    if (specificGravity < 1.005) {
        resultText += "🔴 Specific Gravity < 1.005 — Very dilute urine. Consider overhydration, diabetes insipidus, or renal concentration defect.<br>";
    } 
    else if (specificGravity >= 1.005 && specificGravity <= 1.030) {
        resultText += `✅ Specific Gravity: ${specificGravity} — Normal (1.005–1.030). Hydration and renal concentration capacity intact.<br>`;
    } 
    else if (specificGravity > 1.030 && specificGravity <= 1.035) {
        resultText += "🟡 Specific Gravity 1.031–1.035 — Concentrated urine. May reflect dehydration, intense sweating, or limited fluid intake.<br>";
    } 
    else {
        resultText += "🔴 Specific Gravity > 1.035 — Highly concentrated urine. Consider dehydration, heart failure, proteinuria, or glycosuria.<br>";
    }

    result.innerHTML = resultText;
}













function calculateRenalProteinCreatinineRatio() {
    const urinaryProtein = parseFloat(document.getElementById("renal-urinary-protein").value);
    const urinaryCreatinine = parseFloat(document.getElementById("renal-urinary-creatinine").value);
    const result = document.getElementById("renal-protein-creatinine-result");

    if (isNaN(urinaryProtein) || isNaN(urinaryCreatinine) || urinaryCreatinine === 0) {
        result.innerHTML = "⛔ Please enter valid values for both protein and creatinine.";
        return;
    }

    const ratio = urinaryProtein / urinaryCreatinine;
    const ratioFixed = ratio.toFixed(2);

    let resultText = `🧪 Protein-to-Creatinine Ratio<br><br>`;
    resultText += `Ratio: ${ratioFixed} mg/g — `;

    if (ratio < 0.2) {
        resultText += "✅ Normal — no significant proteinuria. Kidney filtration appears intact.<br>";
    } 
    else if (ratio >= 0.2 && ratio < 0.5) {
        resultText += "🟡 Slightly elevated — could be early glomerular leakage or transient (e.g., exercise, fever). Retest recommended.<br>";
    } 
    else if (ratio >= 0.5 && ratio < 3.5) {
        resultText += "🔴 Moderate proteinuria — often reflects glomerular damage from diabetes, hypertension, or CKD. Requires ongoing renal monitoring.<br>";
    } 
    else {
        resultText += "🔴 Severe proteinuria (nephrotic range) — >3.5 mg/g. Suggests marked glomerular damage. Urgent nephrology referral advised.<br>";
    }

    result.innerHTML = resultText;
}










function submitThyroidResult() {
    const tsh = parseFloat(document.getElementById("tshLevel").value);
    const t4 = parseFloat(document.getElementById("t4Level").value);
    const t3 = parseFloat(document.getElementById("t3Level").value);
    const resultLabel = document.getElementById("thyroid-result");

    let resultText = "Thyroid Function\n";
    let filled = 0;
    let missing = [];

    // TSH
    if (!isNaN(tsh)) {
        filled++;
        resultText += `TSH: ${tsh} mIU/L — `;
        if (tsh >= 0.4 && tsh <= 4.0) {
            resultText += "✅ Normal (0.4–4.0)\n";
        } else if (tsh >= 0.2 && tsh < 0.4) {
            resultText += "🟡 Borderline low — possible early hyperthyroidism\n";
        } else if (tsh > 4.0 && tsh <= 6.0) {
            resultText += "🟡 Borderline high — possible subclinical hypothyroidism\n";
        } else if (tsh < 0.2) {
            resultText += "🔴 Too low — suppressed TSH, likely hyperthyroidism or pituitary dysfunction\n";
            resultText += "\nHyperthyroidism (overactive thyroid):\n";
            resultText += "Your thyroid is producing too much hormone. This accelerates metabolism and overstimulates many systems.\n";
            resultText += "Symptoms: anxiety, insomnia, heat intolerance, weight loss, sweating, palpitations, tremor, irritability.\n";
            resultText += "Watch: low TSH + high T4/T3 = primary hyperthyroidism. Risk: AFib, osteoporosis, thyroid storm.\n";
            resultText += "Do: check TRAb antibodies, thyroid ultrasound or scintigraphy if nodules suspected.\n";
        } else {
            resultText += "🔴 Too high — likely hypothyroidism or iodine deficiency\n";
            resultText += "\nHypothyroidism (underactive thyroid):\n";
            resultText += "Your thyroid isn't producing enough hormone. This slows metabolism and affects many systems.\n";
            resultText += "Symptoms: fatigue, cold intolerance, weight gain, dry skin, constipation, depression, heavy periods.\n";
            resultText += "Watch: high TSH + low T4 = primary hypothyroidism. Risk: bradycardia, infertility, myxedema.\n";
            resultText += "Do: test thyroid antibodies (TPOAb, TgAb), review meds, assess iodine and selenium status.\n";
        }
    } else {
        missing.push("TSH");
    }

    // T4
    if (!isNaN(t4)) {
        filled++;
        resultText += `T4: ${t4} pmol/L — `;
        if (t4 >= 9.0 && t4 <= 25.0) {
            resultText += "✅ Normal (9.0–25.0)\n";
        } else if (t4 >= 7.0 && t4 < 9.0) {
            resultText += "🟡 Borderline low — may indicate underactive thyroid or conversion issue\n";
        } else if (t4 > 25.0 && t4 <= 28.0) {
            resultText += "🟡 Borderline high — possible excess dosing or elevated activity\n";
        } else if (t4 < 7.0) {
            resultText += "🔴 Too low — likely hypothyroidism or poor hormone production\n";
        } else {
            resultText += "🔴 Too high — hyperthyroidism or overmedication\n";
        }
    } else {
        missing.push("T4");
    }

    // T3
    if (!isNaN(t3)) {
        filled++;
        resultText += `T3: ${t3} pmol/L — `;
        if (t3 >= 3.5 && t3 <= 6.5) {
            resultText += "✅ Normal (3.5–6.5)\n";
        } else if (t3 >= 2.8 && t3 < 3.5) {
            resultText += "🟡 Borderline low — could indicate slowed conversion from T4\n";
        } else if (t3 > 6.5 && t3 <= 7.2) {
            resultText += "🟡 Borderline high — may reflect excess conversion or dosing\n";
        } else if (t3 < 2.8) {
            resultText += "🔴 Too low — underconversion or hypothyroidism\n";
        } else {
            resultText += "🔴 Too high — hyperthyroidism or overmedication\n";
        }
    } else {
        missing.push("T3");
    }

    if (filled === 0) {
        resultLabel.innerText = "⛔ Enter at least one value.";
        return;
    }

    if (missing.length > 0) {
        resultText += "\nMissing: " + missing.join(", ");
    }

    resultLabel.innerText = resultText.trim();
}












function submitThyroidAutoimmunity() {
    const history = document.querySelector('input[name="autoimmuneHistory"]:checked');
    const symptoms = document.querySelector('input[name="autoimmuneSymptoms"]:checked');
    const TPOAb = parseFloat(document.getElementById("TPOAb").value.trim());
    const TgAb = parseFloat(document.getElementById("TgAb").value.trim());
    const resultLabel = document.getElementById("thyroid-autoimmunity-result");

    let resultText = "Thyroid Autoimmunity\n";
    let filled = 0;
    const lines = [];
    const missing = [];

    // TPOAb
    if (!isNaN(TPOAb)) {
        filled++;
        if (TPOAb <= 35) {
            lines.push(`TPOAb: ${TPOAb} IU/mL — ✅ Normal (≤35) — no active thyroid autoimmunity detected.`);
        } else {
            lines.push(`TPOAb: ${TPOAb} IU/mL — 🔴 Elevated — may indicate Hashimoto’s or Graves’.`);
            lines.push(`Hashimoto’s thyroiditis (chronic autoimmune):\nDestruction of thyroid tissue over time.\nSymptoms: fatigue, cold intolerance, weight gain, depression, dry skin.\nWhat to check: TSH, T4, ultrasound (hypoechoic pattern).\n`);
            lines.push(`Graves’ disease (stimulatory autoimmunity):\nAutoantibodies overstimulate the thyroid.\nSymptoms: anxiety, weight loss, tremor, heat intolerance, eye signs.\nWhat to check: TRAb, TSH, Free T4/T3, eye symptoms.\n`);
        }
    } else {
        missing.push("TPOAb");
    }

    // TgAb
    if (!isNaN(TgAb)) {
        filled++;
        if (TgAb <= 40) {
            lines.push(`TgAb: ${TgAb} IU/mL — ✅ Normal (≤40) — no autoimmune thyroglobulin activity.`);
        } else {
            lines.push(`TgAb: ${TgAb} IU/mL — 🔴 Elevated — suggests autoimmune thyroid disorder.`);
        }
    } else {
        missing.push("TgAb");
    }

    // History + symptoms
    if (history || symptoms) filled++;
    if (history && symptoms && history.value === "yes" && symptoms.value === "yes") {
        lines.push("🟡 Family history + symptoms — increased risk for autoimmune thyroid disorder.");
    }

    if (!history) missing.push("Autoimmune history");
    if (!symptoms) missing.push("Symptoms");

    // Nothing filled at all
    if (filled === 0) {
        resultLabel.innerText = "⛔ Please enter at least one value.";
        return;
    }

    // Combine all
    if (lines.length > 0) {
        resultText += lines.join("\n");
    }

    if (missing.length > 0) {
        resultText += `\nMissing: ${missing.join(", ")}`;
    }

    resultLabel.innerText = resultText.trim();
}






function analyzeAdrenalFunction() {
    const cortisol = parseFloat(document.getElementById("morningCortisol").value.trim());
    const acth = parseFloat(document.getElementById("acthResponse").value.trim());
    const resultLabel = document.getElementById("adrenal-function-result");

    let resultText = "Adrenal Function\n";
    const lines = [];
    const missing = [];
    let filled = 0;

    // Morning cortisol
    if (!isNaN(cortisol)) {
        filled++;
        if (cortisol < 5) {
            lines.push("🔴 Morning cortisol is critically low. Suggests possible adrenal insufficiency. Consider ACTH stimulation test or further endocrine evaluation.");
        } else if (cortisol >= 5 && cortisol < 10) {
            lines.push("🟡 Morning cortisol is borderline low. May reflect insufficient adrenal output or stress-related suppression. Consider clinical correlation.");
        } else {
            lines.push("✅ Morning cortisol is within normal range.");
        }
    } else {
        missing.push("Morning Cortisol");
    }

    // ACTH stimulation response
    if (!isNaN(acth)) {
        filled++;
        if (acth < 18) {
            lines.push("🔴 ACTH stimulation test response is suboptimal. May indicate adrenal insufficiency (primary or secondary). Further testing advised.");
        } else {
            lines.push("✅ ACTH stimulation test result is adequate.");
        }
    } else {
        missing.push("ACTH Stimulation Test");
    }

    // No data at all
    if (filled === 0) {
        resultLabel.innerText = "⛔ Enter at least one value.";
        return;
    }

    // Combine result
    if (lines.length > 0) {
        resultText += lines.join("\n");
    }

    if (missing.length > 0) {
        resultText += `\nMissing: ${missing.join(", ")}`;
    }

    resultLabel.innerText = resultText.trim();
}

















function analyzeHormones() {
    const estrogen = parseFloat(document.getElementById("estrogenLevel").value) || 0;
    const testosterone = parseFloat(document.getElementById("testosteroneLevel").value) || 0;
    const progesterone = parseFloat(document.getElementById("progesteroneLevel").value) || 0;
    const resultField = document.getElementById("hormone-analysis-result");

    if (estrogen === 0 || testosterone === 0 || progesterone === 0) {
        resultField.innerText = "⛔ Please enter all hormone values.";
        return;
    }

    let resultText = "Hormonal Balance Analysis:\n";
    let messages = [];

    // Estrogen (E2) — normal: 30–300 pg/mL (female mid-cycle)
    if (estrogen < 20) {
        messages.push("🔴 Estrogen low — may cause fatigue, hot flashes, depression, dry skin, poor memory, and menstrual irregularity. Often seen in menopause, underweight, or HPO axis dysfunction. Consider estradiol support or endocrine evaluation.");
    } else if (estrogen > 350) {
        messages.push("🔴 Estrogen high — suggests estrogen dominance. May lead to heavy periods, breast tenderness, mood swings, water retention, and increased clotting risk. Often linked to low progesterone or impaired detoxification. Consider cycle regulation and liver support.");
    } else if (estrogen < 30 || estrogen > 300) {
        messages.push("🟡 Estrogen borderline — values slightly outside optimal range. Monitor symptoms like PMS, fluid retention, or emotional lability. Adjustments in lifestyle or phytoestrogen intake may help.");
    } else {
        messages.push("✅ Estrogen within range — supports stable mood, cycle, skin health, and reproductive function.");
    }

    // Testosterone — normal: 350–950 ng/dL (adult male)
    if (testosterone < 300) {
        messages.push("🔴 Testosterone low — may lead to fatigue, low libido, depression, reduced muscle mass, poor motivation, and metabolic slowdown. Seen in stress, aging, sleep deficiency, or HPG axis suppression. Evaluate DHEA, LH, sleep, and stress load.");
    } else if (testosterone > 1000) {
        messages.push("🔴 Testosterone high — possible anabolic overuse, tumor activity, or SHBG imbalance. May cause aggression, oily skin, hair loss, or elevated hematocrit. Monitor for androgen excess effects.");
    } else if (testosterone < 350 || testosterone > 950) {
        messages.push("🟡 Testosterone borderline — subtle symptoms may include irritability, low energy, or suboptimal body composition. Consider lifestyle, zinc, and androgen rhythm.");
    } else {
        messages.push("✅ Testosterone within range — supports strength, libido, mood, drive, and metabolic health.");
    }

    // Progesterone — normal: 6–18 ng/mL (luteal phase)
    if (progesterone < 5) {
        messages.push("🔴 Progesterone low — commonly causes estrogen dominance. May present with anxiety, insomnia, breast pain, short luteal phase, and PMS. Suggests luteal defect or chronic stress. Consider chasteberry, magnesium, and adrenal review.");
    } else if (progesterone > 20) {
        messages.push("🔴 Progesterone high — uncommon but may indicate exogenous hormone use, ovarian cysts, or luteal overactivity. Rule out artificial hormone exposure.");
    } else if (progesterone < 6 || progesterone > 18) {
        messages.push("🟡 Progesterone borderline — may contribute to mood instability, poor sleep, or irregular cycles. Consider testing mid-luteal and supporting adrenal rhythm.");
    } else {
        messages.push("✅ Progesterone within range — promotes calm, sleep, cycle balance, and endometrial integrity.");
    }

    resultField.innerText = resultText + messages.join("\n");
}











function analyzeTemperatureSensitivity() {
    const sensitivity = document.querySelector('input[name="tempSensitivity"]:checked');
    const discomfort = document.querySelector('input[name="tempDiscomfort"]:checked');
    const bbt = parseFloat(document.getElementById("basalBodyTemp").value);
    const resultField = document.getElementById("temperature-sensitivity-result");

    let resultText = "Temperature Sensitivity\n";
    let lines = [];
    let missing = [];

    // Sensitivity
    if (sensitivity) {
        if (sensitivity.value === "cold") {
            lines.push("🟡 You feel unusually cold — may suggest low metabolic rate, possible hypothyroidism, anemia, or low cortisol. Consider checking TSH, T4, iron status, and morning cortisol.");
        } else if (sensitivity.value === "hot") {
            lines.push("🟡 You feel unusually hot — may suggest hypermetabolism, elevated thyroid activity, low estrogen, or autonomic imbalance. Consider checking TSH, T3, estradiol, and cortisol rhythm.");
        } else {
            lines.push("✅ Temperature sensitivity appears normal.");
        }
    } else {
        missing.push("Temperature sensitivity");
    }

    // Discomfort
    if (discomfort) {
        if (discomfort.value === "Yes") {
            lines.push("🟡 You report temperature-related discomfort — may reflect hormonal or autonomic dysregulation. Track symptoms in context of cycle, sleep, and stress.");
        } else {
            lines.push("✅ No significant temperature-related discomfort reported.");
        }
    } else {
        missing.push("Discomfort question");
    }

    // BBT
    if (!isNaN(bbt)) {
        if (bbt < 36.1) {
            lines.push("🔴 BBT is low — may suggest underactive thyroid, low progesterone, or chronic stress. Check TSH, T4, adrenal markers.");
        } else if (bbt >= 36.1 && bbt <= 36.8) {
            lines.push("✅ BBT is in the optimal range — suggests stable metabolism and cycle regulation.");
        } else if (bbt > 36.8 && bbt < 37.2) {
            lines.push("🟡 Slightly elevated BBT — may reflect luteal phase, stress, or subclinical inflammation.");
        } else {
            lines.push("🔴 High BBT — possible fever, infection, or hyperthyroid state. Correlate with symptoms and repeat if unsure.");
        }
    } else {
        missing.push("Basal Body Temperature");
    }

    if (!sensitivity && !discomfort && isNaN(bbt)) {
        resultField.innerText = "⛔ Please enter at least one value.";
        return;
    }

    if (missing.length > 0) {
        lines.push("Missing: " + missing.join(", "));
    }

    resultField.innerText = resultText + lines.join("\n");
}










function analyzeThirst() {
    const aldosterone = parseFloat(document.getElementById("aldosteroneLevel").value);
    const vasopressin = parseFloat(document.getElementById("vasopressinLevel").value);
    const thirstResult = document.getElementById("thirst-result");

    let output = "Thirst Regulation\n";
    let hasData = false;
    let missing = [];

    if (!isNaN(aldosterone) && !isNaN(vasopressin)) {
        hasData = true;
        if (aldosterone < 100 && vasopressin < 2) {
            output += "🔴 Both Aldosterone and Vasopressin are low.\n";
            output += "This may reflect suppression of the HPA axis or central regulatory dysfunction. Possible causes include adrenal insufficiency, chronic steroid use, or hypothalamic damage. Monitor hydration, blood pressure, and electrolytes. Consider ACTH stimulation test if symptoms suggest fatigue, salt craving, or low BP.\n";
        } else if (aldosterone > 200 || vasopressin > 6) {
            output += "🔴 One or both hormones are elevated.\n";
            output += "May indicate volume depletion, hypotension, or compensatory activation. High vasopressin can occur in SIADH; high aldosterone may result from dehydration, stress, or secondary hyperaldosteronism. Evaluate sodium, osmolality, and hydration.\n";
        } else if (
            aldosterone >= 100 && aldosterone <= 200 &&
            vasopressin >= 2 && vasopressin <= 6
        ) {
            output += "✅ Regulation appears intact.\n";
            output += "Hormones are within expected ranges. Suggests preserved fluid balance and normal hypothalamic-renal feedback.\n";
        } else {
            output += "🟡 Mild hormonal shift detected.\n";
            output += "Values near threshold. May reflect early compensatory changes, mild imbalance, or stress modulation. Monitor clinically.\n";
        }
    } else {
        if (!isNaN(aldosterone)) {
            hasData = true;
            output += "🟡 Aldosterone entered, Vasopressin missing.\n";
        }
        if (!isNaN(vasopressin)) {
            hasData = true;
            output += "🟡 Vasopressin entered, Aldosterone missing.\n";
        }
    }

    if (!hasData) {
        thirstResult.innerText = "⛔ Enter at least one value.";
        return;
    }

    if (isNaN(aldosterone)) missing.push("Aldosterone");
    if (isNaN(vasopressin)) missing.push("Vasopressin");
    if (missing.length > 0) output += `\nMissing: ${missing.join(", ")}`;

    thirstResult.innerText = output.trim();
}











function analyzeHunger() {
    const hungerIncrease = document.querySelector('input[name="hungerIncrease"]:checked');
    const leptin = parseFloat(document.getElementById("leptinLevel").value);
    const ghrelin = parseFloat(document.getElementById("ghrelinLevel").value);
    const resultField = document.getElementById("hunger-result");

    let result = "Hunger Regulation\n";
    let filled = 0;
    const missing = [];

    // Leptin
    if (!isNaN(leptin)) {
        filled++;
        if (leptin < 4) {
            result += "🔴 Leptin is low — may lead to increased hunger, reduced energy expenditure, or disrupted satiety signals. Seen in underweight states or leptin deficiency.\n";
        } else if (leptin > 15) {
            result += "🟡 Leptin is elevated — may indicate leptin resistance, commonly linked with obesity, metabolic syndrome, or chronic inflammation.\n";
        } else {
            result += "✅ Leptin is within a functional range. Satiety signaling appears preserved.\n";
        }
    } else {
        missing.push("Leptin");
    }

    // Ghrelin
    if (!isNaN(ghrelin)) {
        filled++;
        if (ghrelin > 100) {
            result += "🔴 Ghrelin is elevated — strong hunger signal. Often seen in caloric restriction, poor sleep, or stress-induced cravings.\n";
        } else if (ghrelin < 40) {
            result += "🟡 Ghrelin is low — could reflect suppressed appetite, illness, or abnormal signaling.\n";
        } else {
            result += "✅ Ghrelin is within expected range. Hunger regulation seems balanced.\n";
        }
    } else {
        missing.push("Ghrelin");
    }

    // Hunger experience
    if (hungerIncrease) {
        filled++;
        if (hungerIncrease.value === "yes") {
            result += "🟡 You reported increased hunger or cravings — consider evaluating stress, insulin, sleep, and leptin-ghrelin rhythm.\n";
        } else {
            result += "✅ No subjective hunger increase reported.\n";
        }
    } else {
        missing.push("Hunger experience");
    }

    if (filled === 0) {
        resultField.innerText = "⛔ Enter at least one value.";
        return;
    }

    if (missing.length > 0) {
        result += `\nMissing: ${missing.join(", ")}`;
    }

    resultField.innerText = result.trim();
}









function analyzeHair() {
    const ferritin = parseFloat(document.getElementById("ferritinLevel").value);
    const thyroid = parseFloat(document.getElementById("thyroidLevel").value);
    const hairResult = document.getElementById("hair-result");

    let output = "Hair Growth Factors\n";
    let hasData = false;
    const missing = [];

    if (!isNaN(ferritin)) hasData = true;
    else missing.push("Ferritin");

    if (!isNaN(thyroid)) hasData = true;
    else missing.push("Thyroid");

    if (!hasData) {
        hairResult.innerText = "⛔ Enter at least one value.";
        return;
    }

    if (!isNaN(ferritin) && ferritin < 30) {
        output += "🔴 Low ferritin — iron stores insufficient to support active hair growth. May lead to thinning, increased shedding, and slowed regrowth. Boost iron intake and retest.\n";
    } else if (!isNaN(ferritin) && ferritin >= 30 && ferritin <= 70) {
        output += "✅ Ferritin in supportive range.\n";
    } else if (!isNaN(ferritin)) {
        output += "🟡 Ferritin borderline — may affect follicle cycling if under stress or demand is high.\n";
    }

    if (!isNaN(thyroid) && thyroid < 3.0) {
        output += "🔴 Low thyroid hormone — reduced T3/T4 can disrupt follicle cycling and slow hair regeneration. May reflect hypothyroidism. Check TSH and consider full thyroid panel.\n";
    } else if (!isNaN(thyroid) && thyroid >= 3.0 && thyroid <= 6.5) {
        output += "✅ Thyroid hormone within range — supports normal follicle cycling and growth.\n";
    } else if (!isNaN(thyroid)) {
        output += "🟡 Thyroid borderline — could impact hair renewal or texture over time.\n";
    }

    if (missing.length > 0) {
        output += `\nMissing: ${missing.join(", ")}`;
    }

    hairResult.innerText = output.trim();
}








function analyzeMenstrual() {
    const cycleLength = parseFloat(document.getElementById("cycleLength").value);
    const periodDuration = parseFloat(document.getElementById("periodDuration").value);
    const periodPain = parseFloat(document.getElementById("periodPain").value);
    const result = document.getElementById("menstrual-result");

    if (isNaN(cycleLength) || isNaN(periodDuration) || isNaN(periodPain)) {
        result.innerHTML = "⛔ Please enter valid values for cycle length variation, period duration, and pain level.";
        return;
    }

    let message = "";

    // Cycle Length Variation (e.g., number of days the cycle varies month-to-month)
    if (cycleLength <= 7) {
        message += "✅ Cycle length variation is within normal range (≤7 days) — indicates hormonal rhythm is stable.<br>";
    } else if (cycleLength > 7 && cycleLength <= 10) {
        message += "🟡 Cycle variability is slightly elevated — may reflect mild luteal or follicular phase irregularities. Monitor for cycle tracking irregularity or hormonal shifts.<br>";
    } else {
        message += "🔴 Highly irregular cycles (>10 day variation) — may suggest ovulatory dysfunction, PCOS, thyroid imbalance, or stress-related hormonal disruption. Consider full hormonal workup.<br>";
    }

    // Period Duration
    if (periodDuration <= 7) {
        message += "✅ Period duration is within the normal range (≤7 days).<br>";
    } else if (periodDuration > 7 && periodDuration <= 10) {
        message += "🟡 Slightly prolonged bleeding — could indicate mild estrogen dominance or delayed shedding. Monitor for spotting or clotting.<br>";
    } else {
        message += "🔴 Prolonged menstruation (>10 days) — may reflect endometrial hyperplasia, clotting disorders, or estrogen-progesterone imbalance. Medical review is advised.<br>";
    }

    // Period Pain (scale 0–10)
    if (periodPain <= 4) {
        message += "✅ Mild to no menstrual pain — consistent with normal uterine function.<br>";
    } else if (periodPain > 4 && periodPain <= 7) {
        message += "🟡 Moderate pain — common, but may reflect subclinical inflammation, prostaglandin excess, or hormonal imbalance. May benefit from anti-inflammatory or hormonal support.<br>";
    } else {
        message += "🔴 Severe menstrual pain (>7) — could signal endometriosis, adenomyosis, or pelvic inflammatory disorder. Gynecological assessment recommended.<br>";
    }

    result.innerHTML = message;
}






















function showInjuryDetails(show) {
    document.getElementById("injuryDetailsSection").style.display = show ? "block" : "none";
}

function updateBodyPartOptions() {
    const injuryType = document.getElementById("injuryType").value;
    const bodyPartSelect = document.getElementById("bodyPart");

    // Clear previous options
    bodyPartSelect.innerHTML = '<option value="">Select...</option>';

    // Define body parts based on injury type
    const bodyParts = {
        "Sprain": ["Wrist", "Ankle", "Knee", "Elbow"],
        "Fracture": ["Arm", "Leg", "Skull", "Spine", "Pelvis", "Ribs"],
        "Dislocation": ["Shoulder", "Hip", "Knee", "Finger", "Elbow"]
    };

    // Add new options if an injury type is selected
    if (injuryType in bodyParts) {
        bodyParts[injuryType].forEach(part => {
            const option = document.createElement("option");
            option.value = part;
            option.textContent = part;
            bodyPartSelect.appendChild(option);
        });
    }
}






   





async function adjustForPreconditionsAndMeds(patientData) {
    let fullMeds = await loadMedicationDetails(patientData.medications);
    let adjustments = {};

    // 🔸 Apply Pre-existing Conditions
    patientData.preconditions.forEach(condition => {
        if (predefinedPreconditionData[condition]) {
            let effects = predefinedPreconditionData[condition];

            effects.affects.forEach(effect => {
                if (!adjustments[effect]) adjustments[effect] = 0;
                adjustments[effect] += 1;
            });

            Object.keys(fullMeds).forEach(med => {
                if (effects.drug_interactions[med]) {
                    let interaction = effects.drug_interactions[med];
                    adjustments[interaction.adjustment] = interaction.risk_factor;
                }
            });
        }
    });

    // 🔸 Apply Medication Effects
    Object.keys(fullMeds).forEach(med => {
        let medData = fullMeds[med];

        if (medData.pharmacodynamics) {
            let effect = medData.pharmacodynamics.effect;
            adjustments[effect] = medData.pharmacodynamics.timeframe;
        }

        if (medData.interactions) {
            adjustments[`${med} Interactions`] = medData.interactions;
        }
    });

    return adjustments;
}











function loadUserProfile() {
    let storedProfile = JSON.parse(localStorage.getItem("userProfile"));
    if (storedProfile) {
        userProfile = storedProfile;

        // Restore previous selections
        document.querySelectorAll("input[type='radio']").forEach(radio => {
            let category = radio.dataset.category;
            let question = radio.dataset.question;
            if (userProfile.diagnostics[category] && userProfile.diagnostics[category][question] === radio.value) {
                radio.checked = true;
            }
        });
    }
}

// Run on page load
loadUserProfile();










const medications = [
  
{
    "iupac_name": "",
    "chemical_formula": "",
    "brand_names": [],
    "category": "",
    "dosage_forms": [],
    "strengths": [],
    "mechanism_of_action": {
        "site_of_action": "",
        "physiological_mechanism": ""
    },
    "pharmacodynamic_effects": [
        {
            "system": "",
            "effect": "",
            "timeframe": ""
        }
    ],
    "molecular_pathways": {
        "pathway_name": "",
        "key_targets": [],
        "related_conditions": []
    },
    "pharmacokinetics": {
        "absorption": "",
        "metabolism": {
            "primary_site": "",
            "enzymes": [],
            "notes": ""
        },
        "elimination": ""
    },
    "interactions": {
        "": {
            "site_of_interaction": "",
            "mechanism": "",
            "effect": "",
            "recommendation": ""
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [],
        "microbiota_effects": ""
    },
    "effects_on_symptoms": {
        "": {
            "site_of_effect": "",
            "mechanism": "",
            "direction": "",
            "magnitude": "",
            "timeframe": ""
        }
    },
    "diagnostic_conditions": {
        "": {
            "symptoms_addressed": [],
            "therapeutic_action": "",
            "optimal_dosage": "",
            "response_time": ""
        }
    },
    "adverse_effects": {
        "mild": [],
        "moderate": [],
        "severe": []
    },
    "long_term_monitoring": {
        "parameters": [],
        "frequency": "",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "": {
            "adjustments": "",
            "rationale": ""
        }
    },
    "alternative_therapies": [],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": [],
    "precautions": [],
    "side_effects": [],
    "overdose_management": {
        "symptoms": [],
        "treatment": []
    },
    "notes": ""
},

  
  
  
{
    "iupac_name": "3-Methylmethcathinone",
    "chemical_formula": "C11H15NO",
    "brand_names": ["3-MMC", "Meow Meow"],
    "category": "Stimulant / Empathogen",
    "dosage_forms": ["Powder", "Capsule", "Tablet"],
    "strengths": ["10mg", "50mg", "100mg"],
    "mechanism_of_action": {
        "site_of_action": "Dopaminergic and serotonergic systems",
        "physiological_mechanism": "Increases release and inhibits reuptake of dopamine and serotonin, leading to enhanced mood, empathy, and energy."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Elevated mood and increased sociability.",
            "timeframe": "Onset within 20-40 minutes; lasts 4-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Monoamine reuptake inhibition",
        "key_targets": ["Dopamine transporters (DAT)", "Serotonin transporters (SERT)"],
        "related_conditions": ["Euphoria", "Empathy enhancement"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally, peak effects occur within 1-2 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6", "CYP3A4"],
            "notes": "Partially metabolized to active compounds, contributing to prolonged effects."
        },
        "elimination": "Excreted via urine; half-life of 5-7 hours."
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Synergistic increase in euphoria but higher dehydration and neurotoxicity risk.",
            "effect": "Increased risk of dehydration and overheating.",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Alcohol (increases neurotoxicity)"],
        "microbiota_effects": "Minimal known impact."
    },
    "effects_on_symptoms": {
        "mood": {
            "site_of_effect": "Dopaminergic and serotonergic pathways",
            "mechanism": "Enhances neurotransmitter availability in the synaptic cleft.",
            "direction": "Increase",
            "magnitude": "Moderate to high",
            "timeframe": "Within 20-40 minutes."
        }
    },
    "diagnostic_conditions": {
        "euphoria": {
            "symptoms_addressed": ["Low mood", "Social anxiety"],
            "therapeutic_action": "Increases dopamine and serotonin release.",
            "optimal_dosage": "50-100mg (recreational, non-prescription).",
            "response_time": "1-2 hours."
        }
    },
    "adverse_effects": {
        "mild": ["Dry mouth", "Increased sweating"],
        "moderate": ["Elevated heart rate", "Jaw clenching"],
        "severe": ["Serotonin syndrome", "Cardiac arrhythmia"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart rate", "Electrolyte balance"],
        "frequency": "Every 6 months with repeated use.",
        "clinical_thresholds": {
            "normal_range": {"Heart rate": "60-100 bpm"},
            "alert_threshold": {"Heart rate": ">120 bpm"}
        }
    },
    "population_specific": {
        "pregnant": {
            "adjustments": "Avoid use.",
            "rationale": "Potential teratogenic effects and cardiovascular stress."
        }
    },
    "alternative_therapies": ["Therapy (e.g., CBT)", "Meditation", "Physical exercise"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Avoid combining with other stimulants."]
    },
    "contraindications": ["Cardiac arrhythmias", "History of serotonin syndrome"],
    "precautions": ["Hydrate regularly and monitor body temperature."],
    "side_effects": ["Dry mouth", "Dehydration", "Elevated heart rate"],
    "overdose_management": {
        "symptoms": ["Severe agitation", "Serotonin syndrome", "Seizures"],
        "treatment": ["Supportive care", "Cooling for hyperthermia", "Benzodiazepines for agitation."]
    },
    "notes": "3-MMC, often nicknamed 'Meow Meow,' is a synthetic cathinone with stimulant and empathogenic properties. Known for its similarities to MDMA but shorter duration and milder effects."
},
  
  {
    "iupac_name": "3,4-Methylenedioxyamphetamine",
    "chemical_formula": "C10H13NO2",
    "brand_names": ["MDA", "Sass", "Sally"],
    "category": "Empathogen / Psychoactive Stimulant",
    "dosage_forms": ["Capsule", "Powder", "Tablet"],
    "strengths": ["75mg", "100mg"],
    "mechanism_of_action": {
        "site_of_action": "Serotonergic and dopaminergic systems",
        "physiological_mechanism": "Stimulates release of serotonin and dopamine, enhancing empathy, mood, and sensory perception."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Increases emotional openness and sensory enhancement.",
            "timeframe": "Onset within 30-45 minutes; lasts 3-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Monoamine release enhancement",
        "key_targets": ["Serotonin transporters (SERT)", "Dopamine transporters (DAT)"],
        "related_conditions": ["Mood enhancement", "Empathy facilitation"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally with peak plasma levels in 1-2 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Metabolized to active metabolites contributing to its effects."
        },
        "elimination": "Excreted via urine; half-life of 6-8 hours."
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Serotonergic system",
            "mechanism": "May reduce efficacy by competing for serotonin receptors.",
            "effect": "Reduced empathogenic effects.",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin C (potentially reduces oxidative stress)"],
        "toxins": ["Alcohol (increased dehydration and neurotoxicity risk)"],
        "microbiota_effects": "Minimal known impact."
    },
    "effects_on_symptoms": {
        "empathy": {
            "site_of_effect": "Serotonin pathways",
            "mechanism": "Enhances release and binding of serotonin.",
            "direction": "Increase",
            "magnitude": "High",
            "timeframe": "Within 1 hour."
        }
    },
    "diagnostic_conditions": {
        "mood_elevation": {
            "symptoms_addressed": ["Depressed mood", "Anxiety"],
            "therapeutic_action": "Enhances serotonin release.",
            "optimal_dosage": "75-100mg (recreational use, non-prescription).",
            "response_time": "1-2 hours."
        }
    },
    "adverse_effects": {
        "mild": ["Dry mouth", "Jaw clenching"],
        "moderate": ["Increased heart rate", "Mild hallucinations"],
        "severe": ["Serotonin syndrome", "Hyperthermia"]
    },
    "long_term_monitoring": {
        "parameters": ["Serotonin levels", "Cardiac function"],
        "frequency": "Every 3-6 months with chronic use.",
        "clinical_thresholds": {
            "normal_range": {"Serotonin": "120-240 ng/mL"},
            "alert_threshold": {"Serotonin": ">300 ng/mL"}
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Avoid use.",
            "rationale": "Increased cardiovascular risk."
        }
    },
    "alternative_therapies": ["Meditation", "Therapy (e.g., CBT)"],
    "combination_therapies": {
        "recommended_combinations": ["MDA + guided psychotherapy (experimental)."],
        "cautions": ["Avoid combining with alcohol or other stimulants."]
    },
    "contraindications": ["Cardiac conditions", "History of serotonin syndrome"],
    "precautions": ["Monitor hydration and temperature during use."],
    "side_effects": ["Dry mouth", "Hyperthermia", "Hallucinations"],
    "overdose_management": {
        "symptoms": ["Agitation", "Serotonin syndrome", "Seizures"],
        "treatment": ["Supportive care", "Benzodiazepines for agitation", "Cooling for hyperthermia."]
    },
    "notes": "MDA, known colloquially as 'Sass,' is a psychoactive stimulant and empathogen. It is chemically similar to MDMA but exhibits stronger hallucinogenic properties."
},

  
  
  
  
  
  
  
  
  

 {
    "iupac_name": "2-Acetoxybenzoic acid",
    "chemical_formula": "C9H8O4",
    "brand_names": [
    "Anadin",
    "Disprin",
    "Aspro Clear",
    "Alka-Seltzer",
    "Empirin",
    "Ecotrin",
    "Bufferin",
    "Ascriptin",
    "St. Joseph",
    "Halfprin",
    "Easprin",
    "ZORprin",
    "Medi-Seltzer",
    "Aspiritab",
    "Sloprin",
    "Aspir-Low",
    "Aspir 81",
    "Aspi-Cor",
    "Arthritis Pain",
    "Bayer Plus",
      "Aspirin"
],
    "category": "NSAID (Non-Steroidal Anti-Inflammatory Drug)",
    "dosage_forms": ["Tablet", "Powder", "Effervescent Tablet"],
    "strengths": ["75mg", "300mg", "500mg"],
    "mechanism_of_action": {
        "site_of_action": "Cyclooxygenase enzymes (COX-1 and COX-2)",
        "physiological_mechanism": "Inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis, which lowers inflammation, pain, and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Inflammatory System",
            "effect": "Reduces inflammation by decreasing prostaglandin levels.",
            "timeframe": "Effect seen within 30 minutes to 1 hour."
        },
        {
            "system": "Cardiovascular System",
            "effect": "Prevents platelet aggregation by inhibiting thromboxane A2 production.",
            "timeframe": "Antiplatelet effect lasts 7-10 days (lifespan of platelets)."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Prostaglandin synthesis inhibition",
        "key_targets": ["COX-1", "COX-2"],
        "related_conditions": ["Inflammation", "Pain", "Fever", "Thrombosis"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the gastrointestinal tract with peak plasma levels in 1-2 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Hydrolyzed to salicylic acid, which is the active form."
        },
        "elimination": "Excreted primarily by the kidneys; half-life of salicylic acid varies with dose."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver (CYP enzymes)",
            "mechanism": "Enhances anticoagulant effect.",
            "effect": "Increased bleeding risk.",
            "recommendation": "Monitor INR and adjust warfarin dose if necessary."
        },
        "Alcohol": {
            "site_of_interaction": "Gastrointestinal tract and liver",
            "mechanism": "Increases risk of gastrointestinal bleeding.",
            "effect": "Higher risk of gastric mucosal damage.",
            "recommendation": "Avoid alcohol consumption while taking aspirin."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin K (antagonistic effect on clotting)"],
        "toxins": ["Alcohol (increased GI bleeding risk)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "pain": {
            "site_of_effect": "Peripheral and central prostaglandin synthesis inhibition",
            "mechanism": "Reduces sensitivity of nociceptors to pain stimuli.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "Within 30 minutes."
        },
        "fever": {
            "site_of_effect": "Hypothalamus",
            "mechanism": "Inhibits prostaglandin-mediated temperature elevation.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "Within 30 minutes."
        }
    },
    "diagnostic_conditions": {
        "fever": {
            "symptoms_addressed": ["Elevated body temperature"],
            "therapeutic_action": "Reduces fever by inhibiting prostaglandin synthesis in the hypothalamus.",
            "optimal_dosage": "300-500mg every 4-6 hours as needed.",
            "response_time": "Effect observed within 30 minutes."
        },
        "mild_to_moderate_pain": {
            "symptoms_addressed": ["Headache", "Muscle pain", "Toothache"],
            "therapeutic_action": "Reduces pain perception.",
            "optimal_dosage": "300-500mg every 4-6 hours as needed.",
            "response_time": "Pain relief observed within 30-60 minutes."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Heartburn"],
        "moderate": ["Gastrointestinal irritation", "Rash"],
        "severe": ["Gastrointestinal bleeding", "Anaphylaxis (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Platelet count", "Liver enzymes (ALT/AST)"],
        "frequency": "Monitor every 6-12 months for chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Platelets": "150,000-450,000 per microliter"
            },
            "alert_threshold": {
                "Platelets": "<100,000 per microliter"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use with caution; lower doses recommended.",
            "rationale": "Increased risk of gastrointestinal bleeding and renal impairment."
        },
        "children": {
            "adjustments": "Avoid due to risk of Reye's syndrome.",
            "rationale": "Aspirin-associated Reye's syndrome is a rare but severe condition in children."
        },
        "pregnant": {
            "adjustments": "Avoid in the third trimester.",
            "rationale": "Risk of premature closure of the ductus arteriosus in the fetus."
        }
    },
    "alternative_therapies": [
        "Willow bark extract (natural source of salicin)",
        "Curcumin (anti-inflammatory properties)",
        "Boswellia serrata (herbal anti-inflammatory)",
        "Ginger (reduces inflammation and pain)",
        "Devil's claw (herbal pain reliever)",
        "White willow bark (plant-based anti-inflammatory)",
        "Omega-3 fatty acids (reduce inflammation via prostaglandin pathways)",
        "Quercetin (natural anti-inflammatory flavonoid)"
    ],
    "combination_therapies": {
        "recommended_combinations": ["Aspirin + Clopidogrel (for dual antiplatelet therapy)"],
        "cautions": ["Avoid combining with other NSAIDs (e.g., ibuprofen)."]
    },
    "contraindications": [
        "Active peptic ulcer disease",
        "Hypersensitivity to aspirin",
        "Severe renal or hepatic impairment"
    ],
    "precautions": [
        "Monitor for signs of gastrointestinal bleeding.",
        "Use with caution in asthma patients due to risk of bronchospasm."
    ],
    "side_effects": [
        "Nausea",
        "Heartburn",
        "Gastrointestinal bleeding (in high doses)"
    ],
    "overdose_management": {
        "symptoms": [
            "Tinnitus",
            "Nausea",
            "Hyperventilation",
            "Metabolic acidosis"
        ],
        "treatment": [
            "Administer activated charcoal within 1 hour of ingestion.",
            "Correct acid-base imbalance with intravenous bicarbonate.",
            "Consider hemodialysis in severe cases."
        ]
    },
    "notes": "This medication, commonly referred to as Aspirin, is sold under various brand names including Etopirin, Aspro, Bayer Aspirin, and Bufferin. It functions as an analgesic, antipyretic, and anti-inflammatory agent. The wide availability of brands ensures accessibility while providing the same therapeutic effects."

},

  {
    "iupac_name": "N-(4-hydroxyphenyl)acetamide",
    "chemical_formula": "C8H9NO2",
    "brand_names": ["Paracetamol", "Panadol", "Calpol", "Tylenol", "Acamol", "Alvedon", "Dafalgan", "Doliprane", "Efferalgan", "Crocin", "Tempra", "Panado", "Paralen", "Perfalgan", "Tachipirina", "Tafirol", "Pamol", "Panamax", "Panodil", "Paracet", "Pinex"],
    "category": "Analgesic / Antipyretic",
    "dosage_forms": ["Tablet", "Syrup", "Capsule", "Suppository", "Injection"],
    "strengths": ["500mg", "650mg", "1g"],
    "mechanism_of_action": {
        "site_of_action": "Central nervous system (CNS) and hypothalamus",
        "physiological_mechanism": "Inhibits prostaglandin synthesis in the CNS and acts on the hypothalamic heat-regulating center to reduce fever. The exact mechanism of analgesic action is not fully understood but involves modulation of pain pathways."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Reduces pain perception via prostaglandin inhibition.",
            "timeframe": "Onset within 30-60 minutes; lasts 4-6 hours."
        },
        {
            "system": "Thermoregulatory",
            "effect": "Reduces fever by lowering hypothalamic set point.",
            "timeframe": "Onset within 30 minutes; lasts 4-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Prostaglandin synthesis inhibition",
        "key_targets": ["COX-2 (in CNS)"],
        "related_conditions": ["Pain", "Fever"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the gastrointestinal tract with peak plasma levels in 30-60 minutes.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2", "CYP2E1"],
            "notes": "Metabolized to non-toxic glucuronide and sulfate conjugates; minor pathway forms hepatotoxic NAPQI metabolite."
        },
        "elimination": "Primarily excreted via the kidneys as conjugates; half-life ~2-3 hours."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver (CYP enzymes)",
            "mechanism": "Prolonged use may enhance anticoagulant effects.",
            "effect": "Increased risk of bleeding.",
            "recommendation": "Monitor INR closely with long-term use."
        },
        "Alcohol": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased production of toxic NAPQI metabolite.",
            "effect": "Higher risk of hepatotoxicity.",
            "recommendation": "Avoid excessive alcohol consumption."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Alcohol (increases NAPQI production)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "pain": {
            "site_of_effect": "CNS (prostaglandin synthesis inhibition)",
            "mechanism": "Reduces pain signal transmission via decreased prostaglandin levels.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "Onset within 30-60 minutes."
        },
        "fever": {
            "site_of_effect": "Hypothalamus",
            "mechanism": "Reduces hypothalamic set point through prostaglandin inhibition.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "Onset within 30 minutes."
        }
    },
    "diagnostic_conditions": {
        "fever": {
            "symptoms_addressed": ["Elevated body temperature"],
            "therapeutic_action": "Reduces fever by lowering hypothalamic set point.",
            "optimal_dosage": "500mg-1g every 4-6 hours as needed.",
            "response_time": "Effect observed within 30 minutes."
        },
        "mild_to_moderate_pain": {
            "symptoms_addressed": ["Headache", "Muscle pain", "Toothache"],
            "therapeutic_action": "Reduces pain perception.",
            "optimal_dosage": "500mg-1g every 4-6 hours as needed.",
            "response_time": "Pain relief observed within 30-60 minutes."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dizziness"],
        "moderate": ["Rash", "Allergic reactions"],
        "severe": ["Hepatotoxicity (in overdose)", "Anaphylaxis (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver enzymes (ALT/AST)"],
        "frequency": "Monitor every 6 months for chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "ALT/AST": ">2x upper normal limit"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use with caution; monitor liver function.",
            "rationale": "Increased risk of hepatotoxicity with age."
        },
        "children": {
            "adjustments": "Dose based on weight (10-15mg/kg every 4-6 hours).",
            "rationale": "Ensure correct dosing to avoid overdose."
        },
        "pregnant": {
            "adjustments": "Generally considered safe; use lowest effective dose.",
            "rationale": "Limited evidence of harm but caution advised."
        }
    },
    "alternative_therapies": ["Ginger", "Turmeric (Curcumin)", "Cold Compress", "Heat Therapy", "Meditation", "Hydration", "Acupressure"],
    "combination_therapies": {
        "recommended_combinations": ["Heat Therapy + Meditation", "Ginger Tea + Hydration"],
        "cautions": ["Avoid with other prostaglandin inhibitors to prevent overdose."]
    },
    "contraindications": [
        "Severe liver impairment",
        "Hypersensitivity to paracetamol"
    ],
    "precautions": [
        "Use with caution in hepatic impairment.",
        "Avoid concurrent use with other acetaminophen-containing products."
    ],
    "side_effects": [
        "Nausea",
        "Rash",
        "Hepatic toxicity (in overdose)"
    ],
    "overdose_management": {
        "symptoms": [
            "Nausea",
            "Vomiting",
            "Abdominal pain",
            "Hepatotoxicity"
        ],
        "treatment": [
            "Administer activated charcoal within 1 hour of overdose.",
            "Use N-acetylcysteine as an antidote."
        ]
    },
    "notes": "Paracetamol, known by various brand names including Panadol, Calpol, Tylenol, Acamol, Alvedon, Dafalgan, Doliprane, Efferalgan, Crocin, Tempra, Panado, Paralen, Perfalgan, Tachipirina, Tafirol, Pamol, Panamax, Panodil, Paracet, and Pinex, is generally safe within the therapeutic dose range. Avoid exceeding the recommended daily dose to prevent hepatotoxicity."

},

  
  
  
  
  
    
{
    "iupac_name": "1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxy)phenyl]propan-2-ol",
    "chemical_formula": "C18H31NO4",
    "brand_names": ["Zebeta", "Monocor", "Concor", "Cardicor", "Congescor", "Biselect", "Bisocor", "Bisoprolol Sandoz", "Bisoprolol Teva", "Bisoprolol-ratiopharm", "Bisohexal", "Bisoratio", "BisoLich", "BisoMylan", "BisoMepha", "BisoEgis", "BisoPharma", "BisoKrka", "BisoStada", "BisoActavis", "BisoAristo", "BisoBetapharm", "BisoCT", "Biso1A", "BisoAbZ", "BisoAliud", "BisoBasics", "BisoBiomo", "BisoHeumann", "BisoHexal", "BisoJenapharm", "BisoLich", "BisoMylan", "BisoRatiopharm", "BisoSandoz", "BisoStada", "BisoTAD", "BisoTeva", "BisoZentiva"],
    "category": "Beta Blocker (Cardioselective)",
    "dosage_forms": ["Tablet"],
    "strengths": ["1.25mg", "2.5mg", "5mg", "10mg"],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 adrenergic receptors in the heart",
        "physiological_mechanism": "Blocks beta-1 adrenergic receptors, reducing heart rate and myocardial oxygen demand."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular",
            "effect": "Decreases heart rate and cardiac output",
            "timeframe": "Onset within 1-2 hours"
        },
        {
            "system": "Renin-Angiotensin System",
            "effect": "Inhibits renin release from the kidneys",
            "timeframe": "Effect builds over weeks of use"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic signaling",
        "key_targets": ["Beta-1 adrenergic receptor"],
        "related_conditions": ["Hypertension", "Heart Failure", "Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with ~90% bioavailability",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450 (minor pathway)"],
            "notes": "Primarily excreted unchanged in urine"
        },
        "elimination": "Renal excretion; half-life ~10-12 hours"
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Heart (SA/AV nodes)",
            "mechanism": "Additive effects on heart rate reduction",
            "effect": "Bradycardia, hypotension",
            "recommendation": "Monitor heart rate and blood pressure closely"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium"],
        "toxins": ["Alcohol"],
        "microbiota_effects": "No significant effects known"
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Heart and vascular system",
            "mechanism": "Reduces cardiac output and renin release",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 hours of dose"
        },
        "Arrhythmia": {
            "site_of_effect": "Cardiac conduction system",
            "mechanism": "Slows atrioventricular conduction",
            "direction": "Decrease",
            "magnitude": "Moderate",
            "timeframe": "Onset within 2 hours"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated blood pressure"],
            "therapeutic_action": "Reduces blood pressure",
            "optimal_dosage": "2.5-10mg daily",
            "response_time": "Improvement seen within 1-2 weeks"
        },
        "Heart Failure": {
            "symptoms_addressed": ["Shortness of breath", "Edema"],
            "therapeutic_action": "Improves cardiac function",
            "optimal_dosage": "1.25-10mg daily",
            "response_time": "Effect builds over weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart block", "Severe bronchospasm in asthmatics"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart rate", "Blood pressure", "Renal function"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Heart rate": "60-100 bpm",
                "Blood pressure": "<140/90 mmHg"
            },
            "alert_threshold": {
                "Heart rate": "<50 bpm",
                "Blood pressure": "<90/60 mmHg"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower doses due to slower metabolism",
            "rationale": "Increased risk of bradycardia and hypotension"
        },
        "Asthmatics": {
            "adjustments": "Avoid use due to risk of bronchospasm",
            "rationale": "Potential beta-2 receptor blockade"
        }
    },
    "alternative_therapies": ["Hawthorn extract (Crataegus)", "Magnesium supplementation", "Mindfulness-Based Stress Reduction (MBSR)", "Aerobic Exercise"],
    "combination_therapies": {
        "recommended_combinations": ["Hawthorn + Omega-3 Fatty Acids (e.g., Fish Oil)", "Yoga + Biofeedback Training"],
        "cautions": ["Avoid combining with caffeine or other stimulants due to potential cardiovascular effects."]
    },
    "contraindications": ["Severe bradycardia", "Cardiogenic shock", "Asthma"],
    "precautions": ["Use with caution in diabetic patients as it may mask hypoglycemia symptoms"],
    "side_effects": ["Fatigue", "Dizziness", "Bradycardia"],
    "overdose_management": {
        "symptoms": ["Severe bradycardia", "Hypotension", "Heart block"],
        "treatment": ["Atropine for bradycardia", "Glucagon to counteract beta-blockade"]
    },
    "notes": "Bisoprolol is a cardioselective beta-blocker preferred in patients with coexisting respiratory conditions."
},


 {
    "iupac_name": "1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid",
    "chemical_formula": "C17H18FN3O3",
    "brand_names": ["Ciprol", "Ciproxin", "Ciprolet", "Cifran", "Cilodex", "Quinabic", "Ciflox", "Cyprobay", "Prociflor", "Baycip", "Cetraxal Plus", "Ciprodex", "Ciprosol", "Ciproxina"],
    "category": "Antibiotic (Fluoroquinolone)",
    "dosage_forms": ["Tablet", "Suspension", "Injection", "Eye Drops", "Ear Drops"],
    "strengths": ["250mg", "500mg", "750mg"],
    "mechanism_of_action": {
        "site_of_action": "Bacterial DNA gyrase and topoisomerase IV",
        "physiological_mechanism": "Inhibits bacterial DNA synthesis by targeting DNA gyrase and topoisomerase IV, leading to bacterial cell death."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Cells",
            "effect": "Prevents replication and repair of bacterial DNA, causing cell death.",
            "timeframe": "Bactericidal effects typically occur within hours after administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "DNA replication inhibition",
        "key_targets": ["DNA Gyrase", "Topoisomerase IV"],
        "related_conditions": ["Bacterial Infections", "UTI", "Respiratory Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with ~70% bioavailability.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2"],
            "notes": "Minimal metabolism; mostly excreted unchanged."
        },
        "elimination": "Primarily excreted in the urine; half-life ~4 hours."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Chelation with ciprofloxacin reduces absorption.",
            "effect": "Decreased effectiveness of ciprofloxacin.",
            "recommendation": "Take ciprofloxacin 2 hours before or 6 hours after antacids."
        },
        "Theophylline": {
            "site_of_interaction": "Liver (CYP1A2)",
            "mechanism": "Inhibits theophylline metabolism, increasing levels.",
            "effect": "Risk of theophylline toxicity.",
            "recommendation": "Monitor theophylline levels closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Calcium (reduces absorption)", "Magnesium"],
        "toxins": ["Alcohol"],
        "microbiota_effects": "Disrupts gut flora, leading to dysbiosis and potential secondary infections like C. difficile."
    },
    "effects_on_symptoms": {
        "bacterial_infections": {
            "site_of_effect": "Infected tissues",
            "mechanism": "Eliminates bacteria causing infection.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Symptom relief within 48-72 hours."
        }
    },
    "diagnostic_conditions": {
        "UTI": {
            "symptoms_addressed": ["Frequent urination", "Burning sensation during urination"],
            "therapeutic_action": "Eliminates causative bacterial pathogens.",
            "optimal_dosage": "250-500mg twice daily for 3-14 days.",
            "response_time": "Improvement seen within 48-72 hours."
        },
        "Respiratory Infections": {
            "symptoms_addressed": ["Cough", "Shortness of breath", "Chest pain"],
            "therapeutic_action": "Targets bacterial pathogens causing respiratory infections.",
            "optimal_dosage": "500-750mg twice daily for 7-14 days.",
            "response_time": "Improvement seen within 3-5 days."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea"],
        "moderate": ["Dizziness", "Photosensitivity"],
        "severe": ["Tendon rupture", "QT prolongation"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal function", "Tendon integrity"],
        "frequency": "Monitor renal function every week during extended use.",
        "clinical_thresholds": {
            "normal_range": {
                "Creatinine Clearance": ">90 mL/min"
            },
            "alert_threshold": {
                "Creatinine Clearance": "<30 mL/min"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Lower doses due to reduced renal function.",
            "rationale": "Increased risk of tendon rupture and CNS effects."
        },
        "children": {
            "adjustments": "Not recommended unless absolutely necessary.",
            "rationale": "Potential for joint and cartilage damage."
        },
        "pregnant": {
            "adjustments": "Avoid use unless benefits outweigh risks.",
            "rationale": "Potential teratogenic effects."
        }
    },
    "alternative_therapies": ["Garlic extract (Allicin)", "Honey (Manuka honey)", "Berberine (found in goldenseal)", "Cranberry extract (for UTIs)", "Probiotics (gut health restoration)"],
    "combination_therapies": {
        "recommended_combinations": ["Cranberry Extract + Probiotics for UTI prevention", "Garlic + Honey for localized infections"],
        "cautions": ["Avoid combining with substances that chelate ciprofloxacin (e.g., calcium)."]
    },
    "contraindications": [
        "Myasthenia gravis",
        "Hypersensitivity to ciprofloxacin or other fluoroquinolones"
    ],
    "precautions": [
        "Avoid excessive sun exposure due to photosensitivity.",
        "Caution in patients with a history of seizures."
    ],
    "side_effects": [
        "Nausea",
        "Diarrhea",
        "Headache",
        "Tendonitis"
    ],
    "overdose_management": {
        "symptoms": [
            "Nausea",
            "Dizziness",
            "Seizures"
        ],
        "treatment": [
            "Gastric lavage",
            "Activated charcoal",
            "Supportive measures"
        ]
    },
    "notes": "Ciprofloxacin is effective but should be used judiciously to prevent resistance. Avoid unnecessary use for viral infections."
},

  
  {
    "iupac_name": "9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione",
    "chemical_formula": "C22H29FO5",
    "brand_names": ["Decadron", "DexPak", "Ozurdex", "Baycadron", "Dexasone", "Hexadrol", "Maxidex", "Dexaven", "Dexameth", "Neofordex", "Dexamethasone Intensol", "Dexone", "Solurex", "Baycadron Elixir", "Dekpak 13 Day Taperpak", "DexPak 10 Day TaperPak", "DexPak Jr", "Zema-Pak", "Dexacort", "Dexacort Phosphate in Turbinaire", "Dexafree", "Dropodex", "Eythalm", "Dexycu", "Dextenza", "Dexacine", "Dexacidin", "TobraDex", "TobraDex ST", "Ciprodex", "Neo-Dex", "Neo-Decadron", "Maxitrol", "Poly-Dex", "Dexasporin", "Dexair"],
    "category": "Corticosteroid / Anti-inflammatory",
    "dosage_forms": ["Tablet", "Injection", "Ophthalmic Solution", "Cream", "Ointment"],
    "strengths": ["0.5mg", "4mg", "8mg", "40mg/mL (Injection)"],
    "mechanism_of_action": {
        "site_of_action": "Glucocorticoid receptors in cells throughout the body",
        "physiological_mechanism": "Suppresses inflammation and immune response by inhibiting cytokine production and prostaglandin synthesis, reducing leukocyte migration and capillary permeability."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Immunosuppression via cytokine inhibition.",
            "timeframe": "Onset within 1-2 hours."
        },
        {
            "system": "Inflammatory Response",
            "effect": "Reduction of inflammation through inhibition of prostaglandin and leukotriene pathways.",
            "timeframe": "Onset within 1-2 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Glucocorticoid signaling pathway",
        "key_targets": ["Glucocorticoid receptor", "Cytokines", "Prostaglandins"],
        "related_conditions": ["Inflammation", "Autoimmune diseases", "Allergic reactions"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally; peak plasma levels reached within 1-2 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to inactive metabolites for renal excretion."
        },
        "elimination": "Primarily excreted via the kidneys; half-life of 36-54 hours."
    },
    "interactions": {
        "NSAIDs": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Increased risk of GI bleeding and ulceration.",
            "effect": "Additive gastrointestinal toxicity.",
            "recommendation": "Use with caution; consider gastroprotective agents."
        },
        "Rifampin": {
            "site_of_interaction": "Liver enzymes (CYP3A4)",
            "mechanism": "Induces metabolism, reducing efficacy.",
            "effect": "Decreased therapeutic effect of dexamethasone.",
            "recommendation": "Adjust dose if used concurrently."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Calcium", "Vitamin D"],
        "toxins": ["Alcohol (increases risk of gastrointestinal bleeding)"],
        "microbiota_effects": "Potential alteration of gut flora with prolonged use."
    },
    "effects_on_symptoms": {
        "inflammation": {
            "site_of_effect": "Inflamed tissues",
            "mechanism": "Reduces cytokine and mediator release.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Onset within 1-2 hours."
        },
        "allergic_reaction": {
            "site_of_effect": "Immune cells",
            "mechanism": "Suppresses hypersensitivity response.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Onset within 1-2 hours."
        }
    },
    "diagnostic_conditions": {
        "inflammation": {
            "symptoms_addressed": ["Swelling", "Pain", "Redness"],
            "therapeutic_action": "Reduces inflammation.",
            "optimal_dosage": "4-8mg per day in divided doses.",
            "response_time": "Improvement seen within hours."
        },
        "allergic_reactions": {
            "symptoms_addressed": ["Itching", "Hives", "Rash"],
            "therapeutic_action": "Suppresses immune overreaction.",
            "optimal_dosage": "0.5-4mg per day depending on severity.",
            "response_time": "Rapid symptom control within hours."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Insomnia"],
        "moderate": ["Weight gain", "Mood swings"],
        "severe": ["Adrenal suppression", "Osteoporosis", "Cushing's syndrome"]
    },
    "long_term_monitoring": {
        "parameters": ["Bone density", "Blood glucose", "Electrolytes"],
        "frequency": "Every 6 months for long-term use.",
        "clinical_thresholds": {
            "normal_range": {
                "Blood glucose": "70-140 mg/dL",
                "Bone density": "Normal for age and sex"
            },
            "alert_threshold": {
                "Blood glucose": ">200 mg/dL",
                "Bone density": "T-score below -2.5"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use lower doses to reduce risk of osteoporosis.",
            "rationale": "Increased susceptibility to bone loss."
        },
        "children": {
            "adjustments": "Use with caution; monitor growth and development.",
            "rationale": "Risk of growth suppression with long-term use."
        },
        "pregnant": {
            "adjustments": "Use only if benefits outweigh risks.",
            "rationale": "Potential risks to fetal development."
        }
    },
    "alternative_therapies": ["Turmeric (Curcumin)", "Boswellia serrata (Frankincense)", "Omega-3 Fatty Acids"],
    "combination_therapies": {
        "recommended_combinations": ["Dexamethasone + Antihistamines (for severe allergies)"],
        "cautions": ["Avoid combining with other immunosuppressants unless necessary."]
    },
    "contraindications": [
        "Systemic fungal infections",
        "Hypersensitivity to dexamethasone or other corticosteroids"
    ],
    "precautions": [
        "Monitor for adrenal suppression with prolonged use.",
        "Use with caution in diabetic patients due to hyperglycemia risk."
    ],
    "side_effects": [
        "Nausea",
        "Mood changes",
        "Hyperglycemia",
        "Fluid retention"
    ],
    "overdose_management": {
        "symptoms": ["Cushingoid appearance", "Hypertension", "Hyperglycemia"],
        "treatment": ["Gradual dose reduction", "Supportive care"]
    },
    "notes": "Dexamethasone is a potent anti-inflammatory and immunosuppressive agent. Prolonged use requires monitoring for side effects such as adrenal suppression and osteoporosis."
},

  {
    "iupac_name": "(S)-1-[4-(dimethylamino)phenyl]-1-hydroxy-3-(4-fluorophenyl)propan-1-one",
    "chemical_formula": "C20H21FN2O",
    "brand_names": ["Lexapro", "Cipralex", "Escitalopram Oxalate", "Esipram", "Esertia", "Lexamil", "Lexapram", "Seroplex", "Seroplex Duo", "Zentro", "Nexpram", "Cittac", "Relaxion", "Eltropram"],
    "category": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "dosage_forms": ["Tablet", "Oral solution"],
    "strengths": ["5mg", "10mg", "20mg"],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System (CNS)",
        "physiological_mechanism": "Inhibits the reuptake of serotonin (5-HT) in the synaptic cleft by selectively targeting the serotonin transporter (SERT), increasing serotonin availability."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Improved mood, reduction in anxiety symptoms.",
            "timeframe": "Onset in 1-2 weeks; full effects within 4-6 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin reuptake inhibition",
        "key_targets": ["Serotonin transporter (SERT)"],
        "related_conditions": ["Major Depressive Disorder", "Generalized Anxiety Disorder"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with peak plasma levels in 4-5 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4", "CYP2D6"],
            "notes": "Metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted in urine; half-life ~27-32 hours."
    },
    "interactions": {
        "Monoamine Oxidase Inhibitors (MAOIs)": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Risk of serotonin syndrome due to excessive serotonin levels.",
            "effect": "Agitation, hypertension, hyperthermia.",
            "recommendation": "Avoid concurrent use; maintain a 14-day washout period."
        },
        "NSAIDs": {
            "site_of_interaction": "Platelets",
            "mechanism": "Reduced platelet aggregation.",
            "effect": "Increased risk of bleeding.",
            "recommendation": "Monitor for signs of bleeding; use caution."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Alcohol (increased sedation)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "depression": {
            "site_of_effect": "CNS (serotonin reuptake inhibition)",
            "mechanism": "Increases serotonin availability to alleviate depressive symptoms.",
            "direction": "decrease",
            "magnitude": "moderate to significant",
            "timeframe": "1-2 weeks for noticeable improvement."
        },
        "anxiety": {
            "site_of_effect": "CNS",
            "mechanism": "Increases serotonin levels, reducing anxiety symptoms.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "2-4 weeks for significant reduction."
        }
    },
    "diagnostic_conditions": {
        "major_depressive_disorder": {
            "symptoms_addressed": ["Persistent sadness", "Lack of energy", "Sleep disturbances"],
            "therapeutic_action": "Improves mood and energy levels.",
            "optimal_dosage": "10-20mg daily.",
            "response_time": "Improvement within 1-2 weeks; full effects in 4-6 weeks."
        },
        "generalized_anxiety_disorder": {
            "symptoms_addressed": ["Excessive worry", "Restlessness", "Difficulty concentrating"],
            "therapeutic_action": "Reduces anxiety symptoms.",
            "optimal_dosage": "10-20mg daily.",
            "response_time": "Improvement within 2-4 weeks."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dry mouth", "Fatigue"],
        "moderate": ["Insomnia", "Sexual dysfunction"],
        "severe": ["Serotonin syndrome", "QT prolongation (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Electrocardiogram (ECG)", "Electrolytes"],
        "frequency": "Monitor every 6-12 months.",
        "clinical_thresholds": {
            "normal_range": {
                "QT interval": "<450ms"
            },
            "alert_threshold": {
                "QT interval": ">500ms"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Start at lower doses (5-10mg daily).",
            "rationale": "Increased sensitivity to side effects and prolonged drug half-life."
        },
        "children": {
            "adjustments": "Not recommended for individuals under 18 without specific clinical indication.",
            "rationale": "Limited evidence of safety and efficacy."
        },
        "pregnant": {
            "adjustments": "Use only if benefits outweigh risks.",
            "rationale": "Potential for neonatal adaptation syndrome."
        }
    },
    "alternative_therapies": ["St. John's Wort", "Mindfulness-Based Cognitive Therapy (MBCT)", "Omega-3 Fatty Acid Supplementation", "Regular Physical Exercise"],
    "combination_therapies": {
        "recommended_combinations": ["SSRI + CBT (Cognitive Behavioral Therapy)", "SSRI + Omega-3 Supplementation"],
        "cautions": ["Avoid combining with other serotonergic drugs due to serotonin syndrome risk."]
    },
    "contraindications": [
        "Concurrent use of MAOIs",
        "Known hypersensitivity to escitalopram or its components"
    ],
    "precautions": [
        "Monitor for worsening depression or suicidal ideation, especially in the first few weeks of treatment.",
        "Caution in patients with hepatic impairment."
    ],
    "side_effects": [
        "Nausea",
        "Insomnia",
        "Fatigue",
        "Sexual dysfunction"
    ],
    "overdose_management": {
        "symptoms": [
            "Dizziness",
            "Tremors",
            "Agitation",
            "Seizures"
        ],
        "treatment": [
            "Supportive care",
            "Activated charcoal if within 1 hour of ingestion."
        ]
    },
    "notes": "Escitalopram is effective for both depression and anxiety disorders, with a favorable side effect profile compared to older antidepressants. Monitor patients for adherence and symptom improvement."
},

  
  {
    "iupac_name": "N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide",
    "chemical_formula": "C22H28N2O",
    "brand_names": [
    "Duragesic", 
    "Actiq", 
    "Sublimaze", 
    "Fentora", 
    "Abstral", 
    "Lazanda", 
    "Onsolis", 
    "Subsys", 
    "Instanyl", 
    "Matrifen", 
    "Durogesic", 
    "Effentora", 
    "Fentanyl"
]
,
    "category": "Opioid Analgesic",
    "dosage_forms": ["Transdermal patch", "Lozenge", "Buccal tablet", "Nasal spray", "Injectable solution"],
    "strengths": ["12 mcg/h", "25 mcg/h", "50 mcg/h", "75 mcg/h", "100 mcg/h"],
    "mechanism_of_action": {
        "site_of_action": "Central nervous system (CNS)",
        "physiological_mechanism": "Binds to μ-opioid receptors in the CNS to produce analgesia and euphoria."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Pain relief and sedation.",
            "timeframe": "Onset within minutes (IV) to hours (patch); duration depends on the route."
        },
        {
            "system": "Respiratory System",
            "effect": "Respiratory depression.",
            "timeframe": "Onset within minutes (IV); duration depends on the dose."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Opioid receptor signaling",
        "key_targets": ["μ-opioid receptor"],
        "related_conditions": ["Severe pain", "Breakthrough cancer pain"]
    },
    "pharmacokinetics": {
        "absorption": "Varies by route; transdermal provides steady absorption over 72 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Excreted primarily in urine; half-life varies by route (transdermal ~17 hours)."
    },
    "interactions": {
        "Benzodiazepines": {
            "site_of_interaction": "CNS",
            "mechanism": "Additive respiratory depression.",
            "effect": "Increased risk of fatal respiratory depression.",
            "recommendation": "Avoid concurrent use unless medically necessary."
        },
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Reduced metabolism of fentanyl.",
            "effect": "Increased fentanyl plasma levels and risk of toxicity.",
            "recommendation": "Monitor and adjust dose."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Alcohol (increases CNS depression)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "pain": {
            "site_of_effect": "CNS (μ-opioid receptor activation)",
            "mechanism": "Blocks pain signal transmission in the spinal cord and brain.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Onset within minutes to hours depending on route."
        }
    },
    "diagnostic_conditions": {
        "severe_pain": {
            "symptoms_addressed": ["Severe and chronic pain"],
            "therapeutic_action": "Provides significant analgesia.",
            "optimal_dosage": "Depends on route; transdermal patch typically 12-100 mcg/h.",
            "response_time": "Effect observed within minutes to hours."
        },
        "breakthrough_cancer_pain": {
            "symptoms_addressed": ["Severe episodic pain in cancer patients"],
            "therapeutic_action": "Rapid pain relief.",
            "optimal_dosage": "Buccal or nasal forms tailored to patient needs.",
            "response_time": "Onset within 5-10 minutes."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Constipation"],
        "moderate": ["Sedation", "Confusion"],
        "severe": ["Respiratory depression", "Bradycardia", "Addiction"]
    },
    "long_term_monitoring": {
        "parameters": ["Respiratory rate", "Liver function tests"],
        "frequency": "Monitor regularly during chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Respiratory rate": ">12 breaths/min"
            },
            "alert_threshold": {
                "Respiratory rate": "<10 breaths/min"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use with caution; start at lower doses.",
            "rationale": "Increased sensitivity to opioids."
        },
        "children": {
            "adjustments": "Not recommended for children under 2 years.",
            "rationale": "Safety and efficacy not established."
        },
        "pregnant": {
            "adjustments": "Avoid use unless clearly needed.",
            "rationale": "Risk of neonatal withdrawal syndrome."
        }
    },
    "alternative_therapies": ["Acupuncture", "Mindfulness-Based Stress Reduction (MBSR)", "Physical therapy"],
    "combination_therapies": {
        "recommended_combinations": ["Fentanyl + Adjuvant Analgesics (e.g., Gabapentin)"],
        "cautions": ["Avoid combining with CNS depressants like benzodiazepines."]
    },
    "contraindications": [
        "Severe respiratory depression",
        "Acute or severe asthma"
    ],
    "precautions": [
        "Use with caution in hepatic or renal impairment.",
        "Avoid concurrent alcohol use."
    ],
    "side_effects": [
        "Nausea",
        "Drowsiness",
        "Respiratory depression"
    ],
    "overdose_management": {
        "symptoms": [
            "Severe respiratory depression",
            "Unconsciousness",
            "Bradycardia"
        ],
        "treatment": [
            "Administer naloxone as an antidote.",
            "Provide supportive care (e.g., oxygen therapy)."
        ]
    },
    "notes": "Fentanyl is a potent opioid analgesic with high risk of addiction and overdose; use under strict medical supervision."
},
  {
    "iupac_name": "1-(aminomethyl)cyclohexaneacetic acid",
    "chemical_formula": "C9H17NO2",
     
    "brand_names": ["Gabapentin", "Neurontin", "Gralise", "Horizant", "Gabarone", "Fanatrex", "Gabapin", "Gabix", "Gabatrex", "Nupentin", "Gabastar", "Gabafix", "Gapentin", "Neuropentin", "Pregaba", "Gabamax", "Gabantin", "Enantyum", "Lyrica (related, not identical)"],


    "category": "Anticonvulsant / Neuropathic Pain Relief",
    "dosage_forms": ["Tablet", "Capsule", "Oral Solution"],
    "strengths": ["100mg", "300mg", "400mg", "600mg", "800mg"],
    "mechanism_of_action": {
        "site_of_action": "Voltage-gated calcium channels in the central nervous system",
        "physiological_mechanism": "Modulates the release of excitatory neurotransmitters by binding to the α2δ subunit of voltage-gated calcium channels, reducing neuronal excitability."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous System",
            "effect": "Reduces neuropathic pain and seizure frequency.",
            "timeframe": "Onset of pain relief within 2-4 weeks; anticonvulsant effects may vary."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Neurotransmitter modulation via calcium channel inhibition",
        "key_targets": ["α2δ subunit of calcium channels"],
        "related_conditions": ["Neuropathic Pain", "Partial Seizures"]
    },
    "pharmacokinetics": {
        "absorption": "Slowly absorbed in the gastrointestinal tract; bioavailability decreases with higher doses.",
        "metabolism": {
            "primary_site": "Not significantly metabolized (eliminated unchanged in urine)",
            "enzymes": [],
            "notes": "Minimal involvement of liver metabolism, reducing risk of hepatic interactions."
        },
        "elimination": "Renal excretion; half-life ~5-7 hours."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Reduces gabapentin absorption.",
            "effect": "Decreased bioavailability.",
            "recommendation": "Separate administration by at least 2 hours."
        },
        "CNS Depressants": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Additive sedative effects.",
            "effect": "Increased drowsiness and dizziness.",
            "recommendation": "Use caution; avoid alcohol."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Minimal known interactions"],
        "toxins": ["Alcohol (increased CNS depression)"],
        "microbiota_effects": "No significant effects reported."
    },
    "effects_on_symptoms": {
        "neuropathic_pain": {
            "site_of_effect": "Peripheral and central nervous system",
            "mechanism": "Inhibits excitatory neurotransmitter release by modulating calcium channels.",
            "direction": "decrease",
            "magnitude": "moderate to significant",
            "timeframe": "Within 2-4 weeks of therapy initiation."
        },
        "seizures": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Modulates excitatory signaling pathways.",
            "direction": "decrease",
            "magnitude": "moderate",
            "timeframe": "Variable; dependent on dose titration."
        }
    },
    "diagnostic_conditions": {
        "neuropathic_pain": {
            "symptoms_addressed": ["Burning pain", "Tingling", "Electric shock sensations"],
            "therapeutic_action": "Reduces nerve pain through calcium channel modulation.",
            "optimal_dosage": "300mg-600mg three times daily.",
            "response_time": "Improvement observed within 2-4 weeks."
        },
        "partial_seizures": {
            "symptoms_addressed": ["Focal seizures"],
            "therapeutic_action": "Decreases seizure frequency.",
            "optimal_dosage": "900mg-1,800mg daily in divided doses.",
            "response_time": "Efficacy seen after dose stabilization."
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Dizziness", "Fatigue"],
        "moderate": ["Ataxia", "Peripheral edema"],
        "severe": ["Severe hypersensitivity reactions", "Suicidal thoughts (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal function (creatinine clearance)"],
        "frequency": "Baseline and periodically during therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Creatinine Clearance": "≥60 mL/min"
            },
            "alert_threshold": {
                "Creatinine Clearance": "<30 mL/min"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Lower initial doses due to reduced renal clearance.",
            "rationale": "Increased risk of accumulation and adverse effects."
        },
        "renal_impairment": {
            "adjustments": "Dose adjustment based on creatinine clearance.",
            "rationale": "Elimination is entirely renal."
        },
        "pregnant": {
            "adjustments": "Use only if benefits outweigh risks.",
            "rationale": "Limited safety data in pregnancy."
        }
    },
    "alternative_therapies": ["Capsaicin Cream", "Alpha-lipoic Acid", "Acupuncture"],
    "combination_therapies": {
        "recommended_combinations": ["Gabapentin + Nortriptyline (for neuropathic pain)", "Gabapentin + Pregabalin (if monotherapy fails)"],
        "cautions": ["Avoid combining with CNS depressants without medical supervision."]
    },
    "contraindications": [
        "Severe renal impairment without dose adjustment",
        "Hypersensitivity to gabapentin"
    ],
    "precautions": [
        "Avoid abrupt discontinuation to prevent withdrawal seizures.",
        "Use with caution in patients with depression or suicidal ideation."
    ],
    "side_effects": [
        "Dizziness",
        "Fatigue",
        "Peripheral edema"
    ],
    "overdose_management": {
        "symptoms": [
            "Severe drowsiness",
            "Slurred speech",
            "Respiratory depression"
        ],
        "treatment": [
            "Supportive care",
            "Hemodialysis in severe cases."
        ]
    },
    "notes": "Gabapentin is effective for neuropathic pain but requires careful dose titration to balance efficacy and side effects."
},

  {
    "iupac_name": "3-[(4-methylpiperazin-1-yl)imino]methyl]rifamycin",
    "chemical_formula": "C43H58N4O12",
    "brand_names": ["Rifampicin", "Rifadin", "Rimactane", "R-cin", "Rifa", "Rifazid", "Rifater", "Rifamate", "Mycobutin", "Rifabutin", "Rifa-X"],
    "category": "Antibiotic (Rifamycin class)",
    "dosage_forms": ["Capsule", "Tablet", "Injection", "Syrup"],
    "strengths": ["150mg", "300mg", "600mg"],
    "mechanism_of_action": {
        "site_of_action": "RNA polymerase in bacteria",
        "physiological_mechanism": "Inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, suppressing transcription."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Infectious agent",
            "effect": "Inhibits bacterial replication.",
            "timeframe": "Rapid bactericidal action within hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Bacterial RNA transcription inhibition",
        "key_targets": ["RNA polymerase"],
        "related_conditions": ["Tuberculosis", "Leprosy", "Brucellosis"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally; bioavailability reduced by food.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Induces its own metabolism with chronic use."
        },
        "elimination": "Primarily excreted in bile and urine; half-life ~3-5 hours."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver (CYP enzymes)",
            "mechanism": "Induces metabolism of warfarin.",
            "effect": "Decreased anticoagulant effect.",
            "recommendation": "Monitor INR and adjust dose as needed."
        },
        "Oral Contraceptives": {
            "site_of_interaction": "Liver (CYP enzymes)",
            "mechanism": "Increased metabolism of contraceptives.",
            "effect": "Reduced efficacy of contraception.",
            "recommendation": "Use alternative or additional contraception methods."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin D metabolism alteration"],
        "toxins": ["Alcohol (increased hepatotoxicity risk)"],
        "microbiota_effects": "Disrupts gut flora, potentially leading to diarrhea."
    },
    "effects_on_symptoms": {
        "Tuberculosis": {
            "site_of_effect": "Lungs and systemic circulation",
            "mechanism": "Kills Mycobacterium tuberculosis through RNA synthesis inhibition.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Improvement within weeks of therapy."
        }
    },
    "diagnostic_conditions": {
        "Tuberculosis": {
            "symptoms_addressed": ["Chronic cough", "Weight loss", "Night sweats"],
            "therapeutic_action": "Kills mycobacteria.",
            "optimal_dosage": "600mg once daily.",
            "response_time": "Significant improvement within 2-4 weeks."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Rash"],
        "moderate": ["Hepatitis", "Flu-like symptoms"],
        "severe": ["Severe liver toxicity", "Hypersensitivity reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver enzymes (ALT/AST)", "Complete blood count (CBC)"],
        "frequency": "Monitor monthly during treatment.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "ALT/AST": ">2x upper normal limit"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Monitor liver function closely.",
            "rationale": "Increased risk of hepatotoxicity."
        },
        "children": {
            "adjustments": "Weight-based dosing required.",
            "rationale": "Ensure accurate dosing to avoid toxicity."
        },
        "pregnant": {
            "adjustments": "Use with caution; benefits should outweigh risks.",
            "rationale": "Potential teratogenic effects in first trimester."
        }
    },
    "alternative_therapies": ["Herbal remedies (e.g., Andrographis paniculata)", "Dietary supplementation with curcumin (anti-inflammatory properties)"],
    "combination_therapies": {
        "recommended_combinations": ["Rifampicin + Isoniazid (for tuberculosis)", "Rifampicin + Pyrazinamide"],
        "cautions": ["Avoid with strong CYP3A4 inducers."]
    },
    "contraindications": [
        "Severe liver disease",
        "Hypersensitivity to rifampicin or other rifamycins"
    ],
    "precautions": [
        "Monitor liver function tests regularly.",
        "Avoid alcohol during treatment."
    ],
    "side_effects": [
        "Nausea",
        "Vomiting",
        "Orange discoloration of bodily fluids"
    ],
    "overdose_management": {
        "symptoms": [
            "Nausea",
            "Vomiting",
            "Abdominal pain",
            "Liver failure"
        ],
        "treatment": [
            "Supportive care",
            "Activated charcoal if within 1-2 hours of ingestion"
        ]
    },
    "notes": "Rifampicin is a key drug in tuberculosis treatment but requires adherence to monitoring due to its hepatotoxicity potential."
},

  
 {
    "iupac_name": "methyl 2-phenyl-2-(piperidin-2-yl)acetate",
    "chemical_formula": "C14H19NO2",
    "brand_names": ["Ritalin", "Concerta", "Concerta XL", "Metadate", "Quillivant XR", "Daytrana", "Aptensio XR", "Cotempla XR-ODT", "Methylin", "Ritalin LA", "Ritalin-SR", "Equasym XL", "Foquest", "Tranquilyn", "Medikinet", "Relexxii"],
    "category": "CNS Stimulant",
    "dosage_forms": ["Tablet", "Capsule", "Oral Solution", "Transdermal Patch"],
    "strengths": ["5mg", "10mg", "20mg", "30mg", "40mg", "54mg"],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Blocks dopamine and norepinephrine reuptake transporters, increasing their availability in the synaptic cleft."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Improves attention span and reduces impulsivity.",
            "timeframe": "Effect observed within 30-60 minutes; duration varies by formulation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Dopaminergic and noradrenergic signaling pathways",
        "key_targets": ["Dopamine transporter (DAT)", "Norepinephrine transporter (NET)"],
        "related_conditions": ["ADHD", "Narcolepsy"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed orally; bioavailability varies by formulation.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Carboxylesterase 1"],
            "notes": "Metabolized to inactive ritalinic acid."
        },
        "elimination": "Primarily excreted via the urine; half-life ~2-4 hours for immediate-release."
    },
    "interactions": {
        "Monoamine Oxidase Inhibitors (MAOIs)": {
            "site_of_interaction": "CNS",
            "mechanism": "Potentiates release of norepinephrine and dopamine.",
            "effect": "Increased risk of hypertensive crisis.",
            "recommendation": "Avoid concurrent use or use within 14 days of MAOI therapy."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin C (may reduce absorption)"],
        "toxins": ["Alcohol (may increase release rate of extended-release formulations)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "ADHD": {
            "site_of_effect": "Prefrontal Cortex",
            "mechanism": "Enhances dopamine and norepinephrine activity.",
            "direction": "Decrease in hyperactivity and inattention.",
            "magnitude": "Significant",
            "timeframe": "Within 30-60 minutes."
        }
    },
    "diagnostic_conditions": {
        "ADHD": {
            "symptoms_addressed": ["Inattention", "Hyperactivity", "Impulsivity"],
            "therapeutic_action": "Improves attention span and reduces impulsivity.",
            "optimal_dosage": "Varies by formulation and patient response; generally 10mg-54mg daily.",
            "response_time": "Improvement observed within the first week."
        }
    },
    "adverse_effects": {
        "mild": ["Loss of appetite", "Insomnia"],
        "moderate": ["Irritability", "Tachycardia"],
        "severe": ["Hypertension", "Psychosis (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart rate", "Blood pressure", "Weight"],
        "frequency": "Monitor every 6 months during chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Heart rate": "60-100 bpm",
                "Blood pressure": "120/80 mmHg"
            },
            "alert_threshold": {
                "Heart rate": ">100 bpm",
                "Blood pressure": ">140/90 mmHg"
            }
        }
    },
    "population_specific": {
        "children": {
            "adjustments": "Dose based on weight; typically 0.3-1mg/kg.",
            "rationale": "Avoid excessive dosing to minimize side effects."
        },
        "elderly": {
            "adjustments": "Use with caution; monitor cardiovascular status.",
            "rationale": "Increased sensitivity to stimulants."
        }
    },
    "alternative_therapies": ["Ephedra sinica (natural stimulant)", "Rhodiola rosea (adaptogen)", "Ginkgo biloba (memory enhancement)", "Behavioral therapy", "Cognitive-behavioral therapy"],
    "combination_therapies": {
        "recommended_combinations": ["Methylphenidate + Behavioral Therapy"],
        "cautions": ["Avoid combining with other CNS stimulants."]
    },
    "contraindications": [
        "Severe anxiety",
        "Tourette syndrome",
        "Cardiac arrhythmias"
    ],
    "precautions": [
        "Use cautiously in patients with a history of substance abuse.",
        "Monitor growth in pediatric patients."
    ],
    "side_effects": [
        "Headache",
        "Decreased appetite",
        "Nervousness",
        "Insomnia"
    ],
    "overdose_management": {
        "symptoms": [
            "Agitation",
            "Tachycardia",
            "Seizures"
        ],
        "treatment": [
            "Supportive care",
            "Cooling measures for hyperthermia"
        ]
    },
    "notes": "Plant-based alternatives like Ephedra sinica may provide mild stimulation but require caution due to cardiovascular risks."
},
 
  
  
  
  
  
  

{
    "iupac_name": "1-phenylpropan-2-amine",
    "chemical_formula": "C9H13N",
    "brand_names": ["Adderall", "Adderall XR", "Mydayis", "Evekeo", "Dyanavel XR", "Adzenys XR-ODT", "Adzenys ER", "Vyvanse"],
    "category": "Central Nervous System Stimulant",
    "dosage_forms": ["Tablet", "Extended-Release Capsule", "Oral Suspension"],
    "strengths": ["5mg", "10mg", "20mg", "30mg"],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Increases the release of norepinephrine and dopamine by stimulating adrenergic receptors and inhibiting reuptake at synapses."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Increases alertness, focus, and energy levels.",
            "timeframe": "Onset within 30-60 minutes; lasts 4-6 hours for immediate-release formulations."
        },
        {
            "system": "Cardiovascular System",
            "effect": "Increases heart rate and blood pressure.",
            "timeframe": "Onset within 30 minutes."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic signaling",
        "key_targets": ["Dopamine transporter (DAT)", "Norepinephrine transporter (NET)"],
        "related_conditions": ["Attention Deficit Hyperactivity Disorder (ADHD)", "Narcolepsy"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the gastrointestinal tract; peak plasma concentrations reached within 3 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Metabolized to active metabolites."
        },
        "elimination": "Primarily excreted via urine; half-life ~10 hours."
    },
    "interactions": {
        "Monoamine Oxidase Inhibitors (MAOIs)": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Increased release of monoamines leading to hypertensive crisis.",
            "effect": "Severe increase in blood pressure.",
            "recommendation": "Avoid use within 14 days of MAOI administration."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin C (reduces absorption)"],
        "toxins": ["Alcohol (increases CNS stimulation)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "ADHD symptoms": {
            "site_of_effect": "Prefrontal Cortex",
            "mechanism": "Increases norepinephrine and dopamine availability, improving executive function.",
            "direction": "decrease",
            "magnitude": "significant",
            "timeframe": "Noticeable effects within 1-2 hours."
        }
    },
    "diagnostic_conditions": {
        "ADHD": {
            "symptoms_addressed": ["Inattention", "Hyperactivity", "Impulsivity"],
            "therapeutic_action": "Improves focus and reduces hyperactivity.",
            "optimal_dosage": "5-30mg per day as needed.",
            "response_time": "Effects within 1-2 hours."
        }
    },
    "adverse_effects": {
        "mild": ["Nervousness", "Insomnia", "Loss of appetite"],
        "moderate": ["Increased blood pressure", "Palpitations", "Tachycardia"],
        "severe": ["Psychosis", "Mania", "Addiction potential"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood pressure", "Heart rate", "Growth in children"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Blood Pressure": "<120/80 mmHg",
                "Heart Rate": "<100 bpm"
            },
            "alert_threshold": {
                "Blood Pressure": ">140/90 mmHg",
                "Heart Rate": ">120 bpm"
            }
        }
    },
    "population_specific": {
        "children": {
            "adjustments": "Dose based on weight and response.",
            "rationale": "Higher risk of growth suppression."
        },
        "elderly": {
            "adjustments": "Use with caution; monitor cardiovascular health.",
            "rationale": "Increased risk of cardiovascular effects."
        }
    },
    "alternative_therapies": ["Ephedra sinica (natural stimulant)", "Rhodiola rosea (adaptogen)", "Cognitive Behavioral Therapy (CBT)", "Meditation and Mindfulness"],
    "combination_therapies": {
        "recommended_combinations": ["Therapy + Omega-3 Fatty Acids", "Behavioral Therapy + Biofeedback"],
        "cautions": ["Avoid combining with other stimulants."]
    },
    "contraindications": [
        "Severe cardiovascular conditions",
        "History of drug abuse"
    ],
    "precautions": [
        "Use with caution in patients with a history of psychosis.",
        "Avoid abrupt discontinuation due to withdrawal effects."
    ],
    "side_effects": [
        "Loss of appetite",
        "Insomnia",
        "Increased heart rate"
    ],
    "overdose_management": {
        "symptoms": [
            "Agitation",
            "Tremors",
            "Cardiac arrhythmias"
        ],
        "treatment": [
            "Supportive care",
            "Benzodiazepines for agitation",
            "Beta-blockers for cardiovascular symptoms"
        ]
    },
    "notes": "Ephedra sinica contains ephedrine, a natural stimulant that was historically used for respiratory conditions and as a CNS stimulant. Its use requires caution due to cardiovascular risks."
},
{
    "iupac_name": "7-(2-Aminoethyl)-1,3-dimethylpurine-2,6-dione",
    "chemical_formula": "C9H12N4O2",
    "brand_names": ["Phyllocontin", "Truphylline", "Aminophyllin", "Theophyllamin", "Norphyl", "Phyllocontin Forte", "Somophyllin Oral Solution", "Truphylline Suppositories", "Uniphyl", "Minomal", "Mudrane", "Mudrane GG", "Mudrane GG-2"],
    "category": "Bronchodilator",
    "dosage_forms": ["Tablet", "Injection", "Syrup"],
    "strengths": ["100mg", "200mg", "500mg"],
    "mechanism_of_action": {
        "site_of_action": "Smooth muscle in the bronchi",
        "physiological_mechanism": "Inhibits phosphodiesterase (PDE), leading to an increase in cAMP and relaxation of bronchial smooth muscle."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Respiratory System",
            "effect": "Relieves bronchospasm and improves airflow.",
            "timeframe": "Onset within 30 minutes for intravenous administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "cAMP signaling pathway",
        "key_targets": ["Phosphodiesterase (PDE)"],
        "related_conditions": ["Asthma", "Chronic Obstructive Pulmonary Disease (COPD)"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the gastrointestinal tract; bioavailability is ~90%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2"],
            "notes": "Metabolized to theophylline and further degraded."
        },
        "elimination": "Primarily excreted in urine; half-life ~7-9 hours."
    },
    "interactions": {
        "Caffeine": {
            "site_of_interaction": "CNS",
            "mechanism": "Additive stimulant effects.",
            "effect": "Increased risk of side effects like tachycardia.",
            "recommendation": "Limit caffeine intake during treatment."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Tobacco smoke (induces CYP1A2, reducing drug levels)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "bronchospasm": {
            "site_of_effect": "Bronchial smooth muscle",
            "mechanism": "Relaxes smooth muscle by increasing cAMP.",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "Within 30 minutes (IV)."
        }
    },
    "diagnostic_conditions": {
        "Asthma": {
            "symptoms_addressed": ["Wheezing", "Shortness of breath"],
            "therapeutic_action": "Improves airflow by relaxing bronchial smooth muscle.",
            "optimal_dosage": "Varies; typically 200-400mg orally every 6-8 hours.",
            "response_time": "Improvement observed within 30 minutes for IV."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache"],
        "moderate": ["Tachycardia", "Restlessness"],
        "severe": ["Seizures", "Arrhythmias"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum theophylline levels", "Heart rate"],
        "frequency": "Monitor every 6 months during chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Serum theophylline": "10-20 mcg/mL"
            },
            "alert_threshold": {
                "Serum theophylline": ">20 mcg/mL"
            }
        }
    },
    "population_specific": {
        "children": {
            "adjustments": "Lower doses based on body weight.",
            "rationale": "Increased sensitivity to side effects."
        },
        "elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Reduced metabolism may lead to toxicity."
        }
    },
    "alternative_therapies": ["Honey and ginger (for mild bronchospasm)", "Licorice root extract (anti-inflammatory)", "Steam inhalation"],
    "combination_therapies": {
        "recommended_combinations": ["Aminophylline + Beta-2 agonists (e.g., Albuterol)"],
        "cautions": ["Avoid combining with other xanthines."]
    },
    "contraindications": [
        "Severe cardiac arrhythmias",
        "Active peptic ulcer disease"
    ],
    "precautions": [
        "Use cautiously in patients with hepatic impairment.",
        "Avoid in patients with a history of seizures."
    ],
    "side_effects": [
        "Nausea",
        "Insomnia",
        "Tremors"
    ],
    "overdose_management": {
        "symptoms": [
            "Vomiting",
            "Severe tachycardia",
            "Seizures"
        ],
        "treatment": [
            "Activated charcoal for recent ingestion.",
            "Beta-blockers for tachycardia."
        ]
    },
    "notes": "Monitor serum levels closely to avoid toxicity, especially in patients with altered metabolism."
},

  {
    "iupac_name": "3β,12β-Dihydroxy-5β,14β-card-20(22)-enolide",
    "chemical_formula": "C41H64O14",
    "brand_names": ["Lanoxin", "Cardoxin", "Digitek", "Digox", "Lanoxicaps", "Digoxin"],

    "category": "Cardiac Glycoside",
    "dosage_forms": ["Tablet", "Oral Solution", "Injection"],
    "strengths": ["0.125mg", "0.25mg"],
    "mechanism_of_action": {
        "site_of_action": "Na+/K+-ATPase pump in cardiac myocytes",
        "physiological_mechanism": "Inhibits Na+/K+-ATPase, leading to increased intracellular calcium and enhanced cardiac contractility."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular",
            "effect": "Increases force of myocardial contraction (positive inotropy) and decreases heart rate (negative chronotropy).",
            "timeframe": "Onset within 30-120 minutes; duration up to 6 days for oral forms."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Na+/K+-ATPase inhibition",
        "key_targets": ["Na+/K+-ATPase pump"],
        "related_conditions": ["Heart Failure", "Atrial Fibrillation"]
    },
    "pharmacokinetics": {
        "absorption": "60-80% bioavailability for oral formulations.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["None significant"],
            "notes": "Primarily excreted unchanged by the kidneys."
        },
        "elimination": "Primarily renal excretion; half-life ~36-48 hours in normal renal function."
    },
    "interactions": {
        "Amiodarone": {
            "site_of_interaction": "Na+/K+-ATPase and renal clearance",
            "mechanism": "Increases digoxin levels by decreasing renal clearance.",
            "effect": "Increased risk of digoxin toxicity.",
            "recommendation": "Monitor digoxin levels and adjust dosage as needed."
        },
        "Calcium": {
            "site_of_interaction": "Cardiac myocytes",
            "mechanism": "May enhance effects of digoxin, increasing toxicity risk.",
            "effect": "Increased risk of arrhythmias.",
            "recommendation": "Use calcium cautiously in patients on digoxin."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["High-fiber foods (may reduce absorption)"],
        "toxins": ["Potassium-depleting diuretics (increase toxicity risk)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "heart_failure": {
            "site_of_effect": "Heart muscle",
            "mechanism": "Improves cardiac output by increasing myocardial contractility.",
            "direction": "Improvement",
            "magnitude": "Moderate",
            "timeframe": "Within 30-120 minutes."
        },
        "atrial_fibrillation": {
            "site_of_effect": "AV Node",
            "mechanism": "Slows conduction through AV node to control ventricular rate.",
            "direction": "Improvement",
            "magnitude": "Moderate",
            "timeframe": "Within 30-120 minutes."
        }
    },
    "diagnostic_conditions": {
        "heart_failure": {
            "symptoms_addressed": ["Fatigue", "Dyspnea", "Edema"],
            "therapeutic_action": "Improves cardiac output and reduces symptoms.",
            "optimal_dosage": "0.125-0.25mg daily based on patient response.",
            "response_time": "Symptomatic improvement within days."
        },
        "atrial_fibrillation": {
            "symptoms_addressed": ["Palpitations", "Fatigue"],
            "therapeutic_action": "Controls ventricular rate.",
            "optimal_dosage": "0.125-0.25mg daily.",
            "response_time": "Rate control observed within hours."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Fatigue"],
        "moderate": ["Blurred vision", "Bradycardia"],
        "severe": ["Arrhythmias", "Digoxin toxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum digoxin levels", "Potassium levels", "Renal function"],
        "frequency": "Monitor every 6 months or as clinically indicated.",
        "clinical_thresholds": {
            "normal_range": {
                "Serum digoxin": "0.5-2 ng/mL"
            },
            "alert_threshold": {
                "Serum digoxin": ">2 ng/mL"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use lower doses due to reduced renal clearance.",
            "rationale": "Increased risk of toxicity."
        },
        "children": {
            "adjustments": "Dose based on body weight.",
            "rationale": "Pediatric patients require individualized dosing."
        }
    },
    "alternative_therapies": ["Hawthorn extract (Crataegus)", "Coenzyme Q10", "Magnesium supplementation"],
    "combination_therapies": {
        "recommended_combinations": ["Digoxin + Beta-blockers (e.g., Metoprolol)"],
        "cautions": ["Avoid combining with other drugs affecting potassium levels."]
    },
    "contraindications": [
        "Ventricular fibrillation",
        "Hypersensitivity to digoxin"
    ],
    "precautions": [
        "Use cautiously in renal impairment.",
        "Monitor closely in patients with hypokalemia or hypercalcemia."
    ],
    "side_effects": [
        "Nausea",
        "Vomiting",
        "Blurred vision",
        "Arrhythmias"
    ],
    "overdose_management": {
        "symptoms": [
            "Confusion",
            "Nausea",
            "Arrhythmias"
        ],
        "treatment": [
            "Discontinue digoxin.",
            "Administer Digoxin-specific antibody fragments (e.g., DigiFab).",
            "Supportive care for arrhythmias."
        ]
    },
    "notes": "Digoxin requires careful monitoring due to its narrow therapeutic index."
},

  {
    "iupac_name": "6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",
    "chemical_formula": "C7H8ClN3O4S2",
    "brand_names": ["Diuril", "Esidrix", "Hydrosaluretil", "Microzide", "Hygroton", "Saluretic", "Aquazide H", "HydroDiuril", "Dichlotride", "Oretic", "Urozide", "Neo-Codema", "HCTZ", "Neo-Tiazide"],
    "category": "Diuretic / Antihypertensive",
    "dosage_forms": ["Tablet", "Capsule", "Injection"],
    "strengths": ["12.5mg", "25mg", "50mg", "100mg"],
    "mechanism_of_action": {
        "site_of_action": "Distal convoluted tubule in the kidney",
        "physiological_mechanism": "Inhibits sodium-chloride symporter, leading to increased excretion of sodium and water."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urine production and reduces fluid retention.",
            "timeframe": "Onset within 1-2 hours; lasts 6-12 hours."
        },
        {
            "system": "Cardiovascular System",
            "effect": "Decreases blood pressure via reduced plasma volume.",
            "timeframe": "Effect observed over several days of regular use."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-angiotensin-aldosterone system modulation",
        "key_targets": ["Sodium-chloride symporter"],
        "related_conditions": ["Hypertension", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed orally; bioavailability ~70%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450 enzymes"],
            "notes": "Limited hepatic metabolism; primarily excreted unchanged."
        },
        "elimination": "Excreted via the kidneys; half-life ~6-15 hours."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal system",
            "mechanism": "Enhanced potassium excretion.",
            "effect": "Increased risk of hypokalemia.",
            "recommendation": "Monitor potassium levels closely."
        },
        "NSAIDs": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Reduces diuretic efficacy by inhibiting renal prostaglandins.",
            "effect": "Diminished blood pressure control.",
            "recommendation": "Avoid concurrent use or adjust dose."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium", "Magnesium"],
        "toxins": ["Alcohol (may increase risk of hypotension)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "hypertension": {
            "site_of_effect": "Kidneys and vascular system",
            "mechanism": "Reduces plasma volume and systemic vascular resistance.",
            "direction": "Decrease",
            "magnitude": "Moderate to significant",
            "timeframe": "Several days to weeks."
        },
        "edema": {
            "site_of_effect": "Kidneys",
            "mechanism": "Increases sodium and water excretion.",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration."
        }
    },
    "diagnostic_conditions": {
        "hypertension": {
            "symptoms_addressed": ["High blood pressure", "Fluid retention"],
            "therapeutic_action": "Reduces blood pressure via diuresis.",
            "optimal_dosage": "25-50mg daily in single or divided doses.",
            "response_time": "Reduction observed within days to weeks."
        },
        "edema": {
            "symptoms_addressed": ["Swelling", "Fluid overload"],
            "therapeutic_action": "Promotes fluid excretion.",
            "optimal_dosage": "25-100mg daily as needed.",
            "response_time": "Effect within hours."
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue"],
        "moderate": ["Hypokalemia", "Hyperuricemia"],
        "severe": ["Electrolyte imbalance", "Dehydration"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum potassium", "Renal function", "Blood pressure"],
        "frequency": "Monitor every 1-3 months during chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Serum potassium": "3.5-5.0 mEq/L"
            },
            "alert_threshold": {
                "Serum potassium": "<3.0 mEq/L"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Initiate at lower doses; monitor renal function closely.",
            "rationale": "Increased sensitivity to diuretics and risk of dehydration."
        },
        "children": {
            "adjustments": "Dose based on weight; typically 0.5-1mg/kg daily.",
            "rationale": "Avoid excessive dosing to minimize side effects."
        }
    },
    "alternative_therapies": ["Dandelion root (natural diuretic)", "Parsley (diuretic effect)"],
    "combination_therapies": {
        "recommended_combinations": ["Chlorothiazide + ACE Inhibitor", "Thiazide diuretic + Potassium-sparing diuretic"],
        "cautions": ["Avoid combining with lithium due to toxicity risk."]
    },
    "contraindications": [
        "Severe renal impairment",
        "Hypersensitivity to sulfonamides"
    ],
    "precautions": [
        "Use cautiously in patients with gout.",
        "Monitor electrolytes regularly to prevent imbalances."
    ],
    "side_effects": [
        "Dizziness",
        "Fatigue",
        "Electrolyte disturbances"
    ],
    "overdose_management": {
        "symptoms": [
            "Severe dehydration",
            "Electrolyte imbalance"
        ],
        "treatment": [
            "Restore fluid and electrolyte balance.",
            "Supportive care as needed."
        ]
    },
    "notes": "Monitor electrolyte levels and renal function during prolonged use."
},

  {
    "iupac_name": "2-(4-Isobutylphenyl)propanoic acid",
    "chemical_formula": "C13H18O2",
    "brand_names": ["Ibuprofen", "Advil", "Motrin", "Nurofen", "Brufen", "Ibugesic", "Ibucap", "Midol", "Addaprin", "Caldolor", "Neoprofen", "Bufen", "Ipren", "Spididol", "Froben", "RhinAdvil", "Profenid", "Pedea"],
    "category": "Non-Steroidal Anti-Inflammatory Drug (NSAID)",
    "dosage_forms": ["Tablet", "Capsule", "Liquid Suspension", "Topical Gel", "Injection"],
    "strengths": ["200mg", "400mg", "600mg", "800mg"],
    "mechanism_of_action": {
        "site_of_action": "Cyclooxygenase enzymes (COX-1 and COX-2)",
        "physiological_mechanism": "Inhibits the synthesis of prostaglandins by blocking COX enzymes, reducing inflammation, pain, and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Musculoskeletal",
            "effect": "Reduces inflammation and alleviates pain.",
            "timeframe": "Onset within 30-60 minutes; duration of 4-6 hours."
        },
        {
            "system": "Thermoregulatory",
            "effect": "Reduces fever by lowering hypothalamic set point.",
            "timeframe": "Onset within 1 hour."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Arachidonic Acid Pathway",
        "key_targets": ["COX-1", "COX-2"],
        "related_conditions": ["Pain", "Fever", "Inflammation"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the gastrointestinal tract; peak plasma levels in 1-2 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via the kidneys; half-life ~2 hours."
    },
    "interactions": {
        "Aspirin": {
            "site_of_interaction": "Platelets",
            "mechanism": "May reduce the antiplatelet effect of aspirin.",
            "effect": "Increased risk of cardiovascular events.",
            "recommendation": "Avoid concurrent use or stagger administration."
        },
        "Warfarin": {
            "site_of_interaction": "Liver (CYP enzymes)",
            "mechanism": "Enhances anticoagulant effects.",
            "effect": "Increased risk of bleeding.",
            "recommendation": "Monitor INR closely during use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin C (may enhance absorption)"],
        "toxins": ["Alcohol (increases risk of gastrointestinal bleeding)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "pain": {
            "site_of_effect": "Peripheral tissues",
            "mechanism": "Reduces prostaglandin-mediated nociceptor activation.",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "30-60 minutes."
        },
        "fever": {
            "site_of_effect": "Hypothalamus",
            "mechanism": "Lowers hypothalamic set point via COX inhibition.",
            "direction": "Decrease",
            "magnitude": "Moderate",
            "timeframe": "Within 1 hour."
        }
    },
    "diagnostic_conditions": {
        "pain": {
            "symptoms_addressed": ["Musculoskeletal pain", "Headache", "Dental pain"],
            "therapeutic_action": "Alleviates pain by reducing inflammation.",
            "optimal_dosage": "200-800mg every 6-8 hours as needed.",
            "response_time": "Onset within 30 minutes."
        },
        "fever": {
            "symptoms_addressed": ["Elevated body temperature"],
            "therapeutic_action": "Reduces fever.",
            "optimal_dosage": "200-400mg every 4-6 hours as needed.",
            "response_time": "Effect observed within 1 hour."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Heartburn"],
        "moderate": ["Gastritis", "Edema"],
        "severe": ["Gastrointestinal bleeding", "Renal dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Kidney function", "Liver enzymes"],
        "frequency": "Monitor every 6 months during chronic use.",
        "clinical_thresholds": {
            "normal_range": {
                "Creatinine": "0.6-1.2 mg/dL",
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "Creatinine": ">1.5 mg/dL",
                "ALT/AST": ">2x upper normal limit"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use with caution; monitor renal function.",
            "rationale": "Increased risk of gastrointestinal and renal adverse effects."
        },
        "children": {
            "adjustments": "Dose based on weight (5-10mg/kg every 6-8 hours).",
            "rationale": "Ensure correct dosing to avoid toxicity."
        },
        "pregnant": {
            "adjustments": "Avoid in third trimester due to risk of premature closure of ductus arteriosus.",
            "rationale": "Potential harm to fetal cardiovascular system."
        }
    },
    "alternative_therapies": ["Willow bark extract (Salix alba)", "Turmeric (Curcuma longa)", "Ginger (Zingiber officinale)"],
    "combination_therapies": {
        "recommended_combinations": ["Ibuprofen + Acetaminophen for enhanced pain relief"],
        "cautions": ["Avoid combining with other NSAIDs to reduce gastrointestinal risk."]
    },
    "contraindications": [
        "Active peptic ulcer disease",
        "Severe renal impairment",
        "Hypersensitivity to ibuprofen or other NSAIDs"
    ],
    "precautions": [
        "Use with caution in patients with a history of gastrointestinal bleeding.",
        "Monitor blood pressure in hypertensive patients."
    ],
    "side_effects": [
        "Nausea",
        "Dizziness",
        "Headache"
    ],
    "overdose_management": {
        "symptoms": [
            "Nausea",
            "Vomiting",
            "Abdominal pain",
            "Drowsiness"
        ],
        "treatment": [
            "Supportive care",
            "Activated charcoal within 1 hour of ingestion"
        ]
    },
    "notes": "Ibuprofen is effective for mild to moderate pain and fever. Prolonged use should be monitored to avoid gastrointestinal and renal complications."
},
{
    "iupac_name": "7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine phosphate",
    "chemical_formula": "C16H15F6N5O",
    "brand_names": ["Januvia", "Ristaben", "Xelevia", "Tesavel", "Galvus Met", "Janumet", "Suganon", "Glactiv"],
    "category": "Antidiabetic (DPP-4 Inhibitor)",
    "dosage_forms": ["Tablet"],
    "strengths": ["25mg", "50mg", "100mg"],
    "mechanism_of_action": {
        "site_of_action": "Dipeptidyl peptidase-4 (DPP-4) enzyme",
        "physiological_mechanism": "Inhibits DPP-4 enzyme, increasing incretin levels (GLP-1 and GIP), which helps regulate blood glucose by increasing insulin release and decreasing glucagon secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Endocrine System",
            "effect": "Improves glycemic control by enhancing incretin levels.",
            "timeframe": "Onset within 1-4 hours; sustained action over 24 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Incretin pathway",
        "key_targets": ["DPP-4 enzyme", "GLP-1 receptor", "GIP receptor"],
        "related_conditions": ["Type 2 Diabetes Mellitus"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally; peak plasma concentration within 1-4 hours.",
        "metabolism": {
            "primary_site": "Minimally metabolized",
            "enzymes": ["CYP3A4 (minor pathway)"],
            "notes": "Primarily excreted unchanged in the urine."
        },
        "elimination": "Primarily excreted via the kidneys; half-life ~12.4 hours."
    },
    "interactions": {
        "Insulin Secretagogues": {
            "site_of_interaction": "Endocrine System",
            "mechanism": "Increases risk of hypoglycemia when combined.",
            "effect": "Potential hypoglycemia.",
            "recommendation": "Monitor glucose levels and adjust insulin secretagogue dose if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["None reported"],
        "microbiota_effects": "Minimal known impact."
    },
    "effects_on_symptoms": {
        "hyperglycemia": {
            "site_of_effect": "Pancreas (beta cells) and liver",
            "mechanism": "Enhances insulin secretion and reduces glucagon secretion.",
            "direction": "Decrease",
            "magnitude": "Moderate to significant",
            "timeframe": "1-4 hours after administration."
        }
    },
    "diagnostic_conditions": {
        "Type 2 Diabetes Mellitus": {
            "symptoms_addressed": ["High blood sugar levels"],
            "therapeutic_action": "Improves glycemic control.",
            "optimal_dosage": "100mg once daily.",
            "response_time": "Improvements seen within days to weeks."
        }
    },
    "adverse_effects": {
        "mild": ["Nasopharyngitis", "Headache"],
        "moderate": ["Hypoglycemia (when combined with insulin or sulfonylureas)", "Nausea"],
        "severe": ["Pancreatitis", "Severe allergic reactions (e.g., Stevens-Johnson syndrome)"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood glucose levels", "HbA1c", "Pancreatic function"],
        "frequency": "Every 3-6 months for HbA1c monitoring.",
        "clinical_thresholds": {
            "normal_range": {
                "HbA1c": "<7%"
            },
            "alert_threshold": {
                "HbA1c": ">9%"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Dose adjustment based on renal function.",
            "rationale": "Reduced renal clearance in elderly patients."
        },
        "children": {
            "adjustments": "Not recommended; safety and efficacy not established.",
            "rationale": "Limited clinical data in pediatric populations."
        }
    },
    "alternative_therapies": ["Berberine supplementation", "Bitter melon extract", "Low-carbohydrate diet"],
    "combination_therapies": {
        "recommended_combinations": ["Sitagliptin + Metformin", "Sitagliptin + SGLT2 inhibitors"],
        "cautions": ["Avoid combination with other DPP-4 inhibitors."]
    },
    "contraindications": [
        "History of pancreatitis",
        "Hypersensitivity to sitagliptin"
    ],
    "precautions": [
        "Use cautiously in patients with renal impairment.",
        "Monitor for signs of pancreatitis."
    ],
    "side_effects": [
        "Headache",
        "Nasopharyngitis",
        "Upper respiratory tract infection"
    ],
    "overdose_management": {
        "symptoms": [
            "Dizziness",
            "Gastrointestinal discomfort"
        ],
        "treatment": [
            "Supportive care",
            "Hemodialysis (if necessary, though not fully effective due to high plasma protein binding)."
        ]
    },
    "notes": "Sitagliptin is often used as an add-on therapy to metformin or other antidiabetic agents for enhanced glycemic control."
},

 {
    "iupac_name": "5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid",
    "chemical_formula": "C15H13NO3",
    "brand_names": ["Toradol", "Acular", "Acuvail", "Sprix", "Ketoral", "Toractin", "Dolac", "Oruvail", "Ketrodol", "Taradyl", "Ketoflam", "Ketorolac"],
    "category": "NSAID (Nonsteroidal Anti-inflammatory Drug)",
    "dosage_forms": ["Tablet", "Injection", "Ophthalmic Solution", "Nasal Spray"],
    "strengths": ["10mg (tablet)", "15mg/mL (injection)", "30mg/mL (injection)", "0.4% (ophthalmic solution)", "0.5% (ophthalmic solution)", "15.75mg/spray (nasal)"],
    "mechanism_of_action": {
        "site_of_action": "Cyclooxygenase enzymes (COX-1 and COX-2)",
        "physiological_mechanism": "Inhibits prostaglandin synthesis by blocking COX enzymes, resulting in reduced inflammation, pain, and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Musculoskeletal",
            "effect": "Reduces inflammation and pain.",
            "timeframe": "Onset within 30-60 minutes; peak effect in 2-3 hours."
        },
        {
            "system": "Central Nervous System",
            "effect": "Provides analgesic effects.",
            "timeframe": "Duration of action typically 4-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Prostaglandin synthesis inhibition",
        "key_targets": ["COX-1", "COX-2"],
        "related_conditions": ["Pain", "Inflammation"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed following oral or intramuscular administration.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Extensively metabolized to inactive glucuronide conjugates."
        },
        "elimination": "Primarily excreted via the kidneys; half-life ~4-6 hours."
    },
    "interactions": {
        "Aspirin": {
            "site_of_interaction": "COX enzymes",
            "mechanism": "May enhance gastrointestinal toxicity.",
            "effect": "Increased risk of ulcers and bleeding.",
            "recommendation": "Avoid concurrent use unless directed by a physician."
        },
        "Warfarin": {
            "site_of_interaction": "Platelet aggregation",
            "mechanism": "Inhibits platelet function, increasing bleeding risk.",
            "effect": "Prolonged bleeding time.",
            "recommendation": "Monitor INR closely if used together."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin K (may alter clotting function)"],
        "toxins": ["Alcohol (increased risk of GI bleeding)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "pain": {
            "site_of_effect": "Peripheral tissues",
            "mechanism": "Reduces prostaglandin-mediated pain signals.",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "Within 30 minutes."
        }
    },
    "diagnostic_conditions": {
        "postoperative_pain": {
            "symptoms_addressed": ["Moderate to severe pain"],
            "therapeutic_action": "Provides analgesia for short-term management.",
            "optimal_dosage": "10mg every 4-6 hours as needed; maximum 40mg/day.",
            "response_time": "Pain relief observed within 1 hour."
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Nausea"],
        "moderate": ["Dizziness", "Headache"],
        "severe": ["Gastrointestinal bleeding", "Renal impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Kidney function (creatinine)", "Liver enzymes (ALT/AST)", "Hemoglobin"],
        "frequency": "Monitor weekly during prolonged use.",
        "clinical_thresholds": {
            "normal_range": {
                "Creatinine": "0.7-1.3 mg/dL",
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "Creatinine": ">2.0 mg/dL",
                "ALT/AST": ">2x upper normal limit"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Use lower initial doses and monitor renal function closely.",
            "rationale": "Increased susceptibility to adverse effects."
        },
        "children": {
            "adjustments": "Not recommended for pediatric use.",
            "rationale": "Limited safety data in children."
        }
    },
    "alternative_therapies": ["Boswellia serrata (Frankincense extract)", "Willow bark extract (Salix alba)", "Curcumin (Turmeric extract)", "Capsaicin cream"],
    "combination_therapies": {
        "recommended_combinations": ["Ketorolac + Proton Pump Inhibitor (e.g., Omeprazole) for GI protection"],
        "cautions": ["Avoid combining with other NSAIDs to minimize adverse effects."]
    },
    "contraindications": [
        "Active peptic ulcer disease",
        "Severe renal impairment",
        "Hypersensitivity to NSAIDs"
    ],
    "precautions": [
        "Avoid in patients with a history of gastrointestinal bleeding.",
        "Use cautiously in patients with hepatic impairment."
    ],
    "side_effects": [
        "Nausea",
        "Dyspepsia",
        "GI bleeding"
    ],
    "overdose_management": {
        "symptoms": ["Severe abdominal pain", "Vomiting blood", "Hypotension"],
        "treatment": ["Gastric lavage", "Activated charcoal", "Supportive care"]
    },
    "notes": "Ketorolac is intended for short-term use only (up to 5 days) to minimize risk of serious adverse effects."
},
 
  {
    "iupac_name": "N-[(1S)-1-carboxy-3-phenylpropyl]-L-proline",
    "chemical_formula": "C21H31N3O5",
    "brand_names": ["Zestril", "Prinivil", "Qbrelis", "Listril", "Lipril", "Zestoretic", "Sinopril", "Hipril", "Zilopril", "Carace", "Carace Plus", "Dapril", "Lisodur", "Lisinopril Teva", "Lisinopril Actavis"],
    "category": "ACE Inhibitor",
    "dosage_forms": ["Tablet", "Oral Solution"],
    "strengths": ["2.5mg", "5mg", "10mg", "20mg", "40mg"],
    "mechanism_of_action": {
        "site_of_action": "Renin-Angiotensin-Aldosterone System (RAAS)",
        "physiological_mechanism": "Inhibits angiotensin-converting enzyme (ACE), decreasing the production of angiotensin II and reducing blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces blood pressure by vasodilation and decreased blood volume.",
            "timeframe": "Onset within 1 hour; peak effect in 6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-Angiotensin-Aldosterone System Inhibition",
        "key_targets": ["Angiotensin-Converting Enzyme (ACE)"],
        "related_conditions": ["Hypertension", "Heart Failure"]
    },
    "pharmacokinetics": {
        "absorption": "About 25% absorbed in the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "Not metabolized",
            "enzymes": ["N/A"],
            "notes": "Excreted unchanged in the urine."
        },
        "elimination": "Excreted primarily via the kidneys; half-life ~12 hours."
    },
    "interactions": {
        "Potassium Supplements": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Increases risk of hyperkalemia.",
            "effect": "Elevated potassium levels.",
            "recommendation": "Monitor potassium levels during co-administration."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium", "Sodium"],
        "toxins": ["Alcohol (enhances hypotensive effects)"],
        "microbiota_effects": "No significant effects known."
    },
    "effects_on_symptoms": {
        "hypertension": {
            "site_of_effect": "Vascular Smooth Muscle",
            "mechanism": "Decreases systemic vascular resistance.",
            "direction": "Decrease",
            "magnitude": "Significant",
            "timeframe": "Within hours."
        }
    },
    "diagnostic_conditions": {
        "hypertension": {
            "symptoms_addressed": ["Elevated blood pressure"],
            "therapeutic_action": "Lowers blood pressure.",
            "optimal_dosage": "10mg-40mg daily.",
            "response_time": "Improvement observed within a few days."
        }
    },
    "adverse_effects": {
        "mild": ["Cough", "Dizziness"],
        "moderate": ["Headache", "Hyperkalemia"],
        "severe": ["Angioedema", "Renal impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Kidney function", "Potassium levels", "Blood pressure"],
        "frequency": "Monitor every 3-6 months.",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mEq/L",
                "Creatinine": "0.6-1.2 mg/dL"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mEq/L",
                "Creatinine": ">2.0 mg/dL"
            }
        }
    },
    "population_specific": {
        "elderly": {
            "adjustments": "Start at a lower dose; monitor renal function.",
            "rationale": "Increased risk of renal impairment."
        },
        "children": {
            "adjustments": "Dosing based on weight (0.07 mg/kg).",
            "rationale": "Limited data in pediatric populations."
        }
    },
    "alternative_therapies": ["Hawthorn extract (Crataegus spp.)", "Garlic supplements (Allium sativum)", "Meditation for stress management"],
    "combination_therapies": {
        "recommended_combinations": ["Lisinopril + Hydrochlorothiazide"],
        "cautions": ["Avoid combining with NSAIDs due to renal risks."]
    },
    "contraindications": [
        "History of angioedema",
        "Pregnancy",
        "Bilateral renal artery stenosis"
    ],
    "precautions": [
        "Monitor renal function in patients with renal artery stenosis.",
        "Avoid in pregnancy due to teratogenic effects."
      ],
    "side_effects": [
        "Dry cough",
        "Hypotension",
        "Hyperkalemia"
    ],
    "overdose_management": {
        "symptoms": [
            "Severe hypotension",
            "Dizziness",
            "Renal failure"
        ],
        "treatment": [
            "Supportive care",
            "Intravenous fluids",
            "Hemodialysis (if severe renal impairment)"
        ]
    },
    "notes": "Lisinopril is effective for managing hypertension and heart failure. Dry cough is a common side effect due to bradykinin buildup."
},

  
  {
    "iupac_name": "N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine",
    "chemical_formula": "C17H18F3NO",
    "brand_names": ["Fluoxetine", "Prozac", "Sarafem", "Fludac", "Fontex", "Prodep", "Flutop", "Lovan", "Deprex", "Zactin", "Fluoxeren", "Fluoxil", "Flutrax", "Flunil", "Depranil", "Protil", "Seriva", "Flumex", "Flutin"],
    "category": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "dosage_forms": ["Tablet", "Capsule", "Oral Solution"],
    "strengths": ["10mg", "20mg", "40mg"],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Inhibits serotonin reuptake by blocking the serotonin transporter (SERT), increasing serotonin levels in the synaptic cleft."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Improves mood and reduces symptoms of depression and anxiety.",
            "timeframe": "Onset of therapeutic effects within 2-4 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonergic signaling",
        "key_targets": ["Serotonin transporter (SERT)"],
        "related_conditions": ["Major Depressive Disorder", "Obsessive-Compulsive Disorder"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed orally with peak plasma levels in 6-8 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Metabolized to active metabolite norfluoxetine."
        },
        "elimination": "Excreted via urine; half-life ~4-6 days for fluoxetine and ~7-15 days for norfluoxetine."
    },
    "interactions": {
        "Monoamine Oxidase Inhibitors (MAOIs)": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Increased serotonin levels leading to serotonin syndrome.",
            "effect": "Hyperthermia, agitation, and potential life-threatening effects.",
            "recommendation": "Avoid concurrent use or use within 14 days of MAOI therapy."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["None significant"],
        "toxins": ["Alcohol (may potentiate CNS effects)"],
        "microbiota_effects": "Minimal known impact on gut flora."
    },
    "effects_on_symptoms": {
        "depression": {
            "site_of_effect": "Prefrontal Cortex",
            "mechanism": "Enhances serotonergic activity.",
            "direction": "Decrease in depressive symptoms.",
            "magnitude": "Significant",
            "timeframe": "Within 2-4 weeks."
        }
    },
    "diagnostic_conditions": {
        "depression": {
            "symptoms_addressed": ["Low mood", "Anhedonia", "Fatigue"],
            "therapeutic_action": "Improves mood and increases motivation.",
            "optimal_dosage": "20mg-40mg daily.",
            "response_time": "Noticeable improvement within 2-4 weeks."
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Drowsiness"],
        "moderate": ["Insomnia", "Weight changes"],
        "severe": ["Serotonin syndrome", "QT prolongation"]
    },
    "long_term_monitoring": {
        "parameters": ["Mood stability", "Weight", "Sleep patterns"],
        "frequency": "Monitor every 6 months.",
        "clinical_thresholds": {
            "normal_range": {
                "Heart rate": "60-100 bpm"
            },
            "alert_threshold": {
                "QT interval": ">450 ms"
            }
        }
    },
    "population_specific": {
        "children": {
            "adjustments": "Use with caution; typically start at lower doses (10mg daily).",
            "rationale": "Higher sensitivity to side effects."
        },
        "elderly": {
            "adjustments": "Monitor for hyponatremia and falls.",
            "rationale": "Increased risk of electrolyte imbalances."
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "St. John's Wort (Hypericum perforatum)", "Exercise"],
    "combination_therapies": {
        "recommended_combinations": ["Fluoxetine + Psychotherapy"],
        "cautions": ["Avoid combining with other serotonergic drugs."]
    },
    "contraindications": [
        "Use of MAOIs",
        "Uncontrolled epilepsy"
    ],
    "precautions": [
        "Monitor for suicidal ideation in early treatment.",
        "Caution in patients with hepatic impairment."
    ],
    "side_effects": [
        "Nausea",
        "Drowsiness",
        "Dry mouth",
        "Increased anxiety (initially)"
    ],
    "overdose_management": {
        "symptoms": [
            "Seizures",
            "Nausea",
            "Tachycardia",
            "Confusion"
        ],
        "treatment": [
            "Supportive care",
            "Activated charcoal within 1 hour of ingestion"
        ]
    },
    "notes": "This medication, sold under various brand names such as Fluoxetine, Prozac, Sarafem, Fludac, Fontex, Prodep, Flutop, Lovan, Deprex, Zactin, Fluoxeren, Fluoxil, Flutrax, Flunil, Depranil, Protil, Seriva, Flumex, Flutin, has a long half-life, which allows for once-daily dosing and reduces withdrawal risks."

},

  {
    "iupac_name": "N-[(2S)-2-hydroxy-3-phenylpropyl]-(2S)-2-(methylthio)-1-phenylpropan-1-one",
    "chemical_formula": "C18H21NO3",
    "brand_names": [
        "Co-codamol",
        "Tylenol with Codeine",
        "Panadeine",
        "Kapake",
        "Paramol",
        "Co-codamol 8/500",
        "Co-codamol 30/500"
    ],
    "category": "Analgesic",
    "dosage_forms": ["Tablet", "Capsule"],
    "strengths": [
        {
            "paracetamol_mg": 500,
            "codeine_mg": 8
        },
        {
            "paracetamol_mg": 500,
            "codeine_mg": 30
        }
    ],
    "mechanism_of_action": {
        "site_of_action": "Central nervous system",
        "physiological_mechanism": "Codeine acts on opioid receptors and paracetamol inhibits prostaglandin synthesis in the brain."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous system",
            "effect": "Pain relief",
            "timeframe": "1-2 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Pain modulation",
        "key_targets": ["Mu-opioid receptor", "COX enzymes"],
        "related_conditions": ["Pain", "Inflammation"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid absorption, peak plasma concentration in 1 hour",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6 (for codeine)", "CYP1A2 (for paracetamol)"],
            "notes": "Codeine is metabolized to morphine, which has a higher analgesic effect."
        },
        "elimination": "Excreted in urine, with a half-life of 3-4 hours"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Increased sedation",
            "effect": "Enhanced CNS depression",
            "recommendation": "Avoid combining with alcohol"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Alcohol (increases sedative effects)", "Caffeine (may increase analgesic effect)"],
        "toxins": ["Acetaminophen overdose (liver toxicity)"],
        "microbiota_effects": "Codeine may alter gut microbiota due to opioid effects."
    },
    "effects_on_symptoms": {
        "Pain": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Inhibition of pain signals and opioid receptor agonism",
            "direction": "Reduction in pain perception",
            "magnitude": "Moderate",
            "timeframe": "1-2 hours"
        }
    },
    "diagnostic_conditions": {
        "Pain relief": {
            "symptoms_addressed": ["Moderate pain", "Post-surgical pain", "Trauma-induced pain"],
            "therapeutic_action": "Relieves moderate pain through combination of paracetamol and codeine",
            "optimal_dosage": "500 mg paracetamol / 8 mg codeine, 1-2 tablets every 4-6 hours",
            "response_time": "1-2 hours"
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Dizziness", "Constipation"],
        "moderate": ["Nausea", "Dry mouth", "Abdominal pain"],
        "severe": ["Respiratory depression", "Severe allergic reaction", "Hepatotoxicity (overdose)"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function tests", "Kidney function tests"],
        "frequency": "Every 6 months for prolonged use",
        "clinical_thresholds": {
            "normal_range": {"AST": "0-40 U/L", "ALT": "0-35 U/L"},
            "alert_threshold": {"AST": ">40 U/L", "ALT": ">35 U/L"}
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not recommended for children under 12",
            "rationale": "Risk of respiratory depression due to codeine metabolism differences"
        }
    },
    "alternative_therapies": [],
    "combination_therapies": {
        "recommended_combinations": ["Codeine with Diphenhydramine for cough suppression"],
        "cautions": ["Avoid combining with other sedatives or alcohol"]
    },
    "contraindications": ["Hypersensitivity to paracetamol or codeine", "Severe respiratory depression", "Acute alcohol intoxication"],
    "precautions": ["Use with caution in patients with liver disease", "Potential for abuse and addiction with prolonged use"],
    "side_effects": ["Drowsiness", "Constipation", "Nausea", "Respiratory depression (rare)"],
    "overdose_management": {
        "symptoms": ["Severe drowsiness", "Nausea", "Respiratory depression", "Loss of consciousness"],
        "treatment": ["Administer naloxone (opioid antagonist)", "Activated charcoal (if within 1 hour of ingestion)", "Monitor airway and breathing"]
    },
    "notes": "Co-codamol, Tylenol with Codeine, Panadeine, Kapake, Paramol, Co-codamol 8/500, and Co-codamol 30/500 should only be used for moderate pain and for short durations to minimize the risk of addiction and liver damage from paracetamol overdose."

},

  
  {
    "iupac_name": "3-((2S,3S,4R,5S)-3-(Hydroxymethyl)-5-(hydroxymethyl)-4-(hydroxymethyl)-1,3-dioxolan-2-yl)-2-(methylthio)-5-methylphenyl)-1,3-dioxolane",
    "chemical_formula": "C4H11NO3S",
    "brand_names": [
        "Metformin",
        "Glucophage",
        "Glucophage XR",
        "Fortamet",
        "Riomet"
    ],
    "category": "Antidiabetic",
    "dosage_forms": ["Tablet", "Liquid"],
    "strengths": [
        {
            "metformin_mg": 500
        },
        {
            "metformin_mg": 1000
        },
        {
            "metformin_mg": 850
        }
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver, skeletal muscle, and intestines",
        "physiological_mechanism": "Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake by muscle cells."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Endocrine",
            "effect": "Decreases blood glucose levels",
            "timeframe": "4-6 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Insulin signaling pathway",
        "key_targets": ["AMPK", "Glut4", "mTOR"],
        "related_conditions": ["Type 2 Diabetes", "Metabolic Syndrome"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract with a peak plasma concentration occurring in 2-3 hours",
        "metabolism": {
            "primary_site": "Not metabolized (excreted unchanged)",
            "enzymes": [],
            "notes": "Metformin does not undergo significant metabolism in the liver."
        },
        "elimination": "Excreted unchanged in the urine with a half-life of 6.2 hours"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased risk of lactic acidosis",
            "effect": "Risk of hypoglycemia and lactic acidosis",
            "recommendation": "Avoid excessive alcohol consumption"
        },
        "Cationic Drugs": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Competitive renal excretion",
            "effect": "Increased plasma concentrations of metformin",
            "recommendation": "Monitor renal function when using with cationic drugs"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin B12 deficiency (long-term use)"],
        "toxins": ["Lactic acidosis (rare, especially in renal insufficiency)"],
        "microbiota_effects": "Metformin may have effects on gut microbiota composition."
    },
    "effects_on_symptoms": {
        "Hyperglycemia": {
            "site_of_effect": "Endocrine system",
            "mechanism": "Inhibition of hepatic glucose production and enhancement of insulin sensitivity",
            "direction": "Decrease in blood glucose levels",
            "magnitude": "Moderate",
            "timeframe": "Within 2-4 weeks"
        }
    },
    "diagnostic_conditions": {
        "Type 2 Diabetes": {
            "symptoms_addressed": ["Hyperglycemia", "Polydipsia", "Polyuria", "Polyphagia"],
            "therapeutic_action": "Reduces blood glucose by improving insulin sensitivity and reducing hepatic glucose production",
            "optimal_dosage": "500-1000 mg twice daily",
            "response_time": "2-4 weeks for full therapeutic effect"
        }
    },
    "adverse_effects": {
        "mild": ["Gastrointestinal upset", "Nausea", "Diarrhea"],
        "moderate": ["Lactic acidosis (rare)"],
        "severe": ["Severe abdominal pain", "Liver dysfunction", "Renal impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal function", "Liver function", "Vitamin B12 levels"],
        "frequency": "Annually for long-term use",
        "clinical_thresholds": {
            "normal_range": {"Creatinine": "<1.2 mg/dL", "Vitamin B12": "200-900 pg/mL"},
            "alert_threshold": {"Creatinine": ">1.5 mg/dL", "Vitamin B12": "<200 pg/mL"}
        }
    },
    "population_specific": {
        "Renal Impairment": {
            "adjustments": "Avoid use in severe renal dysfunction (eGFR <30 mL/min)",
            "rationale": "Risk of lactic acidosis"
        },
        "Elderly": {
            "adjustments": "Use with caution, monitor renal function closely",
            "rationale": "Age-related decline in renal function increases risk of toxicity"
        }
    },
    "alternative_therapies": ["Sulfonylureas", "GLP-1 receptor agonists", "DPP-4 inhibitors"],
    "combination_therapies": {
        "recommended_combinations": ["Metformin with Sitagliptin", "Metformin with Glimepiride"],
        "cautions": ["Monitor renal function when combining with other antidiabetic drugs"]
    },
    "contraindications": ["Severe renal impairment", "Acute or chronic metabolic acidosis", "Hypersensitivity to metformin"],
    "precautions": ["Use with caution in patients with impaired renal function", "Discontinue if acidosis develops"],
    "side_effects": ["Gastrointestinal discomfort", "Lactic acidosis (rare)", "Hypoglycemia (with other antidiabetic agents)"],
    "overdose_management": {
        "symptoms": ["Lactic acidosis", "Hypotension", "Bradycardia"],
        "treatment": ["Discontinue metformin immediately", "Administer sodium bicarbonate for acidosis", "Hemodialysis may be required"]
    },
    "notes": "Metformin, Glucophage, Glucophage XR, Fortamet, and Riomet should be used as first-line therapy in type 2 diabetes. Caution is required in patients with renal impairment, and it should be discontinued if acidosis develops."

},

  {
    "iupac_name": "2-(Isobutylamino)-methyl-5-methyl-1,3-dioxane-4-carboxamide",
    "chemical_formula": "C8H17NO2",
    "brand_names": [
        "Lyrica",
        "Alzain",
        "Pregabalin",
        "Neurotin",
        "Mysoline",
        "Lyrica CR"
    ],
    "category": "Anticonvulsant, Analgesic",
    "dosage_forms": ["Capsule", "Solution"],
    "strengths": [
        {
            "pregabalin_mg": 25
        },
        {
            "pregabalin_mg": 75
        },
        {
            "pregabalin_mg": 150
        },
        {
            "pregabalin_mg": 300
        }
    ],
    "mechanism_of_action": {
        "site_of_action": "Central nervous system",
        "physiological_mechanism": "Pregabalin binds to the α2-δ subunit of voltage-gated calcium channels in the central nervous system, inhibiting excitatory neurotransmitter release."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous system",
            "effect": "Decreases neuronal excitability and reduces pain transmission",
            "timeframe": "2-4 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Calcium channel regulation",
        "key_targets": ["α2-δ subunit of calcium channels"],
        "related_conditions": ["Neuropathic pain", "Epilepsy", "Generalized anxiety disorder"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with peak plasma concentration occurring within 1.5 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [],
            "notes": "Minimal metabolism; primarily excreted unchanged in the urine."
        },
        "elimination": "Excreted unchanged in the urine with a half-life of 6-7 hours"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Increased CNS depression",
            "effect": "Enhanced sedative effect",
            "recommendation": "Avoid combining with alcohol"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Alcohol (increases sedative effects)"],
        "toxins": ["Opioid use (enhanced sedation)"],
        "microbiota_effects": "Pregabalin may alter the gut microbiota."
    },
    "effects_on_symptoms": {
        "Neuropathic pain": {
            "site_of_effect": "Nervous system",
            "mechanism": "Inhibition of excitatory neurotransmitter release",
            "direction": "Reduction in pain sensation",
            "magnitude": "Moderate to high",
            "timeframe": "1-2 weeks for full effect"
        }
    },
    "diagnostic_conditions": {
        "Neuropathic pain": {
            "symptoms_addressed": ["Pain following nerve injury", "Diabetic neuropathy", "Postherpetic neuralgia"],
            "therapeutic_action": "Reduces neuropathic pain through inhibition of excitatory neurotransmitter release",
            "optimal_dosage": "150-300 mg daily, divided into 2-3 doses",
            "response_time": "1-2 weeks for significant relief"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue", "Dry mouth"],
        "moderate": ["Weight gain", "Peripheral edema", "Cognitive impairment"],
        "severe": ["Angioedema", "Severe allergic reactions", "Suicidal ideation"]
    },
    "long_term_monitoring": {
        "parameters": ["Weight", "Renal function", "Mental health status"],
        "frequency": "Every 6 months for long-term use",
        "clinical_thresholds": {
            "normal_range": {"Weight": "Stable body weight", "Creatinine": "<1.2 mg/dL"},
            "alert_threshold": {"Weight": ">5% increase in body weight", "Creatinine": ">1.5 mg/dL"}
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower starting doses may be required",
            "rationale": "Age-related decline in renal function"
        },
        "Renal Impairment": {
            "adjustments": "Dose reduction required in renal insufficiency",
            "rationale": "Pregabalin is primarily excreted unchanged in the urine"
        }
    },
    "alternative_therapies": ["Gabapentin", "Tricyclic antidepressants (e.g., amitriptyline)", "SNRIs (e.g., duloxetine)"],
    "combination_therapies": {
        "recommended_combinations": ["Pregabalin with Duloxetine (for neuropathic pain)"],
        "cautions": ["Monitor for excessive sedation when combining with other CNS depressants"]
    },
    "contraindications": ["Hypersensitivity to pregabalin or any component of the formulation", "Severe renal impairment (eGFR <30 mL/min)"],
    "precautions": ["Use with caution in patients with a history of substance abuse", "Monitor for signs of suicidal thoughts or behavior"],
    "side_effects": ["Dizziness", "Drowsiness", "Swelling of the hands/feet", "Weight gain"],
    "overdose_management": {
        "symptoms": ["Drowsiness", "Confusion", "Slurred speech", "Respiratory depression"],
        "treatment": ["Supportive care", "Activated charcoal (if within 1 hour of ingestion)", "Monitor airway and breathing"]
    },
    "notes": "Lyrica, Alzain, Pregabalin, Neurotin, Mysoline, and Lyrica CR should be used for the management of neuropathic pain, epilepsy, and generalized anxiety disorder. Caution is required in patients with renal impairment and those with a history of substance abuse. Discontinuation should be gradual to avoid withdrawal symptoms."
},

  
  
  
  {
    "iupac_name": "Sodium (S)-6-methoxy-α-methyl-2-naphthalenepropanoate",
    "chemical_formula": "C14H14O3",
    "brand_names": [
        "Aleve",
        "Naprosyn",
        "Anaprox",
        "Naproxen"
    ],
    "category": "Nonsteroidal anti-inflammatory drug (NSAID)",
    "dosage_forms": ["Tablet", "Capsule", "Suspension"],
    "strengths": [
        {
            "naproxen_mg": 220
        },
        {
            "naproxen_mg": 500
        },
        {
            "naproxen_mg": 250
        }
    ],
    "mechanism_of_action": {
        "site_of_action": "Peripherally in tissues and central nervous system",
        "physiological_mechanism": "Naproxen inhibits cyclooxygenase (COX-1 and COX-2), decreasing the synthesis of prostaglandins responsible for inflammation and pain."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Inflammatory system",
            "effect": "Anti-inflammatory, analgesic, and antipyretic effects",
            "timeframe": "Within 30 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Prostaglandin synthesis inhibition",
        "key_targets": ["COX-1", "COX-2"],
        "related_conditions": ["Arthritis", "Pain", "Fever"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract with peak plasma concentration in 2-4 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Undergoes hepatic metabolism with active metabolites."
        },
        "elimination": "Excreted primarily in the urine with a half-life of 12-17 hours"
    },
    "interactions": {
        "Anticoagulants": {
            "site_of_interaction": "Platelet aggregation",
            "mechanism": "Inhibition of platelet function",
            "effect": "Increased risk of bleeding",
            "recommendation": "Monitor for bleeding complications when used with anticoagulants"
        },
        "Alcohol": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased risk of gastrointestinal irritation and bleeding",
            "effect": "Enhanced risk of stomach ulcers and gastrointestinal bleeding",
            "recommendation": "Avoid excessive alcohol consumption"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Alcohol (increases gastrointestinal irritation)"],
        "toxins": ["Gastrointestinal bleeding (overdose)"],
        "microbiota_effects": "NSAIDs like naproxen can alter gut microbiota balance."
    },
    "effects_on_symptoms": {
        "Pain": {
            "site_of_effect": "Peripheral tissues",
            "mechanism": "Inhibition of prostaglandin synthesis",
            "direction": "Reduction in pain",
            "magnitude": "Moderate",
            "timeframe": "Within 30 minutes"
        },
        "Inflammation": {
            "site_of_effect": "Inflamed tissues",
            "mechanism": "Inhibition of COX-1 and COX-2",
            "direction": "Reduction in inflammation",
            "magnitude": "High",
            "timeframe": "1-2 hours for full anti-inflammatory effect"
        }
    },
    "diagnostic_conditions": {
        "Arthritis": {
            "symptoms_addressed": ["Pain", "Stiffness", "Swelling"],
            "therapeutic_action": "Reduces pain and inflammation associated with arthritis",
            "optimal_dosage": "250-500 mg twice daily",
            "response_time": "1-2 hours for pain relief, up to 2 weeks for maximum anti-inflammatory effect"
        },
        "Fever": {
            "symptoms_addressed": ["Fever", "Chills"],
            "therapeutic_action": "Reduces fever through central action in the hypothalamus",
            "optimal_dosage": "500 mg as a single dose, repeat every 8-12 hours if necessary",
            "response_time": "Within 30 minutes"
        }
    },
    "adverse_effects": {
        "mild": ["Gastrointestinal upset", "Headache", "Dizziness"],
        "moderate": ["Nausea", "Rash", "Edema"],
        "severe": ["Gastrointestinal bleeding", "Kidney dysfunction", "Anaphylaxis"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal function", "Liver function", "Blood pressure"],
        "frequency": "Every 6-12 months for long-term use",
        "clinical_thresholds": {
            "normal_range": {"Creatinine": "<1.2 mg/dL", "AST": "0-40 U/L", "ALT": "0-35 U/L"},
            "alert_threshold": {"Creatinine": ">1.5 mg/dL", "AST": ">40 U/L", "ALT": ">35 U/L"}
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution, lower doses may be required",
            "rationale": "Increased risk of renal impairment and gastrointestinal bleeding"
        },
        "Renal Impairment": {
            "adjustments": "Avoid or reduce dose in patients with severe renal impairment",
            "rationale": "NSAIDs can worsen kidney function"
        }
    },
    "alternative_therapies": ["Ibuprofen", "Diclofenac", "Aspirin"],
    "combination_therapies": {
        "recommended_combinations": ["Naproxen with Proton Pump Inhibitors (PPI) for gastrointestinal protection"],
        "cautions": ["Monitor for gastrointestinal irritation when combining with other NSAIDs"]
    },
    "contraindications": ["Active gastrointestinal bleeding", "Severe renal impairment", "Hypersensitivity to NSAIDs"],
    "precautions": ["Use with caution in patients with a history of gastrointestinal ulcers or bleeding"],
    "side_effects": ["Gastrointestinal irritation", "Headache", "Edema", "Hypertension"],
    "overdose_management": {
        "symptoms": ["Gastrointestinal bleeding", "Drowsiness", "Confusion"],
        "treatment": ["Activated charcoal if within 1 hour", "Gastric lavage if significant ingestion", "Supportive care for bleeding and hypotension"]
    },
    "notes": "Aleve, Naprosyn, Anaprox, and Naproxen should be used for the relief of pain, inflammation, and fever. Caution is required in patients with gastrointestinal, renal, or cardiovascular issues, and the lowest effective dose should be used for the shortest duration."
},

 {
    "iupac_name": "5-Methoxy-2-[[(4-methoxy-3,5-dimethylphenyl)methyl]thio]-1H-benzimidazole",
    "chemical_formula": "C17H19N3O3S",
    "brand_names": [
        "Prilosec",
        "Losec",
        "Omez",
        "Zegerid",
        "Omeprazole",
        "Antra",
        "Omeprazole Magnesium",
        "Gastroloc",
        "Controloc",
        "Prolix",
        "Ulceraz"
    ],
    "category": "Proton pump inhibitor (PPI)",
    "dosage_forms": ["Tablet", "Capsule", "Oral Suspension"],
    "strengths": [
        {
            "omeprazole_mg": 10
        },
        {
            "omeprazole_mg": 20
        },
        {
            "omeprazole_mg": 40
        }
    ],
    "mechanism_of_action": {
        "site_of_action": "Stomach",
        "physiological_mechanism": "Omeprazole works by inhibiting the proton pump (H+/K+ ATPase) in the parietal cells of the stomach lining, reducing gastric acid secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Gastrointestinal system",
            "effect": "Decreased gastric acid secretion",
            "timeframe": "1-2 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Gastric acid secretion inhibition",
        "key_targets": ["H+/K+ ATPase (proton pump)"],
        "related_conditions": ["Gastroesophageal reflux disease (GERD)", "Peptic ulcers", "Helicobacter pylori eradication"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract, peak plasma concentration in 0.5-1 hour",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Omeprazole is metabolized in the liver by cytochrome P450 enzymes."
        },
        "elimination": "Excreted primarily in the urine with a half-life of about 1 hour"
    },
    "interactions": {
        "Clopidogrel": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of CYP2C19 enzyme",
            "effect": "Decreased activation of clopidogrel",
            "recommendation": "Avoid concomitant use with clopidogrel if possible"
        },
        "Warfarin": {
            "site_of_interaction": "Liver",
            "mechanism": "Altered metabolism of warfarin",
            "effect": "Increased risk of bleeding",
            "recommendation": "Monitor INR levels and adjust warfarin dosage accordingly"
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin B12 deficiency (long-term use)"],
        "toxins": ["Liver toxicity (rare, with long-term use)"],
        "microbiota_effects": "Omeprazole may alter gut microbiota by reducing gastric acidity."
    },
    "effects_on_symptoms": {
        "Gastroesophageal reflux disease (GERD)": {
            "site_of_effect": "Gastrointestinal system",
            "mechanism": "Reduction of gastric acid secretion, preventing reflux and irritation",
            "direction": "Reduction in heartburn and acid regurgitation",
            "magnitude": "Moderate to high",
            "timeframe": "Within 1-2 hours"
        }
    },
    "diagnostic_conditions": {
        "GERD": {
            "symptoms_addressed": ["Heartburn", "Acid regurgitation", "Chest pain"],
            "therapeutic_action": "Reduces gastric acid secretion, providing symptomatic relief",
            "optimal_dosage": "20-40 mg daily",
            "response_time": "1-2 hours for symptom relief, 2-4 weeks for full therapeutic effect"
        },
        "Peptic ulcers": {
            "symptoms_addressed": ["Abdominal pain", "Bloating", "Heartburn"],
            "therapeutic_action": "Decreases gastric acid secretion, promoting ulcer healing",
            "optimal_dosage": "20 mg once daily",
            "response_time": "1-2 weeks for symptom improvement"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Diarrhea"],
        "moderate": ["Abdominal pain", "Flatulence", "Dizziness"],
        "severe": ["Clostridium difficile-associated diarrhea", "Liver enzyme elevation", "Osteoporosis (long-term use)"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function tests", "Magnesium levels", "Bone density (for long-term use)"],
        "frequency": "Every 6-12 months for long-term use",
        "clinical_thresholds": {
            "normal_range": {"AST": "0-40 U/L", "ALT": "0-35 U/L", "Magnesium": "1.7-2.2 mg/dL"},
            "alert_threshold": {"AST": ">40 U/L", "ALT": ">35 U/L", "Magnesium": "<1.5 mg/dL"}
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower starting dose may be required, especially in patients with renal or liver impairment",
            "rationale": "Decreased renal and hepatic function with aging may prolong drug effects"
        }
    },
    "alternative_therapies": ["H2 blockers (e.g., ranitidine)", "Antacids", "Sucralfate"],
    "combination_therapies": {
        "recommended_combinations": ["Omeprazole with Clarithromycin for Helicobacter pylori eradication"],
        "cautions": ["Avoid long-term use in high-risk populations to prevent osteoporosis and C. difficile infection"]
    },
    "contraindications": ["Hypersensitivity to omeprazole or any component of the formulation", "Severe hepatic impairment"],
    "precautions": ["Use with caution in patients with liver disease", "Long-term use may increase the risk of fractures and Clostridium difficile infections"],
    "side_effects": ["Headache", "Nausea", "Diarrhea", "Abdominal pain", "Flatulence"],
    "overdose_management": {
        "symptoms": ["Confusion", "Dizziness", "Blurred vision", "Nausea"],
        "treatment": ["Symptomatic and supportive care", "Gastric lavage and activated charcoal if within 1 hour"]
    },
    "notes": "Prilosec, Losec, Omez, Zegerid, Omeprazole, Antra, Omeprazole Magnesium, Gastroloc, Controloc, Prolix, and Ulceraz should be used for the treatment of GERD, peptic ulcers, and other acid-related disorders. Long-term use should be monitored for potential risks such as osteoporosis, Clostridium difficile-associated diarrhea, and liver enzyme elevations."

},
 
  
  {
    "iupac_name": "17,21-dihydroxypregna-1,4-diene-3,11,20-trione",
    "chemical_formula": "C21H26O5",
    "brand_names": [
    "Deltasone",
    "Rayos",
    "Prednicot",
    "Prednisone Intensol",
    "Winpred",
    "Sterapred",
    "Sterapred DS",
    "Liquid Pred",
    "Prednisone",
    "Meticorten",
    "Orasone",
    "Prednicen-M"
],

    "category": "Corticosteroid",
    "dosage_forms": ["Tablets", "Oral solution", "Delayed-release tablets"],
    "strengths": ["1 mg", "2.5 mg", "5 mg", "10 mg", "20 mg", "50 mg"],
    "mechanism_of_action": {
        "site_of_action": "Glucocorticoid receptors",
        "physiological_mechanism": "Reduces inflammation by suppressing leukocyte migration and immune system activity; inhibits cytokine production."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune",
            "effect": "Suppression of inflammatory responses",
            "timeframe": "Within hours to days"
        },
        {
            "system": "Endocrine",
            "effect": "Suppresses adrenal gland activity (HPA axis)",
            "timeframe": "Varies depending on dosage and duration"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "NF-κB signaling pathway",
        "key_targets": ["Glucocorticoid receptor", "Cytokine transcription"],
        "related_conditions": ["Rheumatoid arthritis", "Asthma", "Lupus"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Converted to its active metabolite, prednisolone, in the liver."
        },
        "elimination": "Excreted primarily in urine as inactive metabolites"
    },
    "interactions": {
        "NSAIDs": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Increased risk of gastrointestinal ulcers and bleeding",
            "effect": "May worsen gastric irritation",
            "recommendation": "Use with caution; consider gastroprotective agents."
        },
        "Antidiabetic drugs": {
            "site_of_interaction": "Glucose metabolism",
            "mechanism": "Opposes insulin action, raising blood glucose levels",
            "effect": "Hyperglycemia",
            "recommendation": "Monitor blood glucose closely; adjust antidiabetic therapy if needed."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Vitamin D metabolism suppression"],
        "toxins": ["Alcohol may exacerbate gastric irritation"],
        "microbiota_effects": "May alter gut microbiota due to immune suppression"
    },
    "effects_on_symptoms": {
        "Inflammation": {
            "site_of_effect": "Joints, lungs, and other inflamed tissues",
            "mechanism": "Suppresses cytokine and prostaglandin synthesis",
            "direction": "Decreases",
            "magnitude": "High",
            "timeframe": "Within 24-48 hours"
        }
    },
    "diagnostic_conditions": {
        "Rheumatoid arthritis": {
            "symptoms_addressed": ["Joint pain", "Swelling", "Stiffness"],
            "therapeutic_action": "Reduces inflammation and immune activity",
            "optimal_dosage": "5-10 mg/day",
            "response_time": "Improvement seen in 1-2 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Increased appetite", "Insomnia"],
        "moderate": ["Mood swings", "Elevated blood glucose", "Hypertension"],
        "severe": ["Osteoporosis", "Adrenal suppression", "Peptic ulcers"]
    },
    "long_term_monitoring": {
        "parameters": ["Bone density", "Blood glucose", "Blood pressure"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Bone density": "T-score > -1.0",
                "Blood glucose": "70-100 mg/dL",
                "Blood pressure": "<120/80 mmHg"
            },
            "alert_threshold": {
                "Bone density": "T-score < -2.5",
                "Blood glucose": ">200 mg/dL",
                "Blood pressure": ">140/90 mmHg"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower starting doses; monitor for osteoporosis",
            "rationale": "Higher risk of bone density loss and systemic side effects"
        }
    },
    "alternative_therapies": ["Methotrexate", "Hydroxychloroquine"],
    "combination_therapies": {
        "recommended_combinations": ["Prednisone with DMARDs for rheumatoid arthritis"],
        "cautions": ["Avoid with live vaccines due to immunosuppression"]
    },
    "contraindications": ["Systemic fungal infections", "Untreated tuberculosis"],
    "precautions": ["Use with caution in diabetic patients and those with hypertension"],
    "side_effects": ["Weight gain", "Mood changes", "Thin skin"],
    "overdose_management": {
        "symptoms": ["Severe hypertension", "Hyperglycemia", "Psychosis"],
        "treatment": ["Supportive care, tapering doses, monitor electrolytes"]
    },
    "notes": "Prednisone, marketed under brand names such as Deltasone, Rayos, Prednicot, Prednisone Intensol, Winpred, Sterapred, Sterapred DS, Liquid Pred, Meticorten, Orasone, and Prednicen-M, is commonly used to treat conditions such as inflammatory diseases, autoimmune disorders, and allergic reactions. Long-term use should be monitored for potential risks, including osteoporosis, adrenal suppression, hyperglycemia, hypertension, and increased susceptibility to infections."

},

  
  {
    "iupac_name": "(-)-trans-Δ⁹-tetrahydrocannabinol",
    "chemical_formula": "C21H30O2",
    "brand_names": [
        "Marinol",
        "Syndros",
        "Cesamet",
        "Epidiolex",
        "Sativex"
    ],
    "category": "Cannabinoid",
    "dosage_forms": ["Oral capsules", "Oral solution", "Spray", "Inhalation"],
    "strengths": ["2.5 mg", "5 mg", "10 mg", "100 mg/mL"],
    "mechanism_of_action": {
        "site_of_action": "Cannabinoid receptors (CB1 and CB2)",
        "physiological_mechanism": "Modulates neurotransmitter release in the central and peripheral nervous systems; reduces inflammation and alters pain perception."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Euphoria, altered sensory perception",
            "timeframe": "Within minutes to hours"
        },
        {
            "system": "Immune",
            "effect": "Anti-inflammatory response",
            "timeframe": "Within hours to days"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Endocannabinoid system",
        "key_targets": ["CB1 receptor", "CB2 receptor"],
        "related_conditions": ["Chronic pain", "Epilepsy", "Multiple sclerosis"]
    },
    "pharmacokinetics": {
        "absorption": "Variable, depending on route of administration (oral, inhalation)",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9", "CYP3A4"],
            "notes": "Extensively metabolized to active and inactive metabolites."
        },
        "elimination": "Excreted primarily in feces and urine"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Additive sedative effects",
            "effect": "Enhanced drowsiness",
            "recommendation": "Avoid concurrent use."
        },
        "CYP3A4 inhibitors": {
            "site_of_interaction": "Liver enzymes",
            "mechanism": "Reduced metabolism of cannabis components",
            "effect": "Increased effects of THC",
            "recommendation": "Monitor for enhanced side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Possible impact on fatty acid metabolism"],
        "toxins": ["Smoke inhalation may contain harmful byproducts"],
        "microbiota_effects": "Potential modulation of gut microbiota"
    },
    "effects_on_symptoms": {
        "Chronic pain": {
            "site_of_effect": "Peripheral and central nervous system",
            "mechanism": "Alters pain signaling pathways",
            "direction": "Decreases",
            "magnitude": "Moderate to high",
            "timeframe": "Within 30 minutes (inhalation) to 1-2 hours (oral)"
        }
    },
    "diagnostic_conditions": {
        "Epilepsy": {
            "symptoms_addressed": ["Seizures"],
            "therapeutic_action": "Reduces seizure frequency",
            "optimal_dosage": "5-10 mg/kg/day (CBD-based)",
            "response_time": "Improvement within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dry mouth", "Drowsiness", "Increased appetite"],
        "moderate": ["Paranoia", "Anxiety", "Dizziness"],
        "severe": ["Psychosis", "Severe hypotension", "Dependency"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver enzymes", "Mental health status"],
        "frequency": "Every 6-12 months",
        "clinical_thresholds": {
            "normal_range": {
                "Liver enzymes": "ALT <40 IU/L",
                "Mental health": "No psychotic episodes"
            },
            "alert_threshold": {
                "Liver enzymes": "ALT >60 IU/L",
                "Mental health": "Onset of psychosis or severe anxiety"
            }
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use",
            "rationale": "Potential adverse effects on fetal development"
        }
    },
    "alternative_therapies": ["Gabapentin", "Duloxetine"],
    "combination_therapies": {
        "recommended_combinations": ["Cannabis with analgesics for chronic pain"],
        "cautions": ["Avoid with sedatives due to increased drowsiness"]
    },
    "contraindications": ["History of psychosis", "Severe cardiovascular disease"],
    "precautions": ["Use with caution in patients with liver disease or substance abuse history"],
    "side_effects": ["Dry mouth", "Fatigue", "Altered concentration"],
    "overdose_management": {
        "symptoms": ["Severe anxiety", "Paranoia", "Tachycardia"],
        "treatment": ["Supportive care, reassurance, benzodiazepines if severe"]
    },
    "notes": "Cannabis has a wide range of therapeutic applications but requires careful monitoring for adverse effects, especially in vulnerable populations."
},

  
  
  {
    "iupac_name": "Methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate",
    "chemical_formula": "C17H21NO4",
    "brand_names": [
        "Cocaine Hydrochloride",
        "Goprelto",
        "Numbrino"
    ],
    "category": "Local Anesthetic, CNS Stimulant",
    "dosage_forms": ["Topical solution", "Intranasal solution"],
    "strengths": ["4%", "10%"],
    "mechanism_of_action": {
        "site_of_action": "Voltage-gated sodium channels",
        "physiological_mechanism": "Blocks sodium channels, preventing nerve signal propagation; indirectly increases dopamine levels by inhibiting dopamine reuptake."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Euphoria, increased alertness",
            "timeframe": "Within seconds to minutes"
        },
        {
            "system": "Cardiovascular",
            "effect": "Increased heart rate and blood pressure",
            "timeframe": "Within minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Monoamine reuptake inhibition",
        "key_targets": ["Dopamine transporter (DAT)", "Norepinephrine transporter (NET)"],
        "related_conditions": ["Topical anesthesia", "Vasoconstriction for mucosal procedures"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed through mucous membranes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Butyrylcholinesterase", "CYP3A4"],
            "notes": "Metabolized to benzoylecgonine and ecgonine methyl ester."
        },
        "elimination": "Excreted in urine as metabolites"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Liver",
            "mechanism": "Forms cocaethylene, enhancing toxic effects",
            "effect": "Increased cardiovascular risk",
            "recommendation": "Avoid concurrent use."
        },
        "Monoamine Oxidase Inhibitors (MAOIs)": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Excessive monoamine accumulation",
            "effect": "Hypertensive crisis",
            "recommendation": "Contraindicated."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potential reduction in vitamin C levels"],
        "toxins": ["Enhanced risk of cardiovascular toxicity with stimulants"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Topical anesthesia": {
            "site_of_effect": "Mucosal surfaces",
            "mechanism": "Blocks nerve signal conduction",
            "direction": "Decreases",
            "magnitude": "High",
            "timeframe": "Immediate"
        }
    },
    "diagnostic_conditions": {
        "Local anesthesia for procedures": {
            "symptoms_addressed": ["Pain during mucosal procedures"],
            "therapeutic_action": "Provides anesthesia and vasoconstriction",
            "optimal_dosage": "4% topical solution applied sparingly",
            "response_time": "Immediate"
        }
    },
    "adverse_effects": {
        "mild": ["Numbness at application site", "Tingling sensation"],
        "moderate": ["Tachycardia", "Elevated blood pressure"],
        "severe": ["Seizures", "Cardiac arrhythmias", "Respiratory depression"]
    },
    "long_term_monitoring": {
        "parameters": ["Cardiovascular health", "Mental health"],
        "frequency": "Every 6 months (for chronic therapeutic use)",
        "clinical_thresholds": {
            "normal_range": {
                "Heart rate": "60-100 bpm",
                "Blood pressure": "<120/80 mmHg"
            },
            "alert_threshold": {
                "Heart rate": ">120 bpm",
                "Blood pressure": ">140/90 mmHg"
            }
        }
    },
    "population_specific": {
        "Pediatric patients": {
            "adjustments": "Avoid use in children under 12 years",
            "rationale": "Increased sensitivity to systemic effects"
        }
    },
    "alternative_therapies": ["Lidocaine", "Bupivacaine"],
    "combination_therapies": {
        "recommended_combinations": ["Cocaine with epinephrine for enhanced vasoconstriction"],
        "cautions": ["Avoid combination with other stimulants"]
    },
    "contraindications": ["Cardiac arrhythmias", "Severe hypertension"],
    "precautions": ["Use with caution in patients with a history of substance abuse"],
    "side_effects": ["Local irritation", "Dizziness", "Palpitations"],
    "overdose_management": {
        "symptoms": ["Severe hypertension", "Seizures", "Cardiac arrest"],
        "treatment": ["Benzodiazepines for seizures, beta-blockers for hypertension, supportive care"]
    },
    "notes": "Cocaine, available under brand names such as Goprelto and Numbrino, is primarily used for topical anesthesia and mucosal vasoconstriction in medical procedures. It should be used with caution due to its potential for abuse, severe cardiovascular effects, and interactions with alcohol or MAOIs."
},

  {
    "iupac_name": "Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, diacetate (ester), (5α,6α)-",
    "chemical_formula": "C21H23NO5",
    "brand_names": [
        "Diacetylmorphine",
        "Heroin",
        "Acetomorphine"
    ],
    "category": "Opioid",
    "dosage_forms": ["Powder", "Solution for injection"],
    "strengths": ["Variable, depending on illicit production"],
    "mechanism_of_action": {
        "site_of_action": "Mu-opioid receptors",
        "physiological_mechanism": "Converts to morphine in the body; activates mu-opioid receptors to inhibit pain signaling and produce euphoria."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Euphoria, analgesia",
            "timeframe": "Seconds to minutes"
        },
        {
            "system": "Respiratory",
            "effect": "Respiratory depression",
            "timeframe": "Minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Opioid receptor signaling",
        "key_targets": ["Mu-opioid receptor"],
        "related_conditions": ["Severe pain (historically)", "Illicit use"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid via intravenous or intranasal routes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Carboxylesterases"],
            "notes": "Rapidly metabolized to 6-monoacetylmorphine (6-MAM) and morphine."
        },
        "elimination": "Excreted in urine as morphine metabolites"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Additive depressant effects",
            "effect": "Increased risk of respiratory depression",
            "recommendation": "Avoid concurrent use."
        },
        "Benzodiazepines": {
            "site_of_interaction": "Central nervous system",
            "mechanism": "Potentiation of sedative effects",
            "effect": "Severe respiratory depression and sedation",
            "recommendation": "Contraindicated."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Contaminants in illicit heroin may cause additional toxicity"],
        "microbiota_effects": "May alter gut microbiota due to systemic effects"
    },
    "effects_on_symptoms": {
        "Severe pain": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Inhibits ascending pain pathways and alters pain perception",
            "direction": "Decreases",
            "magnitude": "High",
            "timeframe": "Within minutes"
        }
    },
    "diagnostic_conditions": {
        "Pain management (historical use)": {
            "symptoms_addressed": ["Severe pain"],
            "therapeutic_action": "Provides potent analgesia",
            "optimal_dosage": "Previously 2-10 mg IV (historical)",
            "response_time": "Immediate"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Itching", "Drowsiness"],
        "moderate": ["Constipation", "Dependence", "Sedation"],
        "severe": ["Respiratory arrest", "Coma", "Death"]
    },
    "long_term_monitoring": {
        "parameters": ["Mental health", "Respiratory function"],
        "frequency": "Not applicable (illicit use monitoring varies)",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use; monitor for neonatal abstinence syndrome if exposed",
            "rationale": "High risk of harm to the fetus"
        }
    },
    "alternative_therapies": ["Morphine", "Methadone", "Buprenorphine"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Avoid combining with CNS depressants"]
    },
    "contraindications": ["Severe respiratory disease", "History of substance abuse (precaution in therapeutic context)"],
    "precautions": ["High potential for abuse and dependency"],
    "side_effects": ["Euphoria", "Drowsiness", "Respiratory depression"],
    "overdose_management": {
        "symptoms": ["Respiratory arrest", "Pinpoint pupils", "Unresponsiveness"],
        "treatment": ["Naloxone administration, airway support, hospitalization"]
    },
    "notes": "Heroin, or diacetylmorphine, is an opioid with no approved medical use in most countries due to its high potential for abuse and severe adverse effects. Historically used for pain management, it is now predominantly an illicit substance requiring close monitoring for overdose and dependency risks."
},

  {
    "iupac_name": "(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol",
    "chemical_formula": "C10H15NO",
    "brand_names": [
        "Bronkaid",
        "Primatene",
        "Ephedrine Sulfate",
        "Efedron",
        "Pretz-D"
    ],
    "category": "Sympathomimetic, Bronchodilator",
    "dosage_forms": ["Tablets", "Capsules", "Injectable solution"],
    "strengths": ["12.5 mg", "25 mg", "50 mg"],
    "mechanism_of_action": {
        "site_of_action": "Adrenergic receptors (alpha and beta)",
        "physiological_mechanism": "Stimulates alpha and beta-adrenergic receptors, leading to increased heart rate, bronchodilation, and vasoconstriction. Indirectly stimulates the release of norepinephrine."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Respiratory",
            "effect": "Bronchodilation",
            "timeframe": "Within minutes"
        },
        {
            "system": "Cardiovascular",
            "effect": "Increased heart rate and blood pressure",
            "timeframe": "Within minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic signaling pathway",
        "key_targets": ["Alpha-adrenergic receptors", "Beta-adrenergic receptors"],
        "related_conditions": ["Asthma", "Nasal congestion", "Hypotension"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Monoamine oxidase (MAO)"],
            "notes": "Partially metabolized; excreted unchanged in urine."
        },
        "elimination": "Primarily renal excretion; half-life varies based on urinary pH"
    },
    "interactions": {
        "MAO Inhibitors": {
            "site_of_interaction": "Adrenergic system",
            "mechanism": "Prolonged ephedrine action due to inhibited metabolism",
            "effect": "Severe hypertension",
            "recommendation": "Contraindicated."
        },
        "Beta-blockers": {
            "site_of_interaction": "Adrenergic receptors",
            "mechanism": "Antagonizes ephedrine effects",
            "effect": "Reduced efficacy",
            "recommendation": "Use alternative therapy."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Synergistic effects with other stimulants"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Nasal congestion": {
            "site_of_effect": "Nasal mucosa",
            "mechanism": "Vasoconstriction reduces swelling and congestion",
            "direction": "Decreases",
            "magnitude": "Moderate",
            "timeframe": "Within 30 minutes"
        }
    },
    "diagnostic_conditions": {
        "Hypotension during anesthesia": {
            "symptoms_addressed": ["Low blood pressure"],
            "therapeutic_action": "Increases blood pressure through vasoconstriction",
            "optimal_dosage": "5-10 mg IV as needed",
            "response_time": "Immediate"
        }
    },
    "adverse_effects": {
        "mild": ["Nervousness", "Tremor", "Insomnia"],
        "moderate": ["Palpitations", "Hypertension", "Sweating"],
        "severe": ["Cardiac arrhythmias", "Severe hypertension", "Seizures"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood pressure", "Heart rate"],
        "frequency": "Every 3-6 months (for chronic use)",
        "clinical_thresholds": {
            "normal_range": {
                "Blood pressure": "<120/80 mmHg",
                "Heart rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Blood pressure": ">140/90 mmHg",
                "Heart rate": ">120 bpm"
            }
        }
    },
    "population_specific": {
        "Children": {
            "adjustments": "Lower doses based on weight",
            "rationale": "Reduced tolerance to stimulant effects"
        }
    },
    "alternative_therapies": ["Pseudoephedrine", "Albuterol"],
    "combination_therapies": {
        "recommended_combinations": ["Ephedrine with guaifenesin for congestion relief"],
        "cautions": ["Avoid combining with other CNS stimulants"]
    },
    "contraindications": ["Severe cardiovascular disease", "Hyperthyroidism"],
    "precautions": ["Use with caution in patients with diabetes or glaucoma"],
    "side_effects": ["Nervousness", "Insomnia", "Increased heart rate"],
    "overdose_management": {
        "symptoms": ["Severe hypertension", "Arrhythmias", "Seizures"],
        "treatment": ["Beta-blockers for hypertension, benzodiazepines for seizures, supportive care"]
    },
    "notes": "Ephedrine, sold under brand names like Bronkaid and Primatene, is commonly used for temporary relief of asthma symptoms, nasal congestion, and to treat hypotension during anesthesia. Use should be closely monitored due to potential cardiovascular and CNS side effects, especially with long-term use."
},

  {
    "iupac_name": "1-(1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine",
    "chemical_formula": "C11H15NO2",
    "brand_names": [
        "Ecstasy",
        "Molly",
        "MDMA"
    ],
    "category": "Empathogen, Stimulant",
    "dosage_forms": ["Capsules", "Tablets", "Powder"],
    "strengths": ["Variable, depending on illicit production"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin, dopamine, and norepinephrine transporters",
        "physiological_mechanism": "Promotes release of serotonin, dopamine, and norepinephrine, while inhibiting their reuptake, leading to elevated mood, empathy, and increased energy."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Euphoria, increased sociability",
            "timeframe": "Within 30-60 minutes"
        },
        {
            "system": "Cardiovascular",
            "effect": "Increased heart rate and blood pressure",
            "timeframe": "Within 30 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Monoamine signaling pathway",
        "key_targets": ["Serotonin transporter (SERT)", "Dopamine transporter (DAT)", "Norepinephrine transporter (NET)"],
        "related_conditions": ["Experimental use in PTSD therapy (investigational)", "Illicit recreational use"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Metabolized to active metabolites such as MDA (3,4-methylenedioxyamphetamine)."
        },
        "elimination": "Excreted in urine as metabolites and unchanged drug"
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Serotonin system",
            "mechanism": "Reduced MDMA efficacy by blocking serotonin release",
            "effect": "Decreased psychoactive effects",
            "recommendation": "Avoid due to risk of serotonin syndrome."
        },
        "MAO Inhibitors": {
            "site_of_interaction": "Monoamine system",
            "mechanism": "Excessive monoamine accumulation",
            "effect": "Severe hypertension and serotonin syndrome",
            "recommendation": "Contraindicated."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potential depletion of serotonin precursors (e.g., tryptophan)"],
        "toxins": ["Adulterants in illicit MDMA may increase toxicity"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Social anxiety (investigational)": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Enhanced empathy and emotional processing",
            "direction": "Decreases",
            "magnitude": "Moderate",
            "timeframe": "Within 1-2 hours"
        }
    },
    "diagnostic_conditions": {
        "PTSD (investigational use)": {
            "symptoms_addressed": ["Emotional numbness", "Anxiety"],
            "therapeutic_action": "Enhances emotional openness and processing during therapy",
            "optimal_dosage": "75-125 mg (investigational)",
            "response_time": "Improvement noted over several therapy sessions"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Jaw clenching", "Blurred vision"],
        "moderate": ["Hyperthermia", "Dehydration", "Anxiety"],
        "severe": ["Serotonin syndrome", "Seizures", "Hyponatremia"]
    },
    "long_term_monitoring": {
        "parameters": ["Mental health", "Liver function"],
        "frequency": "Not applicable for illicit use; therapy settings may vary",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Adolescents": {
            "adjustments": "Avoid use",
            "rationale": "High risk of neurotoxicity and long-term cognitive effects"
        }
    },
    "alternative_therapies": ["Sertraline (PTSD therapy)", "Cognitive Behavioral Therapy (CBT)"],
    "combination_therapies": {
        "recommended_combinations": ["MDMA with psychotherapy (investigational)"],
        "cautions": ["Avoid combining with other serotonergic drugs"]
    },
    "contraindications": ["Cardiovascular disease", "History of serotonin syndrome"],
    "precautions": ["Use with caution in individuals with psychiatric disorders"],
    "side_effects": ["Euphoria", "Increased heart rate", "Hyperthermia"],
    "overdose_management": {
        "symptoms": ["Severe hyperthermia", "Seizures", "Cardiac arrest"],
        "treatment": ["Cooling measures, benzodiazepines for seizures, supportive care"]
    },
    "notes": "MDMA, commonly known as Ecstasy or Molly, is primarily used recreationally but is being investigated for therapeutic use in PTSD. Risks include serotonin syndrome, dehydration, and neurotoxicity, particularly with long-term or high-dose use. Therapy settings require strict monitoring to minimize adverse effects."
},

  {
    "iupac_name": "N,N-Dimethyltryptamine (DMT) and β-carbolines (e.g., Harmine, Harmaline)",
    "chemical_formula": "C12H16N2 (DMT), C13H12N2O (Harmine)",
    "brand_names": ["Ayahuasca"],
    "category": "Psychedelic, Hallucinogen",
    "dosage_forms": ["Brew (oral preparation)"],
    "strengths": ["Variable, dependent on preparation"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin receptors (5-HT2A)",
        "physiological_mechanism": "DMT acts as a serotonin receptor agonist, inducing altered states of consciousness, while β-carbolines inhibit monoamine oxidase (MAO), preventing the breakdown of DMT for oral activity."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Altered perception, vivid imagery, and introspection",
            "timeframe": "Within 30-60 minutes"
        },
        {
            "system": "Digestive",
            "effect": "Purging (nausea and vomiting)",
            "timeframe": "Early in the experience (first 1-2 hours)"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin receptor signaling",
        "key_targets": ["5-HT2A receptor", "Monoamine oxidase"],
        "related_conditions": ["Spiritual insight (cultural use)", "Addiction (investigational)"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid absorption from the gastrointestinal tract when combined with MAO inhibitors",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Monoamine oxidase"],
            "notes": "MAO inhibitors in the brew allow DMT to reach systemic circulation."
        },
        "elimination": "Primarily hepatic metabolism; excreted in urine as inactive metabolites"
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Serotonin system",
            "mechanism": "Increased serotonin activity",
            "effect": "Risk of serotonin syndrome",
            "recommendation": "Avoid concurrent use."
        },
        "Tyramine-rich foods": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Enhanced MAO inhibition",
            "effect": "Risk of hypertensive crisis",
            "recommendation": "Avoid high-tyramine foods during and after consumption."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Tyramine-containing foods can exacerbate effects"],
        "toxins": ["Potential risk from unregulated preparation"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Addiction (investigational)": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Facilitates introspection and emotional processing",
            "direction": "Decreases",
            "magnitude": "Moderate",
            "timeframe": "Over weeks to months of supported therapy"
        }
    },
    "diagnostic_conditions": {
        "Spiritual introspection (traditional)": {
            "symptoms_addressed": ["Emotional detachment", "Existential distress"],
            "therapeutic_action": "Promotes self-awareness and emotional connection",
            "optimal_dosage": "Dependent on preparation and guidance",
            "response_time": "Immediate experiential effects"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Dizziness"],
        "moderate": ["Anxiety", "Transient hypertension", "Diarrhea"],
        "severe": ["Panic reactions", "Persistent psychological distress (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Psychological health"],
        "frequency": "Variable (guided use may involve regular check-ins)",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use",
            "rationale": "Potential risks to fetal development"
        }
    },
    "alternative_therapies": ["Meditation", "Psilocybin (investigational)"],
    "combination_therapies": {
        "recommended_combinations": ["Ayahuasca with guided therapy (traditional use)"],
        "cautions": ["Avoid combining with serotonergic drugs"]
    },
    "contraindications": ["Severe psychiatric disorders (e.g., schizophrenia)"],
    "precautions": ["Ensure preparation by experienced practitioners to avoid contamination"],
    "side_effects": ["Nausea", "Intense emotional experiences", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Severe anxiety", "Hypertensive crisis"],
        "treatment": ["Supportive care, calming measures, antihypertensives if needed"]
    },
    "notes": "Ayahuasca is a traditional brew used for spiritual and introspective purposes, combining DMT and MAO inhibitors. While it has potential therapeutic uses, it requires careful preparation and guidance due to the intensity of its effects and potential risks."
},

  {
    "iupac_name": "4-Phosphoryloxy-N,N-dimethyltryptamine",
    "chemical_formula": "C12H17N2O4P",
    "brand_names": ["Psilocybin", "Magic Mushrooms"],
    "category": "Psychedelic, Hallucinogen",
    "dosage_forms": ["Capsules", "Dried mushrooms", "Extracts"],
    "strengths": ["Variable, dependent on preparation"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin receptors (5-HT2A)",
        "physiological_mechanism": "Psilocybin is metabolized to psilocin, which acts as a serotonin receptor agonist, inducing altered perception, cognition, and mood."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Altered perception, introspection, and euphoria",
            "timeframe": "Within 30-60 minutes"
        },
        {
            "system": "Psychological",
            "effect": "Reduced negative emotional processing",
            "timeframe": "During and after the experience"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin receptor signaling",
        "key_targets": ["5-HT2A receptor"],
        "related_conditions": ["Treatment-resistant depression (investigational)", "Anxiety (investigational)"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Monoamine oxidase"],
            "notes": "Psilocybin is converted to its active metabolite, psilocin."
        },
        "elimination": "Primarily renal excretion as inactive metabolites"
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Serotonin system",
            "mechanism": "Potential reduction in psilocybin effects",
            "effect": "Blunted psychedelic response",
            "recommendation": "Caution; consult a healthcare provider."
        },
        "MAO Inhibitors": {
            "site_of_interaction": "Monoamine system",
            "mechanism": "Prolonged psilocin activity",
            "effect": "Enhanced and prolonged effects",
            "recommendation": "Use under supervision only."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Contamination risks in unregulated preparations"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Depression (investigational)": {
            "site_of_effect": "Central nervous system",
            "mechanism": "Enhances emotional openness and rewiring of thought patterns",
            "direction": "Decreases",
            "magnitude": "Moderate to high",
            "timeframe": "Improvement over days to weeks"
        }
    },
    "diagnostic_conditions": {
        "Anxiety (investigational)": {
            "symptoms_addressed": ["Excessive worry", "Rumination"],
            "therapeutic_action": "Reduces overactivity of negative thought cycles",
            "optimal_dosage": "10-30 mg (investigational)",
            "response_time": "During guided therapy sessions"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dizziness", "Dry mouth"],
        "moderate": ["Anxiety", "Confusion", "Fatigue"],
        "severe": ["Panic attacks", "Persistent perceptual changes (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Psychological health"],
        "frequency": "Periodic check-ins post-therapy sessions",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use",
            "rationale": "Potential unknown risks to fetal development"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy (CBT)", "SSRIs"],
    "combination_therapies": {
        "recommended_combinations": ["Psilocybin with guided therapy (investigational)"],
        "cautions": ["Avoid combining with other serotonergic drugs"]
    },
    "contraindications": ["Severe psychiatric disorders (e.g., schizophrenia)"],
    "precautions": ["Ensure proper preparation and guidance to avoid adverse effects"],
    "side_effects": ["Nausea", "Visual distortions", "Emotional shifts"],
    "overdose_management": {
        "symptoms": ["Severe anxiety", "Confusion", "Hypertension"],
        "treatment": ["Supportive care, calming measures, benzodiazepines if necessary"]
    },
    "notes": "Psilocybin, derived from certain fungi, is being studied for its potential therapeutic effects on depression, anxiety, and other mental health conditions. While promising, its use requires careful preparation and guidance to ensure safety and maximize therapeutic benefit."
},

  
 {
    "iupac_name": "2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone",
    "chemical_formula": "C13H16ClNO",
    "brand_names": [
        "Ketalar",
        "Ketaset",
        "Ketajet",
        "Ketavet",
        "Ketanest",
        "Ketanest-S",
        "Ketamine Hydrochloride",
        "Calypsol",
        "Ketaminol",
        "Tekam",
        "Vetalar",
        "Ketamina",
        "Ketamin",
        "Ketmin",
        "Ketalin",
        "Soon-Soon",
        "Narkamon"
    ],
    "category": "Dissociative Anesthetic",
    "dosage_forms": ["Injectable solution", "Intranasal spray", "Oral lozenges (off-label)"],
    "strengths": ["10 mg/mL", "50 mg/mL", "100 mg/mL"],
    "mechanism_of_action": {
        "site_of_action": "N-methyl-D-aspartate (NMDA) receptors",
        "physiological_mechanism": "Non-competitive NMDA receptor antagonist leading to dissociative anesthesia; also interacts with opioid receptors and monoaminergic pathways."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Analgesia, sedation, dissociation",
            "timeframe": "Onset within 30 seconds (IV); duration 5-10 minutes (IV)"
        },
        {
            "system": "Cardiovascular",
            "effect": "Increased heart rate and blood pressure",
            "timeframe": "Peaks within minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Glutamatergic neurotransmission",
        "key_targets": ["NMDA receptors", "Opioid receptors"],
        "related_conditions": ["Anesthesia", "Chronic pain", "Depression (off-label)"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid absorption via intravenous or intramuscular routes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 enzymes, primarily CYP2B6 and CYP3A4"],
            "notes": "Metabolized to norketamine (active metabolite)"
        },
        "elimination": "Renal excretion; half-life approximately 2.5-3 hours"
    },
    "interactions": {
        "Benzodiazepines": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Enhanced sedative effects",
            "effect": "Increased risk of respiratory depression",
            "recommendation": "Use with caution; monitor respiratory function."
        },
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive CNS depression",
            "effect": "Enhanced sedative and dissociative effects",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Potential for contamination in illicit preparations"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Acute Pain": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "NMDA receptor antagonism leading to analgesia",
            "direction": "Decreases",
            "magnitude": "High",
            "timeframe": "Immediate relief"
        }
    },
    "diagnostic_conditions": {
        "Treatment-Resistant Depression (off-label)": {
            "symptoms_addressed": ["Severe depressive symptoms"],
            "therapeutic_action": "Rapid antidepressant effects",
            "optimal_dosage": "0.5 mg/kg IV infusion over 40 minutes",
            "response_time": "Within hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dizziness", "Blurred vision"],
        "moderate": ["Hypertension", "Tachycardia", "Hallucinations"],
        "severe": ["Respiratory depression", "Severe agitation", "Emergence delirium"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function tests", "Urinary tract health"],
        "frequency": "Every 3-6 months during prolonged use",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pediatric Patients": {
            "adjustments": "Dose adjustments required based on weight",
            "rationale": "Increased sensitivity to anesthetic effects"
        }
    },
    "alternative_therapies": ["Propofol", "Etomidate", "Midazolam"],
    "combination_therapies": {
        "recommended_combinations": ["Ketamine with midazolam for procedural sedation"],
        "cautions": ["Monitor for enhanced respiratory depression"]
    },
    "contraindications": ["Uncontrolled hypertension", "History of psychosis"],
    "precautions": ["Use with caution in patients with cardiovascular disease"],
    "side_effects": ["Dissociation", "Elevated blood pressure", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe respiratory depression", "Loss of consciousness"],
        "treatment": ["Supportive care, airway management, cardiovascular support"]
    },
    "notes": "Ketamine, marketed under various brand names such as Ketalar and Ketaset, is a dissociative anesthetic used in both human and veterinary medicine. It has gained attention for off-label use in treatment-resistant depression. Due to its potential for abuse and psychotropic effects, its administration should be carefully monitored."
},
 
  {
    "iupac_name": "(6aR,9R)-N,N-Diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide",
    "chemical_formula": "C20H25N3O",
    "brand_names": ["Delysid", "LSD", "Acid"],
    "category": "Psychedelic, Hallucinogen",
    "dosage_forms": ["Blotter paper", "Liquid solution", "Gel tabs"],
    "strengths": ["Typically 20-150 µg per dose"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin receptors (5-HT2A)",
        "physiological_mechanism": "Acts as a serotonin receptor agonist, primarily at 5-HT2A receptors, inducing profound changes in perception, mood, and cognition."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Altered sensory perception, euphoria, and introspection",
            "timeframe": "Onset within 30-60 minutes; effects lasting 6-12 hours"
        },
        {
            "system": "Psychological",
            "effect": "Heightened emotional experiences",
            "timeframe": "During the duration of the experience"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin receptor signaling",
        "key_targets": ["5-HT2A receptor", "Dopamine receptors"],
        "related_conditions": ["Experimental use in anxiety and depression (investigational)", "Recreational use"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed through mucosal membranes or the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 enzymes"],
            "notes": "Metabolized to inactive metabolites, primarily 2-oxo-3-hydroxy-LSD."
        },
        "elimination": "Excreted primarily in urine as inactive metabolites; half-life approximately 3-5 hours"
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Serotonin system",
            "mechanism": "Blunted LSD effects due to altered serotonin signaling",
            "effect": "Reduced intensity of psychedelic effects",
            "recommendation": "Consult a healthcare provider before use."
        },
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "May alter the intensity of effects",
            "effect": "Unpredictable interactions",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["No direct toxicity but potential for impurities in illicit preparations"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Existential distress (investigational)": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Enhances introspection and emotional processing",
            "direction": "Decreases",
            "magnitude": "Moderate to high",
            "timeframe": "During guided therapy sessions"
        }
    },
    "diagnostic_conditions": {
        "Anxiety (investigational)": {
            "symptoms_addressed": ["Fear", "Restlessness"],
            "therapeutic_action": "Facilitates emotional processing and acceptance",
            "optimal_dosage": "50-100 µg in a controlled environment",
            "response_time": "Effects within 30-60 minutes"
        }
    },
    "adverse_effects": {
        "mild": ["Dilated pupils", "Dry mouth", "Sweating"],
        "moderate": ["Anxiety", "Confusion", "Paranoia"],
        "severe": ["Panic attacks", "Persistent perceptual changes", "Psychosis (rare in predisposed individuals)"]
    },
    "long_term_monitoring": {
        "parameters": ["Psychological health"],
        "frequency": "As needed post-experience",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Adolescents": {
            "adjustments": "Avoid use",
            "rationale": "Potential for long-term cognitive and psychological effects"
        }
    },
    "alternative_therapies": ["Psilocybin (investigational)", "Meditation"],
    "combination_therapies": {
        "recommended_combinations": ["LSD with guided therapy (investigational)"],
        "cautions": ["Avoid combining with other serotonergic drugs"]
    },
    "contraindications": ["Severe psychiatric disorders (e.g., schizophrenia)"],
    "precautions": ["Ensure use in a controlled and guided setting to avoid adverse psychological effects"],
    "side_effects": ["Visual distortions", "Emotional intensity", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe anxiety", "Paranoia", "Confusion"],
        "treatment": ["Supportive care, calming measures, benzodiazepines if necessary"]
    },
    "notes": "LSD, or Lysergic Acid Diethylamide, is a powerful psychedelic historically used for both recreational and experimental therapeutic purposes. While showing promise in mental health treatments under controlled conditions, its potent effects and unpredictability require caution and professional supervision."
},

 {
    "iupac_name": "3,4,5-Trimethoxyphenethylamine",
    "chemical_formula": "C11H17NO3",
    "brand_names": ["Mescaline", "Peyote (traditional use)", "San Pedro (traditional use)"],
    "category": "Psychedelic, Hallucinogen",
    "dosage_forms": ["Dried cactus buttons", "Powder", "Capsules"],
    "strengths": ["200 mg", "300 mg", "500 mg (variable based on preparation)"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin receptors (5-HT2A)",
        "physiological_mechanism": "Acts as a serotonin receptor agonist, leading to altered perception, introspection, and emotional processing."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Altered perception and introspection",
            "timeframe": "Onset within 1-2 hours; effects last 8-12 hours"
        },
        {
            "system": "Psychological",
            "effect": "Enhanced emotional openness",
            "timeframe": "During the experience"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin receptor signaling",
        "key_targets": ["5-HT2A receptor", "5-HT2C receptor"],
        "related_conditions": ["Traditional spiritual practices", "Experimental mental health therapy (investigational)"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Monoamine oxidase (MAO)"],
            "notes": "Partially metabolized; some excreted unchanged in urine."
        },
        "elimination": "Excreted primarily in urine; half-life approximately 6-8 hours"
    },
    "interactions": {
        "MAO Inhibitors": {
            "site_of_interaction": "Monoamine system",
            "mechanism": "Enhanced mescaline effects due to reduced breakdown",
            "effect": "Prolonged and intensified effects",
            "recommendation": "Use with caution; avoid unsupervised combinations."
        },
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Unpredictable interactions",
            "effect": "Potential for increased sedation or nausea",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Contamination risks in unregulated preparations"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Existential distress (investigational)": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Facilitates emotional processing and connection",
            "direction": "Decreases",
            "magnitude": "Moderate to high",
            "timeframe": "During guided therapy"
        }
    },
    "diagnostic_conditions": {
        "Anxiety (investigational)": {
            "symptoms_addressed": ["Restlessness", "Emotional detachment"],
            "therapeutic_action": "Promotes introspection and emotional release",
            "optimal_dosage": "200-500 mg (investigational)",
            "response_time": "Within 1-2 hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Sweating", "Dilated pupils"],
        "moderate": ["Anxiety", "Confusion", "Fatigue"],
        "severe": ["Panic reactions", "Persistent perceptual changes (rare)"]
    },
    "long_term_monitoring": {
        "parameters": ["Psychological health"],
        "frequency": "Periodic check-ins post-experience",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use",
            "rationale": "Potential unknown risks to fetal development"
        }
    },
    "alternative_therapies": ["Psilocybin (investigational)", "LSD (investigational)"],
    "combination_therapies": {
        "recommended_combinations": ["Mescaline with guided therapy (investigational)"],
        "cautions": ["Avoid combining with other serotonergic drugs"]
    },
    "contraindications": ["Severe psychiatric disorders (e.g., schizophrenia)"],
    "precautions": ["Ensure proper preparation and guidance to avoid adverse psychological effects"],
    "side_effects": ["Nausea", "Visual distortions", "Emotional shifts"],
    "overdose_management": {
        "symptoms": ["Severe anxiety", "Confusion", "Hypertension"],
        "treatment": ["Supportive care, calming measures, benzodiazepines if necessary"]
    },
    "notes": "Mescaline, derived from cacti such as Peyote and San Pedro, is used traditionally in spiritual practices and is being investigated for potential therapeutic effects. Its intense psychological effects require careful preparation and guidance for safe use."
},
  
  {
    "iupac_name": "(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine",
    "chemical_formula": "C17H17Cl2N",
    "brand_names": ["Zoloft", "Lustral", "Serlift", "Asentra", "Stimuloton"],
    "category": "Selective Serotonin Reuptake Inhibitor (SSRI)",
    "dosage_forms": ["Tablets", "Capsules", "Oral solution"],
    "strengths": ["25 mg", "50 mg", "100 mg"],
    "mechanism_of_action": {
        "site_of_action": "Serotonin transporters (SERT)",
        "physiological_mechanism": "Blocks the reuptake of serotonin into presynaptic neurons, increasing serotonin levels in the synaptic cleft to stabilize mood and reduce anxiety."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Mood stabilization, anxiety reduction",
            "timeframe": "Improvement noticed in 2-6 weeks"
        },
        {
            "system": "Psychological",
            "effect": "Reduced negative emotional processing",
            "timeframe": "Gradual over weeks"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Serotonin reuptake inhibition",
        "key_targets": ["Serotonin transporter (SERT)"],
        "related_conditions": ["Depression", "Anxiety disorders", "Obsessive-Compulsive Disorder (OCD)"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed orally, peak plasma concentrations in 4-6 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 enzymes, primarily CYP2B6 and CYP2C19"],
            "notes": "Metabolized to less active compounds."
        },
        "elimination": "Excreted in urine and feces; half-life approximately 26 hours"
    },
    "interactions": {
        "MAO Inhibitors": {
            "site_of_interaction": "Monoamine system",
            "mechanism": "Excessive serotonin accumulation",
            "effect": "Risk of serotonin syndrome",
            "recommendation": "Contraindicated within 14 days of MAOI use."
        },
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Enhanced sedative effects",
            "effect": "Increased drowsiness and impaired coordination",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["No direct toxicity"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Depression": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Increases serotonin levels to stabilize mood",
            "direction": "Decreases depressive symptoms",
            "magnitude": "Moderate to high",
            "timeframe": "2-6 weeks"
        }
    },
    "diagnostic_conditions": {
        "Generalized Anxiety Disorder": {
            "symptoms_addressed": ["Excessive worry", "Restlessness"],
            "therapeutic_action": "Reduces overactivity in serotonin pathways",
            "optimal_dosage": "50 mg daily",
            "response_time": "Improvement noted within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dry mouth", "Drowsiness"],
        "moderate": ["Sexual dysfunction", "Weight gain", "Sweating"],
        "severe": ["Serotonin syndrome", "Suicidal ideation (rare in young adults)"]
    },
    "long_term_monitoring": {
        "parameters": ["Psychological health", "Weight changes"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Use only if benefits outweigh risks",
            "rationale": "Potential for neonatal adaptation syndrome"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy (CBT)", "Fluoxetine"],
    "combination_therapies": {
        "recommended_combinations": ["Sertraline with psychotherapy for maximum efficacy"],
        "cautions": ["Avoid combining with other serotonergic drugs"]
    },
    "contraindications": ["MAO inhibitor use within 14 days", "Known hypersensitivity to sertraline"],
    "precautions": ["Monitor for worsening depression or suicidal thoughts during initial use"],
    "side_effects": ["Nausea", "Insomnia", "Decreased libido"],
    "overdose_management": {
        "symptoms": ["Agitation", "Tremors", "Seizures"],
        "treatment": ["Supportive care, airway management, benzodiazepines if needed"]
    },
    "notes": "Sertraline, marketed as Zoloft, is a widely used SSRI for treating depression, anxiety disorders, and OCD. While effective, it may take several weeks to show results, and side effects such as nausea and sexual dysfunction are common."
},

{
    "iupac_name": "Tropane alkaloids (e.g., scopolamine, atropine, hyoscyamine)",
    "chemical_formula": "Varies (e.g., C17H23NO3 for scopolamine)",
    "brand_names": ["Jimson Weed", "Devil's Trumpet", "Moonflower", "Thorn Apple", "Angel's Trumpet"],
    "category": "Anticholinergic, Hallucinogen (Deliriant)",
    "dosage_forms": ["Raw plant material", "Seeds", "Extracts"],
    "strengths": ["Highly variable, depending on preparation"],
    "mechanism_of_action": {
        "site_of_action": "Muscarinic acetylcholine receptors",
        "physiological_mechanism": "Blocks acetylcholine at muscarinic receptors, causing anticholinergic effects including hallucinations, mydriasis, and dry mouth."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Confusion, hallucinations, and delirium",
            "timeframe": "Onset within 30-60 minutes; effects last up to 24-48 hours"
        },
        {
            "system": "Cardiovascular",
            "effect": "Increased heart rate",
            "timeframe": "Within 30 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cholinergic neurotransmission",
        "key_targets": ["Muscarinic acetylcholine receptors"],
        "related_conditions": ["Recreational use (dangerous)", "Traditional use in spiritual practices"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid absorption via oral and mucosal routes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Partially metabolized by liver enzymes"],
            "notes": "Some alkaloids excreted unchanged."
        },
        "elimination": "Primarily renal excretion; half-life varies by alkaloid"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive sedative and impairing effects",
            "effect": "Increased risk of confusion and respiratory depression",
            "recommendation": "Avoid concurrent use."
        },
        "Anticholinergic drugs": {
            "site_of_interaction": "Cholinergic system",
            "mechanism": "Synergistic effects",
            "effect": "Exacerbated anticholinergic toxicity",
            "recommendation": "Avoid combination."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Toxicity due to high alkaloid content in seeds and leaves"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Traditional spiritual practices": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Induces hallucinations and delirium for spiritual rituals",
            "direction": "Induces altered states of consciousness",
            "magnitude": "High",
            "timeframe": "Immediate to long-lasting"
        }
    },
    "diagnostic_conditions": {
        "Motion Sickness (rare historical use)": {
            "symptoms_addressed": ["Nausea", "Vomiting"],
            "therapeutic_action": "Anticholinergic effect reduces motion sickness symptoms",
            "optimal_dosage": "Not recommended due to toxicity",
            "response_time": "Within 30 minutes"
        }
    },
    "adverse_effects": {
        "mild": ["Dry mouth", "Dilated pupils", "Flushed skin"],
        "moderate": ["Tachycardia", "Urinary retention", "Blurred vision"],
        "severe": ["Delirium", "Seizures", "Respiratory failure"]
    },
    "long_term_monitoring": {
        "parameters": ["Neurological status", "Renal function"],
        "frequency": "Not applicable; acute toxicity is primary concern",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Children": {
            "adjustments": "Avoid use entirely",
            "rationale": "Higher sensitivity to toxic effects"
        }
    },
    "alternative_therapies": ["Scopolamine patches (regulated use for motion sickness)"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Avoid combining with other anticholinergics or CNS depressants"]
    },
    "contraindications": ["Glaucoma", "Urinary retention", "Severe cardiovascular disease"],
    "precautions": ["Highly toxic; even small doses can lead to severe toxicity or death"],
    "side_effects": ["Dry mouth", "Confusion", "Visual distortions"],
    "overdose_management": {
        "symptoms": ["Severe delirium", "Seizures", "Respiratory depression"],
        "treatment": ["Activated charcoal if early, benzodiazepines for seizures, supportive care"]
    },
    "notes": "Datura, including species like Datura stramonium and Datura inoxia, is extremely toxic and poses significant risks of fatal poisoning. While used historically in spiritual rituals, its anticholinergic effects cause dangerous and unpredictable delirium, making it unsuitable for any casual or therapeutic use."
},

  {
    "iupac_name": "Mitragynine: methyl (E)-2-[(2S,3S,12bS)-3-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyacrylate",
    "chemical_formula": "C23H30N2O4",
    "brand_names": ["Kratom", "Biak-Biak", "Thom", "Ketum", "Kakuam"],
    "category": "Plant-based Psychoactive Substance",
    "dosage_forms": ["Raw leaves", "Powder", "Capsules", "Extracts"],
    "strengths": ["Variable, based on preparation and alkaloid content"],
    "mechanism_of_action": {
        "site_of_action": "Opioid receptors (mu, delta), adrenergic receptors",
        "physiological_mechanism": "Mitragynine and 7-hydroxymitragynine act as partial opioid agonists and interact with adrenergic receptors, producing stimulant effects at low doses and sedative or analgesic effects at high doses."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Stimulation at low doses, sedation at high doses",
            "timeframe": "Onset within 15-30 minutes; duration 2-6 hours"
        },
        {
            "system": "Cardiovascular",
            "effect": "Mild blood pressure increase",
            "timeframe": "Within 30 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Opioid receptor modulation",
        "key_targets": ["Mu-opioid receptor", "Delta-opioid receptor"],
        "related_conditions": ["Chronic pain", "Fatigue", "Opioid withdrawal (traditional use)"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed via oral or mucosal routes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 enzymes, primarily CYP3A4"],
            "notes": "Metabolized to active metabolites like 7-hydroxymitragynine."
        },
        "elimination": "Excreted primarily in urine; half-life varies (3-7 hours for mitragynine)"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive depressant effects",
            "effect": "Increased risk of sedation and respiratory depression",
            "recommendation": "Avoid concurrent use."
        },
        "Opioids": {
            "site_of_interaction": "Opioid receptors",
            "mechanism": "Synergistic effects",
            "effect": "Enhanced analgesia and increased risk of dependence",
            "recommendation": "Avoid combination."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Potential for contamination in unregulated products"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Chronic Pain": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Partial agonism at opioid receptors",
            "direction": "Decreases",
            "magnitude": "Moderate",
            "timeframe": "Within 30 minutes"
        }
    },
    "diagnostic_conditions": {
        "Opioid Withdrawal (traditional use)": {
            "symptoms_addressed": ["Cravings", "Anxiety"],
            "therapeutic_action": "Mitigates withdrawal symptoms via opioid receptor interaction",
            "optimal_dosage": "2-5 grams (powdered leaves, oral use)",
            "response_time": "Within 15-30 minutes"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Constipation", "Dizziness"],
        "moderate": ["Increased heart rate", "Irritability", "Sweating"],
        "severe": ["Seizures (in high doses)", "Liver toxicity (rare)", "Respiratory depression"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function", "Cardiovascular health"],
        "frequency": "Every 3-6 months during regular use",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Avoid use",
            "rationale": "Potential risks to fetal development and neonatal withdrawal symptoms"
        }
    },
    "alternative_therapies": ["Acupuncture", "Ibuprofen", "Cognitive Behavioral Therapy (CBT)"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Avoid combining with other sedatives or opioids"]
    },
    "contraindications": ["Severe liver disease", "Cardiovascular disorders"],
    "precautions": ["Monitor for signs of dependence or misuse"],
    "side_effects": ["Nausea", "Fatigue", "Sweating"],
    "overdose_management": {
        "symptoms": ["Respiratory depression", "Severe sedation", "Confusion"],
        "treatment": ["Supportive care, airway management, benzodiazepines if seizures occur"]
    },
    "notes": "Kratom, derived from the leaves of Mitragyna speciosa, is traditionally used in Southeast Asia for pain relief, increased energy, and opioid withdrawal management. While it shows potential benefits, its use carries risks of dependence, adverse effects, and unregulated product contamination."
},

 {
    "iupac_name": "4-Hydroxybutanoic acid",
    "chemical_formula": "C4H8O3",
    "brand_names": ["Xyrem", "Xywav", "Alcover", "Gamma-OH", "Somsanit"],
    "category": "Central Nervous System Depressant",
    "dosage_forms": ["Oral solution"],
    "strengths": ["500 mg/mL"],
    "mechanism_of_action": {
        "site_of_action": "GHB receptors, GABA_B receptors",
        "physiological_mechanism": "Acts as an agonist at GHB receptors and a weak agonist at GABA_B receptors, leading to sedative and hypnotic effects."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Sedation, hypnosis, and euphoria",
            "timeframe": "Onset within 15-30 minutes; duration 3-4 hours"
        },
        {
            "system": "Muscular",
            "effect": "Reduction in cataplexy episodes",
            "timeframe": "Within 30 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "GABAergic neurotransmission",
        "key_targets": ["GHB receptor", "GABA_B receptor"],
        "related_conditions": ["Narcolepsy with cataplexy", "Excessive daytime sleepiness"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally, peak plasma concentrations in 30-60 minutes",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["GHB dehydrogenase"],
            "notes": "Metabolized to succinic acid, entering the Krebs cycle."
        },
        "elimination": "Excreted primarily as carbon dioxide and water; half-life approximately 30-60 minutes"
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive depressant effects",
            "effect": "Increased risk of respiratory depression and sedation",
            "recommendation": "Avoid concurrent use."
        },
        "CNS Depressants": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Synergistic sedative effects",
            "effect": "Enhanced sedation and risk of respiratory depression",
            "recommendation": "Use with caution; monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Potential for misuse and overdose"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Cataplexy": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Reduces frequency of cataplexy attacks",
            "direction": "Decreases",
            "magnitude": "Significant",
            "timeframe": "Within weeks of initiation"
        }
    },
    "diagnostic_conditions": {
        "Narcolepsy with Cataplexy": {
            "symptoms_addressed": ["Excessive daytime sleepiness", "Sudden muscle weakness"],
            "therapeutic_action": "Improves nocturnal sleep and reduces cataplexy episodes",
            "optimal_dosage": "4.5 to 9 grams per night, divided into two doses",
            "response_time": "Improvement noted within days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dizziness", "Headache"],
        "moderate": ["Confusion", "Incontinence", "Sleepwalking"],
        "severe": ["Respiratory depression", "Seizures", "Coma"]
    },
    "long_term_monitoring": {
        "parameters": ["Respiratory function", "Mental health status"],
        "frequency": "Regular follow-up every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Pregnant women": {
            "adjustments": "Use only if benefits outweigh risks",
            "rationale": "Limited data on safety in pregnancy"
        }
    },
    "alternative_therapies": ["Modafinil", "Methylphenidate", "Behavioral interventions"],
    "combination_therapies": {
        "recommended_combinations": ["Stimulants for daytime sleepiness"],
        "cautions": ["Avoid combining with other CNS depressants"]
    },
    "contraindications": ["Succinic semialdehyde dehydrogenase deficiency", "Concomitant use with alcohol or sedative hypnotics"],
    "precautions": ["Potential for abuse and dependence; monitor for signs of misuse"],
    "side_effects": ["Nausea", "Dizziness", "Enuresis"],
    "overdose_management": {
        "symptoms": ["Respiratory depression", "Bradycardia", "Hypotension"],
        "treatment": ["Supportive care, airway management, consider activated charcoal if within 1 hour of ingestion"]
    },
    "notes": "GHB, available under brand names like Xyrem and Xywav, is used medically to treat narcolepsy with cataplexy. It has a high potential for abuse and is associated with serious adverse effects, including respiratory depression and coma, particularly when combined with other CNS depressants."
},
 
  
  {
    "iupac_name": "2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol",
    "chemical_formula": "C21H25N3O2S",
    "brand_names": [
        "Seroquel",
        "Seroquel XR",
        "Atrolak",
        "Biquelle",
        "Sondate",
        "Zaluron",
        "Actawell",
        "Adequet",
        "Aebol",
        "Asicot",
        "As-Kalmeks",
        "Atip",
        "Atip XR",
        "Atrolak XL",
        "Biquelle XL",
        "Biquetan",
        "Bonogren",
        "Bonogren SR",
        "Brancico XL",
        "Catepsin",
        "Cizyapine",
        "Dopaquel",
        "Equelib",
        "Esertia",
        "Etiagen XR",
        "Etipin",
        "Geldoren",
        "Gofyl",
        "Hedonin",
        "Ketipinor",
        "Kventiax",
        "Nantarid",
        "Norsic",
        "Quetialan",
        "Quetidin",
        "Quetidin XR",
        "Quetil XR",
        "Quetiagen",
        "Quetidin",
        "Quetidin XR",
        "Quetil XR",
        "Quetiagen",
        "Quetimed",
        "Quetimed XR",
        "Quetipin",
        "Quetipin XR",
        "Quetirel",
        "Quetirel XR",
        "Quetix",
        "Quetix XR",
        "Seroquel Prolong",
        "Seroquel XR",
        "Tenprolide",
        "Zaluron"
    ],
    "category": "Atypical Antipsychotic",
    "dosage_forms": ["Immediate-release tablets", "Extended-release tablets"],
    "strengths": ["25 mg", "50 mg", "100 mg", "200 mg", "300 mg", "400 mg"],
    "mechanism_of_action": {
        "site_of_action": "Dopamine D2 receptors, Serotonin 5-HT2A receptors",
        "physiological_mechanism": "Antagonizes dopamine D2 and serotonin 5-HT2A receptors, leading to antipsychotic effects. It also interacts with histamine H1 and adrenergic alpha1 receptors, contributing to sedation and anxiolytic effects."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Reduction in psychotic symptoms and mood stabilization",
            "timeframe": "Onset within 1-2 weeks; full effect may take several weeks"
        },
        {
            "system": "Metabolic",
            "effect": "Potential weight gain and lipid profile changes",
            "timeframe": "Varies; may occur over weeks to months"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Dopamine and serotonin receptor modulation",
        "key_targets": ["Dopamine D2 receptor", "Serotonin 5-HT2A receptor", "Histamine H1 receptor"],
        "related_conditions": ["Schizophrenia", "Bipolar Disorder", "Major Depressive Disorder (adjunct therapy)"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally, peak plasma concentrations in 1.5 hours (immediate-release) or 6 hours (extended-release)",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 3A4 (CYP3A4)"],
            "notes": "Metabolized to active metabolite norquetiapine."
        },
        "elimination": "Excreted primarily in urine (73%) and feces (20%); half-life approximately 6 hours (quetiapine) and 12 hours (norquetiapine)"
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver enzymes",
            "mechanism": "Inhibition of quetiapine metabolism",
            "effect": "Increased plasma levels of quetiapine",
            "recommendation": "Use with caution; may require dose adjustment."
        },
        "CYP3A4 Inducers": {
            "site_of_interaction": "Liver enzymes",
            "mechanism": "Induction of quetiapine metabolism",
            "effect": "Decreased plasma levels of quetiapine",
            "recommendation": "Use with caution; may require dose adjustment."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Avoid alcohol due to additive CNS depressant effects"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Schizophrenia": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "D2 and 5-HT2A receptor antagonism",
            "direction": "Decreases",
            "magnitude": "Significant",
            "timeframe": "Improvement within 1-2 weeks; full effect in 4-6 weeks"
        }
    },
    "diagnostic_conditions": {
        "Bipolar Disorder": {
            "symptoms_addressed": ["Mania", "Depression"],
            "therapeutic_action": "Mood stabilization through receptor modulation",
            "optimal_dosage": "300-600 mg daily, depending on phase and response",
            "response_time": "Improvement within 1 week for mania; longer for depression"
        }
    },
    "adverse_effects": {
        "mild": ["Dry mouth", "Drowsiness", "Dizziness"],
        "moderate": ["Weight gain", "Increased appetite", "Constipation"],
        "severe": ["Orthostatic hypotension", "Seizures", "Neuroleptic Malignant Syndrome"]
    },
    "long_term_monitoring": {
        "parameters": ["Weight", "Blood glucose", "Lipid profile"],
        "frequency": "Baseline, then periodically (e.g., every 3-6 months)",
        "clinical_thresholds": {
            "normal_range": {},
            "alert_threshold": {}
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower starting dose; monitor for orthostatic hypotension",
            "rationale": "Increased sensitivity to side effects"
        }
    },
    "alternative_therapies": ["Olanzapine", "Risperidone", "Aripiprazole"],
    "combination_therapies": {
        "recommended_combinations": ["Mood stabilizers in bipolar disorder"],
        "cautions": ["Avoid combining with other CNS depressants without medical supervision"]
    },
    "contraindications": ["Severe liver impairment", "Known hypersensitivity to quetiapine"],
    "precautions": ["Monitor for worsening depression or suicidal thoughts during initial use"],
    "side_effects": ["Dry mouth", "Sedation", "Weight gain"],
    "overdose_management": {
        "symptoms": ["Drowsiness", "Tachycardia", "Hypotension"],
        "treatment": ["Supportive care, airway management, monitoring cardiac function"]
    },
    "notes": "Quetiapine, marketed under various brand names like Seroquel, is a widely used atypical antipsychotic for treating schizophrenia, bipolar disorder, and as an adjunct in depression. Side effects like sedation and weight gain are common, and long-term monitoring is essential."
},

  {
    "iupac_name": "(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-methylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid",
    "chemical_formula": "C22H28FN3O6S",
    "brand_names":[
    "Crestor",
    "Ezallor",
    "Rosulip",
    "Roxardio",
    "Rosuvas",
    "Rosuvast",
    "Rosuless",
    "Roswin",
    "Rovista",
    "Rustor",
    "Rosuvastatin",
    "Rosutor",
    "Liporosa",
    "Rostor",
    "Rozavel",
    "Rozor",
    "Cholstor",
    "Rosuvagen"
],
    "category": "HMG-CoA Reductase Inhibitor (Statin)",
    "dosage_forms": ["Tablets"],
    "strengths": ["5 mg", "10 mg", "20 mg", "40 mg"],
    "mechanism_of_action": {
        "site_of_action": "HMG-CoA reductase enzyme in the liver",
        "physiological_mechanism": "Inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver, and increases LDL receptor activity, enhancing clearance of LDL cholesterol from the blood."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular",
            "effect": "Reduction in LDL cholesterol and triglycerides",
            "timeframe": "Noticeable within 2-4 weeks"
        },
        {
            "system": "Metabolic",
            "effect": "Increase in HDL cholesterol",
            "timeframe": "Gradual improvement over weeks to months"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cholesterol biosynthesis pathway",
        "key_targets": ["HMG-CoA reductase", "LDL receptors"],
        "related_conditions": ["Hypercholesterolemia", "Cardiovascular disease prevention"]
    },
    "pharmacokinetics": {
        "absorption": "Bioavailability approximately 20%; peak plasma concentrations in 3-5 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Minimal metabolism via CYP2C9"],
            "notes": "Primarily excreted unchanged in feces"
        },
        "elimination": "Primarily biliary excretion; half-life approximately 19 hours"
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Reduces rosuvastatin absorption",
            "effect": "Decreased efficacy",
            "recommendation": "Administer antacids at least 2 hours after rosuvastatin."
        },
        "Warfarin": {
            "site_of_interaction": "Liver enzymes",
            "mechanism": "Potential for increased anticoagulant effect",
            "effect": "Risk of bleeding",
            "recommendation": "Monitor INR closely when initiating or adjusting dose."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["No significant toxin-related interactions reported"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Hypercholesterolemia": {
            "site_of_effect": "Liver and blood plasma",
            "mechanism": "Inhibits cholesterol synthesis and increases LDL clearance",
            "direction": "Decreases LDL levels",
            "magnitude": "Significant",
            "timeframe": "Improvement within 2-4 weeks"
        }
    },
    "diagnostic_conditions": {
        "Cardiovascular Disease Prevention": {
            "symptoms_addressed": ["Elevated LDL cholesterol", "High risk of atherosclerosis"],
            "therapeutic_action": "Reduces LDL cholesterol and prevents plaque buildup",
            "optimal_dosage": "10-20 mg daily for primary prevention; up to 40 mg for high-risk patients",
            "response_time": "Significant reduction within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Abdominal pain"],
        "moderate": ["Muscle pain (myalgia)", "Liver enzyme abnormalities"],
        "severe": ["Rhabdomyolysis (rare)", "Hepatotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function tests", "Lipid profile", "CK levels (if muscle symptoms occur)"],
        "frequency": "Baseline, then periodically (e.g., every 6-12 months)",
        "clinical_thresholds": {
            "normal_range": {
                "LDL cholesterol": "<100 mg/dL (optimal)",
                "Liver enzymes (ALT/AST)": "<40 IU/L"
            },
            "alert_threshold": {
                "CK levels": ">10x normal",
                "ALT/AST levels": ">3x normal"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Contraindicated",
            "rationale": "Risk of teratogenicity; cholesterol synthesis is essential during fetal development"
        },
        "Elderly": {
            "adjustments": "Use with caution; start with lower doses",
            "rationale": "Increased risk of myopathy"
        }
    },
    "alternative_therapies": ["Atorvastatin", "Simvastatin", "Ezetimibe"],
    "combination_therapies": {
        "recommended_combinations": ["Ezetimibe for synergistic cholesterol-lowering effect"],
        "cautions": ["Avoid combining with fibrates due to increased risk of myopathy"]
    },
    "contraindications": ["Active liver disease", "Pregnancy and breastfeeding"],
    "precautions": ["Monitor for muscle pain or weakness, particularly in high doses"],
    "side_effects": ["Headache", "Muscle pain", "Abdominal pain"],
    "overdose_management": {
        "symptoms": ["Severe nausea", "Liver enzyme abnormalities", "Myopathy"],
        "treatment": ["Supportive care, liver function monitoring"]
    },
    "notes": "Rosuvastatin, marketed under brand names like Crestor and Ezallor, is a high-potency statin effective in reducing LDL cholesterol and preventing cardiovascular disease. It requires regular monitoring to detect and prevent potential adverse effects such as liver toxicity or muscle-related complications."
},

  
  {
    "iupac_name": "2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester",
    "chemical_formula": "C25H38O5",
    "brand_names": [
        "Zocor",
        "FloLipid",
        "Simlup",
        "Simvotin",
        "Simcard",
        "Denan",
        "Liponorm",
        "Sinvacor",
        "Sivastin",
        "Lipovas",
        "Lodales",
        "Zocord",
        "Zimstat",
        "Simvahexal",
        "Lipex",
        "Simvastatin-Teva",
        "Simvacor",
        "Simvaxon",
        "Simovil",
        "Vytorin (Simvastatin and Ezetimibe combination)"
    ],
    "category": "HMG-CoA Reductase Inhibitor (Statin)",
    "dosage_forms": ["Tablets", "Oral suspension"],
    "strengths": ["5 mg", "10 mg", "20 mg", "40 mg", "80 mg"],
    "mechanism_of_action": {
        "site_of_action": "HMG-CoA reductase enzyme in the liver",
        "physiological_mechanism": "Inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver, and increases LDL receptor activity, enhancing clearance of LDL cholesterol from the bloodstream."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular",
            "effect": "Reduction in LDL cholesterol and triglycerides",
            "timeframe": "Noticeable within 2 weeks; maximum effect in 4-6 weeks"
        },
        {
            "system": "Metabolic",
            "effect": "Potential increase in HDL cholesterol",
            "timeframe": "Gradual improvement over weeks to months"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cholesterol biosynthesis pathway",
        "key_targets": ["HMG-CoA reductase", "LDL receptors"],
        "related_conditions": ["Hypercholesterolemia", "Cardiovascular disease prevention"]
    },
    "pharmacokinetics": {
        "absorption": "Approximately 85% absorbed orally; extensive first-pass metabolism; peak plasma concentrations in 1.3-2.4 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450 3A4 (CYP3A4)"],
            "notes": "Metabolized to active β-hydroxyacid form"
        },
        "elimination": "Excreted primarily in feces; half-life of active metabolites approximately 1.9 hours"
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver enzymes",
            "mechanism": "Inhibition of simvastatin metabolism",
            "effect": "Increased plasma levels of simvastatin",
            "recommendation": "Avoid concomitant use; if necessary, use the lowest possible dose and monitor for adverse effects."
        },
        "Grapefruit Juice": {
            "site_of_interaction": "Gastrointestinal tract and liver",
            "mechanism": "Inhibition of CYP3A4",
            "effect": "Increased plasma levels of simvastatin",
            "recommendation": "Limit grapefruit juice intake; avoid large quantities."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Avoid excessive alcohol due to potential liver damage"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Hypercholesterolemia": {
            "site_of_effect": "Liver and blood plasma",
            "mechanism": "Inhibits cholesterol synthesis and increases LDL clearance",
            "direction": "Decreases LDL levels",
            "magnitude": "Significant",
            "timeframe": "Improvement within 2 weeks; maximum effect in 4-6 weeks"
        }
    },
    "diagnostic_conditions": {
        "Cardiovascular Disease Prevention": {
            "symptoms_addressed": ["Elevated LDL cholesterol", "High risk of atherosclerosis"],
            "therapeutic_action": "Reduces LDL cholesterol and prevents plaque buildup",
            "optimal_dosage": "10-40 mg daily in the evening; up to 80 mg for high-risk patients",
            "response_time": "Significant reduction within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Abdominal pain"],
        "moderate": ["Muscle pain (myalgia)", "Liver enzyme abnormalities"],
        "severe": ["Rhabdomyolysis (rare)", "Hepatotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver function tests", "Lipid profile", "CK levels (if muscle symptoms occur)"],
        "frequency": "Baseline, then periodically (e.g., every 6-12 months)",
        "clinical_thresholds": {
            "normal_range": {
                "LDL cholesterol": "<100 mg/dL (optimal)",
                "Liver enzymes (ALT/AST)": "<40 IU/L"
            },
            "alert_threshold": {
                "CK levels": ">10x normal",
                "ALT/AST levels": ">3x normal"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Contraindicated",
            "rationale": "Risk of teratogenicity; cholesterol synthesis is essential during fetal development"
        },
        "Elderly": {
            "adjustments": "Use with caution; start with lower doses",
            "rationale": "Increased risk of myopathy"
        }
    },
    "alternative_therapies": ["Atorvastatin", "Rosuvastatin", "Pravastatin"],
    "combination_therapies": {
        "recommended_combinations": ["Ezetimibe for synergistic cholesterol-lowering effect"],
        "cautions": ["Avoid combining with fibrates due to increased risk of myopathy"]
    },
    "contraindications": ["Active liver disease", "Pregnancy and breastfeeding"],
    "precautions": ["Monitor for muscle pain or weakness, particularly at higher doses"],
    "side_effects": ["Headache", "Muscle pain", "Abdominal pain"],
    "overdose_management": {
        "symptoms": ["Severe nausea", "Liver enzyme abnormalities", "Myopathy"],
        "treatment": ["Supportive care, liver function monitoring"]
    },
    "notes": "Simvastatin, marketed under brand names such as Zocor and FloLipid, is a widely used statin for reducing cholesterol and preventing cardiovascular disease. Regular monitoring is necessary to minimize the risk of adverse effects such as muscle damage or liver toxicity."
},

  {
    "iupac_name": "Hydrocodone: 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one; Acetaminophen: N-(4-hydroxyphenyl)acetamide",
    "chemical_formula": {
        "hydrocodone": "C18H21NO3",
        "acetaminophen": "C8H9NO2"
    },
    "brand_names": [
        "Vicodin",
        "Norco",
        "Lortab",
        "Lorcet",
        "Anexsia",
        "Zamicet",
        "Verdrocet",
        "Xodol",
        "Hycet",
        "Maxidone"
    ],
    "category": "Opioid Analgesic",
    "dosage_forms": ["Tablets", "Oral solution"],
    "strengths": [
        "Hydrocodone 5 mg / Acetaminophen 325 mg",
        "Hydrocodone 7.5 mg / Acetaminophen 325 mg",
        "Hydrocodone 10 mg / Acetaminophen 325 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": {
            "hydrocodone": "Mu-opioid receptors in the central nervous system",
            "acetaminophen": "COX enzyme inhibition (analgesic/antipyretic effects)"
        },
        "physiological_mechanism": "Hydrocodone binds to mu-opioid receptors, altering pain perception; acetaminophen inhibits prostaglandin synthesis, reducing pain and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Pain relief, euphoria, sedation",
            "timeframe": "Onset within 30-60 minutes; duration 4-6 hours"
        },
        {
            "system": "Respiratory",
            "effect": "Respiratory depression (at high doses)",
            "timeframe": "Peak effect within 1-2 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": {
            "hydrocodone": "Opioid receptor pathway",
            "acetaminophen": "Prostaglandin synthesis inhibition"
        },
        "key_targets": {
            "hydrocodone": ["Mu-opioid receptor"],
            "acetaminophen": ["Cyclooxygenase (COX) enzymes"]
        },
        "related_conditions": ["Severe pain", "Post-operative pain"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally, peak plasma concentration in 1.3-1.8 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP3A4 (hydrocodone)",
                "CYP2D6 (conversion to hydromorphone)",
                "UGT enzymes (acetaminophen conjugation)"
            ],
            "notes": "Hydrocodone is partially metabolized to hydromorphone, a more potent opioid metabolite."
        },
        "elimination": "Primarily renal excretion; half-life approximately 3.8 hours (hydrocodone), 2 hours (acetaminophen)"
    },
    "interactions": {
        "CNS Depressants": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive depressant effects",
            "effect": "Increased risk of sedation and respiratory depression",
            "recommendation": "Use with caution; avoid alcohol."
        },
        "Acetaminophen-containing products": {
            "site_of_interaction": "Liver",
            "mechanism": "Cumulative acetaminophen dose",
            "effect": "Increased risk of hepatotoxicity",
            "recommendation": "Limit total acetaminophen dose to 4 grams/day."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol increases risk of liver damage and sedation"],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Severe Pain": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Mu-opioid receptor activation reduces pain perception",
            "direction": "Decreases",
            "magnitude": "Significant",
            "timeframe": "Within 30-60 minutes"
        }
    },
    "diagnostic_conditions": {
        "Post-Surgical Pain": {
            "symptoms_addressed": ["Acute pain"],
            "therapeutic_action": "Relieves pain and reduces associated discomfort",
            "optimal_dosage": "1-2 tablets every 4-6 hours as needed (maximum dose based on acetaminophen limit)",
            "response_time": "Relief within 1 hour"
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Nausea", "Dizziness"],
        "moderate": ["Constipation", "Dry mouth", "Sweating"],
        "severe": ["Respiratory depression", "Addiction", "Hepatotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Respiratory function", "Liver function (acetaminophen exposure)", "Signs of dependence"],
        "frequency": "Monitor periodically in long-term use",
        "clinical_thresholds": {
            "normal_range": {
                "Respiratory rate": "12-20 breaths per minute",
                "Liver enzymes (ALT/AST)": "<40 IU/L"
            },
            "alert_threshold": {
                "Respiratory rate": "<10 breaths per minute",
                "ALT/AST levels": ">3x normal"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Avoid chronic use; risk of neonatal withdrawal syndrome",
            "rationale": "Potential for opioid dependence in the fetus"
        },
        "Elderly": {
            "adjustments": "Use lower doses; increased risk of sedation and respiratory depression",
            "rationale": "Higher sensitivity to opioids"
        }
    },
    "alternative_therapies": ["Ibuprofen", "Acetaminophen (alone)", "Tramadol"],
    "combination_therapies": {
        "recommended_combinations": ["Adjuvant therapy with non-opioid analgesics for severe pain"],
        "cautions": ["Avoid concurrent CNS depressants without monitoring"]
    },
    "contraindications": ["Severe respiratory depression", "Acute liver failure", "Known hypersensitivity to hydrocodone or acetaminophen"],
    "precautions": ["Monitor for signs of misuse, abuse, or dependence in chronic use"],
    "side_effects": ["Nausea", "Constipation", "Drowsiness"],
    "overdose_management": {
        "symptoms": ["Severe respiratory depression", "Coma", "Hepatic failure (acetaminophen overdose)"],
        "treatment": ["Naloxone for opioid overdose, N-acetylcysteine for acetaminophen toxicity, supportive care"]
    },
    "notes": "Vicodin, combining hydrocodone and acetaminophen, is a potent pain reliever but carries a high risk of addiction, particularly with long-term use. Liver damage is a significant risk if acetaminophen limits are exceeded."
},

  {
    "iupac_name": "3α,7β-dihydroxy-5β-cholan-24-oic acid",
    "chemical_formula": "C24H40O4",
    "brand_names": [
        "Actigall",
        "Urso",
        "Urso Forte",
        "Urso DS",
        "Reltone",
        "Urso 250",
        "Ursodiol"
    ],
    "category": "Gallstone Solubilizing Agent",
    "dosage_forms": [
        "Capsules",
        "Tablets"
    ],
    "strengths": [
        "250 mg",
        "500 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver and bile",
        "physiological_mechanism": "Ursodiol reduces the cholesterol content of bile by suppressing hepatic synthesis and secretion of cholesterol, and by inhibiting its intestinal absorption. This promotes the gradual dissolution of cholesterol gallstones."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hepatobiliary",
            "effect": "Dissolution of cholesterol gallstones",
            "timeframe": "May take several months to achieve complete dissolution"
        },
        {
            "system": "Liver",
            "effect": "Improvement in liver enzyme levels in primary biliary cholangitis",
            "timeframe": "Improvements may be observed within weeks to months"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Bile acid metabolism",
        "key_targets": [
            "Cholesterol 7α-hydroxylase",
            "Bile salt export pump"
        ],
        "related_conditions": [
            "Cholesterol gallstones",
            "Primary biliary cholangitis"
        ]
    },
    "pharmacokinetics": {
        "absorption": "About 90% of a therapeutic dose is absorbed in the small bowel after oral administration.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "Conjugation with glycine or taurine"
            ],
            "notes": "Undergoes enterohepatic circulation"
        },
        "elimination": "Excreted primarily in feces; small amounts in urine. Half-life is approximately 3.5-5.8 days."
    },
    "interactions": {
        "Bile Acid Sequestering Agents": {
            "site_of_interaction": "Intestinal tract",
            "mechanism": "May reduce the absorption of ursodiol",
            "effect": "Decreased efficacy",
            "recommendation": "Avoid concomitant use or administer ursodiol at least 2 hours before or after these agents."
        },
        "Aluminum-based Antacids": {
            "site_of_interaction": "Intestinal tract",
            "mechanism": "May adsorb bile acids",
            "effect": "Reduced ursodiol absorption",
            "recommendation": "Avoid concomitant use or separate dosing times."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Cholesterol Gallstones": {
            "site_of_effect": "Gallbladder",
            "mechanism": "Dissolves cholesterol gallstones by reducing cholesterol saturation in bile",
            "direction": "Decreases gallstone size",
            "magnitude": "Variable; complete dissolution in some patients",
            "timeframe": "Several months to years"
        }
    },
    "diagnostic_conditions": {
        "Primary Biliary Cholangitis": {
            "symptoms_addressed": [
                "Fatigue",
                "Pruritus",
                "Elevated liver enzymes"
            ],
            "therapeutic_action": "Slows disease progression and improves liver function",
            "optimal_dosage": "13-15 mg/kg/day, divided into two to four doses",
            "response_time": "Clinical improvement may be seen within months"
        }
    },
    "adverse_effects": {
        "mild": [
            "Diarrhea",
            "Constipation",
            "Nausea"
        ],
        "moderate": [
            "Abdominal discomfort",
            "Pruritus",
            "Elevated liver enzymes"
        ],
        "severe": [
            "Severe abdominal pain",
            "Allergic reactions"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Liver function tests",
            "Ultrasound of gallbladder"
        ],
        "frequency": "Baseline and periodically during treatment",
        "clinical_thresholds": {
            "normal_range": {
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "ALT/AST": ">3x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Use only if clearly needed",
            "rationale": "Limited data on safety in pregnancy"
        },
        "Elderly": {
            "adjustments": "No specific adjustments; monitor liver function",
            "rationale": "Potential for decreased hepatic function"
        }
    },
    "alternative_therapies": [
        "Chenodeoxycholic acid",
        "Surgical removal of gallstones"
    ],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": [
            "Avoid combination with bile acid sequestering agents"
        ]
    },
    "contraindications": [
        "Complete biliary obstruction",
        "Known hypersensitivity to ursodiol"
    ],
    "precautions": [
        "Monitor liver function tests regularly",
        "Assess for signs of gallstone complications"
    ],
    "side_effects": [
        "Diarrhea",
        "Nausea",
        "Abdominal discomfort"
    ],
    "overdose_management": {
        "symptoms": [
            "Diarrhea"
        ],
        "treatment": [
            "Supportive care; discontinue ursodiol"
        ]
    },
    "notes": "Ursodiol is a naturally occurring bile acid used to dissolve cholesterol gallstones and to treat primary biliary cholangitis. Treatment duration can be long, and regular monitoring is essential to assess efficacy and safety."
},

 {
    "iupac_name": "2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol",
    "chemical_formula": "C16H25NO2",
    "brand_names": [
        "Ultram",
        "ConZip",
        "Qdolo",
        "Ralivia",
        "Zydol",
        "Tramal",
        "Adolonta",
        "Tramahexal",
        "Tramadura",
        "Tramundin",
        "Tramadol"
    ],
    "category": "Opioid Analgesic",
    "dosage_forms": [
        "Immediate-release tablets",
        "Extended-release tablets",
        "Capsules",
        "Oral solution",
        "Injectable solution"
    ],
    "strengths": [
        "50 mg",
        "100 mg",
        "150 mg",
        "200 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Tramadol acts as a mu-opioid receptor agonist and inhibits the reuptake of norepinephrine and serotonin, leading to altered pain perception and modulation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Nervous",
            "effect": "Analgesia, sedation",
            "timeframe": "Onset within 1 hour; duration of action approximately 6 hours"
        },
        {
            "system": "Gastrointestinal",
            "effect": "Reduced gastrointestinal motility",
            "timeframe": "May occur within hours of dosing"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Opioid receptor signaling and monoamine reuptake inhibition",
        "key_targets": [
            "Mu-opioid receptors",
            "Norepinephrine transporters",
            "Serotonin transporters"
        ],
        "related_conditions": [
            "Moderate to moderately severe pain"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral administration; bioavailability approximately 68% due to first-pass metabolism",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP2D6",
                "CYP3A4"
            ],
            "notes": "Metabolized to active metabolite O-desmethyltramadol"
        },
        "elimination": "Excreted primarily via kidneys; elimination half-life approximately 6.3 hours"
    },
    "interactions": {
        "SSRIs": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Increased risk of serotonin syndrome",
            "effect": "Potentially life-threatening condition",
            "recommendation": "Use with caution; monitor for symptoms of serotonin syndrome."
        },
        "CNS Depressants": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive sedative effects",
            "effect": "Enhanced sedation and respiratory depression",
            "recommendation": "Avoid concomitant use; if necessary, monitor closely for respiratory depression."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [
            "Alcohol increases risk of CNS depression and hepatotoxicity"
        ],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Pain": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Mu-opioid receptor activation and monoamine reuptake inhibition",
            "direction": "Decreases",
            "magnitude": "Moderate to significant",
            "timeframe": "Within 1 hour of administration"
        }
    },
    "diagnostic_conditions": {
        "Chronic Pain": {
            "symptoms_addressed": [
                "Persistent moderate to severe pain"
            ],
            "therapeutic_action": "Provides analgesia to improve quality of life",
            "optimal_dosage": "50-100 mg every 4-6 hours as needed; maximum 400 mg per day",
            "response_time": "Pain relief typically within 1 hour"
        }
    },
    "adverse_effects": {
        "mild": [
            "Dizziness",
            "Nausea",
            "Constipation"
        ],
        "moderate": [
            "Sedation",
            "Sweating",
            "Dry mouth"
        ],
        "severe": [
            "Seizures",
            "Serotonin syndrome",
            "Respiratory depression"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Renal function",
            "Liver function",
            "Signs of misuse or dependence"
        ],
        "frequency": "Baseline assessment; periodic monitoring during prolonged therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Serum creatinine": "0.6-1.2 mg/dL",
                "Liver enzymes (ALT/AST)": "<40 IU/L"
            },
            "alert_threshold": {
                "Respiratory rate": "<12 breaths per minute",
                "Signs of serotonin syndrome": "Agitation, hallucinations, rapid heart rate"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Use only if potential benefit justifies potential risk",
            "rationale": "Potential for neonatal opioid withdrawal syndrome"
        },
        "Elderly": {
            "adjustments": "Initiate at lower doses; monitor for increased sensitivity",
            "rationale": "Increased risk of adverse effects due to altered pharmacokinetics"
        }
    },
    "alternative_therapies": [
        "Nonsteroidal anti-inflammatory drugs (NSAIDs)",
        "Acetaminophen",
        "Gabapentin"
    ],
    "combination_therapies": {
        "recommended_combinations": [
            "Acetaminophen for enhanced analgesic effect"
        ],
        "cautions": [
            "Avoid combining with other serotonergic drugs without medical supervision"
        ]
    },
    "contraindications": [
        "Acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids, or psychotropic drugs",
        "Uncontrolled epilepsy"
    ],
    "precautions": [
        "Risk of addiction, abuse, and misuse",
        "Potential for life-threatening respiratory depression"
    ],
    "side_effects": [
        "Dizziness",
        "Nausea",
        "Constipation",
        "Headache",
        "Somnolence"
    ],
    "overdose_management": {
        "symptoms": [
            "Respiratory depression",
            "Seizures",
            "Coma"
        ],
        "treatment": [
            "Supportive measures",
            "Naloxone administration for opioid toxicity",
            "Monitoring of vital signs"
        ]
    },
    "notes": "Tramadol is a centrally acting synthetic opioid analgesic used for moderate to moderately severe pain. Its dual mechanism of action makes it effective but carries risks of serotonin syndrome, seizures, and respiratory depression in certain populations."
},
 
  
  {
    "iupac_name": "2-[(2-Amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate",
    "chemical_formula": "C13H20N6O4",
    "brand_names": [
        "Valtrex",
        "Zelitrex",
        "Valtrexil",
        "Valcivir",
        "Valtrexum",
        "Valacyclovir Hydrochloride"
    ],
    "category": "Antiviral",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "500 mg",
        "1000 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Viral DNA polymerase",
        "physiological_mechanism": "Valacyclovir is a prodrug that is rapidly converted to acyclovir in the body. Acyclovir inhibits viral DNA synthesis by competing with deoxyguanosine triphosphate for viral DNA polymerase, leading to chain termination and preventing viral replication."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune",
            "effect": "Reduction in viral load",
            "timeframe": "Within 2 hours of administration"
        },
        {
            "system": "Dermatological",
            "effect": "Reduction in lesion formation",
            "timeframe": "Varies depending on infection type"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Viral DNA replication inhibition",
        "key_targets": [
            "Viral DNA polymerase"
        ],
        "related_conditions": [
            "Herpes simplex infections",
            "Herpes zoster (shingles)",
            "Varicella (chickenpox)"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract; bioavailability approximately 54% due to first-pass metabolism",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "Valacyclovir hydrolase"
            ],
            "notes": "Converted to acyclovir and L-valine"
        },
        "elimination": "Excreted primarily in urine as acyclovir; elimination half-life of acyclovir is approximately 2.5 to 3.3 hours"
    },
    "interactions": {
        "Nephrotoxic Agents": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Additive nephrotoxicity",
            "effect": "Increased risk of renal impairment",
            "recommendation": "Monitor renal function; adjust dosage if necessary."
        },
        "Probenecid": {
            "site_of_interaction": "Renal tubules",
            "mechanism": "Inhibition of renal tubular secretion",
            "effect": "Increased plasma concentrations of acyclovir",
            "recommendation": "Monitor for increased effects or toxicity of acyclovir."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Herpes Simplex Outbreaks": {
            "site_of_effect": "Skin and mucous membranes",
            "mechanism": "Inhibition of viral replication",
            "direction": "Decreases",
            "magnitude": "Significant reduction in duration and severity",
            "timeframe": "Symptom improvement within 2 days"
        }
    },
    "diagnostic_conditions": {
        "Herpes Zoster (Shingles)": {
            "symptoms_addressed": [
                "Painful rash",
                "Blisters"
            ],
            "therapeutic_action": "Reduces viral replication, alleviating symptoms and promoting healing",
            "optimal_dosage": "1000 mg three times daily for 7 days",
            "response_time": "Symptom improvement within 3 days"
        }
    },
    "adverse_effects": {
        "mild": [
            "Headache",
            "Nausea",
            "Abdominal pain"
        ],
        "moderate": [
            "Vomiting",
            "Dizziness",
            "Diarrhea"
        ],
        "severe": [
            "Acute renal failure",
            "Thrombotic thrombocytopenic purpura",
            "Hemolytic uremic syndrome"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Renal function",
            "Complete blood count"
        ],
        "frequency": "Baseline assessment; periodic monitoring during prolonged therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Serum creatinine": "0.6-1.2 mg/dL",
                "White blood cell count": "4,000-11,000 cells/µL"
            },
            "alert_threshold": {
                "Serum creatinine": ">1.5 mg/dL",
                "Platelet count": "<150,000 cells/µL"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Use only if potential benefit justifies potential risk",
            "rationale": "Limited data on use in pregnancy; potential risk to fetus"
        },
        "Elderly": {
            "adjustments": "Consider renal function; adjust dosage if necessary",
            "rationale": "Increased risk of renal impairment"
        }
    },
    "alternative_therapies": [
        "Acyclovir",
        "Famciclovir"
    ],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": [
            "Avoid combining with nephrotoxic drugs without monitoring"
        ]
    },
    "contraindications": [
        "Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation"
    ],
    "precautions": [
        "Maintain adequate hydration to prevent renal complications"
    ],
    "side_effects": [
        "Headache",
        "Nausea",
        "Abdominal pain",
        "Dizziness",
        "Fatigue"
    ],
    "overdose_management": {
        "symptoms": [
            "Renal failure",
            "Neurological symptoms (e.g., confusion, hallucinations)"
        ],
        "treatment": [
            "Supportive measures",
            "Hemodialysis if necessary"
        ]
    },
    "notes": "Valacyclovir is a prodrug of acyclovir with improved oral bioavailability, used to treat herpes virus infections. It is generally well-tolerated but requires dose adjustment in renal impairment."
},

{
    "iupac_name": "(RS)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one",
    "chemical_formula": "C19H16O4",
    "brand_names": [
        "warfarin",
        "Coumadin",
        "Jantoven",
        "Marevan",
        "Panwarfin",
        "Aldocumar",
        "Warfarina",
        "Warfarine"
    ],
    "category": "Anticoagulant",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "1 mg",
        "2 mg",
        "2.5 mg",
        "3 mg",
        "4 mg",
        "5 mg",
        "6 mg",
        "7.5 mg",
        "10 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver",
        "physiological_mechanism": "Warfarin inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X) by antagonizing vitamin K epoxide reductase, leading to reduced blood coagulation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematologic",
            "effect": "Anticoagulation",
            "timeframe": "Onset within 24 hours; full therapeutic effect in 72-96 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Vitamin K cycle inhibition",
        "key_targets": [
            "Vitamin K epoxide reductase"
        ],
        "related_conditions": [
            "Deep vein thrombosis",
            "Pulmonary embolism",
            "Atrial fibrillation",
            "Mechanical heart valves"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Nearly complete absorption after oral administration",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP2C9",
                "CYP1A2",
                "CYP3A4"
            ],
            "notes": "Warfarin is a racemic mixture; S-warfarin is more potent and primarily metabolized by CYP2C9."
        },
        "elimination": "Excreted mainly in urine; half-life ranges from 20 to 60 hours"
    },
    "interactions": {
        "Antibiotics": {
            "site_of_interaction": "Liver",
            "mechanism": "Alteration of gut flora and inhibition of warfarin metabolism",
            "effect": "Increased anticoagulant effect",
            "recommendation": "Monitor INR closely; adjust dosage as needed."
        },
        "NSAIDs": {
            "site_of_interaction": "Gastrointestinal tract",
            "mechanism": "Increased risk of gastrointestinal bleeding",
            "effect": "Enhanced bleeding risk",
            "recommendation": "Avoid concurrent use if possible; monitor for signs of bleeding."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [
            "Vitamin K-rich foods can decrease warfarin's effectiveness."
        ],
        "toxins": [],
        "microbiota_effects": "Alteration of gut flora by antibiotics can affect vitamin K synthesis, influencing warfarin activity."
    },
    "effects_on_symptoms": {
        "Thromboembolism Prevention": {
            "site_of_effect": "Blood",
            "mechanism": "Inhibition of clotting factor synthesis",
            "direction": "Decreases",
            "magnitude": "Significant reduction in clot formation",
            "timeframe": "Therapeutic effect achieved within 3-5 days"
        }
    },
    "diagnostic_conditions": {
        "Atrial Fibrillation": {
            "symptoms_addressed": [
                "Risk of stroke"
            ],
            "therapeutic_action": "Reduces risk of thromboembolic events",
            "optimal_dosage": "Dose adjusted to maintain INR between 2.0 and 3.0",
            "response_time": "INR stabilization within 1-2 weeks"
        }
    },
    "adverse_effects": {
        "mild": [
            "Bruising",
            "Nausea",
            "Fatigue"
        ],
        "moderate": [
            "Bleeding gums",
            "Hematuria",
            "Epistaxis"
        ],
        "severe": [
            "Intracranial hemorrhage",
            "Gastrointestinal bleeding",
            "Skin necrosis"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "International Normalized Ratio (INR)"
        ],
        "frequency": "Initially daily or every few days; then at least once a month when stable",
        "clinical_thresholds": {
            "normal_range": {
                "INR": "2.0-3.0 for most indications"
            },
            "alert_threshold": {
                "INR": "<2.0 (risk of thrombosis), >3.5 (risk of bleeding)"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Contraindicated due to teratogenicity; use alternative anticoagulants",
            "rationale": "Risk of fetal hemorrhage and congenital malformations"
        },
        "Elderly": {
            "adjustments": "Initiate at lower doses; monitor INR closely",
            "rationale": "Increased sensitivity and higher risk of bleeding complications"
        }
    },
    "alternative_therapies": [
        "Direct oral anticoagulants (e.g., apixaban, rivaroxaban)",
        "Low molecular weight heparin"
    ],
    "combination_therapies": {
        "recommended_combinations": [
            "Bridging with heparin during initiation in high-risk patients"
        ],
        "cautions": [
            "Avoid concurrent use with antiplatelet agents unless clearly indicated"
        ]
    },
    "contraindications": [
        "Active bleeding",
        "Recent major surgery",
        "Severe uncontrolled hypertension"
    ],
    "precautions": [
        "Regular monitoring of INR is essential to ensure therapeutic range.",
        "Maintain consistent dietary vitamin K intake to avoid fluctuations in INR."
    ],
    "side_effects": [
        "Bleeding",
        "Alopecia",
        "Rash",
        "Diarrhea"
    ],
    "overdose_management": {
        "symptoms": [
            "Excessive bleeding",
            "Elevated INR"
        ],
        "treatment": [
            "Discontinue warfarin",
            "Administer vitamin K",
            "Fresh frozen plasma or prothrombin complex concentrate in severe cases"
        ]
    },
    "notes": "Warfarin is marketed under various brand names, including Coumadin, Jantoven, Marevan, Panwarfin, Aldocumar, and Warfarine. It requires careful monitoring of INR to ensure therapeutic efficacy and safety."
},

{
    "iupac_name": "4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide",
    "chemical_formula": "C17H14F3N3O2S",
    "brand_names": [
        "celecoxib",
        "Celebrex",
        "Elyxyb",
        "Onsenal",
        "Consensi",
        "Seglentis"
    ],
    "category": "Nonsteroidal Anti-Inflammatory Drug (NSAID)",
    "dosage_forms": [
        "Capsules",
        "Oral solution"
    ],
    "strengths": [
        "50 mg",
        "100 mg",
        "200 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Cyclooxygenase-2 (COX-2) enzyme",
        "physiological_mechanism": "Celecoxib selectively inhibits the COX-2 enzyme, reducing the synthesis of prostaglandins involved in inflammation, pain, and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Musculoskeletal",
            "effect": "Reduction of inflammation and pain",
            "timeframe": "Onset within 1 hour; peak effect in 3 hours"
        },
        {
            "system": "Gastrointestinal",
            "effect": "Lower risk of gastric ulceration compared to non-selective NSAIDs",
            "timeframe": "Dependent on duration of use"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Arachidonic acid pathway",
        "key_targets": [
            "Cyclooxygenase-2 (COX-2)"
        ],
        "related_conditions": [
            "Osteoarthritis",
            "Rheumatoid arthritis",
            "Ankylosing spondylitis",
            "Acute pain",
            "Primary dysmenorrhea"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally; peak plasma concentrations reached in approximately 3 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP2C9"
            ],
            "notes": "Metabolized to inactive metabolites"
        },
        "elimination": "Excreted primarily in feces (57%) and urine (27%); half-life approximately 11 hours"
    },
    "interactions": {
        "Anticoagulants": {
            "site_of_interaction": "Blood",
            "mechanism": "Increased risk of bleeding",
            "effect": "Enhanced anticoagulant effect",
            "recommendation": "Monitor for signs of bleeding; adjust dosage if necessary."
        },
        "ACE Inhibitors": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Reduced antihypertensive effect",
            "effect": "Potential increase in blood pressure",
            "recommendation": "Monitor blood pressure; consider alternative therapies."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [
            "Alcohol may increase the risk of gastrointestinal bleeding."
        ],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Arthritis Pain": {
            "site_of_effect": "Joints",
            "mechanism": "Reduction of prostaglandin synthesis",
            "direction": "Decreases",
            "magnitude": "Moderate to significant",
            "timeframe": "Symptom relief within hours; sustained with continued use"
        }
    },
    "diagnostic_conditions": {
        "Osteoarthritis": {
            "symptoms_addressed": [
                "Joint pain",
                "Stiffness",
                "Swelling"
            ],
            "therapeutic_action": "Reduces inflammation and pain, improving joint function",
            "optimal_dosage": "200 mg once daily or 100 mg twice daily",
            "response_time": "Symptom improvement within days; maximum effect in 2 weeks"
        }
    },
    "adverse_effects": {
        "mild": [
            "Headache",
            "Dyspepsia",
            "Diarrhea"
        ],
        "moderate": [
            "Hypertension",
            "Edema",
            "Dizziness"
        ],
        "severe": [
            "Cardiovascular thrombotic events",
            "Gastrointestinal bleeding",
            "Renal toxicity"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Blood pressure",
            "Renal function",
            "Liver enzymes"
        ],
        "frequency": "Baseline assessment; periodic monitoring during prolonged therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Blood pressure": "<120/80 mmHg",
                "Serum creatinine": "0.6-1.2 mg/dL",
                "ALT/AST": "<40 IU/L"
            },
            "alert_threshold": {
                "Blood pressure": ">140/90 mmHg",
                "Serum creatinine": ">1.5 mg/dL",
                "ALT/AST": ">2 times upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Avoid use, especially in the third trimester",
            "rationale": "Risk of premature closure of the ductus arteriosus and fetal renal impairment"
        },
        "Elderly": {
            "adjustments": "Use with caution; monitor renal and hepatic function",
            "rationale": "Increased risk of adverse effects due to age-related organ function decline"
        }
    },
    "alternative_therapies": [
        "Ibuprofen",
        "Naproxen",
        "Diclofenac"
    ],
    "combination_therapies": {
        "recommended_combinations": [
            "May be combined with acetaminophen for enhanced pain relief"
        ],
        "cautions": [
            "Avoid concurrent use with other NSAIDs to reduce risk of adverse effects"
        ]
    },
    "contraindications": [
        "Hypersensitivity to celecoxib or sulfonamides",
        "History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs",
        "Use in the setting of coronary artery bypass graft (CABG) surgery"
    ],
    "precautions": [
        "Monitor for signs of gastrointestinal bleeding, especially in high-risk patients.",
        "Use the lowest effective dose for the shortest duration consistent with treatment goals."
    ],
    "side_effects": [
        "Abdominal pain",
        "Nausea",
        "Flatulence",
        "Insomnia",
        "Upper respiratory tract infection"
    ],
    "overdose_management": {
        "symptoms": [
            "Lethargy",
            "Nausea",
            "Vomiting",
            "Epigastric pain"
        ],
        "treatment": [
            "Supportive measures",
            "Activated charcoal if ingestion occurred recently",
            "Monitoring of vital signs and renal function"
        ]
    },
    "notes": "Celecoxib, marketed under brand names such as Celebrex, Elyxyb, Onsenal, Consensi, and Seglentis, is a COX-2 selective NSAID used for pain and inflammation. It offers a lower risk of gastrointestinal side effects compared to non-selective NSAIDs but carries cardiovascular risks."
},
  
  {
    "iupac_name": {
        "drospirenone": "6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone",
        "ethinyl_estradiol": "(17α)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol"
    },
    "chemical_formula": {
        "drospirenone": "C24H30O3",
        "ethinyl_estradiol": "C20H24O2"
    },
    "brand_names": [
        "drospirenone",
        "ethinyl estradiol",
        "Yasmin",
        "Yaz",
        "Ocella",
        "Gianvi",
        "Loryna",
        "Syeda",
        "Zarah",
        "Nikki",
        "Vestura",
        "Jasmiel",
        "Lo-Zumandimine",
        "Zumandimine"
    ],
    "category": "Combined Oral Contraceptive",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "3 mg drospirenone / 0.03 mg ethinyl estradiol",
        "3 mg drospirenone / 0.02 mg ethinyl estradiol"
    ],
    "mechanism_of_action": {
        "site_of_action": "Ovaries, Uterus, Cervical mucus",
        "physiological_mechanism": "Inhibits ovulation, alters endometrial lining, and thickens cervical mucus to prevent sperm penetration."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Reproductive",
            "effect": "Prevention of ovulation",
            "timeframe": "Within the first cycle of use"
        },
        {
            "system": "Endocrine",
            "effect": "Regulation of menstrual cycle",
            "timeframe": "Typically within 1-2 cycles"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Hypothalamic-Pituitary-Ovarian Axis Suppression",
        "key_targets": [
            "Gonadotropin-releasing hormone (GnRH)",
            "Luteinizing hormone (LH)",
            "Follicle-stimulating hormone (FSH)"
        ],
        "related_conditions": [
            "Contraception",
            "Acne vulgaris",
            "Premenstrual dysphoric disorder (PMDD)"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed from the gastrointestinal tract",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP3A4"
            ],
            "notes": "Subject to first-pass metabolism; bioavailability ~76% for drospirenone and ~40% for ethinyl estradiol"
        },
        "elimination": "Excreted in urine and feces; half-life approximately 30 hours for drospirenone and 20 hours for ethinyl estradiol"
    },
    "interactions": {
        "Antibiotics": {
            "site_of_interaction": "Liver",
            "mechanism": "Induction of hepatic enzymes",
            "effect": "Reduced contraceptive efficacy",
            "recommendation": "Use additional non-hormonal contraception during and for 7 days after antibiotic treatment."
        },
        "Antiepileptics": {
            "site_of_interaction": "Liver",
            "mechanism": "Enzyme induction",
            "effect": "Decreased plasma concentrations of contraceptive hormones",
            "recommendation": "Consider alternative or additional contraceptive methods."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [
            "Smoking increases the risk of cardiovascular side effects."
        ],
        "microbiota_effects": "Certain antibiotics may alter gut flora, potentially affecting hormone reabsorption."
    },
    "effects_on_symptoms": {
        "Contraception": {
            "site_of_effect": "Reproductive system",
            "mechanism": "Prevention of ovulation and sperm penetration",
            "direction": "Prevents",
            "magnitude": "Highly effective with typical use",
            "timeframe": "Effective within the first cycle if taken as directed"
        }
    },
    "diagnostic_conditions": {
        "Acne Vulgaris": {
            "symptoms_addressed": [
                "Facial acne lesions"
            ],
            "therapeutic_action": "Reduction in acne lesion count",
            "optimal_dosage": "3 mg drospirenone / 0.02 mg ethinyl estradiol daily",
            "response_time": "Improvement typically observed after 3-6 months of use"
        }
    },
    "adverse_effects": {
        "mild": [
            "Nausea",
            "Breast tenderness",
            "Headache"
        ],
        "moderate": [
            "Weight changes",
            "Mood swings",
            "Menstrual irregularities"
        ],
        "severe": [
            "Thromboembolic events",
            "Hypertension",
            "Gallbladder disease"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Blood pressure",
            "Liver function tests"
        ],
        "frequency": "Baseline assessment; periodic monitoring during prolonged therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Blood pressure": "<120/80 mmHg",
                "Liver enzymes": "ALT/AST <40 IU/L"
            },
            "alert_threshold": {
                "Blood pressure": ">140/90 mmHg",
                "Liver enzymes": "ALT/AST >2 times upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Smokers Over 35": {
            "adjustments": "Contraindicated",
            "rationale": "Increased risk of serious cardiovascular events"
        },
        "Women with Migraine with Aura": {
            "adjustments": "Avoid use",
            "rationale": "Elevated risk of stroke"
        }
    },
    "alternative_therapies": [
        "Progestin-only pills",
        "Intrauterine devices (IUDs)",
        "Contraceptive implants"
    ],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": [
            "Avoid concurrent use with other hormonal contraceptives to prevent hormone overdose."
        ]
    },
    "contraindications": [
        "History of thromboembolic disorders",
        "Breast cancer",
        "Undiagnosed abnormal uterine bleeding"
    ],
    "precautions": [
        "Monitor blood pressure regularly.",
        "Assess for signs of depression or mood changes."
    ],
    "side_effects": [
        "Nausea",
        "Headache",
        "Menstrual spotting"
    ],
    "overdose_management": {
        "symptoms": [
            "Nausea",
            "Vomiting",
            "Vaginal bleeding"
        ],
        "treatment": [
            "Symptomatic treatment and monitoring"
        ]
    },
    "notes": "Drospirenone and Ethinyl Estradiol are marketed under multiple brand names, including Yasmin, Yaz, Ocella, Gianvi, and Loryna. They are used for contraception, acne treatment, and managing premenstrual dysphoric disorder (PMDD)."
},
  
  {
    "iupac_name": "N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide",
    "chemical_formula": "C19H21N3O",
    "brand_names": [
        "zolpidem",
        "Ambien",
        "Ambien CR",
        "Edluar",
        "Intermezzo",
        "Zolpimist",
        "Stilnox",
        "Sublinox"
    ],
    "category": "Nonbenzodiazepine Hypnotic",
    "dosage_forms": [
        "Immediate-release tablets",
        "Extended-release tablets",
        "Sublingual tablets",
        "Oral spray"
    ],
    "strengths": [
        "5 mg",
        "10 mg",
        "6.25 mg (extended-release)",
        "12.5 mg (extended-release)",
        "1.75 mg (sublingual)",
        "3.5 mg (sublingual)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Zolpidem binds to the benzodiazepine site of the GABA_A receptor, enhancing the inhibitory effects of GABA and promoting sedation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Induces sleep",
            "timeframe": "Onset within 30 minutes; duration of action 6–8 hours"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "GABAergic Neurotransmission",
        "key_targets": [
            "GABA_A receptor"
        ],
        "related_conditions": [
            "Insomnia"
        ]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed; peak plasma concentrations reached in 1.6 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [
                "CYP3A4"
            ],
            "notes": "Metabolized to inactive metabolites"
        },
        "elimination": "Excreted primarily in urine; half-life approximately 2.5 hours"
    },
    "interactions": {
        "CNS Depressants": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Additive sedative effects",
            "effect": "Increased risk of CNS depression",
            "recommendation": "Avoid concurrent use; monitor for enhanced sedation."
        },
        "Alcohol": {
            "site_of_interaction": "Central Nervous System",
            "mechanism": "Enhanced sedative effect",
            "effect": "Increased risk of CNS depression",
            "recommendation": "Avoid alcohol consumption during treatment."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": [
            "Alcohol may potentiate sedative effects, increasing the risk of CNS depression."
        ],
        "microbiota_effects": "No significant effects reported"
    },
    "effects_on_symptoms": {
        "Insomnia": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Enhancement of GABAergic inhibition",
            "direction": "Decreases",
            "magnitude": "Significant improvement in sleep onset and duration",
            "timeframe": "Effective within 30 minutes; duration 6–8 hours"
        }
    },
    "diagnostic_conditions": {
        "Insomnia": {
            "symptoms_addressed": [
                "Difficulty falling asleep",
                "Frequent nocturnal awakenings",
                "Early morning awakenings"
            ],
            "therapeutic_action": "Facilitates sleep initiation and maintenance",
            "optimal_dosage": "5–10 mg immediately before bedtime",
            "response_time": "Onset within 30 minutes; improvement observed within the first night of use"
        }
    },
    "adverse_effects": {
        "mild": [
            "Drowsiness",
            "Dizziness",
            "Headache"
        ],
        "moderate": [
            "Memory impairment",
            "Coordination disturbances",
            "Next-day sedation"
        ],
        "severe": [
            "Complex sleep-related behaviors (e.g., sleepwalking, sleep-driving)",
            "Anaphylactic reactions",
            "Depression exacerbation"
        ]
    },
    "long_term_monitoring": {
        "parameters": [
            "Assessment for dependence",
            "Evaluation of efficacy",
            "Monitoring for adverse effects"
        ],
        "frequency": "Regular follow-up every 4 weeks during prolonged therapy",
        "clinical_thresholds": {
            "normal_range": {
                "dependence": "No signs of dependence or tolerance",
                "efficacy": "Effective sleep induction and maintenance",
                "adverse_effects": "Absence of significant adverse effects"
            },
            "alert_threshold": {
                "dependence": "Development of tolerance or dependence",
                "insomnia": "Persistent insomnia despite treatment",
                "adverse_effects": "Occurrence of severe adverse effects"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Initiate at lower doses (e.g., 5 mg)",
            "rationale": "Increased sensitivity to sedative effects; higher risk of falls and cognitive impairment"
        },
        "Hepatic Impairment": {
            "adjustments": "Use with caution; consider dose reduction",
            "rationale": "Reduced metabolism may lead to increased plasma levels and prolonged effects"
        }
    },
    "alternative_therapies": [
        "Cognitive Behavioral Therapy for Insomnia (CBT-I)",
        "Other nonbenzodiazepine hypnotics (e.g., eszopiclone, zaleplon)",
        "Melatonin receptor agonists (e.g., ramelteon)"
    ],
    "combination_therapies": {
        "recommended_combinations": [
            "Sleep hygiene education",
            "Relaxation techniques"
        ],
        "cautions": [
            "Avoid combining with other CNS depressants to reduce risk of additive sedation."
        ]
    },
    "contraindications": [
        "Hypersensitivity to zolpidem",
        "History of complex sleep behaviors after zolpidem use"
    ],
    "precautions": [
        "Use the lowest effective dose to minimize risks.",
        "Avoid use in patients with a history of substance abuse."
    ],
    "side_effects": [
        "Somnolence",
        "Dizziness",
        "Diarrhea"
    ],
    "overdose_management": {
        "symptoms": [
            "Excessive sedation",
            "Respiratory depression",
            "Coma"
        ],
        "treatment": [
            "Supportive measures",
            "Gastric lavage if recent ingestion",
            "Administration of flumazenil may be considered"
        ]
    },
    "notes": "Zolpidem, marketed under brand names such as Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist, Stilnox, and Sublinox, is a widely used hypnotic medication for the short-term treatment of insomnia. It carries a risk of dependence and complex sleep-related behaviors."
},
  {
    "iupac_name": "7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one",
    "chemical_formula": "C23H27Cl2N3O2",
    "brand_names": [
        "Abilify",
        "Aristada",
        "Aripiprex",
        "Abilitat",
        "Abilify Maintena",
        "Aripraz",
        "Arpil",
        "Aripla",
        "Apliz",
        "Arap",
        "Pexipraz"
    ],
    "category": "Atypical Antipsychotic",
    "dosage_forms": [
        "Tablets",
        "Orally Disintegrating Tablets",
        "Oral Solution",
        "Intramuscular Injection"
    ],
    "strengths": [
        "2 mg",
        "5 mg",
        "10 mg",
        "15 mg",
        "20 mg",
        "30 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Partial agonist at D2 dopamine and 5-HT1A serotonin receptors, antagonist at 5-HT2A serotonin receptors."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Dopaminergic System",
            "effect": "Modulates dopamine activity in mesolimbic and mesocortical pathways",
            "timeframe": "Onset within 1-2 hours"
        },
        {
            "system": "Serotonergic System",
            "effect": "Balances serotonin-dopamine interactions",
            "timeframe": "Steady-state effects in 2 weeks"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Dopaminergic and Serotonergic Neurotransmission",
        "key_targets": ["D2 Receptors", "5-HT1A Receptors", "5-HT2A Receptors"],
        "related_conditions": ["Schizophrenia", "Bipolar Disorder", "Major Depressive Disorder"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral bioavailability of ~87%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6", "CYP3A4"],
            "notes": "Extensive hepatic metabolism; active metabolite dehydroaripiprazole."
        },
        "elimination": "Primarily excreted via feces (~60%) and urine (~25%)."
    },
    "interactions": {
        "CYP3A4 inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased plasma levels of aripiprazole",
            "recommendation": "Reduce dosage of aripiprazole."
        },
        "CYP3A4 inducers": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased metabolism",
            "effect": "Decreased plasma levels of aripiprazole",
            "recommendation": "Increase dosage of aripiprazole."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased sedation)", "Cannabis (enhanced CNS effects)"],
        "microbiota_effects": "Minimal impact on gut microbiota reported."
    },
    "effects_on_symptoms": {
        "Psychosis": {
            "site_of_effect": "Brain",
            "mechanism": "Modulates dopamine and serotonin receptor activity",
            "direction": "Reduction in positive and negative symptoms",
            "magnitude": "Significant",
            "timeframe": "Observable within 1-2 weeks"
        }
    },
    "diagnostic_conditions": {
        "Schizophrenia": {
            "symptoms_addressed": ["Hallucinations", "Delusions", "Disorganized Thinking"],
            "therapeutic_action": "Symptom control",
            "optimal_dosage": "10-15 mg/day",
            "response_time": "2-4 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Insomnia", "Anxiety"],
        "moderate": ["Akathisia", "Weight Gain", "Fatigue"],
        "severe": ["Tardive Dyskinesia", "Neuroleptic Malignant Syndrome", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Weight", "Lipid Profile", "Glucose Levels"],
        "frequency": "Every 6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Weight": "BMI 18.5-24.9",
                "Glucose Levels": "Fasting glucose < 100 mg/dL"
            },
            "alert_threshold": {
                "Weight": "BMI > 30",
                "Glucose Levels": "Fasting glucose > 126 mg/dL"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Reduced hepatic clearance"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "Family Support Interventions"],
    "combination_therapies": {
        "recommended_combinations": ["Mood Stabilizers", "Antidepressants"],
        "cautions": ["Increased risk of serotonin syndrome"]
    },
    "contraindications": ["Hypersensitivity to aripiprazole", "Severe hepatic impairment"],
    "precautions": ["Monitor for suicidal ideation", "Caution in cardiovascular disease"],
    "side_effects": ["Dizziness", "Sedation", "Restlessness"],
    "overdose_management": {
        "symptoms": ["Somnolence", "Hypotension", "Respiratory Depression"],
        "treatment": ["Supportive Care", "Gastric Lavage", "Activated Charcoal"]
    },
    "notes": "Aripiprazole is marketed under various brand names, including Abilify, Aristada, Aripiprex, Abilitat, Abilify Maintena, Aripraz, Arpil, Aripla, Apliz, Arap, and Pexipraz. It is used to treat schizophrenia, bipolar disorder, and major depressive disorder, with a well-established safety profile for long-term use in specific populations."
},
  {
    "iupac_name": "2-Methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine",
    "chemical_formula": "C17H20N4S",
    "brand_names": [
        "Zyprexa",
        "Zyprexa Zydis",
        "Symbyax",
        "Lanzek",
        "Olapin",
        "Rexapin",
        "Oliza",
        "Oleanz",
        "Onzapin",
        "Zylap",
        "Zapos"
    ],
    "category": "Atypical Antipsychotic",
    "dosage_forms": [
        "Tablets",
        "Orally Disintegrating Tablets",
        "Intramuscular Injection"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "7.5 mg",
        "10 mg",
        "15 mg",
        "20 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Antagonist at dopamine D2 and serotonin 5-HT2A receptors, with activity on multiple neurotransmitter receptors."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Dopaminergic System",
            "effect": "Reduces dopaminergic hyperactivity in mesolimbic pathways",
            "timeframe": "Onset within 1-2 hours"
        },
        {
            "system": "Serotonergic System",
            "effect": "Balances serotonin-dopamine interactions",
            "timeframe": "Steady-state effects in 1-2 weeks"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Dopaminergic and Serotonergic Neurotransmission",
        "key_targets": ["D2 Receptors", "5-HT2A Receptors"],
        "related_conditions": ["Schizophrenia", "Bipolar Disorder"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with oral bioavailability of ~60%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2", "CYP2D6"],
            "notes": "Metabolized extensively via hepatic pathways."
        },
        "elimination": "Primarily excreted via feces (~60%) and urine (~30%)."
    },
    "interactions": {
        "CYP1A2 inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased plasma levels of olanzapine",
            "recommendation": "Reduce dosage of olanzapine."
        },
        "CYP1A2 inducers": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased metabolism",
            "effect": "Decreased plasma levels of olanzapine",
            "recommendation": "Increase dosage of olanzapine."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased sedation)", "Cannabis (enhanced CNS effects)"],
        "microbiota_effects": "Minimal impact on gut microbiota reported."
    },
    "effects_on_symptoms": {
        "Psychosis": {
            "site_of_effect": "Brain",
            "mechanism": "Modulates dopamine and serotonin receptor activity",
            "direction": "Reduction in positive and negative symptoms",
            "magnitude": "Significant",
            "timeframe": "Observable within 1-2 weeks"
        }
    },
    "diagnostic_conditions": {
        "Schizophrenia": {
            "symptoms_addressed": ["Hallucinations", "Delusions", "Disorganized Thinking"],
            "therapeutic_action": "Symptom control",
            "optimal_dosage": "10-20 mg/day",
            "response_time": "2-4 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Weight Gain", "Sedation", "Dry Mouth"],
        "moderate": ["Hyperglycemia", "Orthostatic Hypotension"],
        "severe": ["Tardive Dyskinesia", "Neuroleptic Malignant Syndrome"]
    },
    "long_term_monitoring": {
        "parameters": ["Weight", "Lipid Profile", "Glucose Levels"],
        "frequency": "Every 6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Weight": "BMI 18.5-24.9",
                "Glucose Levels": "Fasting glucose < 100 mg/dL"
            },
            "alert_threshold": {
                "Weight": "BMI > 30",
                "Glucose Levels": "Fasting glucose > 126 mg/dL"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Reduced hepatic clearance"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "Family Support Interventions"],
    "combination_therapies": {
        "recommended_combinations": ["Mood Stabilizers", "Antidepressants"],
        "cautions": ["Increased risk of serotonin syndrome"]
    },
    "contraindications": ["Hypersensitivity to olanzapine", "Severe hepatic impairment"],
    "precautions": ["Monitor for metabolic syndrome", "Caution in cardiovascular disease"],
    "side_effects": ["Sedation", "Weight Gain", "Dry Mouth"],
    "overdose_management": {
        "symptoms": ["Somnolence", "Hypotension", "Respiratory Depression"],
        "treatment": ["Supportive Care", "Gastric Lavage", "Activated Charcoal"]
    },
    "notes": "Olanzapine is marketed under various brand names, including Zyprexa, Zyprexa Zydis, Symbyax, Lanzek, Olapin, Rexapin, Oliza, Oleanz, Onzapin, Zylap, and Zapos. It is primarily used to treat schizophrenia and bipolar disorder, with off-label use for treatment-resistant depression. Long-term monitoring is essential to mitigate potential metabolic side effects."
},
  
  {
    "iupac_name": "8-Chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",
    "chemical_formula": "C18H19ClN4",
    "brand_names": [
        "Clozaril",
        "FazaClo",
        "Versacloz",
        "Clopine",
        "Zaponex",
        "Clonex",
        "Denzapine",
        "Leponex",
        "Clozapine"
    ],
    "category": "Atypical Antipsychotic",
    "dosage_forms": [
        "Tablets",
        "Orally Disintegrating Tablets",
        "Oral Suspension"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg",
        "200 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Antagonist at dopamine D2 and serotonin 5-HT2A receptors; modulates glutamatergic and cholinergic pathways."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Dopaminergic System",
            "effect": "Reduces dopaminergic hyperactivity in mesolimbic pathways",
            "timeframe": "Onset within 1-2 weeks"
        },
        {
            "system": "Serotonergic System",
            "effect": "Balances serotonin-dopamine interactions",
            "timeframe": "Steady-state effects in 2-4 weeks"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Dopaminergic and Serotonergic Neurotransmission",
        "key_targets": ["D2 Receptors", "5-HT2A Receptors", "M1 Muscarinic Receptors"],
        "related_conditions": ["Schizophrenia", "Treatment-Resistant Schizophrenia"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~60-70%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2", "CYP3A4"],
            "notes": "Extensive hepatic metabolism with active metabolites."
        },
        "elimination": "Primarily excreted via urine (~50%) and feces (~30%)."
    },
    "interactions": {
        "CYP1A2 inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased plasma levels of clozapine",
            "recommendation": "Reduce dosage of clozapine."
        },
        "CYP1A2 inducers": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased metabolism",
            "effect": "Decreased plasma levels of clozapine",
            "recommendation": "Increase dosage of clozapine."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased sedation)", "Cannabis (enhanced CNS effects)"],
        "microbiota_effects": "Minimal impact on gut microbiota reported."
    },
    "effects_on_symptoms": {
        "Psychosis": {
            "site_of_effect": "Brain",
            "mechanism": "Modulates dopamine and serotonin receptor activity",
            "direction": "Reduction in positive and negative symptoms",
            "magnitude": "Significant",
            "timeframe": "Observable within 2-4 weeks"
        }
    },
    "diagnostic_conditions": {
        "Treatment-Resistant Schizophrenia": {
            "symptoms_addressed": ["Hallucinations", "Delusions", "Disorganized Thinking"],
            "therapeutic_action": "Symptom control",
            "optimal_dosage": "300-450 mg/day",
            "response_time": "4-6 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Sedation", "Weight Gain", "Hypersalivation"],
        "moderate": ["Constipation", "Orthostatic Hypotension", "Tachycardia"],
        "severe": ["Agranulocytosis", "Seizures", "Myocarditis"]
    },
    "long_term_monitoring": {
        "parameters": ["White Blood Cell Count", "Weight", "Lipid Profile", "Glucose Levels"],
        "frequency": "Weekly for first 6 months, then biweekly",
        "clinical_thresholds": {
            "normal_range": {
                "WBC Count": "4,000-11,000 cells/uL",
                "Glucose Levels": "Fasting glucose < 100 mg/dL"
            },
            "alert_threshold": {
                "WBC Count": "< 3,000 cells/uL",
                "Glucose Levels": "Fasting glucose > 126 mg/dL"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Reduced hepatic clearance and higher risk of orthostatic hypotension"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "Psychosocial Rehabilitation"],
    "combination_therapies": {
        "recommended_combinations": ["Mood Stabilizers", "Benzodiazepines"],
        "cautions": ["Increased risk of sedation"]
    },
    "contraindications": ["Agranulocytosis history", "Uncontrolled epilepsy"],
    "precautions": ["Monitor for myocarditis", "Caution in cardiovascular disease"],
    "side_effects": ["Sedation", "Weight Gain", "Constipation"],
    "overdose_management": {
        "symptoms": ["Somnolence", "Seizures", "Hypotension"],
        "treatment": ["Supportive Care", "Gastric Lavage", "Activated Charcoal"]
    },
    "notes": "Clozapine is marketed under various brand names, including Clozaril, FazaClo, Versacloz, Clopine, Zaponex, Clonex, Denzapine, and Leponex. It is the gold-standard treatment for treatment-resistant schizophrenia but requires strict monitoring due to risks of agranulocytosis and other severe side effects. Regular blood work is mandatory for patients on clozapine."
},
  
  {
    "iupac_name": "(Â±)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one",
    "chemical_formula": "C13H18ClNO",
    "brand_names": [
        "Wellbutrin",
        "Zyban",
        "Aplenzin",
        "Forfivo XL",
        "Budeprion",
        "Prexaton",
        "Voxra",
        "Bupropion VITAL",
        "Amfebutamone",
        "Quomen"
    ],
    "category": "Atypical Antidepressant",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Tablets"
    ],
    "strengths": [
        "75 mg",
        "100 mg",
        "150 mg",
        "200 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Inhibits the reuptake of norepinephrine and dopamine."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Noradrenergic System",
            "effect": "Increases norepinephrine levels, enhancing mood and energy.",
            "timeframe": "Observable within 1-2 weeks"
        },
        {
            "system": "Dopaminergic System",
            "effect": "Increases dopamine levels, reducing anhedonia.",
            "timeframe": "Steady-state effects in 2 weeks"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Noradrenaline and Dopamine Reuptake Inhibition",
        "key_targets": ["Dopamine Transporter (DAT)", "Norepinephrine Transporter (NET)"],
        "related_conditions": ["Depression", "Seasonal Affective Disorder", "Smoking Cessation"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~85%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2B6"],
            "notes": "Metabolized to active metabolites, including hydroxybupropion."
        },
        "elimination": "Primarily excreted via urine (~87%) and feces (~10%)."
    },
    "interactions": {
        "CYP2B6 inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased plasma levels of bupropion",
            "recommendation": "Reduce dosage of bupropion."
        },
        "CYP2B6 inducers": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased metabolism",
            "effect": "Decreased plasma levels of bupropion",
            "recommendation": "Increase dosage of bupropion."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased seizure risk)", "Cannabis (enhanced CNS effects)"],
        "microbiota_effects": "Minimal impact on gut microbiota reported."
    },
    "effects_on_symptoms": {
        "Depression": {
            "site_of_effect": "Brain",
            "mechanism": "Enhances norepinephrine and dopamine neurotransmission",
            "direction": "Reduction in depressive symptoms",
            "magnitude": "Significant",
            "timeframe": "Observable within 1-2 weeks"
        }
    },
    "diagnostic_conditions": {
        "Major Depressive Disorder": {
            "symptoms_addressed": ["Anhedonia", "Low Energy", "Depressed Mood"],
            "therapeutic_action": "Symptom control",
            "optimal_dosage": "150-300 mg/day",
            "response_time": "2-4 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dry Mouth", "Insomnia", "Sweating"],
        "moderate": ["Anxiety", "Tachycardia", "Weight Loss"],
        "severe": ["Seizures", "Hypertension", "Suicidal Ideation"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood Pressure", "Weight", "Mood Stability"],
        "frequency": "Every 6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Blood Pressure": "120/80 mmHg",
                "Weight": "BMI 18.5-24.9"
            },
            "alert_threshold": {
                "Blood Pressure": ">140/90 mmHg",
                "Weight": "BMI < 18.5 or >30"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Reduced hepatic clearance and higher risk of side effects"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "Mindfulness-Based Therapy"],
    "combination_therapies": {
        "recommended_combinations": ["SSRIs", "Mood Stabilizers"],
        "cautions": ["Increased risk of serotonin syndrome"]
    },
    "contraindications": ["Seizure Disorder", "Concurrent MAOI Therapy"],
    "precautions": ["Monitor for hypertension", "Caution in patients with anxiety disorders"],
    "side_effects": ["Insomnia", "Dry Mouth", "Sweating"],
    "overdose_management": {
        "symptoms": ["Seizures", "Cardiac Arrhythmias", "Loss of Consciousness"],
        "treatment": ["Supportive Care", "Benzodiazepines for seizure control"]
    },
    "notes": "Bupropion is marketed under various brand names, including Wellbutrin, Zyban, Aplenzin, Forfivo XL, Budeprion, Prexaton, Voxra, Bupropion VITAL, Amfebutamone, and Quomen. It is widely used for depression, seasonal affective disorder, and smoking cessation, with a unique mechanism compared to other antidepressants. Regular monitoring is advised to minimize side effects."
},
  
  {
    "iupac_name": "7-Chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one",
    "chemical_formula": "C16H13ClN2O",
    "brand_names": [
        "Valium",
        "Diastat",
        "Diazemuls",
        "Seduxen",
        "Stesolid",
        "Antenex",
        "Valpam",
        "Vivol",
        "V-Tab",
        "Diazepam Desitin",
        "Calmepam",
        "Relanium",
        "Zetran",
        "Tranquil",
        "Dialar",
        "Valrelease"
    ],
    "category": "Benzodiazepine (Anxiolytic, Muscle Relaxant, Anticonvulsant)",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Rectal Gel",
        "Intravenous Injection",
        "Intramuscular Injection"
    ],
    "strengths": [
        "2 mg",
        "5 mg",
        "10 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Enhances the effect of GABA at GABA-A receptors, producing sedative, anxiolytic, and muscle-relaxing effects."
    },
    "pharmacodynamic_effects": [
        {
            "system": "GABAergic System",
            "effect": "Increases inhibitory neurotransmission, reducing anxiety and inducing sedation.",
            "timeframe": "Onset within 30-60 minutes"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "GABAergic Neurotransmission",
        "key_targets": ["GABA-A Receptors"],
        "related_conditions": ["Anxiety Disorders", "Muscle Spasms", "Seizures"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral bioavailability of ~90%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Metabolized to active metabolites including desmethyldiazepam."
        },
        "elimination": "Primarily excreted via urine (~70%) as conjugated metabolites."
    },
    "interactions": {
        "CYP3A4 inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased plasma levels of diazepam",
            "recommendation": "Adjust dosage of diazepam accordingly."
        },
        "Alcohol": {
            "site_of_interaction": "CNS",
            "mechanism": "Additive CNS depression",
            "effect": "Increased sedation and risk of respiratory depression",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased sedation)", "Opioids (enhanced CNS depression)"],
        "microbiota_effects": "Minimal impact on gut microbiota reported."
    },
    "effects_on_symptoms": {
        "Anxiety": {
            "site_of_effect": "Brain",
            "mechanism": "Enhances GABAergic inhibitory effects",
            "direction": "Reduction in anxiety symptoms",
            "magnitude": "Significant",
            "timeframe": "Onset within 30-60 minutes"
        }
    },
    "diagnostic_conditions": {
        "Anxiety Disorders": {
            "symptoms_addressed": ["Restlessness", "Tension", "Irritability"],
            "therapeutic_action": "Symptom control",
            "optimal_dosage": "2-10 mg up to 4 times daily",
            "response_time": "1-2 weeks for sustained effects"
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Fatigue", "Dry Mouth"],
        "moderate": ["Confusion", "Ataxia", "Blurred Vision"],
        "severe": ["Respiratory Depression", "Dependence", "Withdrawal Symptoms"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function", "Mental Status", "Dependence Symptoms"],
        "frequency": "Every 6-12 months",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Function Tests": "Within reference range"
            },
            "alert_threshold": {
                "Liver Function Tests": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Higher risk of sedation and falls"
        }
    },
    "alternative_therapies": ["Cognitive Behavioral Therapy", "Relaxation Techniques"],
    "combination_therapies": {
        "recommended_combinations": ["Antidepressants", "Muscle Relaxants"],
        "cautions": ["Increased risk of CNS depression"]
    },
    "contraindications": ["Severe respiratory insufficiency", "Myasthenia gravis", "Acute narrow-angle glaucoma"],
    "precautions": ["Monitor for dependence", "Caution in hepatic impairment"],
    "side_effects": ["Drowsiness", "Fatigue", "Ataxia"],
    "overdose_management": {
        "symptoms": ["Severe drowsiness", "Confusion", "Respiratory depression"],
        "treatment": ["Supportive care", "Flumazenil for benzodiazepine reversal"]
    },
    "notes": "Diazepam is marketed under various brand names, including Valium, Diastat, Diazepam Desitin, Diazemuls, Seduxen, Stesolid, Antenex, Valpam, Vivol, V-Tab, Calmepam, Relanium, Zetran, Tranquil, Dialar, and Valrelease. It is commonly used for anxiety disorders, muscle spasms, and seizures. Long-term use requires careful monitoring due to the risk of dependence and withdrawal symptoms."
},
  
 {
    "iupac_name": "Not applicable (Herbal preparation from Valeriana officinalis)",
    "chemical_formula": "Not applicable (Complex plant extract)",
    "brand_names": [
        "Valerian Root",
        "Valdispert",
        "Kalms",
        "Nature's Way Valerian",
        "Sundown Naturals Valerian",
        "Now Foods Valerian",
        "Valdispert Night",
        "Herb Pharm Valerian",
        "Holland & Barrett Valerian",
        "Vitanica Valerian",
        "Gaia Herbs Valerian Root",
        "Piping Rock Valerian",
        "NutraValerian",
        "SleepEzy",
        "CalmEase",
        "Valeriana Forte"
    ],
    "category": "Herbal Supplement (Sedative, Anxiolytic)",
    "dosage_forms": [
        "Capsules",
        "Tablets",
        "Liquid Extract",
        "Tea"
    ],
    "strengths": [
        "125 mg",
        "250 mg",
        "400 mg",
        "Liquid extracts standardized to valeric acid content"
    ],
    "mechanism_of_action": {
        "site_of_action": "Central Nervous System",
        "physiological_mechanism": "Believed to enhance GABAergic activity and modulate serotonin receptors."
    },
    "pharmacodynamic_effects": [
        {
            "system": "GABAergic System",
            "effect": "Increases inhibitory neurotransmission, promoting relaxation and reducing anxiety.",
            "timeframe": "Effects observed within 30-60 minutes after administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "GABAergic Modulation",
        "key_targets": ["GABA-A Receptors"],
        "related_conditions": ["Insomnia", "Anxiety"]
    },
    "pharmacokinetics": {
        "absorption": "Depends on preparation; generally absorbed within 1-2 hours",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Unknown"],
            "notes": "Complex metabolism involving multiple plant-derived compounds."
        },
        "elimination": "Primarily excreted via urine as metabolites."
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "CNS",
            "mechanism": "Additive sedative effects",
            "effect": "Increased drowsiness and risk of CNS depression",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (enhanced CNS effects)", "Opioids (increased sedation)"]
    },
    "effects_on_symptoms": {
        "Insomnia": {
            "site_of_effect": "Brain",
            "mechanism": "Enhances GABAergic inhibitory effects",
            "direction": "Improves sleep latency and quality",
            "magnitude": "Moderate",
            "timeframe": "Within 30-60 minutes"
        }
    },
    "diagnostic_conditions": {
        "Insomnia": {
            "symptoms_addressed": ["Difficulty falling asleep", "Restlessness"],
            "therapeutic_action": "Promotes relaxation and improves sleep quality",
            "optimal_dosage": "250-600 mg before bedtime",
            "response_time": "1-2 weeks for consistent effects"
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Dry Mouth", "Headache"],
        "moderate": ["Gastrointestinal Upset", "Dizziness"],
        "severe": ["Rare allergic reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Sleep Quality", "Daytime Alertness"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Sleep Quality": "Subjective improvement"
            },
            "alert_threshold": {
                "Daytime Alertness": "Persistent drowsiness"
            }
        }
    },
    "population_specific": {
        "Pregnant Women": {
            "adjustments": "Avoid use unless advised by a healthcare provider",
            "rationale": "Limited safety data."
        }
    },
    "alternative_therapies": ["Chamomile", "Melatonin"],
    "combination_therapies": {
        "recommended_combinations": ["Magnesium Supplements", "L-Theanine"],
        "cautions": ["Increased risk of sedation"]
    },
    "contraindications": ["Severe liver disease", "Known hypersensitivity to Valerian"],
    "precautions": ["Avoid in operating machinery", "Caution in liver disorders"],
    "side_effects": ["Drowsiness", "Dry Mouth", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Excessive Drowsiness", "Stomach Cramps"],
        "treatment": ["Supportive Care", "Activated Charcoal"]
    },
    "notes": "Valerian is marketed under various brand names, including Valerian Root, Valdispert, Kalms, Nature's Way Valerian, Sundown Naturals Valerian, Now Foods Valerian, Valdispert Night, Herb Pharm Valerian, Holland & Barrett Valerian, Vitanica Valerian, Gaia Herbs Valerian Root, Piping Rock Valerian, NutraValerian, SleepEzy, CalmEase, and Valeriana Forte. It is widely used as a natural remedy for insomnia and anxiety, with a generally good safety profile when used as directed."
},
  
  {
    "iupac_name": "Methyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate",
    "chemical_formula": "C16H16ClNO2S",
    "brand_names": [
        "Plavix",
        "Clopilet",
        "Clopivas",
        "Clopirel",
        "Iscover",
        "Deplat",
        "Zylt",
        "Ceruvin",
        "Clopidogrel Winthrop",
        "Clovix",
        "Clopid",
        "Grepid",
        "Trombex",
        "Apo-Clopidogrel",
        "Duoplavin"
    ],
    "category": "Antiplatelet Agent",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "75 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Platelets",
        "physiological_mechanism": "Irreversible inhibition of the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematological System",
            "effect": "Inhibits platelet aggregation",
            "timeframe": "Onset within 2 hours, peak effect in 3-7 days"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "ADP-mediated Platelet Aggregation",
        "key_targets": ["P2Y12 Receptor"],
        "related_conditions": ["Acute Coronary Syndrome", "Stroke Prevention"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral bioavailability of ~50%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4", "CYP1A2"],
            "notes": "Converted to an active thiol metabolite."
        },
        "elimination": "Primarily excreted via urine (~50%) and feces (~46%)."
    },
    "interactions": {
        "Proton Pump Inhibitors (PPIs)": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of CYP2C19",
            "effect": "Reduced efficacy of clopidogrel",
            "recommendation": "Use alternative antacid therapy if possible."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased bleeding risk)", "NSAIDs (enhanced antiplatelet effect)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Thrombosis Prevention": {
            "site_of_effect": "Platelets",
            "mechanism": "Inhibits platelet activation",
            "direction": "Reduction in clot formation",
            "magnitude": "Significant",
            "timeframe": "Observable within 2 hours"
        }
    },
    "diagnostic_conditions": {
        "Acute Coronary Syndrome": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath", "Radiating Pain"],
            "therapeutic_action": "Prevention of thrombotic events",
            "optimal_dosage": "75 mg once daily",
            "response_time": "Immediate with loading dose"
        }
    },
    "adverse_effects": {
        "mild": ["Bruising", "Nausea", "Diarrhea"],
        "moderate": ["Epistaxis", "Rash", "Gastric Irritation"],
        "severe": ["Severe Bleeding", "Thrombocytopenia", "Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Bleeding Time"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Platelet Count": "150,000-450,000 cells/uL"
            },
            "alert_threshold": {
                "Platelet Count": "<100,000 cells/uL"
            }
        }
    },
    "population_specific": {
        "Patients with CYP2C19 Polymorphisms": {
            "adjustments": "Consider alternative antiplatelet agents",
            "rationale": "Reduced metabolic activation of clopidogrel"
        }
    },
    "alternative_therapies": ["Aspirin", "Prasugrel"],
    "combination_therapies": {
        "recommended_combinations": ["Aspirin (Dual Antiplatelet Therapy)", "Statins"],
        "cautions": ["Increased bleeding risk"]
    },
    "contraindications": ["Active bleeding", "Severe hepatic impairment"],
    "precautions": ["Monitor for bleeding", "Caution in renal impairment"],
    "side_effects": ["Bruising", "Nausea", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Prolonged bleeding", "Gastrointestinal distress"],
        "treatment": ["Supportive Care", "Platelet Transfusion"]
    },
    "notes": "Clopidogrel is marketed under various brand names, including Plavix, Clopilet, Clopivas, Clopirel, Iscover, Deplat, Zylt, Ceruvin, Clopidogrel Winthrop, Clovix, Clopid, Grepid, Trombex, Apo-Clopidogrel, and Duoplavin. It is widely used to prevent thrombotic events in conditions such as acute coronary syndrome and ischemic stroke. Careful monitoring is recommended, especially in patients with known CYP2C19 polymorphisms or those at high risk of bleeding."
},
  
  {
    "iupac_name": "(2-{4-[2-(Diethylamino)ethoxy]-3,5-diiodophenyl}ethanone)",
    "chemical_formula": "C25H29I2NO3",
    "brand_names": [
        "Cordarone",
        "Pacerone",
        "Aratac",
        "Amiodar",
        "Cordarone X",
        "Tachyben",
        "Atlansil",
        "Angoron",
        "Rithmik",
        "Amiodacore",
        "Amybene",
        "Sedacoron",
        "Rhythmonorm",
        "Amiodarone Accord",
        "Amiodarone Hydrochloride"
    ],
    "category": "Antiarrhythmic Agent",
    "dosage_forms": [
        "Tablets",
        "Intravenous Injection"
    ],
    "strengths": [
        "100 mg",
        "200 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Cardiac Myocytes",
        "physiological_mechanism": "Prolongs the myocardial cell-action potential duration and refractory period by inhibiting potassium channels, with additional sodium and calcium channel effects."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiac System",
            "effect": "Reduces abnormal electrical activity and stabilizes cardiac rhythm.",
            "timeframe": "Effects observed within hours for IV administration, days to weeks for oral."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cardiac Action Potential Modulation",
        "key_targets": ["Potassium Channels", "Sodium Channels", "Calcium Channels"],
        "related_conditions": ["Atrial Fibrillation", "Ventricular Tachycardia", "Supraventricular Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability ranges from 30-50%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to active metabolite desethylamiodarone."
        },
        "elimination": "Primarily excreted via feces (~85%) and urine (~15%)."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased anticoagulant effect",
            "recommendation": "Monitor INR closely and adjust warfarin dose."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Grapefruit Juice (increased amiodarone levels)", "Alcohol (enhanced side effects)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Arrhythmias": {
            "site_of_effect": "Heart",
            "mechanism": "Stabilizes electrical impulses in cardiac tissue",
            "direction": "Reduction in arrhythmic episodes",
            "magnitude": "Significant",
            "timeframe": "Days to weeks for sustained effects"
        }
    },
    "diagnostic_conditions": {
        "Atrial Fibrillation": {
            "symptoms_addressed": ["Palpitations", "Shortness of Breath", "Chest Discomfort"],
            "therapeutic_action": "Restores normal heart rhythm",
            "optimal_dosage": "200-400 mg/day",
            "response_time": "2-3 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Fatigue", "Tremor"],
        "moderate": ["Photosensitivity", "Thyroid Dysfunction", "Pulmonary Toxicity"],
        "severe": ["Hepatotoxicity", "Pulmonary Fibrosis", "Bradycardia"]
    },
    "long_term_monitoring": {
        "parameters": ["Thyroid Function Tests", "Liver Enzymes", "Chest X-ray"],
        "frequency": "Every 6-12 months",
        "clinical_thresholds": {
            "normal_range": {
                "TSH": "0.4-4.0 mIU/L"
            },
            "alert_threshold": {
                "TSH": "<0.4 or >4.0 mIU/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start at lower dose due to increased sensitivity",
            "rationale": "Higher risk of bradycardia and pulmonary toxicity"
        }
    },
    "alternative_therapies": ["Beta Blockers", "Calcium Channel Blockers"],
    "combination_therapies": {
        "recommended_combinations": ["Anticoagulants", "Digoxin"],
        "cautions": ["Increased risk of bradycardia"]
    },
    "contraindications": ["Severe sinus-node dysfunction", "Second- or third-degree AV block"],
    "precautions": ["Monitor for thyroid dysfunction", "Caution in pulmonary disease"],
    "side_effects": ["Nausea", "Fatigue", "Photosensitivity"],
    "overdose_management": {
        "symptoms": ["Severe bradycardia", "Hypotension", "Cardiac Arrest"],
        "treatment": ["Supportive Care", "Cardiac Monitoring"]
    },
    "notes": "Amiodarone is marketed under various brand names, including Cordarone, Pacerone, Aratac, Amiodar, Cordarone X, Tachyben, Atlansil, Angoron, Rithmik, Amiodacore, Amybene, Sedacoron, Rhythmonorm, Amiodarone Accord, and Amiodarone Hydrochloride. It is a highly effective antiarrhythmic agent but requires careful monitoring due to its potential for serious adverse effects, including thyroid and pulmonary toxicity."
},
 {
    "iupac_name": "(8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",
    "chemical_formula": "C19H28O2",
    "brand_names": [
        "AndroGel",
        "Testim",
        "Depo-Testosterone",
        "Androderm",
        "Natesto",
        "Axiron",
        "Striant",
        "Fortesta",
        "Testosterone Cypionate",
        "Testosterone Enanthate",
        "Aveed",
        "Delatestryl",
        "Nebido",
        "Testoviron",
        "Primoteston"
    ],
    "category": "Hormone Replacement Therapy (HRT), Anabolic Steroid",
    "dosage_forms": [
        "Topical Gel",
        "Transdermal Patch",
        "Intramuscular Injection",
        "Buccal Tablet",
        "Nasal Gel"
    ],
    "strengths": [
        "1% Gel",
        "2% Gel",
        "50 mg Patch",
        "75 mg Patch",
        "100 mg/mL Injection"
    ],
    "mechanism_of_action": {
        "site_of_action": "Androgen Receptors",
        "physiological_mechanism": "Binds to androgen receptors, influencing gene expression and promoting development of male secondary sexual characteristics."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Endocrine System",
            "effect": "Stimulates protein synthesis and increases muscle mass and strength.",
            "timeframe": "Effects observed within weeks of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Androgen Signaling Pathway",
        "key_targets": ["Androgen Receptors"],
        "related_conditions": ["Hypogonadism", "Delayed Puberty"]
    },
    "pharmacokinetics": {
        "absorption": "Varies by dosage form; intramuscular injections have a longer half-life compared to transdermal or buccal forms.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["5-alpha reductase", "CYP3A4"],
            "notes": "Metabolized to dihydrotestosterone (DHT) and estradiol."
        },
        "elimination": "Primarily excreted via urine as conjugates of testosterone and its metabolites."
    },
    "interactions": {
        "Anticoagulants": {
            "site_of_interaction": "Liver",
            "mechanism": "Increased sensitivity to anticoagulants",
            "effect": "Enhanced anticoagulant effect",
            "recommendation": "Monitor INR closely and adjust anticoagulant dose."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased risk of hepatotoxicity)", "Anabolic Steroids (synergistic effects)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Low Testosterone Symptoms": {
            "site_of_effect": "Systemic",
            "mechanism": "Restores normal testosterone levels",
            "direction": "Improvement in energy, libido, and muscle mass",
            "magnitude": "Significant",
            "timeframe": "Observable within 2-4 weeks"
        }
    },
    "diagnostic_conditions": {
        "Hypogonadism": {
            "symptoms_addressed": ["Fatigue", "Decreased Libido", "Muscle Weakness"],
            "therapeutic_action": "Restores normal androgen levels",
            "optimal_dosage": "75-100 mg per week (injection)",
            "response_time": "4-6 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Acne", "Oily Skin", "Injection Site Reactions"],
        "moderate": ["Gynecomastia", "Mood Swings", "Fluid Retention"],
        "severe": ["Polycythemia", "Liver Dysfunction", "Cardiovascular Events"]
    },
    "long_term_monitoring": {
        "parameters": ["Hematocrit Levels", "Liver Function Tests", "PSA Levels"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Hematocrit": "40-50%"
            },
            "alert_threshold": {
                "Hematocrit": ">52%"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower starting dose to minimize cardiovascular risk",
            "rationale": "Higher sensitivity to androgens."
        }
    },
    "alternative_therapies": ["Clomiphene Citrate", "Human Chorionic Gonadotropin (hCG)"],
    "combination_therapies": {
        "recommended_combinations": ["Vitamin D", "Zinc Supplements"],
        "cautions": ["Monitor for hypercalcemia"]
    },
    "contraindications": ["Prostate Cancer", "Breast Cancer in Men"],
    "precautions": ["Monitor for erythrocytosis", "Caution in sleep apnea"],
    "side_effects": ["Acne", "Oily Skin", "Mood Swings"],
    "overdose_management": {
        "symptoms": ["Severe Polycythemia", "Priapism", "Liver Dysfunction"],
        "treatment": ["Supportive Care", "Phlebotomy"]
    },
    "notes": "Testosterone is marketed under various brand names, including AndroGel, Testim, Depo-Testosterone, Androderm, Natesto, Axiron, Striant, Fortesta, Testosterone Cypionate, Testosterone Enanthate, Aveed, Delatestryl, Nebido, Testoviron, and Primoteston. It is widely used in hormone replacement therapy for hypogonadism and other conditions requiring androgen supplementation. Close monitoring is essential to mitigate risks of cardiovascular and hepatic side effects."
},
  
  {
    "iupac_name": "2-[4-(2-Chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine",
    "chemical_formula": "C26H28ClNO",
    "brand_names": [
        "Clomid",
        "Serophene",
        "Omifin",
        "Clomifene",
        "Milophene",
        "Fertyl",
        "Clostilbegyt",
        "Clostil",
        "Fertomid",
        "Ova-Mit",
        "Zimaquin",
        "Pergotime",
        "Serpafar",
        "Ovamit",
        "Rejun 50"
    ],
    "category": "Selective Estrogen Receptor Modulator (SERM)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Hypothalamus and Pituitary Gland",
        "physiological_mechanism": "Blocks estrogen receptors in the hypothalamus, leading to increased secretion of gonadotropins (LH and FSH) and stimulating ovulation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Reproductive System",
            "effect": "Stimulates follicular development and ovulation.",
            "timeframe": "Ovulation typically occurs 5-10 days after administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Gonadotropin Regulation Pathway",
        "key_targets": ["Estrogen Receptors", "FSH", "LH"],
        "related_conditions": ["Anovulation", "Infertility"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with peak plasma concentrations in 6 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Metabolized to active metabolites with prolonged half-life."
        },
        "elimination": "Primarily excreted via feces (~85%)."
    },
    "interactions": {
        "Oral Contraceptives": {
            "site_of_interaction": "Hypothalamus",
            "mechanism": "Antagonistic effects",
            "effect": "Reduced efficacy of clomiphene",
            "recommendation": "Avoid concurrent use."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased side effects)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Infertility": {
            "site_of_effect": "Ovaries",
            "mechanism": "Stimulates ovulation",
            "direction": "Improvement in ovulatory function",
            "magnitude": "Significant",
            "timeframe": "Within 5-10 days"
        }
    },
    "diagnostic_conditions": {
        "Anovulation": {
            "symptoms_addressed": ["Irregular Periods", "Absent Ovulation"],
            "therapeutic_action": "Restores ovulation",
            "optimal_dosage": "50 mg daily for 5 days",
            "response_time": "1 cycle"
        }
    },
    "adverse_effects": {
        "mild": ["Hot Flashes", "Nausea", "Breast Tenderness"],
        "moderate": ["Ovarian Cysts", "Visual Disturbances"],
        "severe": ["Ovarian Hyperstimulation Syndrome", "Multiple Pregnancies"]
    },
    "long_term_monitoring": {
        "parameters": ["Ovulatory Response", "Endometrial Thickness"],
        "frequency": "Per cycle of use",
        "clinical_thresholds": {
            "normal_range": {
                "Endometrial Thickness": "7-14 mm"
            },
            "alert_threshold": {
                "Endometrial Thickness": "<7 mm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Not indicated for postmenopausal women",
            "rationale": "Ineffective in this population."
        }
    },
    "alternative_therapies": ["Letrozole", "Gonadotropin Injections"],
    "combination_therapies": {
        "recommended_combinations": ["Metformin", "Progesterone Supplements"],
        "cautions": ["Monitor for ovarian hyperstimulation"]
    },
    "contraindications": ["Pregnancy", "Liver Disease", "Uncontrolled Thyroid Dysfunction"],
    "precautions": ["Monitor for ovarian hyperstimulation", "Caution in visual disturbances"],
    "side_effects": ["Hot Flashes", "Nausea", "Breast Tenderness"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Blurred Vision"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Clomiphene is marketed under various brand names, including Clomid, Serophene, Omifin, Clomifene, Milophene, Fertyl, Clostilbegyt, Clostil, Fertomid, Ova-Mit, Zimaquin, Pergotime, Serpafar, Ovamit, and Rejun 50. It is widely used for the treatment of infertility due to anovulation and has a well-established efficacy profile in promoting ovulation. Monitoring during use is critical to avoid complications such as ovarian hyperstimulation."
},
  
  {
    "iupac_name": "Varies by type (e.g., Insulin glargine: Human insulin analog)",
    "chemical_formula": "C257H383N65O77S6 (Insulin glargine, for example)",
    "brand_names": [
        "Lantus",
        "Toujeo",
        "Basaglar",
        "Levemir",
        "Tresiba",
        "Humalog",
        "Admelog",
        "Novolog",
        "Fiasp",
        "Apidra",
        "Insuman",
        "Ryzodeg",
        "Humulin",
        "Novolin",
        "Afrezza"
    ],
    "category": "Antidiabetic Agent (Insulin Analog)",
    "dosage_forms": [
        "Subcutaneous Injection",
        "Intravenous Injection",
        "Inhalation (Afrezza)"
    ],
    "strengths": [
        "100 units/mL",
        "200 units/mL",
        "300 units/mL",
        "500 units/mL"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver, Muscle, Adipose Tissue",
        "physiological_mechanism": "Promotes glucose uptake, glycogen storage, and inhibits hepatic glucose production."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Metabolic System",
            "effect": "Lowers blood glucose levels by facilitating cellular uptake of glucose.",
            "timeframe": "Varies by type (e.g., Rapid-acting: within 15 minutes; Long-acting: 1-2 hours for onset)"
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Insulin Receptor Signaling Pathway",
        "key_targets": ["Insulin Receptor"],
        "related_conditions": ["Type 1 Diabetes", "Type 2 Diabetes"]
    },
    "pharmacokinetics": {
        "absorption": "Varies by formulation; rapid-acting absorbed in minutes, long-acting absorbed over hours.",
        "metabolism": {
            "primary_site": "Liver and Kidney",
            "enzymes": ["Insulin-Degrading Enzyme"],
            "notes": "Cleared by liver and kidney pathways."
        },
        "elimination": "Primarily excreted via kidneys."
    },
    "interactions": {
        "Beta-Blockers": {
            "site_of_interaction": "Systemic",
            "mechanism": "Masking of hypoglycemia symptoms",
            "effect": "Increased risk of severe hypoglycemia",
            "recommendation": "Monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased risk of hypoglycemia)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Hyperglycemia": {
            "site_of_effect": "Systemic",
            "mechanism": "Enhances cellular glucose uptake and reduces hepatic glucose production.",
            "direction": "Reduction in blood glucose levels",
            "magnitude": "Significant",
            "timeframe": "Varies by insulin type (e.g., Rapid-acting: within minutes; Long-acting: gradual over hours)"
        }
    },
    "diagnostic_conditions": {
        "Diabetes Mellitus": {
            "symptoms_addressed": ["Hyperglycemia", "Polydipsia", "Polyuria"],
            "therapeutic_action": "Regulation of blood glucose levels",
            "optimal_dosage": "Individualized based on blood glucose monitoring",
            "response_time": "Immediate for rapid-acting; hours for long-acting"
        }
    },
    "adverse_effects": {
        "mild": ["Injection Site Reactions", "Weight Gain"],
        "moderate": ["Hypoglycemia", "Edema"],
        "severe": ["Severe Hypoglycemia", "Ketoacidosis (with inappropriate dosing)"]
    },
    "long_term_monitoring": {
        "parameters": ["HbA1c Levels", "Fasting Blood Glucose"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "HbA1c": "<7.0%"
            },
            "alert_threshold": {
                "HbA1c": ">8.0%"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage adjustments based on weight and growth needs.",
            "rationale": "Different metabolic rates in children."
        }
    },
    "alternative_therapies": ["Oral Hypoglycemic Agents", "GLP-1 Agonists"],
    "combination_therapies": {
        "recommended_combinations": ["Metformin", "GLP-1 Receptor Agonists"],
        "cautions": ["Monitor for overlapping side effects"]
    },
    "contraindications": ["Hypoglycemia", "Allergy to insulin or excipients"],
    "precautions": ["Monitor for hypoglycemia", "Adjust dose in renal impairment"],
    "side_effects": ["Injection Site Reactions", "Hypoglycemia", "Weight Gain"],
    "overdose_management": {
        "symptoms": ["Severe Hypoglycemia", "Seizures", "Coma"],
        "treatment": ["Glucose Administration", "Glucagon Injection"]
    },
    "notes": "Insulin is marketed under various brand names, including Lantus, Toujeo, Basaglar, Levemir, Tresiba, Humalog, Admelog, Novolog, Fiasp, Apidra, Insuman, Ryzodeg, Humulin, Novolin, and Afrezza. It is an essential treatment for diabetes management, with formulations tailored to rapid, intermediate, and long-acting needs. Close monitoring of blood glucose and patient-specific dosing is required to avoid complications."
},
  {
    "iupac_name": "(2S)-2-[[4-[(2,4-Diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid",
    "chemical_formula": "C20H22N8O5",
    "brand_names": [
        "Trexall",
        "Rheumatrex",
        "Otrexup",
        "Xatmep",
        "RediTrex",
        "Metoject",
        "Maxtrex",
        "Jylamvo",
        "Zexate",
        "Methoblastin",
        "Emthexat",
        "Ebetrex",
        "Novatrex",
        "Methotrexate Accord",
        "Methotrexate Teva"
    ],
    "category": "Antimetabolite (Antineoplastic, Immunosuppressant)",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Subcutaneous Injection",
        "Intravenous Injection"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "7.5 mg",
        "10 mg",
        "15 mg",
        "25 mg/mL (injection)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Cellular Enzymes",
        "physiological_mechanism": "Inhibits dihydrofolate reductase, disrupting DNA synthesis and cell replication."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Reduces autoimmune activity by suppressing rapid cell division in immune cells.",
            "timeframe": "Effects observed within weeks of therapy initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Folate Metabolism Pathway",
        "key_targets": ["Dihydrofolate Reductase", "Thymidylate Synthase"],
        "related_conditions": ["Rheumatoid Arthritis", "Psoriasis", "Cancer"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally; bioavailability decreases with higher doses.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Dihydrofolate Reductase"],
            "notes": "Partially metabolized to active polyglutamate derivatives."
        },
        "elimination": "Primarily excreted unchanged in urine (~80-90%)."
    },
    "interactions": {
        "NSAIDs": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Reduced renal clearance of methotrexate",
            "effect": "Increased toxicity risk",
            "recommendation": "Avoid or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Folic Acid (reduces side effects)"],
        "toxins": ["Alcohol (increased risk of hepatotoxicity)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Rheumatoid Arthritis": {
            "site_of_effect": "Synovial Tissue",
            "mechanism": "Reduces inflammatory cell activity and cytokine production.",
            "direction": "Improvement in joint pain and swelling",
            "magnitude": "Moderate to significant",
            "timeframe": "Within 4-6 weeks"
        }
    },
    "diagnostic_conditions": {
        "Rheumatoid Arthritis": {
            "symptoms_addressed": ["Joint Swelling", "Pain", "Stiffness"],
            "therapeutic_action": "Reduces inflammation and slows disease progression",
            "optimal_dosage": "7.5-25 mg once weekly",
            "response_time": "4-6 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Fatigue", "Hair Thinning"],
        "moderate": ["Mouth Sores", "Liver Enzyme Elevation"],
        "severe": ["Bone Marrow Suppression", "Hepatotoxicity", "Pulmonary Fibrosis"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Complete Blood Count", "Renal Function"],
        "frequency": "Every 4-8 weeks during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on body surface area.",
            "rationale": "Higher sensitivity to drug effects in children."
        }
    },
    "alternative_therapies": ["Leflunomide", "Biologic DMARDs"],
    "combination_therapies": {
        "recommended_combinations": ["Folic Acid", "Biologics (e.g., TNF inhibitors)"],
        "cautions": ["Increased risk of infections"]
    },
    "contraindications": ["Pregnancy", "Severe Liver Disease", "Alcoholism"],
    "precautions": ["Monitor for signs of infection", "Avoid in severe renal impairment"],
    "side_effects": ["Nausea", "Fatigue", "Mouth Sores"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Vomiting", "Hematologic Toxicity"],
        "treatment": ["Leucovorin Rescue", "Supportive Care"]
    },
    "notes": "Methotrexate is marketed under various brand names, including Trexall, Rheumatrex, Otrexup, Xatmep, RediTrex, Metoject, Maxtrex, Jylamvo, Zexate, Methoblastin, Emthexat, Ebetrex, Novatrex, Methotrexate Accord, and Methotrexate Teva. It is a cornerstone treatment for rheumatoid arthritis, psoriasis, and certain cancers. Regular monitoring is critical to manage potential side effects such as hepatotoxicity and bone marrow suppression."
},
  
  {
    "iupac_name": "Recombinant Human Monoclonal Antibody",
    "chemical_formula": "C6428H9912N1694O1987S46",
    "brand_names": [
        "Humira",
        "Amgevita",
        "Hyrimoz",
        "Idacio",
        "Imraldi",
        "Abrilada",
        "Cyltezo",
        "Hadlima",
        "Yuflyma",
        "Adalirel",
        "Exemptia",
        "Adfrar",
        "Torlan",
        "Adaly"
    ],
    "category": "Biologic DMARD (Tumor Necrosis Factor-alpha Inhibitor)",
    "dosage_forms": [
        "Pre-filled Syringe",
        "Pre-filled Pen",
        "Vial for Injection"
    ],
    "strengths": [
        "40 mg/0.8 mL",
        "20 mg/0.4 mL",
        "80 mg/0.8 mL"
    ],
    "mechanism_of_action": {
        "site_of_action": "Immune System",
        "physiological_mechanism": "Binds to TNF-alpha, preventing its interaction with TNF receptors and reducing inflammation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Inhibits TNF-mediated inflammatory responses.",
            "timeframe": "Improvement in symptoms typically observed within 2-4 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "TNF-alpha Signaling Pathway",
        "key_targets": ["TNF-alpha"],
        "related_conditions": ["Rheumatoid Arthritis", "Psoriasis", "Crohn's Disease", "Ulcerative Colitis"]
    },
    "pharmacokinetics": {
        "absorption": "Subcutaneous bioavailability is approximately 64%",
        "metabolism": {
            "primary_site": "Reticuloendothelial System",
            "enzymes": ["Proteolytic Enzymes"],
            "notes": "Degraded to peptides and amino acids."
        },
        "elimination": "Cleared via reticuloendothelial system; minimal renal or hepatic involvement."
    },
    "interactions": {
        "Live Vaccines": {
            "site_of_interaction": "Systemic",
            "mechanism": "Immunosuppression",
            "effect": "Increased risk of infection",
            "recommendation": "Avoid administration of live vaccines during treatment."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (potential liver impact with combination therapies)"],
        "microbiota_effects": "Minimal direct impact reported."
    },
    "effects_on_symptoms": {
        "Autoimmune Inflammation": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces TNF-alpha activity and downstream inflammatory responses.",
            "direction": "Significant reduction in inflammation",
            "magnitude": "High",
            "timeframe": "Within 2-4 weeks"
        }
    },
    "diagnostic_conditions": {
        "Rheumatoid Arthritis": {
            "symptoms_addressed": ["Joint Pain", "Swelling", "Stiffness"],
            "therapeutic_action": "Reduces joint inflammation and prevents damage",
            "optimal_dosage": "40 mg every other week",
            "response_time": "2-4 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Injection Site Reactions", "Headache", "Nausea"],
        "moderate": ["Upper Respiratory Infections", "Rash", "Fatigue"],
        "severe": ["Serious Infections", "Lymphoma", "Demyelinating Disease"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Liver Function Tests", "Tuberculosis Screening"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight and indication.",
            "rationale": "Higher metabolic rate and immune variability in children."
        }
    },
    "alternative_therapies": ["Etanercept", "Infliximab"],
    "combination_therapies": {
        "recommended_combinations": ["Methotrexate", "NSAIDs"],
        "cautions": ["Increased risk of infections"]
    },
    "contraindications": ["Active Tuberculosis", "Severe Infections", "Allergy to adalimumab"],
    "precautions": ["Monitor for infections", "Avoid in demyelinating disorders"],
    "side_effects": ["Injection Site Reactions", "Headache", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Exaggerated immunosuppression", "Infections"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Adalimumab is marketed under various brand names, including Humira, Amgevita, Hyrimoz, Idacio, Imraldi, Abrilada, Cyltezo, Hadlima, Yuflyma, Adalirel, Exemptia, Adfrar, Torlan, and Adaly. It is a cornerstone therapy for multiple autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. Long-term use requires regular monitoring for infections and potential side effects such as hepatotoxicity and demyelinating disorders."
},
  
  {
    "iupac_name": "(2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one",
    "chemical_formula": "C38H72N2O12",
    "brand_names": [
        "Zithromax",
        "Azithrocin",
        "Zmax",
        "Azax",
        "Azipro",
        "Azee",
        "Zithrox",
        "Sumamed",
        "Azomax",
        "Azimed",
        "Zpack",
        "Azimac",
        "Azithral",
        "Zeto",
        "Macrozit"
    ],
    "category": "Macrolide Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Oral Suspension",
        "Intravenous Injection"
    ],
    "strengths": [
        "250 mg",
        "500 mg",
        "1 g",
        "200 mg/5 mL (suspension)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Ribosome",
        "physiological_mechanism": "Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bacteriostatic or bactericidal depending on concentration.",
            "timeframe": "Activity begins within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Protein Synthesis Inhibition",
        "key_targets": ["50S Ribosomal Subunit"],
        "related_conditions": ["Respiratory Infections", "Skin Infections", "Sexually Transmitted Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with peak plasma concentrations in 2-3 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Partially metabolized with a long tissue half-life."
        },
        "elimination": "Primarily excreted via bile; minimal renal clearance."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Reduces absorption",
            "effect": "Decreased efficacy",
            "recommendation": "Separate dosing by at least 2 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may enhance gastrointestinal side effects)"],
        "microbiota_effects": "Can cause temporary gut dysbiosis."
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "Within 24-48 hours"
        }
    },
    "diagnostic_conditions": {
        "Respiratory Tract Infections": {
            "symptoms_addressed": ["Cough", "Fever", "Sore Throat"],
            "therapeutic_action": "Eliminates bacterial infection",
            "optimal_dosage": "500 mg on day 1, then 250 mg daily for 4 days",
            "response_time": "2-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Abdominal Pain"],
        "moderate": ["Headache", "Rash", "Dizziness"],
        "severe": ["QT Prolongation", "Hepatotoxicity", "Severe Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "As clinically indicated",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dose based on weight.",
            "rationale": "Higher clearance rates in children."
        }
    },
    "alternative_therapies": ["Clarithromycin", "Doxycycline"],
    "combination_therapies": {
        "recommended_combinations": ["Amoxicillin for H. pylori eradication"],
        "cautions": ["Monitor for overlapping side effects"]
    },
    "contraindications": ["Severe Liver Disease", "Known Hypersensitivity to Macrolides"],
    "precautions": ["Monitor for QT prolongation", "Caution in hepatic impairment"],
    "side_effects": ["Nausea", "Diarrhea", "Abdominal Pain"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Vomiting", "Diarrhea"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Azithromycin is marketed under various brand names, including Zithromax, Azithrocin, Zmax, Azax, Azipro, Azee, Zithrox, Sumamed, Azomax, Azimed, Zpack, Azimac, Azithral, Zeto, and Macrozit. It is widely used to treat respiratory tract infections, skin infections, and sexually transmitted infections. Azithromycin is known for its long tissue half-life, allowing for short-course therapy. Monitoring for QT prolongation is recommended in at-risk populations."
},
  
  {
    "iupac_name": "(3R,4R,5S)-4-Acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid ethyl ester",
    "chemical_formula": "C16H28N2O4",
    "brand_names": [
        "Tamiflu",
        "Fluvirin",
        "Flumivir",
        "Natflu",
        "Osel",
        "Antiflu",
        "Oseltamivir Bluefish",
        "Tamiflu-Zydus",
        "Oscivin",
        "Zeflurex",
        "Oselta",
        "Tamiflu Hetero",
        "Oseltamivir Medreich",
        "Flutotal",
        "Viraflu"
    ],
    "category": "Antiviral Agent (Neuraminidase Inhibitor)",
    "dosage_forms": [
        "Capsules",
        "Oral Suspension"
    ],
    "strengths": [
        "30 mg",
        "45 mg",
        "75 mg",
        "6 mg/mL (suspension)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Viral Neuraminidase Enzyme",
        "physiological_mechanism": "Inhibits neuraminidase, preventing the release of new viral particles from infected cells."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Reduces viral replication and spread.",
            "timeframe": "Within 24-48 hours of initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Neuraminidase Inhibition Pathway",
        "key_targets": ["Viral Neuraminidase"],
        "related_conditions": ["Influenza A", "Influenza B"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral bioavailability of ~75%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Carboxylesterase"],
            "notes": "Converted to active metabolite oseltamivir carboxylate."
        },
        "elimination": "Primarily excreted unchanged via kidneys (~99%)."
    },
    "interactions": {
        "Probenecid": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Inhibits renal excretion",
            "effect": "Increased levels of oseltamivir carboxylate",
            "recommendation": "Monitor for enhanced effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may enhance dizziness or nausea)"]
    },
    "effects_on_symptoms": {
        "Influenza Symptoms": {
            "site_of_effect": "Systemic",
            "mechanism": "Inhibits viral replication, reducing symptom severity and duration.",
            "direction": "Reduction in symptom duration",
            "magnitude": "1-2 days shorter illness duration",
            "timeframe": "Within 48 hours of initiation"
        }
    },
    "diagnostic_conditions": {
        "Influenza": {
            "symptoms_addressed": ["Fever", "Cough", "Muscle Aches"],
            "therapeutic_action": "Reduces severity and duration of illness",
            "optimal_dosage": "75 mg twice daily for 5 days",
            "response_time": "1-2 days for symptom relief"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Headache"],
        "moderate": ["Abdominal Pain", "Fatigue"],
        "severe": ["Neuropsychiatric Events", "Serious Skin Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function"],
        "frequency": "As clinically indicated",
        "clinical_thresholds": {
            "normal_range": {
                "Renal Function Tests": "Within normal limits"
            },
            "alert_threshold": {
                "Renal Function Tests": "Significant deviation from normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Higher sensitivity in children."
        }
    },
    "alternative_therapies": ["Zanamivir", "Peramivir"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Severe Renal Impairment", "Known Hypersensitivity to Oseltamivir"],
    "precautions": ["Monitor for neuropsychiatric events", "Caution in renal impairment"],
    "side_effects": ["Nausea", "Vomiting", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Dizziness", "Confusion"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Oseltamivir is marketed under various brand names, including Tamiflu, Fluvirin, Flumivir, Natflu, Osel, Antiflu, Oseltamivir Bluefish, Tamiflu-Zydus, Oscivin, Zeflurex, Oselta, Tamiflu Hetero, Oseltamivir Medreich, Flutotal, and Viraflu. It is a widely used antiviral for the treatment and prevention of influenza A and B. Early initiation within 48 hours of symptom onset is critical for optimal efficacy. Monitoring for neuropsychiatric side effects is recommended in at-risk populations."
},
  
  {
    "iupac_name": "(RS)-2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol",
    "chemical_formula": "C18H26ClN3O",
    "brand_names": [
        "Plaquenil",
        "Quineprox",
        "Hydroquin",
        "Axemal",
        "Dolquine",
        "Quensyl",
        "Hidroxicloroquina Aristo",
        "Oxaquine",
        "Hydroxychloroquine Winthrop",
        "Malarex",
        "Imprins",
        "Resochin",
        "Hydroquinone",
        "Q-Pro",
        "Hydroxychloroquine Teva"
    ],
    "category": "Antimalarial, Immunomodulator",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "200 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Lysosomes in Immune Cells",
        "physiological_mechanism": "Inhibits lysosomal activity and autophagy, reducing immune response. Also raises lysosomal pH to interfere with antigen processing."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Reduces inflammatory response in autoimmune diseases.",
            "timeframe": "Effects observed within weeks of therapy."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Autophagy and Immune Modulation",
        "key_targets": ["Lysosomes", "Toll-like Receptors"],
        "related_conditions": ["Rheumatoid Arthritis", "Systemic Lupus Erythematosus", "Malaria"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~74%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4", "CYP2D6"],
            "notes": "Metabolized to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~50-60%) and feces."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Reduces absorption",
            "effect": "Decreased efficacy",
            "recommendation": "Separate doses by at least 4 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased risk of liver toxicity)"]
    },
    "effects_on_symptoms": {
        "Autoimmune Inflammation": {
            "site_of_effect": "Systemic",
            "mechanism": "Modulates immune system activity to reduce inflammation.",
            "direction": "Reduction in inflammatory symptoms",
            "magnitude": "Moderate to significant",
            "timeframe": "Within 4-6 weeks"
        }
    },
    "diagnostic_conditions": {
        "Rheumatoid Arthritis": {
            "symptoms_addressed": ["Joint Pain", "Swelling", "Stiffness"],
            "therapeutic_action": "Reduces inflammation and slows disease progression",
            "optimal_dosage": "200-400 mg daily",
            "response_time": "4-6 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Dizziness", "Headache"],
        "moderate": ["Skin Rash", "Photosensitivity"],
        "severe": ["Retinal Toxicity", "Severe Hypersensitivity Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Ophthalmologic Examination", "Liver Function Tests"],
        "frequency": "Every 6-12 months",
        "clinical_thresholds": {
            "normal_range": {
                "Retinal Exam": "No signs of retinopathy"
            },
            "alert_threshold": {
                "Retinal Exam": "Evidence of macular damage"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Monitor closely for retinal toxicity.",
            "rationale": "Increased risk of accumulation and adverse effects."
        }
    },
    "alternative_therapies": ["Methotrexate", "Biologic DMARDs"],
    "combination_therapies": {
        "recommended_combinations": ["Methotrexate", "Corticosteroids"],
        "cautions": ["Increased risk of immunosuppression"]
    },
    "contraindications": ["Retinal Disease", "Severe Hepatic or Renal Impairment"],
    "precautions": ["Monitor for visual disturbances", "Avoid in G6PD deficiency"],
    "side_effects": ["Nausea", "Dizziness", "Photosensitivity"],
    "overdose_management": {
        "symptoms": ["Severe Vomiting", "Hypokalemia", "Seizures"],
        "treatment": ["Activated Charcoal", "Supportive Care"]
    },
    "notes": "Hydroxychloroquine is marketed under various brand names, including Plaquenil, Quineprox, Hydroquin, Axemal, Dolquine, Quensyl, Hidroxicloroquina Aristo, Oxaquine, Hydroxychloroquine Winthrop, Malarex, Imprins, Resochin, Hydroquinone, Q-Pro, and Hydroxychloroquine Teva. It is widely used for autoimmune conditions like rheumatoid arthritis and lupus, as well as for malaria prevention and treatment. Long-term use requires monitoring for retinal toxicity and liver function."
},
  {
    "iupac_name": "(Z)-2-[4-[(1,2-Diphenylbut-1-en-1-yl)phenoxy]ethylamino]ethanol",
    "chemical_formula": "C26H29NO",
    "brand_names": [
        "Nolvadex",
        "Soltamox",
        "Tamofen",
        "Tamizam",
        "Taxifen",
        "Tamox",
        "Valodex",
        "Bikalen",
        "Oncomox",
        "Istubal",
        "Noltam",
        "Tamoplex",
        "Genox",
        "Novofen",
        "Tamosin"
    ],
    "category": "Selective Estrogen Receptor Modulator (SERM)",
    "dosage_forms": [
        "Tablets",
        "Oral Solution"
    ],
    "strengths": [
        "10 mg",
        "20 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Estrogen Receptors",
        "physiological_mechanism": "Binds to estrogen receptors, inhibiting estrogen-mediated signaling in breast tissue."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Endocrine System",
            "effect": "Reduces estrogen-stimulated growth in estrogen receptor-positive breast cancer.",
            "timeframe": "Effects observed within weeks to months of therapy initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Estrogen Receptor Signaling Inhibition",
        "key_targets": ["Estrogen Receptors"],
        "related_conditions": ["Breast Cancer", "Gynecomastia"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~100%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6", "CYP3A4"],
            "notes": "Metabolized to active metabolites, including endoxifen."
        },
        "elimination": "Primarily excreted via feces (~65%) and urine (~35%)."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of metabolism",
            "effect": "Increased anticoagulant effect",
            "recommendation": "Monitor INR closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase liver toxicity risk)"]
    },
    "effects_on_symptoms": {
        "Breast Cancer Symptoms": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces estrogen-driven tumor growth.",
            "direction": "Reduction in tumor size and disease progression",
            "magnitude": "Significant",
            "timeframe": "Within months of therapy initiation"
        }
    },
    "diagnostic_conditions": {
        "Breast Cancer": {
            "symptoms_addressed": ["Lump in Breast", "Breast Pain"],
            "therapeutic_action": "Inhibits tumor progression",
            "optimal_dosage": "20 mg daily",
            "response_time": "Weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Hot Flashes", "Nausea", "Fatigue"],
        "moderate": ["Weight Gain", "Mood Changes", "Leg Cramps"],
        "severe": ["Venous Thromboembolism", "Endometrial Cancer", "Severe Hepatotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Endometrial Ultrasound"],
        "frequency": "Every 6-12 months",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not typically indicated in children.",
            "rationale": "Limited data on safety and efficacy."
        }
    },
    "alternative_therapies": ["Aromatase Inhibitors", "Fulvestrant"],
    "combination_therapies": {
        "recommended_combinations": ["Chemotherapy", "Radiotherapy"],
        "cautions": ["Monitor for additive side effects"]
    },
    "contraindications": ["Pregnancy", "History of Deep Vein Thrombosis"],
    "precautions": ["Monitor for thromboembolic events", "Caution in hepatic impairment"],
    "side_effects": ["Hot Flashes", "Nausea", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Vomiting", "Dizziness"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Tamoxifen is marketed under various brand names, including Nolvadex, Soltamox, Tamofen, Tamizam, Taxifen, Tamox, Valodex, Bikalen, Oncomox, Istubal, Noltam, Tamoplex, Genox, Novofen, and Tamosin. It is widely used for the treatment and prevention of estrogen receptor-positive breast cancer. Regular monitoring is essential to manage risks such as thromboembolic events and endometrial changes."
},
  {
    "iupac_name": "4-((4-Methylpiperazin-1-yl)methyl)-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide",
    "chemical_formula": "C29H31N7O",
    "brand_names": [
        "Gleevec",
        "Glivec",
        "Imatib",
        "Imatinib Accord",
        "Imanix",
        "Imavec",
        "Imatib Hexal",
        "Imadiv",
        "Aptivus",
        "Zynovate",
        "Leukeran",
        "Matenib",
        "Imatinib Meda",
        "Imatinib Teva",
        "Intas Imatinib"
    ],
    "category": "Tyrosine Kinase Inhibitor (Antineoplastic Agent)",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "100 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Tyrosine Kinases in Cancer Cells",
        "physiological_mechanism": "Inhibits BCR-ABL tyrosine kinase, blocking proliferation of cancer cells."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematological System",
            "effect": "Prevents uncontrolled cell division in leukemia.",
            "timeframe": "Effects observed within weeks of therapy initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "BCR-ABL Signal Transduction",
        "key_targets": ["BCR-ABL Kinase", "KIT", "PDGF Receptors"],
        "related_conditions": ["Chronic Myeloid Leukemia (CML)", "Gastrointestinal Stromal Tumors (GIST)"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~98%",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4", "CYP2C9"],
            "notes": "Metabolized to active metabolite N-desmethyl imatinib."
        },
        "elimination": "Primarily excreted via feces (~68%) and urine (~13%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibits metabolism",
            "effect": "Increased levels of imatinib",
            "recommendation": "Monitor for enhanced effects or toxicity."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (increased liver toxicity risk)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Leukemia Symptoms": {
            "site_of_effect": "Bone Marrow",
            "mechanism": "Inhibits proliferation of leukemic cells.",
            "direction": "Reduction in abnormal cell counts",
            "magnitude": "Significant",
            "timeframe": "Within weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Chronic Myeloid Leukemia": {
            "symptoms_addressed": ["Fatigue", "Night Sweats", "Weight Loss"],
            "therapeutic_action": "Slows disease progression and reduces cell proliferation",
            "optimal_dosage": "400 mg daily",
            "response_time": "2-4 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Fatigue"],
        "moderate": ["Edema", "Rash", "Muscle Cramps"],
        "severe": ["Hepatotoxicity", "Severe Myelosuppression", "Cardiotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Liver Function Tests", "Renal Function Tests"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "White Blood Cell Count": "4,000-11,000 cells/uL"
            },
            "alert_threshold": {
                "White Blood Cell Count": "<2,000 cells/uL"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on body surface area.",
            "rationale": "Higher metabolic rates in children."
        }
    },
    "alternative_therapies": ["Dasatinib", "Nilotinib"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Monitor for overlapping toxicities"]
    },
    "contraindications": ["Severe Liver Dysfunction", "Known Hypersensitivity to Imatinib"],
    "precautions": ["Monitor for fluid retention", "Caution in cardiac dysfunction"],
    "side_effects": ["Nausea", "Fatigue", "Rash"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Vomiting", "Confusion"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Imatinib is marketed under various brand names, including Gleevec, Glivec, Imatib, Imatinib Accord, Imanix, Imavec, Imatib Hexal, Imadiv, Aptivus, Zynovate, Leukeran, Matenib, Imatinib Meda, Imatinib Teva, and Intas Imatinib. It is a first-line treatment for chronic myeloid leukemia and gastrointestinal stromal tumors. Regular monitoring of blood counts and liver function is essential to minimize adverse effects."
},
  
  {
    "iupac_name": "(4R,4aS,7aR,12bS)-3-[(Cyclopropylmethyl)amino]-4,10-dihydroxy-1,2,4a,5,6,7a-hexahydro-12H-[1]benzofuro[3,2-e]isoquinolin-9-one",
    "chemical_formula": "C19H21NO4",
    "brand_names": [
        "Narcan",
        "Evzio",
        "Prenoxad",
        "Kloxxado",
        "Zimhi",
        "Naloxone Hydrochloride Injection",
        "Nalone",
        "Intranasal Naloxone",
        "Nalox",
        "Narcan Nasal Spray",
        "Naloxone Amphastar",
        "Naloxone Adamis",
        "Naloxone Teva",
        "Naloxone Mylan",
        "Naloxone Hikma"
    ],
    "category": "Opioid Antagonist",
    "dosage_forms": [
        "Intramuscular Injection",
        "Intravenous Injection",
        "Intranasal Spray",
        "Subcutaneous Injection"
    ],
    "strengths": [
        "0.4 mg/mL",
        "1 mg/mL",
        "4 mg (nasal spray)",
        "8 mg (nasal spray)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Opioid Receptors in the Central Nervous System",
        "physiological_mechanism": "Competes with and displaces opioids at the receptor sites, reversing respiratory depression caused by opioid overdose."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Central Nervous System",
            "effect": "Rapid reversal of opioid-induced respiratory depression.",
            "timeframe": "Effects observed within 2-5 minutes of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Opioid Receptor Antagonism",
        "key_targets": ["Mu-opioid Receptor", "Kappa-opioid Receptor", "Delta-opioid Receptor"],
        "related_conditions": ["Opioid Overdose"]
    },
    "pharmacokinetics": {
        "absorption": "Rapid onset with intravenous administration; slower with intramuscular or subcutaneous routes.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["UGT2B7"],
            "notes": "Extensively metabolized to naloxone-3-glucuronide."
        },
        "elimination": "Primarily excreted via urine (~60-70%)."
    },
    "interactions": {
        "Opioid Analgesics": {
            "site_of_interaction": "Opioid Receptors",
            "mechanism": "Competitive displacement",
            "effect": "Reversal of opioid effects",
            "recommendation": "Monitor for re-sedation due to short half-life of naloxone compared to some opioids."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may compound respiratory depression in overdose scenarios)"]
    },
    "effects_on_symptoms": {
        "Opioid Overdose Symptoms": {
            "site_of_effect": "Central Nervous System",
            "mechanism": "Reverses opioid receptor activation.",
            "direction": "Restores respiratory function",
            "magnitude": "Significant",
            "timeframe": "Within minutes"
        }
    },
    "diagnostic_conditions": {
        "Opioid Overdose": {
            "symptoms_addressed": ["Respiratory Depression", "Unconsciousness", "Pinpoint Pupils"],
            "therapeutic_action": "Reverses opioid toxicity",
            "optimal_dosage": "0.4-2 mg intravenously or intramuscularly, repeat every 2-3 minutes as needed",
            "response_time": "Immediate"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Sweating"],
        "moderate": ["Tachycardia", "Agitation", "Hypertension"],
        "severe": ["Pulmonary Edema", "Severe Hypertension", "Seizures"]
    },
    "long_term_monitoring": {
        "parameters": ["Respiratory Function"],
        "frequency": "As clinically indicated during acute care",
        "clinical_thresholds": {
            "normal_range": {
                "Respiratory Rate": "12-20 breaths per minute"
            },
            "alert_threshold": {
                "Respiratory Rate": "<8 breaths per minute"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage adjusted by weight.",
            "rationale": "Different pharmacokinetics in children."
        }
    },
    "alternative_therapies": [],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Known Hypersensitivity to Naloxone"],
    "precautions": ["Monitor for withdrawal symptoms in opioid-dependent patients", "Caution in cardiovascular conditions"],
    "side_effects": ["Nausea", "Sweating", "Tachycardia"],
    "overdose_management": {
        "symptoms": ["Agitation", "Hypertension", "Seizures"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Naloxone is marketed under various brand names, including Narcan, Evzio, Prenoxad, Kloxxado, Zimhi, Naloxone Hydrochloride Injection, Nalone, Intranasal Naloxone, Nalox, Narcan Nasal Spray, Naloxone Amphastar, Naloxone Adamis, Naloxone Teva, Naloxone Mylan, and Naloxone Hikma. It is a life-saving opioid antagonist used in emergency settings to rapidly reverse opioid overdose. Due to its short half-life, repeated dosing may be required for longer-acting opioids. Monitoring is essential during acute care to prevent re-sedation or withdrawal symptoms in opioid-dependent individuals."
},
  
  {
    "iupac_name": "1-(Diethylthiocarbamoyldisulfanyl)-N,N-diethylmethanethioamide",
    "chemical_formula": "C10H20N2S4",
    "brand_names": [
        "Antabuse",
        "Antabus",
        "Disulfiram Teva",
        "Esperal",
        "Anticol",
        "Refusal",
        "Disulfiram Accord",
        "Disulphur",
        "Stopetyl",
        "Abstinyl",
        "Antipol",
        "Nozinan",
        "Alkophobin",
        "Sulfiram",
        "Teturam"
    ],
    "category": "Alcohol Deterrent",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "250 mg",
        "500 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver Enzymes",
        "physiological_mechanism": "Inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol consumption, leading to unpleasant effects."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Metabolic System",
            "effect": "Prevents metabolism of acetaldehyde, causing adverse reactions when alcohol is consumed.",
            "timeframe": "Effects occur within 10-30 minutes of alcohol ingestion."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Ethanol Metabolism Pathway",
        "key_targets": ["Aldehyde Dehydrogenase"],
        "related_conditions": ["Alcohol Dependence"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed orally with peak plasma concentrations in 8-12 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Cytochrome P450"],
            "notes": "Metabolized to diethyldithiocarbamate, an active metabolite."
        },
        "elimination": "Primarily excreted via urine as metabolites."
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibition of aldehyde dehydrogenase",
            "effect": "Severe adverse reactions",
            "recommendation": "Strictly avoid alcohol while on disulfiram."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (causes severe reactions when consumed)"],
        "microbiota_effects": "Minimal impact reported."
    },
    "effects_on_symptoms": {
        "Alcohol Dependence": {
            "site_of_effect": "Systemic",
            "mechanism": "Deters alcohol consumption by inducing unpleasant effects.",
            "direction": "Reduction in alcohol intake",
            "magnitude": "Significant",
            "timeframe": "Immediate upon alcohol ingestion"
        }
    },
    "diagnostic_conditions": {
        "Alcohol Use Disorder": {
            "symptoms_addressed": ["Compulsive Drinking", "Inability to Abstain"],
            "therapeutic_action": "Prevents alcohol consumption",
            "optimal_dosage": "250-500 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Drowsiness", "Fatigue", "Headache"],
        "moderate": ["Skin Rash", "Metallic Taste", "Mild Hepatotoxicity"],
        "severe": ["Severe Hepatotoxicity", "Peripheral Neuropathy", "Psychosis"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "Every 3-6 months",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Monitor closely for hepatotoxicity.",
            "rationale": "Increased sensitivity in older adults."
        }
    },
    "alternative_therapies": ["Naltrexone", "Acamprosate"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Severe Liver Disease", "Psychiatric Disorders"],
    "precautions": ["Monitor for hepatotoxicity", "Avoid in severe cardiac disease"],
    "side_effects": ["Drowsiness", "Metallic Taste", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Severe Hepatotoxicity"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Disulfiram is marketed under various brand names, including Antabuse, Antabus, Disulfiram Teva, Esperal, Anticol, Refusal, Disulfiram Accord, Disulphur, Stopetyl, Abstinyl, Antipol, Nozinan, Alkophobin, Sulfiram, and Teturam. It is a well-established therapy for alcohol dependence, providing a deterrent effect by causing severe reactions upon alcohol ingestion. Regular monitoring of liver function is essential to ensure safety during long-term use."
},
  {
    "iupac_name": "(2S,5R,6R)-6-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",
    "chemical_formula": "C16H19N3O5S",
    "brand_names": [
        "Amoxil",
        "Augmentin",
        "Moxatag",
        "Trimox",
        "Clavulin",
        "Co-Amoxiclav",
        "Amoclav",
        "Amopen",
        "Amoclan",
        "Curam",
        "Hiconcil",
        "Augmentin ES",
        "Amoxil Forte",
        "Moxilin",
        "Amoxiclav"
    ],
    "category": "Penicillin Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Oral Suspension",
        "Chewable Tablets",
        "Intravenous Injection"
    ],
    "strengths": [
        "125 mg",
        "250 mg",
        "500 mg",
        "875 mg",
        "1000 mg",
        "400 mg/5 mL (suspension)",
        "600 mg/42.9 mg (Augmentin ES)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Cell Wall",
        "physiological_mechanism": "Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bactericidal action against susceptible bacteria.",
            "timeframe": "Starts within 1-2 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cell Wall Synthesis Inhibition",
        "key_targets": ["Penicillin-Binding Proteins"],
        "related_conditions": ["Respiratory Infections", "Skin Infections", "Urinary Tract Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally; bioavailability ~70%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Excreted via kidneys (~60-70%)."
    },
    "interactions": {
        "Allopurinol": {
            "site_of_interaction": "Systemic",
            "mechanism": "Increased risk of rash",
            "effect": "Hypersensitivity reaction",
            "recommendation": "Monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (minimal interaction, but may worsen side effects like nausea)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "2-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Respiratory Infections": {
            "symptoms_addressed": ["Cough", "Fever", "Sore Throat"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "500 mg every 8 hours or 875 mg every 12 hours",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Abdominal Pain"],
        "moderate": ["Rash", "Yeast Infections"],
        "severe": ["Anaphylaxis", "Stevens-Johnson Syndrome", "Clostridioides difficile Infection"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Renal Function": "Within normal limits"
            },
            "alert_threshold": {
                "Renal Function": "Significant deviation from baseline"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Higher clearance rates in children."
        }
    },
    "alternative_therapies": ["Cefuroxime", "Clindamycin"],
    "combination_therapies": {
        "recommended_combinations": ["Clavulanate for beta-lactamase-producing bacteria"],
        "cautions": ["Monitor for additive side effects"]
    },
    "contraindications": ["Severe Hypersensitivity to Penicillins", "History of Severe Allergic Reactions"],
    "precautions": ["Monitor for rash or hypersensitivity", "Caution in renal impairment"],
    "side_effects": ["Nausea", "Diarrhea", "Rash"],
    "overdose_management": {
        "symptoms": ["Nausea", "Seizures", "Renal Dysfunction"],
        "treatment": ["Supportive Care", "Hemodialysis in severe cases"]
    },
    "notes": "Amoxicillin and its combinations, such as Amoxicillin-Clavulanate, are marketed under various brand names, including Amoxil, Augmentin, Moxatag, Trimox, Clavulin, Co-Amoxiclav, Amoclav, Amopen, Amoclan, Curam, Hiconcil, Augmentin ES, Amoxil Forte, Moxilin, and Amoxiclav. They are widely used to treat bacterial infections ranging from respiratory to skin and urinary tract infections. Clavulanate enhances efficacy against beta-lactamase-producing bacteria. Regular monitoring is essential in patients with renal impairment to prevent accumulation and toxicity."
},
  
  {
    "iupac_name": "1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid",
    "chemical_formula": "C17H18FN3O3",
    "brand_names": [
        "Cipro",
        "Ciproflox",
        "Cetraxal",
        "Ciloxan",
        "Proquin XR",
        "Ciprolon",
        "Ciflox",
        "Ciproxin",
        "Cifran",
        "Baycip",
        "Ciprolet",
        "Quintor",
        "Ciprodar",
        "Zoxan",
        "Cipromed"
    ],
    "category": "Fluoroquinolone Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Oral Suspension",
        "Intravenous Injection",
        "Ophthalmic Drops",
        "Otic Solution"
    ],
    "strengths": [
        "250 mg",
        "500 mg",
        "750 mg",
        "100 mg/50 mL (IV)",
        "200 mg/100 mL (IV)",
        "0.3% (ophthalmic/otic solutions)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial DNA Gyrase and Topoisomerase IV",
        "physiological_mechanism": "Inhibits bacterial DNA replication, transcription, repair, and recombination by targeting DNA gyrase and topoisomerase IV."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bactericidal action against gram-positive and gram-negative bacteria.",
            "timeframe": "Starts within 1-2 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "DNA Replication Inhibition",
        "key_targets": ["DNA Gyrase", "Topoisomerase IV"],
        "related_conditions": ["Respiratory Infections", "Urinary Tract Infections", "Gastrointestinal Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability ~70%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP1A2"],
            "notes": "Metabolized to four metabolites with limited activity."
        },
        "elimination": "Primarily excreted unchanged in urine (~40-50%)."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Reduces absorption due to chelation with multivalent cations",
            "effect": "Decreased efficacy",
            "recommendation": "Separate dosing by at least 2 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may exacerbate side effects like dizziness)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "2-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Urinary Tract Infections": {
            "symptoms_addressed": ["Frequent Urination", "Burning Sensation", "Cloudy Urine"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "250-500 mg every 12 hours",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Headache"],
        "moderate": ["Rash", "Photosensitivity"],
        "severe": ["Tendon Rupture", "QT Prolongation", "Clostridioides difficile Infection"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Renal Function": "Within normal limits"
            },
            "alert_threshold": {
                "Renal Function": "Significant deviation from baseline"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not typically recommended due to risk of joint toxicity.",
            "rationale": "Increased susceptibility to tendon and joint damage."
        }
    },
    "alternative_therapies": ["Levofloxacin", "Nitrofurantoin"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": ["Monitor for additive side effects"]
    },
    "contraindications": ["Tendon Disorders", "Myasthenia Gravis"],
    "precautions": ["Monitor for tendon pain or rupture", "Avoid in QT prolongation"],
    "side_effects": ["Nausea", "Headache", "Photosensitivity"],
    "overdose_management": {
        "symptoms": ["Seizures", "Tremors", "Renal Impairment"],
        "treatment": ["Supportive Care", "Hemodialysis in severe cases"]
    },
    "notes": "Ciprofloxacin is marketed under various brand names, including Cipro, Ciproflox, Cetraxal, Ciloxan, Proquin XR, Ciprolon, Ciflox, Ciproxin, Cifran, Baycip, Ciprolet, Quintor, Ciprodar, Zoxan, and Cipromed. It is a broad-spectrum fluoroquinolone antibiotic effective against gram-positive and gram-negative bacteria. It is commonly used for respiratory, urinary tract, and gastrointestinal infections. Monitoring for tendon-related side effects and QT prolongation is essential, especially in at-risk populations."
},
  
  {
    "iupac_name": "2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid",
    "chemical_formula": "C14H11Cl2NO2",
    "brand_names": [
        "Voltaren",
        "Cataflam",
        "Zorvolex",
        "Dyloject",
        "Solaraze",
        "Pennsaid",
        "Flector",
        "Dicloflex",
        "Olfen",
        "Diclac",
        "Diclomax",
        "Dicloran",
        "Voveran",
        "Apo-Diclo",
        "Cambia",
        "Diclofenac"
    ],
    "category": "Nonsteroidal Anti-Inflammatory Drug (NSAID)",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Gel",
        "Patch",
        "Eye Drops",
        "Intramuscular Injection"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "75 mg",
        "100 mg",
        "1% Gel",
        "1.5% Gel"
    ],
    "mechanism_of_action": {
        "site_of_action": "Cyclooxygenase Enzymes (COX-1 and COX-2)",
        "physiological_mechanism": "Inhibits cyclooxygenase enzymes, reducing the production of prostaglandins involved in inflammation, pain, and fever."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Inflammatory System",
            "effect": "Reduces inflammation, pain, and fever.",
            "timeframe": "Effects typically observed within 30-60 minutes of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Prostaglandin Synthesis Inhibition",
        "key_targets": ["COX-1", "COX-2"],
        "related_conditions": ["Osteoarthritis", "Rheumatoid Arthritis", "Acute Pain"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with oral administration; peak plasma levels within 2-3 hours.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~65%) and bile (~35%)."
    },
    "interactions": {
        "Anticoagulants": {
            "site_of_interaction": "Blood",
            "mechanism": "Increased risk of bleeding",
            "effect": "Enhanced anticoagulant effect",
            "recommendation": "Monitor closely for signs of bleeding."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase risk of gastrointestinal bleeding)"]
    },
    "effects_on_symptoms": {
        "Pain and Inflammation": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces production of inflammatory mediators.",
            "direction": "Reduction in pain and swelling",
            "magnitude": "Moderate to significant",
            "timeframe": "Within 1 hour of administration"
        }
    },
    "diagnostic_conditions": {
        "Osteoarthritis": {
            "symptoms_addressed": ["Joint Pain", "Stiffness", "Swelling"],
            "therapeutic_action": "Relieves pain and improves joint mobility",
            "optimal_dosage": "50 mg twice daily",
            "response_time": "Days to weeks for symptom improvement"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Dizziness"],
        "moderate": ["Heartburn", "Hypertension", "Edema"],
        "severe": ["Gastrointestinal Bleeding", "Hepatotoxicity", "Renal Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Renal Function Tests", "Blood Pressure"],
        "frequency": "Every 3-6 months for long-term use",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use lowest effective dose.",
            "rationale": "Increased risk of gastrointestinal and renal side effects."
        }
    },
    "alternative_therapies": ["Ibuprofen", "Naproxen"],
    "combination_therapies": {
        "recommended_combinations": ["Proton Pump Inhibitors for GI protection"],
        "cautions": ["Monitor for additive renal effects"]
    },
    "contraindications": ["Active Peptic Ulcer Disease", "Severe Renal Impairment"],
    "precautions": ["Monitor for gastrointestinal bleeding", "Caution in hepatic impairment"],
    "side_effects": ["Nausea", "Heartburn", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Severe Nausea", "Vomiting", "Acute Renal Failure"],
        "treatment": ["Activated Charcoal", "Supportive Care"]
    },
    "notes": "Diclofenac is marketed under various brand names, including Voltaren, Cataflam, Zorvolex, Dyloject, Solaraze, Pennsaid, Flector, Dicloflex, Olfen, Diclac, Diclomax, Dicloran, Voveran, Apo-Diclo, and Cambia. It is a commonly used NSAID for the treatment of pain, inflammation, and fever. Long-term use requires monitoring for gastrointestinal, hepatic, and renal side effects, especially in elderly patients or those with pre-existing conditions."
},
  
  {
    "iupac_name": "4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide",
    "chemical_formula": "C22H24N2O8",
    "brand_names": [
        "Doxycycline",
        "Vibramycin",
        "Doryx",
        "Oracea",
        "Acticlate",
        "Monodox",
        "Adoxa",
        "Avidoxy",
        "Alodox",
        "Doxychel",
        "Periostat",
        "Apprilon",
        "Targadox",
        "Vibra-Tabs",
        "Doxytab"
    ],
    "category": "Tetracycline Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Oral Suspension",
        "Intravenous Injection"
    ],
    "strengths": [
        "20 mg",
        "50 mg",
        "75 mg",
        "100 mg",
        "150 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Ribosome",
        "physiological_mechanism": "Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bacteriostatic action against susceptible bacteria.",
            "timeframe": "Starts within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Protein Synthesis Inhibition",
        "key_targets": ["30S Ribosomal Subunit"],
        "related_conditions": ["Respiratory Infections", "Skin Infections", "Sexually Transmitted Infections", "Tick-Borne Diseases"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~90%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted in feces and urine."
        },
        "elimination": "Excreted via bile and urine (~40%)."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Chelation with divalent and trivalent cations",
            "effect": "Reduced absorption",
            "recommendation": "Separate dosing by at least 2 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may reduce serum concentrations)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "2-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Respiratory Tract Infections": {
            "symptoms_addressed": ["Cough", "Fever", "Shortness of Breath"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "100 mg twice daily",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Photosensitivity"],
        "moderate": ["Esophagitis", "Rash", "Headache"],
        "severe": ["Severe Hypersensitivity Reactions", "Hepatotoxicity", "C. difficile-Associated Diarrhea"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Renal Function Tests"],
        "frequency": "As clinically indicated for long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not recommended for children under 8 years due to risk of tooth discoloration.",
            "rationale": "Tetracyclines can affect bone and teeth development."
        }
    },
    "alternative_therapies": ["Azithromycin", "Levofloxacin"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Severe Hypersensitivity to Tetracyclines", "Pregnancy"],
    "precautions": ["Monitor for photosensitivity", "Avoid use in severe hepatic impairment"],
    "side_effects": ["Nausea", "Photosensitivity", "Esophagitis"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Acute Renal Failure"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Doxycycline is marketed under various brand names, including Doxycycline, Vibramycin, Doryx, Oracea, Acticlate, Monodox, Adoxa, Avidoxy, Alodox, Doxychel, Periostat, Apprilon, Targadox, Vibra-Tabs, and Doxytab. It is a versatile tetracycline antibiotic used for respiratory infections, skin infections, sexually transmitted infections, and tick-borne diseases. Patients should avoid excessive sunlight or UV exposure due to the risk of photosensitivity and take the medication with plenty of water to prevent esophagitis."
},
  
  {
    "iupac_name": "(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",
    "chemical_formula": "C16H17N3O4S",
    "brand_names": [
        "Cephalexin",
        "Keflex",
        "Ceporex",
        "Biocef",
        "Keftab",
        "Lupinex",
        "Novo-Lexin",
        "Rilexine",
        "Cefanox",
        "Lexin",
        "Sporidex",
        "Reflex",
        "Cephoral",
        "Zartan",
        "Ospexin"
    ],
    "category": "Cephalosporin Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Oral Suspension"
    ],
    "strengths": [
        "125 mg",
        "250 mg",
        "500 mg",
        "750 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Cell Wall",
        "physiological_mechanism": "Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bactericidal action against susceptible gram-positive and gram-negative bacteria.",
            "timeframe": "Begins within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cell Wall Synthesis Inhibition",
        "key_targets": ["Penicillin-Binding Proteins"],
        "related_conditions": ["Respiratory Tract Infections", "Skin Infections", "Urinary Tract Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~90%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Excreted via urine (~90%)."
    },
    "interactions": {
        "Probenecid": {
            "site_of_interaction": "Renal Tubules",
            "mechanism": "Inhibits renal excretion",
            "effect": "Increased plasma levels of cephalexin",
            "recommendation": "Monitor for enhanced drug effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (minimal interaction but may worsen side effects like nausea)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "1-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Respiratory Tract Infections": {
            "symptoms_addressed": ["Cough", "Fever", "Shortness of Breath"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "250-500 mg every 6-12 hours",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Dizziness"],
        "moderate": ["Rash", "Abdominal Pain"],
        "severe": ["Severe Hypersensitivity Reactions", "Clostridioides difficile Infection"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Renal Function": "Within normal limits"
            },
            "alert_threshold": {
                "Renal Function": "Significant deviation from baseline"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Higher clearance rates in children."
        }
    },
    "alternative_therapies": ["Amoxicillin", "Cefuroxime"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Severe Hypersensitivity to Cephalosporins", "Severe Renal Impairment"],
    "precautions": ["Monitor for rash or hypersensitivity", "Caution in renal impairment"],
    "side_effects": ["Nausea", "Dizziness", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Seizures"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Cephalexin is marketed under various brand names, including Cephalexin, Keflex, Ceporex, Biocef, Keftab, Lupinex, Novo-Lexin, Rilexine, Cefanox, Lexin, Sporidex, Reflex, Cephoral, Zartan, and Ospexin. It is a first-generation cephalosporin antibiotic effective against a wide range of gram-positive and some gram-negative bacteria. It is commonly used for respiratory, skin, and urinary tract infections. Patients with renal impairment should have their dosage adjusted to prevent accumulation and toxicity."
},
  
  {
    "iupac_name": "(2S,4R)-N-[(1S,2S)-2-Chloro-1-(methylthio)propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide",
    "chemical_formula": "C18H33ClN2O5S",
    "brand_names": [
        "Clindamycin",
        "Cleocin",
        "Dalacin",
        "Clindagel",
        "ClindaMax",
        "Evoclin",
        "Clindesse",
        "Clindacure",
        "Clinacin",
        "Sobelin",
        "Clinsol",
        "Clinagel",
        "Clindalin",
        "Clindamed",
        "Zindaclin"
    ],
    "category": "Lincosamide Antibiotic",
    "dosage_forms": [
        "Capsules",
        "Oral Solution",
        "Topical Gel",
        "Topical Solution",
        "Intravenous Injection",
        "Vaginal Cream"
    ],
    "strengths": [
        "75 mg",
        "150 mg",
        "300 mg",
        "600 mg",
        "1% Gel",
        "2% Vaginal Cream"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Ribosome",
        "physiological_mechanism": "Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bacteriostatic or bactericidal action depending on concentration and bacterial susceptibility.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Protein Synthesis Inhibition",
        "key_targets": ["50S Ribosomal Subunit"],
        "related_conditions": ["Skin and Soft Tissue Infections", "Respiratory Infections", "Bone and Joint Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~90%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to active and inactive metabolites."
        },
        "elimination": "Excreted via bile and urine (~10-20% as unchanged drug)."
    },
    "interactions": {
        "Neuromuscular Blockers": {
            "site_of_interaction": "Neuromuscular Junction",
            "mechanism": "May enhance neuromuscular blocking activity",
            "effect": "Increased risk of respiratory depression",
            "recommendation": "Monitor for additive effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may worsen side effects like nausea)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "1-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Skin and Soft Tissue Infections": {
            "symptoms_addressed": ["Redness", "Swelling", "Pain"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "150-450 mg every 6-8 hours",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Rash"],
        "moderate": ["Abdominal Pain", "Esophagitis"],
        "severe": ["Severe Hypersensitivity Reactions", "Clostridioides difficile Infection", "Stevens-Johnson Syndrome"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Higher clearance rates in children."
        }
    },
    "alternative_therapies": ["Metronidazole", "Doxycycline"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Severe Hypersensitivity to Lincosamides", "History of Clostridioides difficile Infection"],
    "precautions": ["Monitor for rash or hypersensitivity", "Caution in hepatic impairment"],
    "side_effects": ["Nausea", "Rash", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Severe Abdominal Pain"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Clindamycin is marketed under various brand names, including Clindamycin, Cleocin, Dalacin, Clindagel, ClindaMax, Evoclin, Clindesse, Clindacure, Clinacin, Sobelin, Clinsol, Clinagel, Clindalin, Clindamed, and Zindaclin. It is commonly used for bacterial infections such as skin and soft tissue infections, respiratory infections, and bone and joint infections. Monitoring for gastrointestinal side effects, including Clostridioides difficile infection, is essential during therapy."
},
  
  {
    "iupac_name": "(3S,6R,7R,22R,23R,26S,36R)-3-(2-Amino-2-oxoethyl)-44-[(2R)-2-amino-2-oxoethyl]-7,22-bis(2-methylpropyl)-36-(2-methylpropyl)-19-oxa-4,10,16,32,38-pentaazapentacyclo[22.14.2.2^{4,7}.1^{15,18}.0^{23,27}]octatriaconta-1(28),2,9,11,13,15(44),16,18(43),25,27(42),29,31,34,37-tetradecaene-5,6,35,39,40-pentol",
    "chemical_formula": "C66H75Cl2N9O24",
    "brand_names": [
        "Vancomycin",
        "Vancocin",
        "Firvanq",
        "Vancor",
        "Vancoled",
        "Vancodex",
        "Medivanco",
        "Vancogalen",
        "Lyphocin",
        "Edicin",
        "Targocid",
        "Avercin",
        "Vancomed",
        "Anecomycin",
        "Diavanc"
    ],
    "category": "Glycopeptide Antibiotic",
    "dosage_forms": [
        "Capsules",
        "Intravenous Injection",
        "Oral Solution"
    ],
    "strengths": [
        "125 mg",
        "250 mg",
        "500 mg",
        "1 g",
        "5 g (IV Powder)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial Cell Wall",
        "physiological_mechanism": "Inhibits bacterial cell wall synthesis by binding to D-alanyl-D-alanine termini of peptidoglycan precursors, preventing cell wall cross-linking."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bactericidal against gram-positive bacteria.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Cell Wall Synthesis Inhibition",
        "key_targets": ["Peptidoglycan Precursors"],
        "related_conditions": ["Sepsis", "Endocarditis", "Clostridioides difficile Infection"]
    },
    "pharmacokinetics": {
        "absorption": "Poorly absorbed orally; effective only for infections in the gastrointestinal tract when taken orally.",
        "metabolism": {
            "primary_site": "Minimal metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Excreted via urine (~80-90% unchanged)."
    },
    "interactions": {
        "Aminoglycosides": {
            "site_of_interaction": "Kidneys",
            "mechanism": "Increased nephrotoxicity risk",
            "effect": "Enhanced renal toxicity",
            "recommendation": "Monitor renal function closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may exacerbate nephrotoxic effects)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "1-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Sepsis": {
            "symptoms_addressed": ["Fever", "Low Blood Pressure", "Rapid Heart Rate"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "15-20 mg/kg every 8-12 hours",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Rash", "Hypotension"],
        "moderate": ["Red Man Syndrome", "Phlebitis"],
        "severe": ["Nephrotoxicity", "Ototoxicity", "Anaphylaxis"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function Tests", "Serum Vancomycin Levels"],
        "frequency": "Weekly for long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Trough Levels": "15-20 mcg/mL"
            },
            "alert_threshold": {
                "Trough Levels": ">20 mcg/mL"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Higher clearance rates in children."
        }
    },
    "alternative_therapies": ["Linezolid", "Daptomycin"],
    "combination_therapies": {
        "recommended_combinations": ["With Aminoglycosides for synergistic effects"],
        "cautions": ["Increased nephrotoxicity risk"]
    },
    "contraindications": ["Severe Hypersensitivity to Vancomycin"],
    "precautions": ["Monitor for nephrotoxicity", "Monitor infusion rate to prevent Red Man Syndrome"],
    "side_effects": ["Nausea", "Rash", "Phlebitis"],
    "overdose_management": {
        "symptoms": ["Severe Nephrotoxicity", "Hearing Loss", "Hypotension"],
        "treatment": ["Supportive Care", "Hemodialysis"]
    },
    "notes": "Vancomycin is marketed under various brand names, including Vancomycin, Vancocin, Firvanq, Vancor, Vancoled, Vancodex, Medivanco, Vancogalen, Lyphocin, Edicin, Targocid, Avercin, Vancomed, Anecomycin, and Diavanc. It is a potent glycopeptide antibiotic primarily used for severe gram-positive infections, including MRSA and C. difficile. Monitoring serum vancomycin levels and renal function is crucial during therapy to prevent toxicity."
},
  
  {
    "iupac_name": "1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole",
    "chemical_formula": "C6H9N3O3",
    "brand_names": [
        "Metronidazole",
        "Flagyl",
        "Metrogel",
        "Noritate",
        "Nidagel",
        "Rozex",
        "Anabact",
        "Metrolotion",
        "Protostat",
        "Metrocream",
        "Trikacide",
        "Helicol",
        "Clont",
        "Arilin",
        "Efloran"
    ],
    "category": "Nitroimidazole Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Intravenous Injection",
        "Topical Gel",
        "Topical Cream",
        "Vaginal Gel"
    ],
    "strengths": [
        "250 mg",
        "500 mg",
        "0.75% Gel",
        "1% Gel"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial and Protozoal DNA",
        "physiological_mechanism": "Forms reactive nitro radicals that damage microbial DNA, leading to cell death."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial and Protozoal Inhibition",
            "effect": "Bactericidal and antiprotozoal action against susceptible organisms.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "DNA Damage and Inhibition",
        "key_targets": ["Microbial DNA"],
        "related_conditions": ["Anaerobic Bacterial Infections", "Protozoal Infections", "Clostridioides difficile Infection"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~99%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2A6"],
            "notes": "Metabolized to active hydroxyl and acid metabolites."
        },
        "elimination": "Primarily excreted via urine (~60-80%)."
    },
    "interactions": {
        "Alcohol": {
            "site_of_interaction": "Systemic",
            "mechanism": "Inhibits aldehyde dehydrogenase",
            "effect": "Causes disulfiram-like reaction",
            "recommendation": "Avoid alcohol during and up to 48 hours after treatment."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (causes severe adverse reactions when consumed)"]
    },
    "effects_on_symptoms": {
        "Bacterial and Protozoal Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates microbial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "1-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Anaerobic Infections": {
            "symptoms_addressed": ["Fever", "Pain", "Swelling"],
            "therapeutic_action": "Eradicates infection",
            "optimal_dosage": "500 mg every 8 hours",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Metallic Taste"],
        "moderate": ["Rash", "Dizziness"],
        "severe": ["Peripheral Neuropathy", "Seizures", "Severe Hypersensitivity Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Liver Enzymes": "Within normal limits"
            },
            "alert_threshold": {
                "Liver Enzymes": ">2x upper limit of normal"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Dosage based on weight.",
            "rationale": "Adjusted clearance in pediatric populations."
        }
    },
    "alternative_therapies": ["Tinidazole", "Clindamycin"],
    "combination_therapies": {
        "recommended_combinations": ["With Vancomycin for severe C. difficile infections"],
        "cautions": []
    },
    "contraindications": ["Severe Hypersensitivity to Metronidazole"],
    "precautions": ["Avoid prolonged use due to neuropathy risk", "Caution in hepatic impairment"],
    "side_effects": ["Nausea", "Metallic Taste", "Rash"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Seizures"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Metronidazole is marketed under various brand names, including Metronidazole, Flagyl, Metrogel, Noritate, Nidagel, Rozex, Anabact, Metrolotion, Protostat, Metrocream, Trikacide, Helicol, Clont, Arilin, and Efloran. It is effective against anaerobic bacteria and protozoa and is commonly used for conditions like bacterial vaginosis, C. difficile infection, and trichomoniasis. Patients should avoid alcohol during treatment due to the risk of a disulfiram-like reaction."
},
  
  {
    "iupac_name": "(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid",
    "chemical_formula": "C18H20FN3O4",
    "brand_names": [
        "Levofloxacin",
        "Levaquin",
        "Tavanic",
        "Levoday",
        "Levobact",
        "Quixin",
        "Levox",
        "Ocu-Lev",
        "L-Flox",
        "Levocin",
        "Lquin",
        "Levogen",
        "Levoflox",
        "Levokast",
        "Oflevo"
    ],
    "category": "Fluoroquinolone Antibiotic",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Intravenous Injection",
        "Ophthalmic Solution"
    ],
    "strengths": [
        "250 mg",
        "500 mg",
        "750 mg",
        "0.5% Solution"
    ],
    "mechanism_of_action": {
        "site_of_action": "Bacterial DNA Gyrase and Topoisomerase IV",
        "physiological_mechanism": "Inhibits bacterial DNA replication, transcription, repair, and recombination by targeting DNA gyrase and topoisomerase IV."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Bacterial Inhibition",
            "effect": "Bactericidal action against gram-positive and gram-negative bacteria.",
            "timeframe": "Starts within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "DNA Replication Inhibition",
        "key_targets": ["DNA Gyrase", "Topoisomerase IV"],
        "related_conditions": ["Respiratory Infections", "Urinary Tract Infections", "Skin Infections"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed orally with bioavailability of ~99%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Minimal hepatic metabolism."
        },
        "elimination": "Primarily excreted unchanged in urine (~87%)."
    },
    "interactions": {
        "Antacids": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Chelation with multivalent cations",
            "effect": "Reduced absorption",
            "recommendation": "Separate dosing by at least 2 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may worsen dizziness or drowsiness)"]
    },
    "effects_on_symptoms": {
        "Bacterial Infections": {
            "site_of_effect": "Systemic",
            "mechanism": "Eliminates bacterial load in infected tissues.",
            "direction": "Resolution of infection symptoms",
            "magnitude": "Significant",
            "timeframe": "1-3 days after initiation"
        }
    },
    "diagnostic_conditions": {
        "Respiratory Infections": {
            "symptoms_addressed": ["Cough", "Fever", "Shortness of Breath"],
            "therapeutic_action": "Eradicates bacterial infection",
            "optimal_dosage": "500-750 mg once daily",
            "response_time": "1-3 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Headache"],
        "moderate": ["Rash", "Photosensitivity"],
        "severe": ["Tendon Rupture", "QT Prolongation", "Severe Hypersensitivity"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function Tests"],
        "frequency": "As clinically indicated during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Renal Function": "Within normal limits"
            },
            "alert_threshold": {
                "Renal Function": "Significant deviation from baseline"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not typically recommended due to risk of joint toxicity.",
            "rationale": "Increased susceptibility to tendon and joint damage."
        }
    },
    "alternative_therapies": ["Ciprofloxacin", "Azithromycin"],
    "combination_therapies": {
        "recommended_combinations": [],
        "cautions": []
    },
    "contraindications": ["Tendon Disorders", "Myasthenia Gravis"],
    "precautions": ["Monitor for tendon pain or rupture", "Avoid in QT prolongation"],
    "side_effects": ["Nausea", "Diarrhea", "Headache"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Seizures"],
        "treatment": ["Supportive Care"]
    },
    "notes": "Levofloxacin is marketed under various brand names, including Levofloxacin, Levaquin, Tavanic, Levoday, Levobact, Quixin, Levox, Ocu-Lev, L-Flox, Levocin, Lquin, Levogen, Levoflox, Levokast, and Oflevo. It is a broad-spectrum fluoroquinolone antibiotic effective against gram-positive and gram-negative bacteria, commonly used for respiratory, urinary tract, and skin infections. Monitoring for tendon-related side effects and QT prolongation is essential, especially in at-risk populations."
},
  
  {
    "iupac_name": "(RS)-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide",
    "chemical_formula": "C14H22N2O3",
    "brand_names": [
        "Atenolol",
        "Tenormin",
        "Atenix",
        "Betacard",
        "Normiten",
        "Tenolol",
        "Tenorimin",
        "Atenoblock",
        "Atenet",
        "Atenon",
        "Tenovate",
        "Atenil",
        "Betanorm",
        "Atenex",
        "Neotenol"
    ],
    "category": "Beta-1 Adrenergic Receptor Blocker (Beta-Blocker)",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Intravenous Injection"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 Adrenergic Receptors in the Heart",
        "physiological_mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate, cardiac output, and myocardial oxygen demand."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects begin within 1-2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina Pectoris", "Myocardial Infarction"]
    },
    "pharmacokinetics": {
        "absorption": "Approximately 50% absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Excreted via urine (~85%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effect on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor heart rate and blood pressure closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and peripheral resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Angina Pectoris": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath", "Palpitations"],
            "therapeutic_action": "Reduces myocardial oxygen demand",
            "optimal_dosage": "50-100 mg once daily",
            "response_time": "Within hours"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Cold Extremities"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Severe Hypotension", "Bronchospasm"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Metoprolol", "Bisoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for heart failure"],
        "cautions": ["Monitor for additive effects on blood pressure"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Cold Extremities"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Atenolol is marketed under various brand names, including Atenolol, Tenormin, Atenix, Betacard, Normiten, Tenolol, Tenorimin, Atenoblock, Atenet, Atenon, Tenovate, Atenil, Betanorm, Atenex, and Neotenol. It is a cardioselective beta-blocker used for the treatment of hypertension, angina, and myocardial infarction. Regular monitoring of heart rate and blood pressure is recommended during therapy to ensure optimal efficacy and safety."
},
  
  {
    "iupac_name": "(±)-1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]-2-propanol",
    "chemical_formula": "C15H25NO3",
    "brand_names": [
        "Metoprolol",
        "Lopressor",
        "Toprol XL",
        "Betaloc",
        "Seloken",
        "Corvitol",
        "Metolar",
        "Minax",
        "Bloxan",
        "Metoprolol Tartrate",
        "Metoprolol Succinate",
        "Slow Lopresor",
        "Cardiol",
        "Mepril",
        "Lorpressor"
    ],
    "category": "Beta-1 Adrenergic Receptor Blocker (Beta-Blocker)",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Tablets",
        "Intravenous Injection"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg",
        "200 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 Adrenergic Receptors in the Heart",
        "physiological_mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate, cardiac output, and myocardial oxygen demand."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects begin within 1 hour of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina Pectoris", "Heart Failure"]
    },
    "pharmacokinetics": {
        "absorption": "Approximately 50% absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Undergoes extensive first-pass metabolism."
        },
        "elimination": "Excreted via urine (~95%, primarily as metabolites)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effect on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor heart rate and blood pressure closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and peripheral resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within 1 hour of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath", "Edema"],
            "therapeutic_action": "Improves cardiac output and reduces symptoms of heart failure",
            "optimal_dosage": "50-200 mg once daily (extended-release)",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Cold Extremities"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Severe Hypotension", "Bronchospasm"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Atenolol", "Bisoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for heart failure"],
        "cautions": ["Monitor for additive effects on blood pressure"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Cold Extremities"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Metoprolol is marketed under various brand names, including Metoprolol, Lopressor, Toprol XL, Betaloc, Seloken, Corvitol, Metolar, Minax, Bloxan, Metoprolol Tartrate, Metoprolol Succinate, Slow Lopresor, Cardiol, Mepril, and Lorpressor. It is a cardioselective beta-blocker used for the treatment of hypertension, angina, and heart failure. Regular monitoring of heart rate and blood pressure is recommended during therapy to ensure optimal efficacy and safety."
},
  
  {
    "iupac_name": "(RS)-1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol",
    "chemical_formula": "C16H21NO2",
    "brand_names": [
        "Propranolol",
        "Inderal",
        "Inderal LA",
        "Hemangeol",
        "Inderalici",
        "Dociton",
        "Bedranol",
        "Avlocardyl",
        "Propranolol Hydrochloride",
        "Ciplar",
        "Ciplar LA",
        "Sumial",
        "Inderalici Retard",
        "Propanix",
        "Anaprilin"
    ],
    "category": "Non-Selective Beta-Adrenergic Receptor Blocker",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Capsules",
        "Oral Solution",
        "Intravenous Injection"
    ],
    "strengths": [
        "10 mg",
        "20 mg",
        "40 mg",
        "60 mg",
        "80 mg",
        "160 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 and Beta-2 Adrenergic Receptors",
        "physiological_mechanism": "Blocks beta-adrenergic receptors, reducing heart rate, cardiac output, and myocardial oxygen demand while also decreasing renin secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects begin within 1-2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Beta-2 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina", "Arrhythmias", "Migraine Prophylaxis"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract; bioavailability is ~30% due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Extensively metabolized in the liver."
        },
        "elimination": "Primarily excreted via urine (~90% as metabolites)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and renin release.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Migraine Prophylaxis": {
            "symptoms_addressed": ["Headaches", "Nausea", "Sensitivity to Light and Sound"],
            "therapeutic_action": "Prevents migraine attacks",
            "optimal_dosage": "80-160 mg daily in divided doses",
            "response_time": "1-2 weeks for noticeable effect"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Cold Extremities"],
        "severe": ["Heart Block", "Bronchospasm", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Metoprolol", "Atenolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertension"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Asthma", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of bronchospasm", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Bronchospasm"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Propranolol is marketed under various brand names, including Propranolol, Inderal, Inderal LA, Hemangeol, Inderalici, Dociton, Bedranol, Avlocardyl, Propranolol Hydrochloride, Ciplar, Ciplar LA, Sumial, Inderalici Retard, Propanix, and Anaprilin. It is a non-selective beta-blocker used for hypertension, angina, arrhythmias, and migraine prophylaxis. Careful monitoring of heart rate and blood pressure is recommended during therapy to avoid side effects such as bradycardia and hypotension."
},
  
  {
    "iupac_name": "1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol",
    "chemical_formula": "C24H26N2O4",
    "brand_names": [
        "Carvedilol",
        "Coreg",
        "Coreg CR",
        "Dilatrend",
        "Carvil",
        "Carvidon",
        "Carvetrend",
        "Cardivas",
        "Cardilol",
        "Carvol",
        "Coraxan",
        "Cardoprol",
        "Carvibloc",
        "Karvonal",
        "Trandate"
    ],
    "category": "Non-Selective Beta-Blocker with Alpha-Blocking Activity",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Capsules"
    ],
    "strengths": [
        "3.125 mg",
        "6.25 mg",
        "12.5 mg",
        "25 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1, Beta-2, and Alpha-1 Adrenergic Receptors",
        "physiological_mechanism": "Blocks beta-adrenergic receptors, reducing heart rate and myocardial oxygen demand, and alpha-adrenergic receptors, causing vasodilation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate, blood pressure, and vascular resistance.",
            "timeframe": "Effects begin within 1-2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Beta-2 Adrenergic Receptors", "Alpha-1 Adrenergic Receptors"],
        "related_conditions": ["Heart Failure", "Hypertension", "Angina"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract; bioavailability is ~25-35% due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6", "CYP2C9"],
            "notes": "Extensively metabolized in the liver to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via feces (~60%) and urine (~35%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Heart Failure": {
            "site_of_effect": "Systemic",
            "mechanism": "Improves cardiac output and reduces vascular resistance.",
            "direction": "Improved cardiac efficiency",
            "magnitude": "Significant",
            "timeframe": "Weeks to months"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Fatigue", "Headache"],
            "therapeutic_action": "Reduces systemic vascular resistance and cardiac workload",
            "optimal_dosage": "6.25-25 mg twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Diarrhea"],
        "moderate": ["Bradycardia", "Hypotension", "Weight Gain"],
        "severe": ["Heart Block", "Hepatotoxicity", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure", "Liver Function Tests"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Metoprolol", "Labetalol"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for heart failure"],
        "cautions": ["Monitor for additive effects on blood pressure"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Carvedilol is marketed under various brand names, including Carvedilol, Coreg, Coreg CR, Dilatrend, Carvil, Carvidon, Carvetrend, Cardivas, Cardilol, Carvol, Coraxan, Cardoprol, Carvibloc, Karvonal, and Trandate. It is a non-selective beta-blocker with alpha-blocking activity, commonly used for heart failure, hypertension, and angina. Monitoring for heart rate, blood pressure, and liver function is essential during therapy to prevent adverse effects such as hypotension and hepatotoxicity."
},
  
  {
    "iupac_name": "2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide",
    "chemical_formula": "C19H24N2O3",
    "brand_names": [
        "Labetalol",
        "Trandate",
        "Normodyne",
        "Labetalol Hydrochloride",
        "Labrocol",
        "Alpresol",
        "Amipress",
        "Presolol",
        "Trandacor",
        "Lopressor LA",
        "Labocor",
        "Labeta",
        "Tradalat",
        "Medipress"
    ],
    "category": "Non-Selective Beta-Blocker with Alpha-Blocking Activity",
    "dosage_forms": [
        "Tablets",
        "Intravenous Injection"
    ],
    "strengths": [
        "100 mg",
        "200 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1, Beta-2, and Alpha-1 Adrenergic Receptors",
        "physiological_mechanism": "Blocks beta-adrenergic receptors to reduce heart rate and cardiac output while also blocking alpha-adrenergic receptors to decrease peripheral resistance."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces blood pressure and heart rate.",
            "timeframe": "Effects begin within 1-2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Beta-2 Adrenergic Receptors", "Alpha-1 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Hypertensive Emergencies"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~20-40% due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Extensively metabolized in the liver."
        },
        "elimination": "Primarily excreted via feces (~55%) and urine (~40%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertensive Emergencies": {
            "site_of_effect": "Systemic",
            "mechanism": "Rapidly lowers blood pressure by reducing cardiac output and peripheral resistance.",
            "direction": "Decreased systemic vascular resistance",
            "magnitude": "Significant",
            "timeframe": "Within minutes of intravenous administration"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Headache", "Dizziness"],
            "therapeutic_action": "Reduces systemic vascular resistance and cardiac workload",
            "optimal_dosage": "100-300 mg twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Nausea", "Fatigue"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Hepatotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure", "Liver Function Tests"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Carvedilol", "Propranolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertension"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Dizziness", "Fatigue", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Labetalol is marketed under various brand names, including Labetalol, Trandate, Normodyne, Labetalol Hydrochloride, Labrocol, Alpresol, Amipress, Presolol, Trandacor, Lopressor LA, Labocor, Labeta, Tradalat, and Medipress. It is a non-selective beta-blocker with alpha-blocking activity used to manage hypertension and hypertensive emergencies. Regular monitoring of blood pressure, heart rate, and liver function is recommended during therapy to prevent adverse effects."
},
  
  {
    "iupac_name": "methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate",
    "chemical_formula": "C16H25NO4",
    "brand_names": [
        "Esmolol",
        "Brevibloc",
        "Esmocard",
        "Esmolet",
        "Esmorel",
        "Bivosi",
        "Esmotensin"
    ],
    "category": "Beta-1 Adrenergic Receptor Blocker (Beta-Blocker)",
    "dosage_forms": [
        "Intravenous Injection"
    ],
    "strengths": [
        "10 mg/mL",
        "25 mg/mL"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 Adrenergic Receptors in the Heart",
        "physiological_mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate and myocardial oxygen demand."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Rapid reduction of heart rate and blood pressure.",
            "timeframe": "Effects begin within 2 minutes of intravenous administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors"],
        "related_conditions": ["Supraventricular Tachycardia", "Hypertensive Emergencies"]
    },
    "pharmacokinetics": {
        "absorption": "Administered intravenously; immediate bioavailability.",
        "metabolism": {
            "primary_site": "Plasma",
            "enzymes": ["Esterases"],
            "notes": "Rapidly metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~73% as metabolites)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Supraventricular Tachycardia": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces heart rate by inhibiting beta-adrenergic stimulation.",
            "direction": "Normalization of heart rate",
            "magnitude": "Significant",
            "timeframe": "Within minutes of administration"
        }
    },
    "diagnostic_conditions": {
        "Hypertensive Emergencies": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Chest Pain", "Shortness of Breath"],
            "therapeutic_action": "Rapidly reduces blood pressure",
            "optimal_dosage": "50-300 mcg/kg/min",
            "response_time": "Immediate"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Nausea", "Fatigue"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Cardiogenic Shock"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "As needed during acute therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower infusion rates.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Labetalol", "Propranolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertensive emergencies"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Adjust infusion rates based on response"],
    "side_effects": ["Dizziness", "Fatigue", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Esmolol is marketed under various brand names, including Esmolol, Brevibloc, Esmocard, Esmolet, Esmorel, Bivosi, and Esmotensin. It is a cardioselective beta-blocker used for the management of supraventricular tachycardia and hypertensive emergencies, particularly in acute settings. Its rapid onset and short half-life make it ideal for controlled and reversible beta-blockade."
},
  
  {
    "iupac_name": "1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[(2R)-6-fluoro-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-2-yl]ethanol",
    "chemical_formula": "C22H25F2NO4",
    "brand_names": [
        "Nebivolol",
        "Bystolic",
        "Nebilet",
        "Lobivon",
        "Nebilong",
        "Nebinorm",
        "Nebicard",
        "Nodon",
        "Nitrolol",
        "Evoloc",
        "Vasoxen",
        "Nebirex",
        "Nebistar",
        "Nebicip",
        "Dilatrend"
    ],
    "category": "Beta-1 Adrenergic Receptor Blocker (Beta-Blocker)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "10 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 Adrenergic Receptors in the Heart",
        "physiological_mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate and myocardial oxygen demand, and enhances nitric oxide-mediated vasodilation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate, blood pressure, and vascular resistance.",
            "timeframe": "Effects begin within 1-2 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition and Nitric Oxide Enhancement",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Nitric Oxide Pathways"],
        "related_conditions": ["Hypertension", "Heart Failure"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract; bioavailability is ~12% due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2D6"],
            "notes": "Extensively metabolized in the liver to active metabolites."
        },
        "elimination": "Primarily excreted via urine (~38%) and feces (~48%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and enhances vasodilation.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath", "Edema"],
            "therapeutic_action": "Improves cardiac output and reduces symptoms of heart failure.",
            "optimal_dosage": "5-10 mg once daily",
            "response_time": "Weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Bronchospasm", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Atenolol", "Bisoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for heart failure"],
        "cautions": ["Monitor for additive effects on blood pressure"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Nebivolol is marketed under various brand names, including Nebivolol, Bystolic, Nebilet, Lobivon, Nebilong, Nebinorm, Nebicard, Nodon, Nitrolol, Evoloc, Vasoxen, Nebirex, Nebistar, Nebicip, and Dilatrend. It is a cardioselective beta-blocker with nitric oxide-mediated vasodilatory effects, used for managing hypertension and heart failure. Regular monitoring of heart rate and blood pressure is recommended during therapy to ensure optimal efficacy and safety."
},
  
  {
    "iupac_name": "N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide",
    "chemical_formula": "C12H20N2O3S",
    "brand_names": [
        "Sotalol",
        "Betapace",
        "Betapace AF",
        "Sotacor",
        "Cardol",
        "Darob",
        "Rylosol",
        "Sotalex",
        "Sotabeta",
        "Sotalol Hydrochloride",
        "SotaHEXAL",
        "Tachylol",
        "Sorine",
        "Sotalvan",
        "Sotamed"
    ],
    "category": "Non-Selective Beta-Blocker and Class III Antiarrhythmic",
    "dosage_forms": [
        "Tablets",
        "Oral Solution"
    ],
    "strengths": [
        "80 mg",
        "120 mg",
        "160 mg",
        "240 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-Adrenergic Receptors and Cardiac Potassium Channels",
        "physiological_mechanism": "Non-selectively blocks beta-adrenergic receptors and prolongs cardiac action potential by blocking potassium channels, reducing arrhythmias."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate, myocardial oxygen demand, and corrects arrhythmias.",
            "timeframe": "Effects on arrhythmias observed within hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Beta-Adrenergic Blockade and Potassium Channel Inhibition",
        "key_targets": ["Beta-Adrenergic Receptors", "Cardiac Potassium Channels"],
        "related_conditions": ["Atrial Fibrillation", "Ventricular Tachycardia", "Supraventricular Tachycardia"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract; bioavailability is ~90%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged."
        },
        "elimination": "Primarily excreted via urine (~80-90%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Atrial Fibrillation": {
            "site_of_effect": "Systemic",
            "mechanism": "Controls ventricular rate and maintains sinus rhythm.",
            "direction": "Normalization of heart rhythm",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Ventricular Tachycardia": {
            "symptoms_addressed": ["Palpitations", "Dizziness", "Shortness of Breath"],
            "therapeutic_action": "Suppresses ventricular arrhythmias",
            "optimal_dosage": "80-160 mg twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Torsades de Pointes", "Heart Block", "Severe Bradycardia"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Electrocardiogram (QT Interval)", "Renal Function"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "QT Interval": "<440 ms"
            },
            "alert_threshold": {
                "QT Interval": ">500 ms"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses and monitor renal function.",
            "rationale": "Increased risk of bradycardia and prolonged QT interval."
        }
    },
    "alternative_therapies": ["Amiodarone", "Propranolol"],
    "combination_therapies": {
        "recommended_combinations": ["With anticoagulants for atrial fibrillation"],
        "cautions": ["Monitor for additive cardiac effects"]
    },
    "contraindications": ["Severe Bradycardia", "Prolonged QT Syndrome"],
    "precautions": ["Monitor for QT prolongation", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Torsades de Pointes"],
        "treatment": ["Atropine", "Intravenous Fluids", "Magnesium Sulfate"]
    },
    "notes": "Sotalol is marketed under various brand names, including Sotalol, Betapace, Betapace AF, Sotacor, Cardol, Darob, Rylosol, Sotalex, Sotabeta, Sotalol Hydrochloride, SotaHEXAL, Tachylol, Sorine, Sotalvan, and Sotamed. It is a non-selective beta-blocker with antiarrhythmic properties, used for managing atrial fibrillation, ventricular tachycardia, and other arrhythmias. Close monitoring of QT interval and renal function is essential during therapy to prevent serious adverse effects like Torsades de Pointes."
},
  
  {
    "iupac_name": "1-(tert-butylamino)-3-(2,3-dihydroxypropoxy)propan-2-ol",
    "chemical_formula": "C17H27NO4",
    "brand_names": [
        "Nadolol",
        "Corgard",
        "Corzide",
        "Anabet",
        "Nadoten",
        "Betadol",
        "Alti-Nadolol",
        "Apo-Nadolol",
        "Nodac",
        "Nodolor",
        "Nadobloc"
    ],
    "category": "Non-Selective Beta-Adrenergic Receptor Blocker",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "20 mg",
        "40 mg",
        "80 mg",
        "120 mg",
        "160 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 and Beta-2 Adrenergic Receptors",
        "physiological_mechanism": "Non-selectively blocks beta-adrenergic receptors, reducing heart rate, myocardial oxygen demand, and systemic vascular resistance."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects observed within 3-4 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Beta-2 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina", "Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~30%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and peripheral resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Angina": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath", "Palpitations"],
            "therapeutic_action": "Reduces myocardial oxygen demand",
            "optimal_dosage": "40-120 mg once daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Bronchospasm", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Propranolol", "Metoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertension"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Nadolol is marketed under various brand names, including Nadolol, Corgard, Corzide, Anabet, Nadoten, Betadol, Alti-Nadolol, Apo-Nadolol, Nodac, Nodolor, and Nadobloc. It is a non-selective beta-blocker used for the management of hypertension, angina, and arrhythmias. Regular monitoring of heart rate and blood pressure is recommended during therapy to prevent adverse effects such as bradycardia and hypotension."
},
  
  {
    "iupac_name": "1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol",
    "chemical_formula": "C14H20N2O2",
    "brand_names": [
        "Pindolol",
        "Visken",
        "Pindolol Hydrochloride",
        "Betapindol",
        "Calvisken",
        "Pinbetol",
        "Prindolol",
        "Viskaldix",
        "Viskapront",
        "Viskrate",
        "Viskenol",
        "Cardiacor",
        "Pinacor"
    ],
    "category": "Non-Selective Beta-Adrenergic Receptor Blocker",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "5 mg",
        "10 mg",
        "15 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 and Beta-2 Adrenergic Receptors",
        "physiological_mechanism": "Non-selectively blocks beta-adrenergic receptors, reducing heart rate, myocardial oxygen demand, and systemic vascular resistance."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects observed within 1-2 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors", "Beta-2 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina", "Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~90%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~60%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and peripheral resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Angina": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath", "Palpitations"],
            "therapeutic_action": "Reduces myocardial oxygen demand",
            "optimal_dosage": "5-15 mg twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Bronchospasm", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Propranolol", "Metoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertension"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Pindolol is marketed under various brand names, including Pindolol, Visken, Pindolol Hydrochloride, Betapindol, Calvisken, Pinbetol, Prindolol, Viskaldix, Viskapront, Viskrate, Viskenol, Cardiacor, and Pinacor. It is a non-selective beta-blocker used for managing hypertension, angina, and arrhythmias. Regular monitoring of heart rate and blood pressure is recommended during therapy to prevent adverse effects such as bradycardia and hypotension."
},
  
  {
    "iupac_name": "1-(tert-butylamino)-3-[4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl]propan-2-ol",
    "chemical_formula": "C18H28N2O4",
    "brand_names": [
        "Acebutolol",
        "Sectral",
        "Acebutolol Hydrochloride",
        "Monitan",
        "Acecor",
        "Betadural",
        "Acepress",
        "Acedral",
        "Corbetal",
        "Acebuteral",
        "Aceblok",
        "Neobloc",
        "Sectrol",
        "Acecorol",
        "Cardiolol"
    ],
    "category": "Cardioselective Beta-Adrenergic Receptor Blocker with Intrinsic Sympathomimetic Activity (ISA)",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "200 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-1 Adrenergic Receptors",
        "physiological_mechanism": "Selectively blocks beta-1 adrenergic receptors, reducing heart rate and myocardial oxygen demand, with intrinsic sympathomimetic activity to maintain basal sympathetic tone."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces heart rate and blood pressure.",
            "timeframe": "Effects observed within 1-2 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Adrenergic Receptor Inhibition",
        "key_targets": ["Beta-1 Adrenergic Receptors"],
        "related_conditions": ["Hypertension", "Angina"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract with bioavailability of ~50%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["N/A"],
            "notes": "Metabolized to an active metabolite, diacetolol."
        },
        "elimination": "Primarily excreted via urine (~60%)."
    },
    "interactions": {
        "Calcium Channel Blockers": {
            "site_of_interaction": "Cardiovascular System",
            "mechanism": "Additive effects on heart rate and contractility",
            "effect": "Increased risk of bradycardia and hypotension",
            "recommendation": "Monitor closely for cardiac side effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["Alcohol (may increase hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces cardiac output and peripheral resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Angina": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath", "Palpitations"],
            "therapeutic_action": "Reduces myocardial oxygen demand",
            "optimal_dosage": "200-400 mg twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Bronchospasm", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Heart Rate", "Blood Pressure"],
        "frequency": "Every 3-6 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to beta-blockers in elderly patients."
        }
    },
    "alternative_therapies": ["Metoprolol", "Bisoprolol"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for hypertension"],
        "cautions": ["Monitor for additive hypotension"]
    },
    "contraindications": ["Severe Bradycardia", "Cardiogenic Shock"],
    "precautions": ["Monitor for signs of heart failure", "Avoid abrupt discontinuation"],
    "side_effects": ["Fatigue", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Bradycardia", "Hypotension", "Heart Block"],
        "treatment": ["Atropine", "Intravenous Fluids", "Glucagon"]
    },
    "notes": "Acebutolol is marketed under various brand names, including Acebutolol, Sectral, Acebutolol Hydrochloride, Monitan, Acecor, Betadural, Acepress, Acedral, Corbetal, Acebuteral, Aceblok, Neobloc, Sectrol, Acecorol, and Cardiolol. It is a cardioselective beta-blocker with intrinsic sympathomimetic activity used for managing hypertension and angina. Regular monitoring of heart rate and blood pressure is recommended during therapy to prevent adverse effects such as bradycardia and hypotension."
},
  
  {
    "iupac_name": "6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide",
    "chemical_formula": "C7H8ClN3O4S2",
    "brand_names": [
        "Hydrochlorothiazide",
        "HCTZ",
        "Microzide",
        "Esidrix",
        "HydroDIURIL",
        "Oretic",
        "HydroSaluric",
        "Apo-Hydro",
        "Aquazide H",
        "Neo-Diur",
        "Hydrazide",
        "Dichlotride",
        "Urozide",
        "HCT",
        "Diucardin"
    ],
    "category": "Thiazide Diuretic",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "12.5 mg",
        "25 mg",
        "50 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Distal Convoluted Tubules of the Kidney",
        "physiological_mechanism": "Inhibits sodium reabsorption in the distal tubules, promoting diuresis and reducing blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary excretion of sodium and water.",
            "timeframe": "Effects begin within 2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Reabsorption Inhibition",
        "key_targets": ["Na+/Cl- symporter"],
        "related_conditions": ["Hypertension", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "N/A",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~95%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on lowering blood pressure",
            "effect": "Increased risk of hypotension and hyperkalemia",
            "recommendation": "Monitor blood pressure and electrolytes."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium supplements (to counteract hypokalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces plasma volume and vascular resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Edema": {
            "symptoms_addressed": ["Swelling", "Fluid Retention"],
            "therapeutic_action": "Reduces fluid buildup",
            "optimal_dosage": "25-50 mg once daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Headache", "Nausea"],
        "moderate": ["Electrolyte Imbalance", "Muscle Weakness"],
        "severe": ["Severe Hypokalemia", "Hyperglycemia", "Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": "<3.0 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased risk of dehydration and electrolyte imbalances."
        }
    },
    "alternative_therapies": ["Chlorthalidone", "Indapamide"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for hypertension"],
        "cautions": ["Monitor for hypotension and electrolyte imbalances"]
    },
    "contraindications": ["Anuria", "Severe Renal Impairment"],
    "precautions": ["Monitor for signs of dehydration", "Avoid in patients with sulfonamide allergy"],
    "side_effects": ["Dizziness", "Headache", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Electrolyte Imbalance", "Dehydration"],
        "treatment": ["Intravenous Fluids", "Electrolyte Repletion"]
    },
    "notes": "Hydrochlorothiazide (HCTZ) is marketed under various brand names, including Hydrochlorothiazide, HCTZ, Microzide, Esidrix, HydroDIURIL, Oretic, HydroSaluric, Apo-Hydro, Aquazide H, Neo-Diur, Hydrazide, Dichlotride, Urozide, HCT, and Diucardin. It is a thiazide diuretic commonly used to treat hypertension and edema. Regular monitoring of electrolytes, renal function, and blood pressure is recommended to avoid adverse effects like hypokalemia and dehydration."
},
  
  {
    "iupac_name": "2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-2-yl)benzenesulfonamide",
    "chemical_formula": "C14H11ClN2O4S",
    "brand_names": [
        "Chlorthalidone",
        "Hygroton",
        "Thalitone",
        "Clorpres",
        "Tenoretic",
        "Combipres",
        "Hygropres",
        "Chlorpres",
        "Clorpress",
        "Chlorthal",
        "Chlorzide",
        "Edemax"
    ],
    "category": "Thiazide-Like Diuretic",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "12.5 mg",
        "25 mg",
        "50 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Distal Convoluted Tubules of the Kidney",
        "physiological_mechanism": "Inhibits sodium reabsorption in the distal tubules, promoting diuresis and reducing blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary excretion of sodium and water.",
            "timeframe": "Effects begin within 2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Reabsorption Inhibition",
        "key_targets": ["Na+/Cl- symporter"],
        "related_conditions": ["Hypertension", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "N/A",
            "enzymes": ["N/A"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~95%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on lowering blood pressure",
            "effect": "Increased risk of hypotension and hyperkalemia",
            "recommendation": "Monitor blood pressure and electrolytes."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium supplements (to counteract hypokalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces plasma volume and vascular resistance.",
            "direction": "Lowered blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Edema": {
            "symptoms_addressed": ["Swelling", "Fluid Retention"],
            "therapeutic_action": "Reduces fluid buildup",
            "optimal_dosage": "25-50 mg once daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Headache", "Nausea"],
        "moderate": ["Electrolyte Imbalance", "Muscle Weakness"],
        "severe": ["Severe Hypokalemia", "Hyperglycemia", "Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": "<3.0 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased risk of dehydration and electrolyte imbalances."
        }
    },
    "alternative_therapies": ["Hydrochlorothiazide", "Indapamide"],
    "combination_therapies": {
        "recommended_combinations": ["With ACE inhibitors for hypertension"],
        "cautions": ["Monitor for hypotension and electrolyte imbalances"]
    },
    "contraindications": ["Anuria", "Severe Renal Impairment"],
    "precautions": ["Monitor for signs of dehydration", "Avoid in patients with sulfonamide allergy"],
    "side_effects": ["Dizziness", "Headache", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Electrolyte Imbalance", "Dehydration"],
        "treatment": ["Intravenous Fluids", "Electrolyte Repletion"]
    },
    "notes": "Chlorthalidone is marketed under various brand names, including Chlorthalidone, Hygroton, Thalitone, Clorpres, Tenoretic, Combipres, Hygropres, Chlorpres, Clorpress, Chlorthal, Chlorzide, and Edemax. It is a thiazide-like diuretic commonly used to treat hypertension and edema. Regular monitoring of electrolytes, renal function, and blood pressure is recommended to avoid adverse effects like hypokalemia and dehydration."
},
  
  {
    "iupac_name": "4-chloro-2-[(2-furanylmethyl)amino]-5-sulfamoylbenzoic acid",
    "chemical_formula": "C12H11ClN2O5S",
    "brand_names": [
        "Furosemide",
        "Lasix",
        "Fusid",
        "Furosedon",
        "Frumil",
        "Diuresal",
        "Furocet",
        "Fumide",
        "Uremide",
        "Aquafuro",
        "Furix",
        "Lasitone",
        "Lasoride",
        "Furetic",
        "Lo-Aqua"
    ],
    "category": "Loop Diuretic",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Intravenous Injection"
    ],
    "strengths": [
        "20 mg",
        "40 mg",
        "80 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Thick Ascending Limb of the Loop of Henle",
        "physiological_mechanism": "Inhibits the Na+/K+/2Cl- symporter, preventing sodium and chloride reabsorption and increasing water excretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary excretion of sodium, chloride, potassium, and water.",
            "timeframe": "Effects begin within 30-60 minutes of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Reabsorption Inhibition",
        "key_targets": ["Na+/K+/2Cl- symporter"],
        "related_conditions": ["Edema", "Hypertension"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~50-70% (oral).",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Partially metabolized, primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on lowering blood pressure",
            "effect": "Increased risk of hypotension and renal dysfunction",
            "recommendation": "Monitor renal function and blood pressure."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium supplements (to counteract hypokalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Edema": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces fluid overload by increasing urinary output.",
            "direction": "Improved fluid balance",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Fluid Retention"],
            "therapeutic_action": "Lowers blood pressure by reducing plasma volume.",
            "optimal_dosage": "20-40 mg once or twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Headache", "Nausea"],
        "moderate": ["Electrolyte Imbalance", "Dehydration"],
        "severe": ["Severe Hypokalemia", "Hypotension", "Ototoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": "<3.0 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to diuretics and risk of dehydration."
        }
    },
    "alternative_therapies": ["Bumetanide", "Torsemide"],
    "combination_therapies": {
        "recommended_combinations": ["With potassium-sparing diuretics to prevent hypokalemia"],
        "cautions": ["Monitor for electrolyte imbalances"]
    },
    "contraindications": ["Anuria", "Severe Hypokalemia"],
    "precautions": ["Monitor for signs of dehydration", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Headache", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Electrolyte Imbalance", "Dehydration"],
        "treatment": ["Intravenous Fluids", "Electrolyte Repletion"]
    },
    "notes": "Furosemide is marketed under various brand names, including Furosemide, Lasix, Fusid, Furosedon, Frumil, Diuresal, Furocet, Fumide, Uremide, Aquafuro, Furix, Lasitone, Lasoride, Furetic, and Lo-Aqua. It is a loop diuretic commonly used to manage edema and hypertension. Regular monitoring of electrolytes, renal function, and blood pressure is recommended to avoid adverse effects like hypokalemia, dehydration, and ototoxicity."
},
  {
    "iupac_name": "3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid",
    "chemical_formula": "C17H20N2O5S",
    "brand_names": [
        "Bumetanide",
        "Bumex",
        "Burinex",
        "Bumetanil",
        "Bumetan",
        "Loopet",
        "Aquabum",
        "Burmed",
        "Bumic",
        "Rykade",
        "Bumirex",
        "Diurex Bumetanide",
        "Bumelox"
    ],
    "category": "Loop Diuretic",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Intravenous Injection"
    ],
    "strengths": [
        "0.5 mg",
        "1 mg",
        "2 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Thick Ascending Limb of the Loop of Henle",
        "physiological_mechanism": "Inhibits the Na+/K+/2Cl- symporter, preventing sodium and chloride reabsorption and increasing water excretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary excretion of sodium, chloride, potassium, and water.",
            "timeframe": "Effects begin within 30-60 minutes of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Reabsorption Inhibition",
        "key_targets": ["Na+/K+/2Cl- symporter"],
        "related_conditions": ["Edema", "Hypertension"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~80-90% (oral).",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Partially metabolized, primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on lowering blood pressure",
            "effect": "Increased risk of hypotension and renal dysfunction",
            "recommendation": "Monitor renal function and blood pressure."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium supplements (to counteract hypokalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Edema": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces fluid overload by increasing urinary output.",
            "direction": "Improved fluid balance",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Fluid Retention"],
            "therapeutic_action": "Lowers blood pressure by reducing plasma volume.",
            "optimal_dosage": "0.5-1 mg once or twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Headache", "Nausea"],
        "moderate": ["Electrolyte Imbalance", "Dehydration"],
        "severe": ["Severe Hypokalemia", "Hypotension", "Ototoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": "<3.0 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to diuretics and risk of dehydration."
        }
    },
    "alternative_therapies": ["Furosemide", "Torsemide"],
    "combination_therapies": {
        "recommended_combinations": ["With potassium-sparing diuretics to prevent hypokalemia"],
        "cautions": ["Monitor for electrolyte imbalances"]
    },
    "contraindications": ["Anuria", "Severe Hypokalemia"],
    "precautions": ["Monitor for signs of dehydration", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Headache", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Electrolyte Imbalance", "Dehydration"],
        "treatment": ["Intravenous Fluids", "Electrolyte Repletion"]
    },
    "notes": "Bumetanide is marketed under various brand names, including Bumetanide, Bumex, Burinex, Bumetanil, Bumetan, Loopet, Aquabum, Burmed, Bumic, Rykade, Bumirex, Diurex Bumetanide, and Bumelox. It is a loop diuretic commonly used to manage edema and hypertension. Regular monitoring of electrolytes, renal function, and blood pressure is recommended to avoid adverse effects like hypokalemia, dehydration, and ototoxicity."
},
  
  {
    "iupac_name": "1-isopropyl-3-[(4-m-toluidino-3-pyridyl)oxy]propan-2-ol",
    "chemical_formula": "C16H20N4O3S",
    "brand_names": [
        "Torsemide",
        "Demadex",
        "Torem",
        "Torix",
        "Torsid",
        "Torsel",
        "Turosemide",
        "Torsem",
        "Torrestor",
        "Tornex",
        "Aquator",
        "Toravid",
        "Torsan",
        "Torlev",
        "Diurese-T"
    ],
    "category": "Loop Diuretic",
    "dosage_forms": [
        "Tablets",
        "Oral Solution",
        "Intravenous Injection"
    ],
    "strengths": [
        "5 mg",
        "10 mg",
        "20 mg",
        "40 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Thick Ascending Limb of the Loop of Henle",
        "physiological_mechanism": "Inhibits the Na+/K+/2Cl- symporter, preventing sodium and chloride reabsorption and increasing water excretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary excretion of sodium, chloride, potassium, and water.",
            "timeframe": "Effects begin within 30-60 minutes of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Reabsorption Inhibition",
        "key_targets": ["Na+/K+/2Cl- symporter"],
        "related_conditions": ["Edema", "Hypertension"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~80-90% (oral).",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Partially metabolized, primarily excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on lowering blood pressure",
            "effect": "Increased risk of hypotension and renal dysfunction",
            "recommendation": "Monitor renal function and blood pressure."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium supplements (to counteract hypokalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Edema": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces fluid overload by increasing urinary output.",
            "direction": "Improved fluid balance",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Hypertension": {
            "symptoms_addressed": ["Elevated Blood Pressure", "Fluid Retention"],
            "therapeutic_action": "Lowers blood pressure by reducing plasma volume.",
            "optimal_dosage": "5-20 mg once or twice daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Headache", "Nausea"],
        "moderate": ["Electrolyte Imbalance", "Dehydration"],
        "severe": ["Severe Hypokalemia", "Hypotension", "Ototoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": "<3.0 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to diuretics and risk of dehydration."
        }
    },
    "alternative_therapies": ["Furosemide", "Bumetanide"],
    "combination_therapies": {
        "recommended_combinations": ["With potassium-sparing diuretics to prevent hypokalemia"],
        "cautions": ["Monitor for electrolyte imbalances"]
    },
    "contraindications": ["Anuria", "Severe Hypokalemia"],
    "precautions": ["Monitor for signs of dehydration", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Headache", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Electrolyte Imbalance", "Dehydration"],
        "treatment": ["Intravenous Fluids", "Electrolyte Repletion"]
    },
    "notes": "Torsemide is marketed under various brand names, including Torsemide, Demadex, Torem, Torix, Torsid, Torsel, Turosemide, Torsem, Torrestor, Tornex, Aquator, Toravid, Torsan, Torlev, and Diurese-T. It is a loop diuretic commonly used to manage edema and hypertension. Regular monitoring of electrolytes, renal function, and blood pressure is recommended to avoid adverse effects like hypokalemia, dehydration, and ototoxicity."
},
  
  
  {
    "iupac_name": "7α-acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone",
    "chemical_formula": "C24H32O4S",
    "brand_names": [
        "Spironolactone",
        "Aldactone",
        "CaroSpir",
        "Spiractin",
        "Spirolon",
        "Spirotone",
        "Aldactide",
        "Aldactazide",
        "Aldactazine",
        "Spirohexal",
        "Spirone",
        "Uractone",
        "Spiridon",
        "Spironon",
        "Diacloron"
    ],
    "category": "Potassium-Sparing Diuretic and Aldosterone Antagonist",
    "dosage_forms": [
        "Tablets",
        "Oral Suspension"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Distal Convoluted Tubules and Collecting Ducts of the Kidney",
        "physiological_mechanism": "Antagonizes aldosterone at mineralocorticoid receptors, reducing sodium reabsorption and potassium excretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary sodium excretion while conserving potassium.",
            "timeframe": "Effects begin within 1-2 days of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Aldosterone Receptor Antagonism",
        "key_targets": ["Mineralocorticoid Receptors"],
        "related_conditions": ["Heart Failure", "Edema", "Hypertension"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~70%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to active metabolites."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on potassium retention",
            "effect": "Increased risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium-rich foods (may increase risk of hyperkalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Heart Failure": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces fluid retention and improves cardiac workload.",
            "direction": "Improved cardiac output",
            "magnitude": "Moderate to significant",
            "timeframe": "Within days to weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Hyperaldosteronism": {
            "symptoms_addressed": ["High Blood Pressure", "Hypokalemia"],
            "therapeutic_action": "Blocks effects of aldosterone.",
            "optimal_dosage": "25-100 mg daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Nausea", "Headache"],
        "moderate": ["Hyperkalemia", "Gynecomastia"],
        "severe": ["Severe Hyperkalemia", "Renal Impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hyperkalemia and renal dysfunction."
        }
    },
    "alternative_therapies": ["Eplerenone", "Amiloride"],
    "combination_therapies": {
        "recommended_combinations": ["With loop diuretics for severe fluid retention"],
        "cautions": ["Monitor for additive effects on potassium levels"]
    },
    "contraindications": ["Anuria", "Severe Hyperkalemia"],
    "precautions": ["Monitor for signs of dehydration", "Avoid use in patients with Addison's disease"],
    "side_effects": ["Dizziness", "Nausea", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hyperkalemia", "Hypotension", "Arrhythmias"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate", "Insulin with Glucose"]
    },
    "notes": "Spironolactone is marketed under various brand names, including Spironolactone, Aldactone, CaroSpir, Spiractin, Spirolon, Spirotone, Aldactide, Aldactazide, Aldactazine, Spirohexal, Spirone, Uractone, Spiridon, Spironon, and Diacloron. It is a potassium-sparing diuretic and aldosterone antagonist commonly used to manage heart failure, edema, and hyperaldosteronism. Regular monitoring of serum potassium levels, renal function, and blood pressure is essential to prevent adverse effects such as hyperkalemia and renal impairment."
},
  
  {
    "iupac_name": "N-(diaminomethylidene)-2,6-diamino-1,3,5-triazine-4-carboxamide",
    "chemical_formula": "C6H8ClN7O",
    "brand_names": [
        "Amiloride",
        "Midamor",
        "Moduretic",
        "Amilzide",
        "Amilohexal",
        "Kaluril",
        "Diuretamin",
        "Amiretic",
        "Amiloret",
        "Amizo",
        "Amilride",
        "Amicoside",
        "Amicor"
    ],
    "category": "Potassium-Sparing Diuretic",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "5 mg",
        "10 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Distal Convoluted Tubules and Collecting Ducts of the Kidney",
        "physiological_mechanism": "Blocks epithelial sodium channels, reducing sodium reabsorption and potassium excretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases urinary sodium excretion while conserving potassium.",
            "timeframe": "Effects begin within 2-4 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Channel Inhibition",
        "key_targets": ["Epithelial Sodium Channels (ENaC)"],
        "related_conditions": ["Hypertension", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Absorbed from the gastrointestinal tract with bioavailability of ~50%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["N/A"],
            "notes": "Excreted mostly unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~70%)."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on potassium retention",
            "effect": "Increased risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium-rich foods (may increase risk of hyperkalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces sodium reabsorption, lowering plasma volume.",
            "direction": "Lowered blood pressure",
            "magnitude": "Moderate",
            "timeframe": "Within hours of therapy"
        }
    },
    "diagnostic_conditions": {
        "Edema": {
            "symptoms_addressed": ["Swelling", "Fluid Retention"],
            "therapeutic_action": "Reduces fluid retention by promoting diuresis.",
            "optimal_dosage": "5-10 mg daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Nausea", "Headache"],
        "moderate": ["Hyperkalemia", "Fatigue"],
        "severe": ["Severe Hyperkalemia", "Renal Impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hyperkalemia and renal dysfunction."
        }
    },
    "alternative_therapies": ["Spironolactone", "Triamterene"],
    "combination_therapies": {
        "recommended_combinations": ["With thiazide diuretics to counteract potassium loss"],
        "cautions": ["Monitor for additive effects on potassium levels"]
    },
    "contraindications": ["Anuria", "Severe Hyperkalemia"],
    "precautions": ["Monitor for signs of dehydration", "Avoid use in patients with severe renal impairment"],
    "side_effects": ["Dizziness", "Nausea", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hyperkalemia", "Hypotension", "Arrhythmias"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate", "Insulin with Glucose"]
    },
    "notes": "Amiloride is marketed under various brand names, including Amiloride, Midamor, Moduretic, Amilzide, Amilohexal, Kaluril, Diuretamin, Amiretic, Amiloret, Amizo, Amilride, Amicoside, and Amicor. It is a potassium-sparing diuretic commonly used to manage hypertension and edema. Regular monitoring of serum potassium levels, renal function, and blood pressure is essential to prevent adverse effects such as hyperkalemia and renal impairment."
},
  
  {
    "iupac_name": "2,4,7-triamino-6-phenylpteridine",
    "chemical_formula": "C12H11N7",
    "brand_names": [
        "Triamterene",
        "Dyrenium",
        "Dyazide",
        "Maxzide",
        "Triterene",
        "Triazide",
        "Diuretin",
        "Hydriurese",
        "Triampur",
        "Triretic",
        "Apo-Triamterene",
        "Triamthiazide",
        "Triamtide"
    ],
    "category": "Potassium-Sparing Diuretic",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "50 mg",
        "75 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Distal Convoluted Tubules and Collecting Ducts of the Kidney",
        "physiological_mechanism": "Inhibits sodium reabsorption in exchange for potassium and hydrogen ions by blocking epithelial sodium channels."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Increases sodium excretion and decreases potassium excretion.",
            "timeframe": "Effects observed within 2-4 hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Sodium Channel Inhibition",
        "key_targets": ["Epithelial Sodium Channels (ENaC)"],
        "related_conditions": ["Hypertension", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Variable absorption with bioavailability of ~50%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Metabolized to active metabolites."
        },
        "elimination": "Primarily excreted via urine."
    },
    "interactions": {
        "ACE Inhibitors": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive effects on potassium retention",
            "effect": "Increased risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Potassium-rich foods (may increase risk of hyperkalemia)"],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Systemic",
            "mechanism": "Reduces sodium reabsorption, leading to decreased plasma volume.",
            "direction": "Lowered blood pressure",
            "magnitude": "Moderate",
            "timeframe": "Within hours of therapy"
        }
    },
    "diagnostic_conditions": {
        "Edema": {
            "symptoms_addressed": ["Swelling", "Fluid Retention"],
            "therapeutic_action": "Promotes fluid excretion to reduce edema.",
            "optimal_dosage": "50-100 mg daily",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Nausea", "Headache"],
        "moderate": ["Hyperkalemia", "Muscle Cramps"],
        "severe": ["Severe Hyperkalemia", "Renal Impairment"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hyperkalemia and renal dysfunction."
        }
    },
    "alternative_therapies": ["Amiloride", "Spironolactone"],
    "combination_therapies": {
        "recommended_combinations": ["With thiazide diuretics to counteract potassium loss"],
        "cautions": ["Monitor for additive effects on potassium levels"]
    },
    "contraindications": ["Anuria", "Severe Hyperkalemia"],
    "precautions": ["Monitor for signs of dehydration", "Avoid use in patients with severe renal impairment"],
    "side_effects": ["Dizziness", "Nausea", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hyperkalemia", "Hypotension", "Arrhythmias"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate", "Insulin with Glucose"]
    },
    "notes": "Triamterene is marketed under various brand names, including Triamterene, Dyrenium, Dyazide, Maxzide, Triterene, Triazide, Diuretin, Hydriurese, Triampur, Triretic, Apo-Triamterene, Triamthiazide, and Triamtide. It is a potassium-sparing diuretic commonly used to manage hypertension and edema. Regular monitoring of serum potassium levels, renal function, and blood pressure is essential to prevent adverse effects such as hyperkalemia and renal impairment."
},
  
  {
    "iupac_name": "(2R,3R,4R,5R)-1,2,3,4,5,6-hexanehexol",
    "chemical_formula": "C6H14O6",
    "brand_names": [
        "Mannitol",
        "Osmitrol",
        "Resectisol",
        "Aridol",
        "Bronchitol",
        "Mannijet",
        "Mannilax",
        "Mannit",
        "Osmiton",
        "Mannogem",
        "Cryomannitol",
        "Humannitol",
        "Manilax"
    ],
    "category": "Osmotic Diuretic",
    "dosage_forms": [
        "Intravenous Solution",
        "Inhalation Powder",
        "Oral Solution"
    ],
    "strengths": [
        "5%",
        "10%",
        "15%",
        "20%"
    ],
    "mechanism_of_action": {
        "site_of_action": "Renal Tubules and Systemic Circulation",
        "physiological_mechanism": "Increases osmotic pressure in the renal tubules, inhibiting water reabsorption and promoting diuresis."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Promotes excretion of water, sodium, and chloride.",
            "timeframe": "Effects observed within 15-30 minutes of intravenous administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Osmotic Regulation",
        "key_targets": ["Renal Tubules"],
        "related_conditions": ["Cerebral Edema", "Increased Intracranial Pressure", "Oliguria"]
    },
    "pharmacokinetics": {
        "absorption": "Poorly absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "N/A",
            "enzymes": ["N/A"],
            "notes": "Excreted largely unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~80-90%)."
    },
    "interactions": {
        "Loop Diuretics": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive diuretic effects",
            "effect": "Increased risk of dehydration",
            "recommendation": "Monitor fluid and electrolyte balance."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": [],
        "toxins": ["None noted"]
    },
    "effects_on_symptoms": {
        "Cerebral Edema": {
            "site_of_effect": "Brain",
            "mechanism": "Reduces intracranial pressure by drawing fluid out of brain tissue.",
            "direction": "Decreased swelling",
            "magnitude": "Significant",
            "timeframe": "Within minutes of administration"
        }
    },
    "diagnostic_conditions": {
        "Acute Renal Failure": {
            "symptoms_addressed": ["Reduced Urine Output", "Fluid Retention"],
            "therapeutic_action": "Restores renal perfusion.",
            "optimal_dosage": "0.25-2 g/kg body weight IV",
            "response_time": "Minutes to hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Headache"],
        "moderate": ["Electrolyte Imbalance", "Dehydration"],
        "severe": ["Pulmonary Edema", "Heart Failure"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Fluid Balance"],
        "frequency": "Before and during treatment",
        "clinical_thresholds": {
            "normal_range": {
                "Serum Sodium": "135-145 mmol/L"
            },
            "alert_threshold": {
                "Serum Sodium": "<130 or >150 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution.",
            "rationale": "Increased risk of fluid and electrolyte imbalances."
        }
    },
    "alternative_therapies": ["Hypertonic Saline", "Loop Diuretics"],
    "combination_therapies": {
        "recommended_combinations": ["With furosemide for enhanced diuresis"],
        "cautions": ["Monitor for additive dehydration effects"]
    },
    "contraindications": ["Severe Renal Impairment", "Pulmonary Congestion"],
    "precautions": ["Monitor for signs of fluid overload", "Avoid in patients with active intracranial bleeding unless necessary"],
    "side_effects": ["Nausea", "Vomiting", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Dehydration", "Electrolyte Imbalance"],
        "treatment": ["Intravenous Fluids", "Electrolyte Correction"]
    },
    "notes": "Mannitol is marketed under various brand names, including Mannitol, Osmitrol, Resectisol, Aridol, Bronchitol, Mannijet, Mannilax, Mannit, Osmiton, Mannogem, Cryomannitol, Humannitol, and Manilax. It is an osmotic diuretic commonly used to manage cerebral edema, increased intracranial pressure, and acute renal failure. Regular monitoring of fluid balance, renal function, and serum electrolytes is essential to avoid adverse effects such as dehydration and electrolyte imbalances."
},
  
  {
    "iupac_name": "5-acetamido-1,3,4-thiadiazole-2-sulfonamide",
    "chemical_formula": "C4H6N4O3S2",
    "brand_names": [
        "Acetazolamide",
        "Diamox",
        "Diamox Sequels",
        "Acetazolam",
        "Acetazolid",
        "Acetazone",
        "Dazamide",
        "Eumonide",
        "Diurese-A",
        "Acetazolix",
        "Tiazidam",
        "Zolmide",
        "Acetamed",
        "Sulamox"
    ],
    "category": "Carbonic Anhydrase Inhibitor",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Intravenous Solution"
    ],
    "strengths": [
        "125 mg",
        "250 mg",
        "500 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Proximal Tubules of the Kidney",
        "physiological_mechanism": "Inhibits carbonic anhydrase, decreasing reabsorption of bicarbonate, sodium, and water, leading to diuresis."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Renal System",
            "effect": "Promotes urinary excretion of bicarbonate, sodium, potassium, and water.",
            "timeframe": "Effects observed within 1-2 hours of oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Carbonic Anhydrase Inhibition",
        "key_targets": ["Carbonic Anhydrase Enzyme"],
        "related_conditions": ["Glaucoma", "Altitude Sickness", "Edema"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed from the gastrointestinal tract.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["N/A"],
            "notes": "Excreted largely unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~90%)."
    },
    "interactions": {
        "Loop Diuretics": {
            "site_of_interaction": "Renal System",
            "mechanism": "Additive diuretic effects",
            "effect": "Increased risk of electrolyte imbalance",
            "recommendation": "Monitor electrolytes closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["May deplete potassium levels, requiring supplementation."],
        "toxins": ["None noted"]
    },
    "effects_on_symptoms": {
        "Glaucoma": {
            "site_of_effect": "Eye",
            "mechanism": "Reduces production of aqueous humor, lowering intraocular pressure.",
            "direction": "Decreased intraocular pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Altitude Sickness": {
            "symptoms_addressed": ["Headache", "Nausea", "Shortness of Breath"],
            "therapeutic_action": "Reduces respiratory alkalosis and prevents symptoms.",
            "optimal_dosage": "250 mg every 8-12 hours",
            "response_time": "Hours to days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Fatigue", "Dizziness"],
        "moderate": ["Electrolyte Imbalance", "Metabolic Acidosis"],
        "severe": ["Severe Hypokalemia", "Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Electrolytes", "Renal Function", "Blood Gases"],
        "frequency": "Every 1-3 months during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Bicarbonate": "22-28 mmol/L"
            },
            "alert_threshold": {
                "Bicarbonate": "<18 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased risk of electrolyte imbalances."
        }
    },
    "alternative_therapies": ["Mannitol", "Methazolamide"],
    "combination_therapies": {
        "recommended_combinations": ["With loop diuretics for refractory edema"],
        "cautions": ["Monitor for additive dehydration effects"]
    },
    "contraindications": ["Severe Renal Impairment", "Adrenal Insufficiency"],
    "precautions": ["Monitor for signs of metabolic acidosis", "Avoid in patients with sulfonamide allergy"],
    "side_effects": ["Nausea", "Fatigue", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Severe Electrolyte Imbalance", "Metabolic Acidosis"],
        "treatment": ["Intravenous Fluids", "Electrolyte Correction"]
    },
    "notes": "Acetazolamide is marketed under various brand names, including Acetazolamide, Diamox, Diamox Sequels, Acetazolam, Acetazolid, Acetazone, Dazamide, Eumonide, Diurese-A, Acetazolix, Tiazidam, Zolmide, Acetamed, and Sulamox. It is a carbonic anhydrase inhibitor commonly used to treat glaucoma, altitude sickness, and edema. Regular monitoring of serum electrolytes, renal function, and blood gases is essential to avoid adverse effects such as metabolic acidosis and electrolyte imbalances."
},
  {
    "iupac_name": "(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid",
    "chemical_formula": "C33H35FN2O5",
    "brand_names": [
        "Atorvastatin",
        "Lipitor",
        "Atorlip",
        "Torvast",
        "Sortis",
        "Tulip",
        "Torvacard",
        "Lipvas",
        "Atorvagen",
        "Aztor",
        "Xtor",
        "Cardyl",
        "Storvas",
        "Atocor",
        "Torstat"
    ],
    "category": "HMG-CoA Reductase Inhibitor (Statin)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "10 mg",
        "20 mg",
        "40 mg",
        "80 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver (Hepatocytes)",
        "physiological_mechanism": "Inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor expression, which enhances clearance of LDL cholesterol from the bloodstream."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Lipid Metabolism",
            "effect": "Reduces LDL cholesterol, triglycerides, and slightly increases HDL cholesterol.",
            "timeframe": "Onset within 2 weeks, maximum effect within 4-6 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "HMG-CoA Reductase Inhibition",
        "key_targets": ["HMG-CoA Reductase Enzyme"],
        "related_conditions": ["Hyperlipidemia", "Atherosclerosis", "Cardiovascular Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~12%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to active metabolites."
        },
        "elimination": "Primarily excreted via bile; minimal renal excretion (~2%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit atorvastatin metabolism, increasing plasma concentrations",
            "effect": "Increased risk of myopathy and rhabdomyolysis",
            "recommendation": "Avoid or adjust dose when using strong inhibitors like ketoconazole or clarithromycin."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (increases atorvastatin plasma levels)."],
        "toxins": ["Alcohol (may enhance liver toxicity)"]
    },
    "effects_on_symptoms": {
        "Hyperlipidemia": {
            "site_of_effect": "Bloodstream",
            "mechanism": "Lowers LDL cholesterol and triglycerides.",
            "direction": "Decreased LDL and triglycerides",
            "magnitude": "Significant",
            "timeframe": "Within weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Atherosclerosis": {
            "symptoms_addressed": ["Elevated LDL Cholesterol", "Plaque Formation"],
            "therapeutic_action": "Reduces LDL cholesterol and stabilizes plaques.",
            "optimal_dosage": "10-80 mg daily",
            "response_time": "Weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Diarrhea", "Nausea"],
        "moderate": ["Myalgia", "Elevated Liver Enzymes"],
        "severe": ["Rhabdomyolysis", "Severe Liver Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Lipid Profile", "Creatine Kinase Levels"],
        "frequency": "Baseline and periodically during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "LDL Cholesterol": "<100 mg/dL"
            },
            "alert_threshold": {
                "CK Levels": ">5x Upper Limit of Normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution.",
            "rationale": "Increased risk of myopathy and hepatic dysfunction."
        }
    },
    "alternative_therapies": ["Rosuvastatin", "Simvastatin"],
    "combination_therapies": {
        "recommended_combinations": ["With ezetimibe for severe hyperlipidemia"],
        "cautions": ["Monitor for additive liver enzyme elevation"]
    },
    "contraindications": ["Active Liver Disease", "Pregnancy"],
    "precautions": ["Monitor for muscle pain or weakness", "Avoid use in heavy alcohol consumers"],
    "side_effects": ["Headache", "Diarrhea", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Myopathy", "Elevated Liver Enzymes"],
        "treatment": ["Supportive care", "Liver monitoring"]
    },
    "notes": "Atorvastatin is marketed under various brand names, including Atorvastatin, Lipitor, Atorlip, Torvast, Sortis, Tulip, Torvacard, Lipvas, Atorvagen, Aztor, Xtor, Cardyl, Storvas, Atocor, and Torstat. It is a potent HMG-CoA reductase inhibitor commonly used to manage hyperlipidemia and reduce cardiovascular risk. Regular monitoring of lipid profiles and liver function is essential to optimize therapy and avoid adverse effects."
},
  {
    "iupac_name": "(3R,5R)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxyheptanoic acid",
    "chemical_formula": "C23H36O7",
    "brand_names": [
        "Pravastatin",
        "Pravachol",
        "Lipostat",
        "Selektine",
        "Pravator",
        "Pravalip",
        "Pravasin",
        "Cholstat",
        "Statonal",
        "Pravaselect",
        "Liposal",
        "Vasten",
        "Pravidel",
        "Pravatim",
        "Pravagen"
    ],
    "category": "HMG-CoA Reductase Inhibitor (Statin)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "10 mg",
        "20 mg",
        "40 mg",
        "80 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver (Hepatocytes)",
        "physiological_mechanism": "Inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor expression, enhancing clearance of LDL cholesterol from the bloodstream."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Lipid Metabolism",
            "effect": "Reduces LDL cholesterol, triglycerides, and moderately increases HDL cholesterol.",
            "timeframe": "Onset within 1-2 weeks, maximum effect within 4-6 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "HMG-CoA Reductase Inhibition",
        "key_targets": ["HMG-CoA Reductase Enzyme"],
        "related_conditions": ["Hyperlipidemia", "Atherosclerosis", "Cardiovascular Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Moderately absorbed with bioavailability of ~18%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["N/A"],
            "notes": "Minimally metabolized; primarily excreted unchanged."
        },
        "elimination": "Primarily excreted via bile; some renal excretion (~20%)."
    },
    "interactions": {
        "Bile Acid Sequestrants": {
            "site_of_interaction": "Intestines",
            "mechanism": "Reduce pravastatin absorption",
            "effect": "Decreased efficacy",
            "recommendation": "Administer pravastatin 1 hour before or 4 hours after bile acid sequestrants."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (minimal effect compared to other statins)."],
        "toxins": ["Alcohol (may enhance liver toxicity)"]
    },
    "effects_on_symptoms": {
        "Hyperlipidemia": {
            "site_of_effect": "Bloodstream",
            "mechanism": "Lowers LDL cholesterol and triglycerides.",
            "direction": "Decreased LDL and triglycerides",
            "magnitude": "Significant",
            "timeframe": "Within weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Atherosclerosis": {
            "symptoms_addressed": ["Elevated LDL Cholesterol", "Plaque Formation"],
            "therapeutic_action": "Reduces LDL cholesterol and stabilizes plaques.",
            "optimal_dosage": "10-40 mg daily",
            "response_time": "Weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Fatigue"],
        "moderate": ["Myalgia", "Elevated Liver Enzymes"],
        "severe": ["Rhabdomyolysis", "Severe Liver Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Lipid Profile", "Creatine Kinase Levels"],
        "frequency": "Baseline and periodically during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "LDL Cholesterol": "<100 mg/dL"
            },
            "alert_threshold": {
                "CK Levels": ">5x Upper Limit of Normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution.",
            "rationale": "Increased risk of myopathy and hepatic dysfunction."
        }
    },
    "alternative_therapies": ["Rosuvastatin", "Simvastatin"],
    "combination_therapies": {
        "recommended_combinations": ["With ezetimibe for severe hyperlipidemia"],
        "cautions": ["Monitor for additive liver enzyme elevation"]
    },
    "contraindications": ["Active Liver Disease", "Pregnancy"],
    "precautions": ["Monitor for muscle pain or weakness", "Avoid use in heavy alcohol consumers"],
    "side_effects": ["Headache", "Nausea", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Severe Myopathy", "Elevated Liver Enzymes"],
        "treatment": ["Supportive care", "Liver monitoring"]
    },
    "notes": "Pravastatin is marketed under various brand names, including Pravastatin, Pravachol, Lipostat, Selektine, Pravator, Pravalip, Pravasin, Cholstat, Statonal, Pravaselect, Liposal, Vasten, Pravidel, Pravatim, and Pravagen. It is a moderate-intensity statin commonly used to manage hyperlipidemia and reduce cardiovascular risk. Regular monitoring of lipid profiles and liver function is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2-methylbutanoate",
    "chemical_formula": "C24H36O5",
    "brand_names": [
        "Lovastatin",
        "Mevacor",
        "Altocor",
        "Altoprev",
        "Lipex",
        "Lowpez",
        "Lovatime",
        "Lobeta",
        "Statcor",
        "Lovastyl",
        "Lozavel",
        "Lovamax",
        "Lovator",
        "Lovapin"
    ],
    "category": "HMG-CoA Reductase Inhibitor (Statin)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "10 mg",
        "20 mg",
        "40 mg",
        "60 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Liver (Hepatocytes)",
        "physiological_mechanism": "Inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor expression, enhancing clearance of LDL cholesterol from the bloodstream."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Lipid Metabolism",
            "effect": "Reduces LDL cholesterol, triglycerides, and moderately increases HDL cholesterol.",
            "timeframe": "Onset within 1-2 weeks, maximum effect within 4-6 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "HMG-CoA Reductase Inhibition",
        "key_targets": ["HMG-CoA Reductase Enzyme"],
        "related_conditions": ["Hyperlipidemia", "Atherosclerosis", "Cardiovascular Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Moderately absorbed; bioavailability ~30% when taken with food.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to active metabolites."
        },
        "elimination": "Primarily excreted via bile; minimal renal excretion (~10%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit lovastatin metabolism, increasing plasma concentrations",
            "effect": "Increased risk of myopathy and rhabdomyolysis",
            "recommendation": "Avoid or adjust dose when using strong inhibitors like ketoconazole or erythromycin."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (increases lovastatin plasma levels)."],
        "toxins": ["Alcohol (may enhance liver toxicity)"]
    },
    "effects_on_symptoms": {
        "Hyperlipidemia": {
            "site_of_effect": "Bloodstream",
            "mechanism": "Lowers LDL cholesterol and triglycerides.",
            "direction": "Decreased LDL and triglycerides",
            "magnitude": "Significant",
            "timeframe": "Within weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Atherosclerosis": {
            "symptoms_addressed": ["Elevated LDL Cholesterol", "Plaque Formation"],
            "therapeutic_action": "Reduces LDL cholesterol and stabilizes plaques.",
            "optimal_dosage": "20-40 mg daily",
            "response_time": "Weeks to months"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Diarrhea"],
        "moderate": ["Myalgia", "Elevated Liver Enzymes"],
        "severe": ["Rhabdomyolysis", "Severe Liver Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Lipid Profile", "Creatine Kinase Levels"],
        "frequency": "Baseline and periodically during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "LDL Cholesterol": "<100 mg/dL"
            },
            "alert_threshold": {
                "CK Levels": ">5x Upper Limit of Normal"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution.",
            "rationale": "Increased risk of myopathy and hepatic dysfunction."
        }
    },
    "alternative_therapies": ["Rosuvastatin", "Simvastatin"],
    "combination_therapies": {
        "recommended_combinations": ["With ezetimibe for severe hyperlipidemia"],
        "cautions": ["Monitor for additive liver enzyme elevation"]
    },
    "contraindications": ["Active Liver Disease", "Pregnancy"],
    "precautions": ["Monitor for muscle pain or weakness", "Avoid use in heavy alcohol consumers"],
    "side_effects": ["Headache", "Nausea", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Severe Myopathy", "Elevated Liver Enzymes"],
        "treatment": ["Supportive care", "Liver monitoring"]
    },
    "notes": "Lovastatin is marketed under various brand names, including Lovastatin, Mevacor, Altocor, Altoprev, Lipex, Lowpez, Lovatime, Lobeta, Statcor, Lovastyl, Lozavel, Lovamax, Lovator, and Lovapin. It is a moderate-intensity statin commonly used to manage hyperlipidemia and reduce cardiovascular risk. Regular monitoring of lipid profiles and liver function is essential to optimize therapy and avoid adverse effects."
},
  {
    "iupac_name": "(2S)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid",
    "chemical_formula": "C20H28N2O5",
    "brand_names": [
        "Enalapril",
        "Vasotec",
        "Renitec",
        "Enap",
        "Lexxel",
        "Epaned",
        "Cortec",
        "Enapril",
        "Napril",
        "Enahexal",
        "Renapril",
        "Zonapril",
        "Enalix",
        "Cardiprime",
        "Hypace"
    ],
    "category": "ACE Inhibitor",
    "dosage_forms": [
        "Tablets",
        "Oral Solution"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "10 mg",
        "20 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Renin-Angiotensin-Aldosterone System (RAAS)",
        "physiological_mechanism": "Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces systemic vascular resistance and blood pressure.",
            "timeframe": "Onset within 1 hour, peak effect in 4-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-Angiotensin-Aldosterone Pathway",
        "key_targets": ["Angiotensin-Converting Enzyme (ACE)"],
        "related_conditions": ["Hypertension", "Heart Failure", "Diabetic Nephropathy"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~60%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Hepatic Esterases"],
            "notes": "Prodrug converted to active enalaprilat."
        },
        "elimination": "Primarily excreted via urine (~94%)."
    },
    "interactions": {
        "Potassium Supplements": {
            "site_of_interaction": "Renal System",
            "mechanism": "Increases potassium retention",
            "effect": "Risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Avoid potassium-rich foods to prevent hyperkalemia."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels",
            "mechanism": "Reduces vasoconstriction and fluid retention.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath"],
            "therapeutic_action": "Reduces afterload and improves cardiac output.",
            "optimal_dosage": "5-20 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue", "Headache"],
        "moderate": ["Hyperkalemia", "Dry Cough"],
        "severe": ["Angioedema", "Renal Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hypotensive effects."
        }
    },
    "alternative_therapies": ["Lisinopril", "Ramipril"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for resistant hypertension"],
        "cautions": ["Monitor for additive hyperkalemia"]
    },
    "contraindications": ["History of angioedema related to ACE inhibitors", "Bilateral renal artery stenosis"],
    "precautions": ["Monitor for signs of angioedema", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Fatigue", "Dry Cough"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Acute Renal Failure"],
        "treatment": ["Intravenous Fluids", "Hemodialysis"]
    },
    "notes": "Enalapril is marketed under various brand names, including Enalapril, Vasotec, Renitec, Enap, Lexxel, Epaned, Cortec, Enapril, Napril, Enahexal, Renapril, Zonapril, Enalix, Cardiprime, and Hypace. It is a widely used ACE inhibitor for managing hypertension, heart failure, and diabetic nephropathy. Regular monitoring of renal function, serum potassium, and blood pressure is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "(2S)-1-[(2S)-6-amino-2-[((1S)-1-carboxy-3-phenylpropyl)amino]hexanoyl]pyrrolidine-2-carboxylic acid",
    "chemical_formula": "C21H31N3O5",
    "brand_names": [
        "Lisinopril",
        "Prinivil",
        "Zestril",
        "Lisodur",
        "Lipril",
        "Listril",
        "Lisin",
        "Linvas",
        "Lupin-Lisinopril",
        "Lisoretic",
        "Sinopryl",
        "Zestrilex",
        "Lisotec",
        "Zecor",
        "Dapril"
    ],
    "category": "ACE Inhibitor",
    "dosage_forms": [
        "Tablets",
        "Oral Solution"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "10 mg",
        "20 mg",
        "40 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Renin-Angiotensin-Aldosterone System (RAAS)",
        "physiological_mechanism": "Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces systemic vascular resistance and blood pressure.",
            "timeframe": "Onset within 1 hour, peak effect in 6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-Angiotensin-Aldosterone Pathway",
        "key_targets": ["Angiotensin-Converting Enzyme (ACE)"],
        "related_conditions": ["Hypertension", "Heart Failure", "Diabetic Nephropathy"]
    },
    "pharmacokinetics": {
        "absorption": "Slowly absorbed with bioavailability of ~25%.",
        "metabolism": {
            "primary_site": "Not metabolized",
            "enzymes": ["N/A"],
            "notes": "Excreted unchanged in urine."
        },
        "elimination": "Primarily excreted via urine (~100%)."
    },
    "interactions": {
        "Potassium Supplements": {
            "site_of_interaction": "Renal System",
            "mechanism": "Increases potassium retention",
            "effect": "Risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Avoid potassium-rich foods to prevent hyperkalemia."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels",
            "mechanism": "Reduces vasoconstriction and fluid retention.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath"],
            "therapeutic_action": "Reduces afterload and improves cardiac output.",
            "optimal_dosage": "10-40 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue", "Headache"],
        "moderate": ["Hyperkalemia", "Dry Cough"],
        "severe": ["Angioedema", "Renal Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hypotensive effects."
        }
    },
    "alternative_therapies": ["Enalapril", "Ramipril"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for resistant hypertension"],
        "cautions": ["Monitor for additive hyperkalemia"]
    },
    "contraindications": ["History of angioedema related to ACE inhibitors", "Bilateral renal artery stenosis"],
    "precautions": ["Monitor for signs of angioedema", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Fatigue", "Dry Cough"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Acute Renal Failure"],
        "treatment": ["Intravenous Fluids", "Hemodialysis"]
    },
    "notes": "Lisinopril is marketed under various brand names, including Lisinopril, Prinivil, Zestril, Lisodur, Lipril, Listril, Lisin, Linvas, Lupin-Lisinopril, Lisoretic, Sinopryl, Zestrilex, Lisotec, Zecor, and Dapril. It is a widely used ACE inhibitor for managing hypertension, heart failure, and diabetic nephropathy. Regular monitoring of renal function, serum potassium, and blood pressure is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "[2-butyl-5-chloro-3-(4-[[2-(1H-tetrazol-5-yl)phenyl]methyl]phenyl)imidazol-4-yl]methanol",
    "chemical_formula": "C22H23ClN6O",
    "brand_names": [
        "Losartan",
        "Cozaar",
        "Hyzaar",
        "Lortaan",
        "Losatec",
        "Lozartan",
        "Losar",
        "Losazide",
        "Arbistar",
        "Angiotec",
        "Lostar",
        "Lozap",
        "Zisartan",
        "Lorzaar",
        "Vasartan"
    ],
    "category": "Angiotensin II Receptor Blocker (ARB)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "25 mg",
        "50 mg",
        "100 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Renin-Angiotensin-Aldosterone System (RAAS)",
        "physiological_mechanism": "Blocks angiotensin II from binding to its receptor (AT1 subtype), leading to vasodilation, reduced aldosterone secretion, and lower blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces systemic vascular resistance and blood pressure.",
            "timeframe": "Onset within 1 hour, peak effect in 6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-Angiotensin-Aldosterone Pathway",
        "key_targets": ["Angiotensin II Type 1 Receptor (AT1R)"],
        "related_conditions": ["Hypertension", "Heart Failure", "Diabetic Nephropathy"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~33%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9", "CYP3A4"],
            "notes": "Converted to an active metabolite, EXP3174, which is more potent than losartan."
        },
        "elimination": "Primarily excreted via urine (~35%) and bile (~60%)."
    },
    "interactions": {
        "Potassium Supplements": {
            "site_of_interaction": "Renal System",
            "mechanism": "Increases potassium retention",
            "effect": "Risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Avoid potassium-rich foods to prevent hyperkalemia."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels",
            "mechanism": "Reduces vasoconstriction and fluid retention.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath"],
            "therapeutic_action": "Reduces afterload and improves cardiac output.",
            "optimal_dosage": "50-100 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue", "Headache"],
        "moderate": ["Hyperkalemia", "Hypotension"],
        "severe": ["Angioedema", "Renal Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hypotensive effects."
        }
    },
    "alternative_therapies": ["Valsartan", "Irbesartan"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for resistant hypertension"],
        "cautions": ["Monitor for additive hyperkalemia"]
    },
    "contraindications": ["History of angioedema related to ARBs", "Bilateral renal artery stenosis"],
    "precautions": ["Monitor for signs of angioedema", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Fatigue", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Acute Renal Failure"],
        "treatment": ["Intravenous Fluids", "Hemodialysis"]
    },
    "notes": "Losartan is marketed under various brand names, including Losartan, Cozaar, Hyzaar, Lortaan, Losatec, Lozartan, Losar, Losazide, Arbistar, Angiotec, Lostar, Lozap, Zisartan, Lorzaar, and Vasartan. It is a widely used ARB for managing hypertension, heart failure, and diabetic nephropathy. Regular monitoring of renal function, serum potassium, and blood pressure is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "(S)-N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine",
    "chemical_formula": "C24H29N5O3",
    "brand_names": [
        "Valsartan",
        "Diovan",
        "Prexxartan",
        "Exforge",
        "Co-Diovan",
        "Valzaar",
        "Vartan",
        "Tareg",
        "Valpress",
        "Vassel",
        "Sartoval",
        "Valtoval",
        "Valix",
        "Valzide",
        "Valtin"
    ],
    "category": "Angiotensin II Receptor Blocker (ARB)",
    "dosage_forms": [
        "Tablets",
        "Oral Solution"
    ],
    "strengths": [
        "40 mg",
        "80 mg",
        "160 mg",
        "320 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Renin-Angiotensin-Aldosterone System (RAAS)",
        "physiological_mechanism": "Blocks angiotensin II from binding to its receptor (AT1 subtype), leading to vasodilation, reduced aldosterone secretion, and lower blood pressure."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces systemic vascular resistance and blood pressure.",
            "timeframe": "Onset within 2 hours, peak effect in 4-6 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Renin-Angiotensin-Aldosterone Pathway",
        "key_targets": ["Angiotensin II Type 1 Receptor (AT1R)"],
        "related_conditions": ["Hypertension", "Heart Failure", "Diabetic Nephropathy"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~25%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C9"],
            "notes": "Undergoes minimal metabolism; primarily excreted unchanged."
        },
        "elimination": "Primarily excreted via bile (~83%) and urine (~13%)."
    },
    "interactions": {
        "Potassium Supplements": {
            "site_of_interaction": "Renal System",
            "mechanism": "Increases potassium retention",
            "effect": "Risk of hyperkalemia",
            "recommendation": "Monitor serum potassium levels."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Avoid potassium-rich foods to prevent hyperkalemia."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels",
            "mechanism": "Reduces vasoconstriction and fluid retention.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Heart Failure": {
            "symptoms_addressed": ["Fatigue", "Shortness of Breath"],
            "therapeutic_action": "Reduces afterload and improves cardiac output.",
            "optimal_dosage": "80-160 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Dizziness", "Fatigue", "Headache"],
        "moderate": ["Hyperkalemia", "Hypotension"],
        "severe": ["Angioedema", "Renal Dysfunction"]
    },
    "long_term_monitoring": {
        "parameters": ["Serum Potassium", "Renal Function", "Blood Pressure"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Potassium": "3.5-5.0 mmol/L"
            },
            "alert_threshold": {
                "Potassium": ">5.5 mmol/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to hypotensive effects."
        }
    },
    "alternative_therapies": ["Losartan", "Irbesartan"],
    "combination_therapies": {
        "recommended_combinations": ["With diuretics for resistant hypertension"],
        "cautions": ["Monitor for additive hyperkalemia"]
    },
    "contraindications": ["History of angioedema related to ARBs", "Bilateral renal artery stenosis"],
    "precautions": ["Monitor for signs of angioedema", "Adjust dose in renal impairment"],
    "side_effects": ["Dizziness", "Fatigue", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Acute Renal Failure"],
        "treatment": ["Intravenous Fluids", "Hemodialysis"]
    },
    "notes": "Valsartan is marketed under various brand names, including Valsartan, Diovan, Prexxartan, Exforge, Co-Diovan, Valzaar, Vartan, Tareg, Valpress, Vassel, Sartoval, Valtoval, Valix, Valzide, and Valtin. It is a widely used ARB for managing hypertension, heart failure, and diabetic nephropathy. Regular monitoring of renal function, serum potassium, and blood pressure is essential to optimize therapy and avoid adverse effects."
},
  {
    "iupac_name": "3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",
    "chemical_formula": "C20H25ClN2O5",
    "brand_names": [
        "Amlodipine",
        "Norvasc",
        "Amcard",
        "Amvasc",
        "Amodip",
        "Amlo",
        "Amlotop",
        "Amlopin",
        "Cardovas",
        "Stamlo",
        "Istin",
        "Amloc",
        "Amchek",
        "Exforge",
        "Azor"
    ],
    "category": "Calcium Channel Blocker (Dihydropyridine)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "10 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "L-Type Calcium Channels in Vascular Smooth Muscle and Myocardium",
        "physiological_mechanism": "Inhibits calcium influx, leading to relaxation of vascular smooth muscle and myocardial cells, reducing peripheral resistance and oxygen demand."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces systemic vascular resistance and blood pressure.",
            "timeframe": "Onset within 30 minutes, peak effect in 6-12 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Calcium Channel Modulation",
        "key_targets": ["L-Type Calcium Channels"],
        "related_conditions": ["Hypertension", "Angina Pectoris", "Coronary Artery Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~64-90%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~60%) and feces (~40%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit amlodipine metabolism, increasing plasma concentrations",
            "effect": "Enhanced antihypertensive effects",
            "recommendation": "Monitor blood pressure and adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (may slightly increase plasma levels)."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels",
            "mechanism": "Reduces vascular resistance.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Angina Pectoris": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath"],
            "therapeutic_action": "Improves myocardial oxygen delivery and reduces demand.",
            "optimal_dosage": "5-10 mg daily",
            "response_time": "Days to weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Dizziness", "Flushing"],
        "moderate": ["Edema", "Palpitations"],
        "severe": ["Hypotension", "Severe Bradycardia"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood Pressure", "Heart Rate"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Systolic Blood Pressure": "<140 mmHg"
            },
            "alert_threshold": {
                "Systolic Blood Pressure": ">180 mmHg or <90 mmHg"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to antihypertensive effects."
        }
    },
    "alternative_therapies": ["Nifedipine", "Verapamil"],
    "combination_therapies": {
        "recommended_combinations": ["With ARBs for resistant hypertension"],
        "cautions": ["Monitor for additive hypotensive effects"]
    },
    "contraindications": ["Severe Hypotension", "Cardiogenic Shock"],
    "precautions": ["Monitor for worsening of heart failure in susceptible individuals", "Adjust dose in hepatic impairment"],
    "side_effects": ["Headache", "Dizziness", "Flushing"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Bradycardia"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate"]
    },
    "notes": "Amlodipine is marketed under various brand names, including Amlodipine, Norvasc, Amcard, Amvasc, Amodip, Amlo, Amlotop, Amlopin, Cardovas, Stamlo, Istin, Amloc, Amchek, Exforge, and Azor. It is a widely used calcium channel blocker for managing hypertension and angina pectoris. Regular monitoring of blood pressure and heart rate is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "(2R,3S)-2-[(3,4-dimethoxyphenyl)methyl]-3-(3,4-dimethoxyphenyl)-3-prop-2-ynylpyrrolidine-1-carboxylate",
    "chemical_formula": "C27H38N2O4",
    "brand_names": [
        "Verapamil",
        "Calan",
        "Isoptin",
        "Verelan",
        "Covera-HS",
        "Co-verap",
        "Cardil",
        "Calaptin",
        "Univer",
        "Veracor",
        "Vasotop",
        "Verabeta",
        "Vasocard",
        "Anpec",
        "Finoptin"
    ],
    "category": "Calcium Channel Blocker (Non-Dihydropyridine)",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Tablets",
        "Capsules",
        "Intravenous Solution"
    ],
    "strengths": [
        "40 mg",
        "80 mg",
        "120 mg",
        "180 mg",
        "240 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "L-Type Calcium Channels in Vascular Smooth Muscle, Myocardium, and Cardiac Conduction System",
        "physiological_mechanism": "Inhibits calcium influx, reducing myocardial contractility, slowing conduction through the AV node, and relaxing vascular smooth muscle."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces blood pressure, heart rate, and myocardial oxygen demand.",
            "timeframe": "Onset within 1-2 hours for oral forms, immediate for intravenous."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Calcium Channel Modulation",
        "key_targets": ["L-Type Calcium Channels"],
        "related_conditions": ["Hypertension", "Angina Pectoris", "Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed but undergoes extensive first-pass metabolism; bioavailability ~20-35%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~70%) and feces (~16%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit verapamil metabolism, increasing plasma concentrations",
            "effect": "Enhanced cardiovascular effects",
            "recommendation": "Monitor for bradycardia and hypotension; adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (may increase plasma levels)."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels and Heart",
            "mechanism": "Reduces vascular resistance and myocardial contractility.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Arrhythmias": {
            "symptoms_addressed": ["Palpitations", "Irregular Heartbeat"],
            "therapeutic_action": "Slows conduction through the AV node.",
            "optimal_dosage": "240-480 mg daily (oral); 5-10 mg IV for acute arrhythmias",
            "response_time": "Minutes for intravenous; hours for oral."
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Dizziness", "Constipation"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood Pressure", "Heart Rate", "ECG"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm or >120 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to bradycardia and hypotension."
        }
    },
    "alternative_therapies": ["Diltiazem", "Amlodipine"],
    "combination_therapies": {
        "recommended_combinations": ["With ARBs for resistant hypertension"],
        "cautions": ["Monitor for additive bradycardia"]
    },
    "contraindications": ["Severe Hypotension", "Cardiogenic Shock", "Advanced Heart Block"],
    "precautions": ["Monitor for worsening of heart failure in susceptible individuals", "Adjust dose in hepatic impairment"],
    "side_effects": ["Headache", "Dizziness", "Constipation"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Bradycardia", "Heart Block"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate", "Atropine"]
    },
    "notes": "Verapamil is marketed under various brand names, including Verapamil, Calan, Isoptin, Verelan, Covera-HS, Co-verap, Cardil, Calaptin, Univer, Veracor, Vasotop, Verabeta, Vasocard, Anpec, and Finoptin. It is a non-dihydropyridine calcium channel blocker used for managing hypertension, angina pectoris, and arrhythmias. Regular monitoring of blood pressure, heart rate, and ECG is essential to optimize therapy and avoid adverse effects."
},
  {
    "iupac_name": "(2S,3S)-3-(2-(dimethylamino)ethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one",
    "chemical_formula": "C22H26N2O4S",
    "brand_names": [
        "Diltiazem",
        "Cardizem",
        "Dilacor",
        "Tiazac",
        "Cartia XT",
        "Dilt-XR",
        "Dilzem",
        "Adizem",
        "Angizem",
        "Herbesser",
        "Tildiem",
        "Calmady",
        "Cordial",
        "Dilacoron",
        "Blocalcin"
    ],
    "category": "Calcium Channel Blocker (Non-Dihydropyridine)",
    "dosage_forms": [
        "Tablets",
        "Extended-Release Tablets",
        "Capsules",
        "Intravenous Solution"
    ],
    "strengths": [
        "30 mg",
        "60 mg",
        "90 mg",
        "120 mg",
        "180 mg",
        "240 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "L-Type Calcium Channels in Vascular Smooth Muscle, Myocardium, and Cardiac Conduction System",
        "physiological_mechanism": "Inhibits calcium influx, reducing myocardial contractility, slowing conduction through the AV node, and relaxing vascular smooth muscle."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cardiovascular System",
            "effect": "Reduces blood pressure, heart rate, and myocardial oxygen demand.",
            "timeframe": "Onset within 2-4 hours for oral forms, immediate for intravenous."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Calcium Channel Modulation",
        "key_targets": ["L-Type Calcium Channels"],
        "related_conditions": ["Hypertension", "Angina Pectoris", "Arrhythmias"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed but undergoes extensive first-pass metabolism; bioavailability ~40%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~65%) and feces (~35%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit diltiazem metabolism, increasing plasma concentrations",
            "effect": "Enhanced cardiovascular effects",
            "recommendation": "Monitor for bradycardia and hypotension; adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (may increase plasma levels)."],
        "toxins": ["Alcohol (may enhance hypotensive effects)"]
    },
    "effects_on_symptoms": {
        "Hypertension": {
            "site_of_effect": "Blood Vessels and Heart",
            "mechanism": "Reduces vascular resistance and myocardial contractility.",
            "direction": "Decreased blood pressure",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Arrhythmias": {
            "symptoms_addressed": ["Palpitations", "Irregular Heartbeat"],
            "therapeutic_action": "Slows conduction through the AV node.",
            "optimal_dosage": "120-360 mg daily (oral); 0.25 mg/kg IV for acute arrhythmias",
            "response_time": "Minutes for intravenous; hours for oral."
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Dizziness", "Nausea"],
        "moderate": ["Bradycardia", "Hypotension"],
        "severe": ["Heart Block", "Severe Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Blood Pressure", "Heart Rate", "ECG"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": "<50 bpm or >120 bpm"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Start with lower doses.",
            "rationale": "Increased sensitivity to bradycardia and hypotension."
        }
    },
    "alternative_therapies": ["Verapamil", "Amlodipine"],
    "combination_therapies": {
        "recommended_combinations": ["With ARBs for resistant hypertension"],
        "cautions": ["Monitor for additive bradycardia"]
    },
    "contraindications": ["Severe Hypotension", "Cardiogenic Shock", "Advanced Heart Block"],
    "precautions": ["Monitor for worsening of heart failure in susceptible individuals", "Adjust dose in hepatic impairment"],
    "side_effects": ["Headache", "Dizziness", "Nausea"],
    "overdose_management": {
        "symptoms": ["Severe Hypotension", "Bradycardia", "Heart Block"],
        "treatment": ["Intravenous Fluids", "Calcium Gluconate", "Atropine"]
    },
    "notes": "Diltiazem is marketed under various brand names, including Diltiazem, Cardizem, Dilacor, Tiazac, Cartia XT, Dilt-XR, Dilzem, Adizem, Angizem, Herbesser, Tildiem, Calmady, Cordial, Dilacoron, and Blocalcin. It is a non-dihydropyridine calcium channel blocker used for managing hypertension, angina pectoris, and arrhythmias. Regular monitoring of blood pressure, heart rate, and ECG is essential to optimize therapy and avoid adverse effects."
},
  
  {
    "iupac_name": "(2aR,4S,4aS,6R,9S,11S,12R,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,4,4a,5,9,10,11,12a-octahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-1H,2H-oxireno[4,3-b]oxireno[2,3-i]isochromene-7,14-dione",
    "chemical_formula": "C47H51NO14",
    "brand_names": [
        "Paclitaxel",
        "Taxol",
        "Onxol",
        "Abraxane",
        "Intaxel",
        "Paxene",
        "Taxetere",
        "Paclimed",
        "Nanoxel",
        "Anzatax",
        "Asotax",
        "Lipusu",
        "Genetaxel",
        "Biotaxel",
        "Taxofed"
    ],
    "category": "Antineoplastic Agent (Taxane Derivative)",
    "dosage_forms": [
        "Injection Solution",
        "Lyophilized Powder for Injection"
    ],
    "strengths": [
        "30 mg",
        "100 mg",
        "150 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Microtubules in Cancer Cells",
        "physiological_mechanism": "Stabilizes microtubules, preventing their depolymerization during mitosis, which disrupts cell division and leads to apoptosis."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cellular Level",
            "effect": "Inhibits mitotic progression, leading to cell cycle arrest and apoptosis.",
            "timeframe": "Effects observed during active cell division."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Microtubule Dynamics Modulation",
        "key_targets": ["Tubulin"],
        "related_conditions": ["Breast Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer"]
    },
    "pharmacokinetics": {
        "absorption": "Administered intravenously; systemic bioavailability is complete.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C8", "CYP3A4"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via feces (~90%); minimal renal excretion (~10%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit paclitaxel metabolism, increasing plasma concentrations",
            "effect": "Enhanced toxicity",
            "recommendation": "Adjust paclitaxel dosage if co-administered with strong CYP3A4 inhibitors."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (may increase plasma levels)."],
        "toxins": ["Alcohol (may exacerbate hepatic toxicity)"]
    },
    "effects_on_symptoms": {
        "Cancer": {
            "site_of_effect": "Cancer Cells",
            "mechanism": "Disrupts cell division by stabilizing microtubules.",
            "direction": "Inhibits tumor growth",
            "magnitude": "Significant",
            "timeframe": "Within treatment cycles"
        }
    },
    "diagnostic_conditions": {
        "Metastatic Cancer": {
            "symptoms_addressed": ["Tumor Growth", "Metastasis"],
            "therapeutic_action": "Slows progression and induces tumor regression.",
            "optimal_dosage": "175 mg/m2 IV every 3 weeks",
            "response_time": "Within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Alopecia"],
        "moderate": ["Peripheral Neuropathy", "Myelosuppression"],
        "severe": ["Severe Hypersensitivity Reactions", "Cardiac Arrhythmias"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Liver Function Tests", "Neurological Status"],
        "frequency": "Before each treatment cycle",
        "clinical_thresholds": {
            "normal_range": {
                "Neutrophils": ">1.5 x 10^9/L"
            },
            "alert_threshold": {
                "Neutrophils": "<0.5 x 10^9/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution; monitor for enhanced toxicity.",
            "rationale": "Increased sensitivity to myelosuppression and neuropathy."
        }
    },
    "alternative_therapies": ["Docetaxel", "Carboplatin"],
    "combination_therapies": {
        "recommended_combinations": ["With cisplatin for ovarian cancer"],
        "cautions": ["Monitor for additive myelosuppression"]
    },
    "contraindications": ["Severe neutropenia", "Hypersensitivity to paclitaxel or excipients"],
    "precautions": ["Premedicate with corticosteroids and antihistamines to prevent hypersensitivity reactions", "Monitor for signs of peripheral neuropathy"],
    "side_effects": ["Nausea", "Vomiting", "Alopecia"],
    "overdose_management": {
        "symptoms": ["Severe Myelosuppression", "Neurotoxicity"],
        "treatment": ["Supportive care", "G-CSF for neutropenia"]
    },
    "notes": "Paclitaxel is marketed under various brand names, including Paclitaxel, Taxol, Onxol, Abraxane, Intaxel, Paxene, Taxetere, Paclimed, Nanoxel, Anzatax, Asotax, Lipusu, Genetaxel, Biotaxel, and Taxofed. It is an antineoplastic agent widely used in the treatment of breast, ovarian, and non-small cell lung cancers. Premedication to prevent hypersensitivity reactions and regular monitoring of complete blood count and liver function are essential for safe use."
},
  
  {
    "iupac_name": "Methyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate",
    "chemical_formula": "C16H16ClNO2S",
    "brand_names": [
        "Clopidogrel",
        "Plavix",
        "Iscover",
        "Clopilet",
        "Ceruvin",
        "Deplatt",
        "Clopivas",
        "Crestor",
        "Pridogrel",
        "Zyllt",
        "Thrombolet",
        "Egitromb",
        "Myogrel",
        "Clopigrel",
        "Occlusal"
    ],
    "category": "Antiplatelet Agent",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "75 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Platelets",
        "physiological_mechanism": "Irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing ADP-mediated activation of the GPIIb/IIIa complex, reducing platelet aggregation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematologic System",
            "effect": "Inhibits platelet aggregation, reducing the risk of thrombus formation.",
            "timeframe": "Onset within 2 hours, maximum effect in 3-7 days."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Platelet Aggregation Inhibition",
        "key_targets": ["P2Y12 ADP Receptor"],
        "related_conditions": ["Acute Coronary Syndrome", "Stroke Prevention", "Peripheral Arterial Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~50%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Prodrug converted to an active metabolite."
        },
        "elimination": "Primarily excreted via urine (~50%) and feces (~46%)."
    },
    "interactions": {
        "Proton Pump Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit CYP2C19, reducing activation of clopidogrel",
            "effect": "Decreased antiplatelet effect",
            "recommendation": "Use alternative antacid therapy or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may increase bleeding risk)"]
    },
    "effects_on_symptoms": {
        "Thrombosis Prevention": {
            "site_of_effect": "Platelets",
            "mechanism": "Inhibits platelet aggregation.",
            "direction": "Decreased thrombus formation",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Acute Coronary Syndrome": {
            "symptoms_addressed": ["Chest Pain", "Dyspnea"],
            "therapeutic_action": "Reduces the risk of further cardiovascular events.",
            "optimal_dosage": "75 mg daily; initial loading dose of 300 mg may be used.",
            "response_time": "Within hours for acute settings"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Dizziness"],
        "moderate": ["Bleeding", "Bruising"],
        "severe": ["Severe Bleeding", "Thrombotic Thrombocytopenic Purpura (TTP)"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Platelet Function Tests"],
        "frequency": "Periodically during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Platelet Aggregation": "<50%"
            },
            "alert_threshold": {
                "Platelet Aggregation": ">70%"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use with caution; monitor for enhanced bleeding risk.",
            "rationale": "Increased sensitivity to bleeding complications."
        }
    },
    "alternative_therapies": ["Aspirin", "Ticagrelor"],
    "combination_therapies": {
        "recommended_combinations": ["With aspirin for dual antiplatelet therapy"],
        "cautions": ["Monitor for additive bleeding risk"]
    },
    "contraindications": ["Active bleeding", "Severe hepatic impairment"],
    "precautions": ["Monitor for signs of bleeding", "Use with caution in patients with a history of gastrointestinal ulcers"],
    "side_effects": ["Nausea", "Headache", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Severe Bleeding", "Hypotension"],
        "treatment": ["Supportive care", "Platelet transfusion if necessary"]
    },
    "notes": "Clopidogrel is marketed under various brand names, including Clopidogrel, Plavix, Iscover, Clopilet, Ceruvin, Deplatt, Clopivas, Crestor, Pridogrel, Zyllt, Thrombolet, Egitromb, Myogrel, Clopigrel, and Occlusal. It is a widely used antiplatelet agent for the prevention of cardiovascular and cerebrovascular events. Regular monitoring of platelet function and signs of bleeding is essential to optimize therapy and avoid complications."
},
  
  {
    "iupac_name": "5-Chloro-N-({[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl]methyl}amino)-2-thiophenecarboxamide",
    "chemical_formula": "C19H18ClN3O5S",
    "brand_names": [
        "Rivaroxaban",
        "Xarelto",
        "Rivaflo",
        "Rivaxo",
        "Rivaban",
        "Xaroban",
        "Rivabond",
        "Xabin",
        "Zarelto",
        "Rivolar",
        "Ovanox",
        "Rivaxa",
        "Rivact",
        "Rivastop",
        "Baxor"
    ],
    "category": "Direct Oral Anticoagulant (DOAC)",
    "dosage_forms": [
        "Tablets"
    ],
    "strengths": [
        "2.5 mg",
        "10 mg",
        "15 mg",
        "20 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Factor Xa",
        "physiological_mechanism": "Selectively inhibits Factor Xa, reducing thrombin generation and thrombus formation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematologic System",
            "effect": "Reduces clot formation, decreasing the risk of thromboembolic events.",
            "timeframe": "Onset within 2-4 hours after oral administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Coagulation Cascade Inhibition",
        "key_targets": ["Factor Xa"],
        "related_conditions": ["Atrial Fibrillation", "Deep Vein Thrombosis", "Pulmonary Embolism"]
    },
    "pharmacokinetics": {
        "absorption": "Well absorbed with bioavailability of ~80-100% for the 10 mg dose.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4", "CYP2J2"],
            "notes": "Undergoes hepatic metabolism and biliary excretion."
        },
        "elimination": "Primarily excreted via urine (~66%) and feces (~28%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit rivaroxaban metabolism, increasing plasma concentrations",
            "effect": "Enhanced anticoagulant effect",
            "recommendation": "Avoid or adjust dose when co-administered with strong inhibitors like ketoconazole or ritonavir."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may increase bleeding risk)"]
    },
    "effects_on_symptoms": {
        "Thrombosis Prevention": {
            "site_of_effect": "Bloodstream",
            "mechanism": "Inhibits clot formation by blocking Factor Xa activity.",
            "direction": "Decreased thrombus formation",
            "magnitude": "Significant",
            "timeframe": "Within hours of administration"
        }
    },
    "diagnostic_conditions": {
        "Atrial Fibrillation": {
            "symptoms_addressed": ["Irregular Heartbeat", "Palpitations"],
            "therapeutic_action": "Reduces the risk of stroke in non-valvular atrial fibrillation.",
            "optimal_dosage": "20 mg once daily",
            "response_time": "Within hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Dizziness"],
        "moderate": ["Bleeding", "Bruising"],
        "severe": ["Severe Bleeding", "Hemorrhagic Stroke"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function", "Hemoglobin Levels", "Hematocrit"],
        "frequency": "Every 6-12 months or as clinically indicated",
        "clinical_thresholds": {
            "normal_range": {
                "Creatinine Clearance": ">50 mL/min"
            },
            "alert_threshold": {
                "Creatinine Clearance": "<30 mL/min"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use lower doses in patients with renal impairment.",
            "rationale": "Increased risk of bleeding complications."
        }
    },
    "alternative_therapies": ["Dabigatran", "Apixaban"],
    "combination_therapies": {
        "recommended_combinations": ["With aspirin for dual antithrombotic therapy in high-risk patients"],
        "cautions": ["Monitor for additive bleeding risk"]
    },
    "contraindications": ["Active bleeding", "Severe renal impairment"],
    "precautions": ["Monitor for signs of bleeding", "Avoid use in patients with mechanical heart valves"],
    "side_effects": ["Nausea", "Headache", "Bleeding"],
    "overdose_management": {
        "symptoms": ["Severe Bleeding", "Hypotension"],
        "treatment": ["Andexanet alfa for rivaroxaban reversal", "Supportive care"]
    },
    "notes": "Rivaroxaban is marketed under various brand names, including Rivaroxaban, Xarelto, Rivaflo, Rivaxo, Rivaban, Xaroban, Rivabond, Xabin, Zarelto, Rivolar, Ovanox, Rivaxa, Rivact, Rivastop, and Baxor. It is a direct oral anticoagulant used for the prevention and treatment of thromboembolic disorders. Regular monitoring of renal function and signs of bleeding is essential to optimize therapy and avoid complications."
},
  
  {
    "iupac_name":  "(2S,3S,4R,5R,6R)-3,4,5-Trihydroxy-6-[(2S,3R,4S,5S)-3,4,5-trihydroxy-6-[(2R,3R,4R,5R)-3,4,5-trihydroxy-6-[(2S,3R,4R,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-oxan-2-yl]oxyoxan-2-yl]oxy-oxan-2-yl]oxy-oxane-2-carboxylic acid.",
    "chemical_formula": "Variable (glycosaminoglycan)",
    "brand_names": [
        "Heparin",
        "Hep-Lock",
        "HepFlush-10",
        "Calciparine",
        "Liquaemin",
        "Monoject Prefill", 
        "Multiparin",
        "Vitrax",
        "Lipo-Hepin",
        "Porcine Heparin",
        "Thrombolock",
        "Tinzaparin (related LMWH)",
        "Enoxaparin (related LMWH)"
    ],
    "category": "Anticoagulant",
    "dosage_forms": [
        "Injection Solution",
        "Prefilled Syringes",
        "Intravenous Solution"
    ],
    "strengths": [
        "10 U/mL",
        "100 U/mL",
        "1,000 U/mL",
        "5,000 U/mL",
        "10,000 U/mL",
        "20,000 U/mL"
    ],
    "mechanism_of_action": {
        "site_of_action": "Blood Clotting Cascade",
        "physiological_mechanism": "Binds to antithrombin III, increasing its activity to inhibit thrombin (Factor IIa) and Factor Xa, reducing clot formation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Hematologic System",
            "effect": "Inhibits clot formation by targeting the clotting cascade.",
            "timeframe": "Immediate effect with intravenous administration; onset within minutes."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Coagulation Cascade Inhibition",
        "key_targets": ["Thrombin (Factor IIa)", "Factor Xa"],
        "related_conditions": ["Deep Vein Thrombosis", "Pulmonary Embolism", "Atrial Fibrillation"]
    },
    "pharmacokinetics": {
        "absorption": "Not absorbed orally; requires parenteral administration.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Heparinase"],
            "notes": "Metabolized to inactive fragments."
        },
        "elimination": "Primarily excreted via urine."
    },
    "interactions": {
        "Antiplatelet Agents": {
            "site_of_interaction": "Hematologic System",
            "mechanism": "Increased bleeding risk when combined.",
            "effect": "Enhanced anticoagulant effect.",
            "recommendation": "Monitor closely for signs of bleeding."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may increase bleeding risk)"]
    },
    "effects_on_symptoms": {
        "Thrombosis Prevention": {
            "site_of_effect": "Bloodstream",
            "mechanism": "Inhibits clot formation by targeting Factor Xa and thrombin.",
            "direction": "Decreased thrombus formation",
            "magnitude": "Significant",
            "timeframe": "Immediate with IV administration"
        }
    },
    "diagnostic_conditions": {
        "Pulmonary Embolism": {
            "symptoms_addressed": ["Chest Pain", "Shortness of Breath"],
            "therapeutic_action": "Reduces further clot propagation and promotes clot resolution.",
            "optimal_dosage": "Based on body weight and clinical indication.",
            "response_time": "Within hours"
        }
    },
    "adverse_effects": {
        "mild": ["Injection Site Irritation", "Mild Bleeding"],
        "moderate": ["Bruising", "Elevated Liver Enzymes"],
        "severe": ["Severe Bleeding", "Heparin-Induced Thrombocytopenia (HIT)"]
    },
    "long_term_monitoring": {
        "parameters": ["Activated Partial Thromboplastin Time (aPTT)", "Platelet Count", "Hemoglobin Levels"],
        "frequency": "Regular monitoring during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "aPTT": "60-80 seconds"
            },
            "alert_threshold": {
                "aPTT": ">80 seconds"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use lower doses to reduce bleeding risk.",
            "rationale": "Increased sensitivity to anticoagulant effects."
        }
    },
    "alternative_therapies": ["Enoxaparin", "Fondaparinux"],
    "combination_therapies": {
        "recommended_combinations": ["With warfarin for transition to oral anticoagulation"],
        "cautions": ["Monitor for additive bleeding risk"]
    },
    "contraindications": ["Active bleeding", "Severe thrombocytopenia"],
    "precautions": ["Monitor for signs of bleeding", "Avoid intramuscular injections during therapy"],
    "side_effects": ["Injection Site Irritation", "Bruising"],
    "overdose_management": {
        "symptoms": ["Severe Bleeding", "Hypotension"],
        "treatment": ["Protamine sulfate for heparin reversal", "Supportive care"]
    },
    "notes": "Heparin is marketed under various brand names, including Heparin, Hep-Lock, HepFlush-10, Calciparine, Liquaemin, Monoject Prefill, Multiparin, Vitrax, Lipo-Hepin, Porcine Heparin, Thrombolock, and related low-molecular-weight heparins like Tinzaparin and Enoxaparin. It is widely used for the prevention and treatment of thromboembolic disorders. Regular monitoring of aPTT and platelet counts is essential for safe and effective use."
},
  
  {
    "iupac_name": "(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylate",
    "chemical_formula": "C16H28N2O4",
    "brand_names": [
        "Oseltamivir",
        "Tamiflu",
        "Fluvir",
        "Antiflu",
        "Osel",
        "Virovir",
        "Oselta",
        "Natflu",
        "Fluvib",
        "Oseltan",
        "Viraquin",
        "Influvac",
        "StopFlu",
        "TamiFluCaps",
        "Osilvir"
    ],
    "category": "Antiviral (Neuraminidase Inhibitor)",
    "dosage_forms": [
        "Capsules",
        "Oral Suspension"
    ],
    "strengths": [
        "30 mg",
        "45 mg",
        "75 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Influenza Virus Neuraminidase Enzyme",
        "physiological_mechanism": "Inhibits neuraminidase, preventing the release of viral particles from infected cells and reducing viral replication."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Reduces the severity and duration of influenza symptoms.",
            "timeframe": "Effective when administered within 48 hours of symptom onset."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Viral Replication Inhibition",
        "key_targets": ["Neuraminidase Enzyme"],
        "related_conditions": ["Influenza A", "Influenza B"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed with bioavailability of ~75%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Carboxylesterase"],
            "notes": "Prodrug converted to active metabolite (oseltamivir carboxylate)."
        },
        "elimination": "Primarily excreted via urine (~99% as active metabolite)."
    },
    "interactions": {
        "Probenecid": {
            "site_of_interaction": "Renal System",
            "mechanism": "Inhibits renal excretion of oseltamivir carboxylate",
            "effect": "Increases plasma concentration of active metabolite",
            "recommendation": "Monitor for enhanced antiviral effects."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may worsen side effects like nausea)"]
    },
    "effects_on_symptoms": {
        "Influenza Symptoms": {
            "site_of_effect": "Respiratory Tract",
            "mechanism": "Reduces viral replication and spread.",
            "direction": "Decreased symptom severity",
            "magnitude": "Moderate to significant",
            "timeframe": "Within 1-2 days of administration"
        }
    },
    "diagnostic_conditions": {
        "Influenza Infection": {
            "symptoms_addressed": ["Fever", "Cough", "Fatigue", "Body Aches"],
            "therapeutic_action": "Reduces duration and severity of symptoms.",
            "optimal_dosage": "75 mg twice daily for 5 days",
            "response_time": "Within 48 hours of symptom onset"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Headache"],
        "moderate": ["Diarrhea", "Abdominal Pain"],
        "severe": ["Severe Allergic Reactions", "Neuropsychiatric Events"]
    },
    "long_term_monitoring": {
        "parameters": ["Symptom Resolution", "Renal Function"],
        "frequency": "Evaluate during and after therapy as needed",
        "clinical_thresholds": {
            "normal_range": {
                "Symptom Improvement": "Within 2 days"
            },
            "alert_threshold": {
                "Severe Adverse Effects": "Immediately discontinue and report"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures appropriate therapeutic levels without overdose."
        }
    },
    "alternative_therapies": ["Zanamivir"],
    "combination_therapies": {
        "recommended_combinations": ["Supportive care including hydration and antipyretics"],
        "cautions": ["Avoid co-administration with other antivirals targeting neuraminidase"]
    },
    "contraindications": ["Severe renal impairment", "Hypersensitivity to oseltamivir"],
    "precautions": ["Monitor for unusual behavior in pediatric patients", "Use with caution in patients with renal dysfunction"],
    "side_effects": ["Nausea", "Vomiting", "Headache"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Dizziness"],
        "treatment": ["Supportive care"]
    },
    "notes": "Oseltamivir is marketed under various brand names, including Oseltamivir, Tamiflu, Fluvir, Antiflu, Osel, Virovir, Oselta, Natflu, Fluvib, Oseltan, Viraquin, Influvac, StopFlu, TamiFluCaps, and Osilvir. It is an antiviral medication primarily used for the treatment and prevention of influenza. Initiating treatment within 48 hours of symptom onset is critical for optimal effectiveness."
},
  {
    "iupac_name": "(S)-2-ethylbutyl (2S)-2-{[(2R,3R,4R,5R,6R)-4-amino-3-hydroxy-6-(hydroxymethyl)-5-methyloxan-2-yl]oxy}-3,4-dihydroxyoxane-4-carboxylate",
    "chemical_formula": "C27H35N6O8P",
    "brand_names": [
        "Remdesivir",
        "Veklury",
        "Desrem",
        "Ciplenza",
        "Jubi-R",
        "Remdac",
        "Covifor",
        "Remwin",
        "Redivir",
        "Ramsivir",
        "Actemra (related therapeutic)"
    ],
    "category": "Antiviral",
    "dosage_forms": [
        "Intravenous Solution"
    ],
    "strengths": [
        "100 mg/20 mL (5 mg/mL)",
        "Lyophilized Powder for Injection (100 mg)"
    ],
    "mechanism_of_action": {
        "site_of_action": "RNA-Dependent RNA Polymerase (RdRp)",
        "physiological_mechanism": "Inhibits viral replication by acting as an adenosine nucleotide analog, causing premature termination of viral RNA transcription."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Viral Replication System",
            "effect": "Reduces viral replication and progression of viral infection.",
            "timeframe": "Onset within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "RNA Replication Inhibition",
        "key_targets": ["RNA-Dependent RNA Polymerase"],
        "related_conditions": ["COVID-19", "Ebola", "SARS-CoV-2"]
    },
    "pharmacokinetics": {
        "absorption": "Administered intravenously; systemic availability is complete.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CES1", "CYP2C8", "CYP3A4"],
            "notes": "Metabolized to active GS-441524 metabolite."
        },
        "elimination": "Primarily excreted via urine (~74%) and feces (~18%)."
    },
    "interactions": {
        "Chloroquine": {
            "site_of_interaction": "Liver",
            "mechanism": "May reduce the antiviral efficacy of remdesivir.",
            "effect": "Reduced effectiveness",
            "recommendation": "Avoid co-administration."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may worsen hepatic effects)"]
    },
    "effects_on_symptoms": {
        "COVID-19 Symptoms": {
            "site_of_effect": "Respiratory System",
            "mechanism": "Reduces viral replication and inflammation.",
            "direction": "Improved respiratory function",
            "magnitude": "Moderate to significant",
            "timeframe": "Within days of administration"
        }
    },
    "diagnostic_conditions": {
        "COVID-19": {
            "symptoms_addressed": ["Shortness of Breath", "Fever", "Cough"],
            "therapeutic_action": "Improves recovery time and reduces disease progression.",
            "optimal_dosage": "200 mg IV on day 1, followed by 100 mg IV daily for 5-10 days.",
            "response_time": "Within 24-48 hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Injection Site Reactions"],
        "moderate": ["Elevated Liver Enzymes", "Diarrhea"],
        "severe": ["Hepatotoxicity", "Hypersensitivity Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Renal Function"],
        "frequency": "Before and during treatment",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma concentrations."
        }
    },
    "alternative_therapies": ["Molnupiravir"],
    "combination_therapies": {
        "recommended_combinations": ["Dexamethasone for severe cases"],
        "cautions": ["Monitor for additive hepatotoxicity"]
    },
    "contraindications": ["Severe renal impairment", "Hypersensitivity to remdesivir"],
    "precautions": ["Monitor for hepatotoxicity", "Use with caution in renal impairment"],
    "side_effects": ["Nausea", "Headache", "Injection Site Reactions"],
    "overdose_management": {
        "symptoms": ["Hepatic Toxicity", "Gastrointestinal Symptoms"],
        "treatment": ["Supportive care"]
    },
    "notes": "Remdesivir is marketed under various brand names, including Remdesivir, Veklury, Desrem, Ciplenza, Jubi-R, Remdac, Covifor, Remwin, Redivir, and Ramsivir. It is primarily used as an antiviral agent for the treatment of COVID-19 and related viral infections. Close monitoring of liver and renal function is essential to optimize safety and efficacy."
},
  {
    "iupac_name": "9-[(2-hydroxyethoxy)methyl]guanine",
    "chemical_formula": "C8H11N5O3",
    "brand_names": [
        "Acyclovir",
        "Zovirax",
        "Acivir",
        "Avirax",
        "Ciclovir",
        "Acivirax",
        "Virovir",
        "Cyclovir",
        "Herpex",
        "Zoral",
        "Acyclostad",
        "Acyclovirum",
        "Aciclovir",
        "Aciclohexal",
        "Acycram"
    ],
    "category": "Antiviral",
    "dosage_forms": [
        "Tablets",
        "Cream",
        "Ointment",
        "Intravenous Solution"
    ],
    "strengths": [
        "200 mg",
        "400 mg",
        "800 mg",
        "5% Cream"
    ],
    "mechanism_of_action": {
        "site_of_action": "Viral DNA Polymerase",
        "physiological_mechanism": "Acyclovir is phosphorylated by viral thymidine kinase to acyclovir triphosphate, which inhibits viral DNA polymerase, terminating viral DNA synthesis."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Reduces viral replication and lesion formation.",
            "timeframe": "Effective within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Viral DNA Synthesis Inhibition",
        "key_targets": ["Viral DNA Polymerase"],
        "related_conditions": ["Herpes Simplex Virus (HSV)", "Varicella-Zoster Virus (VZV)"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is ~10-20%; higher with IV administration.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Minimal hepatic metabolism"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Renal excretion (~90%)."
    },
    "interactions": {
        "Probenecid": {
            "site_of_interaction": "Renal Tubules",
            "mechanism": "Inhibits renal tubular secretion of acyclovir.",
            "effect": "Increased plasma concentration of acyclovir.",
            "recommendation": "Monitor for enhanced antiviral effects and adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may increase risk of dehydration)"]
    },
    "effects_on_symptoms": {
        "Herpes Simplex Virus Symptoms": {
            "site_of_effect": "Skin and Mucous Membranes",
            "mechanism": "Reduces lesion formation and promotes healing.",
            "direction": "Decreased symptom severity",
            "magnitude": "Significant",
            "timeframe": "Within 24-48 hours"
        }
    },
    "diagnostic_conditions": {
        "Herpes Simplex Virus Infection": {
            "symptoms_addressed": ["Lesions", "Itching", "Burning Sensation"],
            "therapeutic_action": "Reduces lesion formation and duration of outbreaks.",
            "optimal_dosage": "400 mg orally three times daily for 5-10 days",
            "response_time": "Within 1-2 days of administration"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Diarrhea"],
        "moderate": ["Dizziness", "Fatigue"],
        "severe": ["Acute Renal Failure", "Neurotoxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Renal Function", "Symptom Resolution"],
        "frequency": "Periodically during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "Serum Creatinine": "<1.2 mg/dL"
            },
            "alert_threshold": {
                "Serum Creatinine": ">2.0 mg/dL"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures appropriate plasma concentrations."
        }
    },
    "alternative_therapies": ["Valacyclovir", "Famciclovir"],
    "combination_therapies": {
        "recommended_combinations": ["Topical antiviral for localized lesions"],
        "cautions": ["Monitor for additive nephrotoxicity"]
    },
    "contraindications": ["Severe renal impairment", "Hypersensitivity to acyclovir"],
    "precautions": ["Monitor for signs of nephrotoxicity", "Ensure adequate hydration during treatment"],
    "side_effects": ["Nausea", "Headache", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Renal Toxicity", "Neurological Symptoms"],
        "treatment": ["Hemodialysis for severe cases"]
    },
    "notes": "Acyclovir is marketed under various brand names, including Acyclovir, Zovirax, Acivir, Avirax, Ciclovir, Acivirax, Virovir, Cyclovir, Herpex, Zoral, Acyclostad, Acyclovirum, Aciclovir, Aciclohexal, and Acycram. It is widely used for the treatment of herpes simplex and varicella-zoster virus infections. Adequate hydration and monitoring of renal function are essential during therapy."
},
  
  {
    "iupac_name": "(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylmethylamino]benzoyl]amino]pentanedioic acid",
    "chemical_formula": "C20H22N8O5",
    "brand_names": [
        "Methotrexate",
        "Rheumatrex",
        "Trexall",
        "Otrexup",
        "Rasuvo",
        "Methoblastin",
        "Emthexat",
        "Metotrexato",
        "Folex",
        "Zexate",
        "Texate",
        "Ledertrexate",
        "Abitrexate"
    ],
    "category": "Antimetabolite (Antineoplastic and Immunosuppressant)",
    "dosage_forms": [
        "Tablets",
        "Injection Solution",
        "Prefilled Syringes"
    ],
    "strengths": [
        "2.5 mg",
        "5 mg",
        "7.5 mg",
        "10 mg",
        "15 mg",
        "25 mg/mL (Injection)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Dihydrofolate Reductase Enzyme",
        "physiological_mechanism": "Inhibits dihydrofolate reductase, blocking folate synthesis required for DNA, RNA, and protein synthesis in rapidly dividing cells."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Immune System",
            "effect": "Suppresses immune response and cell proliferation.",
            "timeframe": "Onset within days for immunosuppressive effects."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Folate Pathway Inhibition",
        "key_targets": ["Dihydrofolate Reductase"],
        "related_conditions": ["Rheumatoid Arthritis", "Psoriasis", "Acute Lymphoblastic Leukemia"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability varies by dose (~50-90%).",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Aldehyde Oxidase"],
            "notes": "Undergoes hepatic metabolism to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "NSAIDs": {
            "site_of_interaction": "Renal Tubules",
            "mechanism": "Decreases renal clearance of methotrexate.",
            "effect": "Increased toxicity",
            "recommendation": "Monitor closely for enhanced toxicity."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Folic Acid (may reduce side effects without affecting efficacy)."],
        "toxins": ["Alcohol (may exacerbate hepatotoxicity)"]
    },
    "effects_on_symptoms": {
        "Rheumatoid Arthritis Symptoms": {
            "site_of_effect": "Joints",
            "mechanism": "Reduces inflammation and immune-mediated damage.",
            "direction": "Decreased symptom severity",
            "magnitude": "Significant",
            "timeframe": "Within weeks of initiation"
        }
    },
    "diagnostic_conditions": {
        "Rheumatoid Arthritis": {
            "symptoms_addressed": ["Joint Pain", "Swelling", "Stiffness"],
            "therapeutic_action": "Reduces inflammation and slows disease progression.",
            "optimal_dosage": "7.5-25 mg weekly",
            "response_time": "Within 4-6 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Fatigue", "Headache"],
        "moderate": ["Stomatitis", "Elevated Liver Enzymes"],
        "severe": ["Hepatotoxicity", "Myelosuppression", "Pulmonary Fibrosis"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Complete Blood Count", "Renal Function"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Use lower initial doses.",
            "rationale": "Increased risk of toxicity due to reduced renal clearance."
        }
    },
    "alternative_therapies": ["Leflunomide", "Sulfasalazine"],
    "combination_therapies": {
        "recommended_combinations": ["With biologics for severe rheumatoid arthritis"],
        "cautions": ["Monitor for additive immunosuppression"]
    },
    "contraindications": ["Pregnancy", "Severe hepatic impairment"],
    "precautions": ["Monitor for signs of hepatotoxicity", "Ensure adequate hydration during treatment"],
    "side_effects": ["Nausea", "Fatigue", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Myelosuppression", "Hepatic Toxicity"],
        "treatment": ["Leucovorin rescue", "Supportive care"]
    },
    "notes": "Methotrexate is marketed under various brand names, including Methotrexate, Rheumatrex, Trexall, Otrexup, Rasuvo, Methoblastin, Emthexat, Metotrexato, Folex, Zexate, Texate, Ledertrexate, and Abitrexate. It is used as an antineoplastic agent and immunosuppressant for conditions like rheumatoid arthritis, psoriasis, and certain cancers. Regular monitoring of liver, renal, and hematologic parameters is essential for safe use."
},
  {
    "iupac_name": "4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinylamino]phenyl}benzamide",
    "chemical_formula": "C29H31N7O",
    "brand_names": [
        "Imatinib",
        "Gleevec",
        "Imatib",
        "Imavec",
        "Imatnib",
        "Veenat",
        "Glenmark",
        "Zodak",
        "Intas",
        "Leukemia Treat",
        "Tyrokine",
        "Imatis",
        "Myelostat",
        "Glivix",
        "Imacure"
    ],
    "category": "Tyrosine Kinase Inhibitor",
    "dosage_forms": [
        "Tablets",
        "Capsules"
    ],
    "strengths": [
        "100 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "BCR-ABL Tyrosine Kinase",
        "physiological_mechanism": "Inhibits the BCR-ABL tyrosine kinase, which is responsible for the proliferation of malignant cells in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Cellular Level",
            "effect": "Inhibits abnormal cell proliferation and induces apoptosis in cancer cells.",
            "timeframe": "Within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Tyrosine Kinase Inhibition",
        "key_targets": ["BCR-ABL", "c-KIT", "PDGFR"],
        "related_conditions": ["Chronic Myeloid Leukemia", "Gastrointestinal Stromal Tumors"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is ~98%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to an active metabolite (N-desmethyl imatinib)."
        },
        "elimination": "Primarily excreted via feces (~68%) and urine (~13%)."
    },
    "interactions": {
        "CYP3A4 Inhibitors": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibit metabolism of imatinib.",
            "effect": "Increased plasma concentration and toxicity.",
            "recommendation": "Monitor closely and adjust dosage as necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice (may increase plasma levels)."],
        "toxins": ["Alcohol (may exacerbate hepatic effects)"]
    },
    "effects_on_symptoms": {
        "Chronic Myeloid Leukemia Symptoms": {
            "site_of_effect": "Bone Marrow",
            "mechanism": "Reduces proliferation of leukemic cells.",
            "direction": "Decreased leukocyte counts",
            "magnitude": "Significant",
            "timeframe": "Within days to weeks"
        }
    },
    "diagnostic_conditions": {
        "Chronic Myeloid Leukemia": {
            "symptoms_addressed": ["Fatigue", "Weight Loss", "Night Sweats"],
            "therapeutic_action": "Induces remission and slows disease progression.",
            "optimal_dosage": "400-600 mg daily",
            "response_time": "Within weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Vomiting", "Diarrhea"],
        "moderate": ["Edema", "Myalgia"],
        "severe": ["Hepatotoxicity", "Cardiac Toxicity"]
    },
    "long_term_monitoring": {
        "parameters": ["Complete Blood Count", "Liver Function Tests", "Echocardiogram"],
        "frequency": "Every 1-3 months during therapy",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures appropriate therapeutic levels."
        }
    },
    "alternative_therapies": ["Dasatinib", "Nilotinib"],
    "combination_therapies": {
        "recommended_combinations": ["With hydroxyurea for acute leukocytosis"],
        "cautions": ["Monitor for additive toxicity"]
    },
    "contraindications": ["Severe hepatic impairment", "Hypersensitivity to imatinib"],
    "precautions": ["Monitor for signs of fluid retention", "Use with caution in hepatic dysfunction"],
    "side_effects": ["Nausea", "Vomiting", "Edema"],
    "overdose_management": {
        "symptoms": ["Severe Myelosuppression", "Hepatic Toxicity"],
        "treatment": ["Supportive care"]
    },
    "notes": "Imatinib is marketed under various brand names, including Imatinib, Gleevec, Imatib, Imavec, Imatnib, Veenat, Glenmark, Zodak, Intas, Leukemia Treat, Tyrokine, Imatis, Myelostat, Glivix, and Imacure. It is used primarily in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Regular monitoring of hematologic and hepatic parameters is essential for safe and effective use."
},
  
  {
    "iupac_name": "2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol",
    "chemical_formula": "C13H12F2N6O",
    "brand_names": [
        "Fluconazole",
        "Diflucan",
        "Flucoral",
        "Trican",
        "Flukit",
        "Candivast",
        "Fungican",
        "Mycosyst",
        "Fluzole",
        "Zocon",
        "Flucos",
        "Flutec",
        "Azocan",
        "Funzol",
        "Trizol"
    ],
    "category": "Antifungal (Azole Derivative)",
    "dosage_forms": [
        "Tablets",
        "Oral Suspension",
        "Intravenous Solution"
    ],
    "strengths": [
        "50 mg",
        "100 mg",
        "150 mg",
        "200 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Fungal Cell Membranes",
        "physiological_mechanism": "Inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Fungal Cell Membranes",
            "effect": "Disrupts cell membrane synthesis, leading to fungal cell death.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Ergosterol Synthesis Inhibition",
        "key_targets": ["14α-Demethylase"],
        "related_conditions": ["Candidiasis", "Cryptococcosis"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is >90%.",
        "metabolism": {
            "primary_site": "Minimal hepatic metabolism",
            "enzymes": ["CYP2C9", "CYP3A4"],
            "notes": "Primarily excreted unchanged in urine."
        },
        "elimination": "Renal excretion (~80%)."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver",
            "mechanism": "Inhibits metabolism of warfarin, increasing its anticoagulant effect.",
            "effect": "Increased bleeding risk",
            "recommendation": "Monitor INR levels and adjust warfarin dosage as necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may worsen hepatic effects)"]
    },
    "effects_on_symptoms": {
        "Fungal Infections": {
            "site_of_effect": "Affected Tissues",
            "mechanism": "Disrupts fungal cell membranes, reducing infection severity.",
            "direction": "Decreased fungal burden",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 days of treatment"
        }
    },
    "diagnostic_conditions": {
        "Candidiasis": {
            "symptoms_addressed": ["Oral Thrush", "Vaginal Itching", "Skin Rashes"],
            "therapeutic_action": "Eradicates fungal infection.",
            "optimal_dosage": "150 mg orally as a single dose for vaginal candidiasis; 200-400 mg daily for systemic infections.",
            "response_time": "Within 24-48 hours"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Headache", "Abdominal Pain"],
        "moderate": ["Diarrhea", "Dizziness"],
        "severe": ["Hepatotoxicity", "QT Prolongation"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Renal Function"],
        "frequency": "Periodically during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Itraconazole", "Ketoconazole"],
    "combination_therapies": {
        "recommended_combinations": ["Topical antifungals for localized infections"],
        "cautions": ["Monitor for additive hepatotoxicity"]
    },
    "contraindications": ["Severe renal impairment", "Hypersensitivity to fluconazole"],
    "precautions": ["Monitor for signs of hepatotoxicity", "Avoid in pregnancy unless absolutely necessary"],
    "side_effects": ["Nausea", "Headache", "Abdominal Pain"],
    "overdose_management": {
        "symptoms": ["Hepatic Toxicity", "Neurological Symptoms"],
        "treatment": ["Supportive care"]
    },
    "notes": "Fluconazole is marketed under various brand names, including Fluconazole, Diflucan, Flucoral, Trican, Flukit, Candivast, Fungican, Mycosyst, Fluzole, Zocon, Flucos, Flutec, Azocan, Funzol, and Trizol. It is an antifungal agent used for the treatment of candidiasis, cryptococcosis, and other fungal infections. Regular monitoring of liver and renal function is essential during prolonged therapy."
},
  
  {
    "iupac_name": "(±)-1-[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl]-1H-1,2,4-triazole",
    "chemical_formula": "C35H38Cl2N8O4",
    "brand_names": [
        "Itraconazole",
        "Sporanox",
        "Onmel",
        "Tolsura",
        "Itracure",
        "Candistat",
        "Itaspor",
        "Itrocap",
        "Itrotab",
        "Itrazol",
        "Itraspor",
        "Itranox",
        "Orungal",
        "Orungamin",
        "Trisporal"
    ],
    "category": "Antifungal (Azole Derivative)",
    "dosage_forms": [
        "Capsules",
        "Oral Solution",
        "Injection"
    ],
    "strengths": [
        "100 mg",
        "200 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Fungal Cell Membranes",
        "physiological_mechanism": "Inhibits fungal cytochrome P450 enzyme 14α-demethylase, leading to impaired ergosterol synthesis and disruption of fungal cell membranes."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Fungal Cell Membranes",
            "effect": "Disrupts cell membrane synthesis, causing fungal cell death.",
            "timeframe": "Effects observed within days of therapy initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Ergosterol Synthesis Inhibition",
        "key_targets": ["14α-Demethylase"],
        "related_conditions": ["Aspergillosis", "Candidiasis", "Histoplasmosis"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is variable; enhanced by food intake.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Extensively metabolized in the liver."
        },
        "elimination": "Primarily excreted via feces (~80%)."
    },
    "interactions": {
        "Proton Pump Inhibitors": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Reduce gastric acidity, decreasing itraconazole absorption.",
            "effect": "Reduced efficacy",
            "recommendation": "Administer itraconazole with an acidic beverage to enhance absorption."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Food enhances absorption of itraconazole capsules."],
        "toxins": ["Alcohol (may increase risk of hepatotoxicity)"]
    },
    "effects_on_symptoms": {
        "Fungal Infections": {
            "site_of_effect": "Infected Tissues",
            "mechanism": "Inhibits fungal growth and replication.",
            "direction": "Decreased fungal burden",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 weeks of treatment"
        }
    },
    "diagnostic_conditions": {
        "Aspergillosis": {
            "symptoms_addressed": ["Cough", "Shortness of Breath", "Fever"],
            "therapeutic_action": "Reduces fungal load and resolves infection.",
            "optimal_dosage": "200-400 mg daily for 2-6 months, depending on severity.",
            "response_time": "Within 7-14 days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Headache"],
        "moderate": ["Abdominal Pain", "Fatigue"],
        "severe": ["Hepatotoxicity", "Heart Failure"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Cardiac Function"],
        "frequency": "Periodically during long-term therapy",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use with caution; dose adjustments based on weight.",
            "rationale": "Minimizes risk of toxicity."
        }
    },
    "alternative_therapies": ["Fluconazole", "Voriconazole"],
    "combination_therapies": {
        "recommended_combinations": ["With amphotericin B for severe fungal infections"],
        "cautions": ["Monitor for additive hepatotoxicity"]
    },
    "contraindications": ["Congestive heart failure", "Severe hepatic impairment"],
    "precautions": ["Monitor for signs of hepatotoxicity", "Avoid in pregnancy unless benefits outweigh risks"],
    "side_effects": ["Nausea", "Diarrhea", "Headache"],
    "overdose_management": {
        "symptoms": ["Severe Hepatotoxicity", "Gastrointestinal Symptoms"],
        "treatment": ["Supportive care"]
    },
    "notes": "Itraconazole is marketed under various brand names, including Itraconazole, Sporanox, Onmel, Tolsura, Itracure, Candistat, Itaspor, Itrocap, Itrotab, Itrazol, Itraspor, Itranox, Orungal, Orungamin, and Trisporal. It is an antifungal agent used for the treatment of systemic and localized fungal infections. Monitoring liver function is crucial during prolonged therapy."
},
  
  {
    "iupac_name": "(10E,14E,16E,22Z)-(1R,4S,6S,8S,9R,13R,20R,21R,24S)-6,8,24-trihydroxy-21-(2-methoxyethoxy)methyl-4-methyl-2-oxo-1-[5-(propan-2-yl)oxolan-2-yl]oxy-11,17-dioxo-13-[(2S)-butan-2-yl]-3,7,19-trioxabicyclo[22.3.1]heptacos-10,14,16,22-tetraene",
    "chemical_formula": "C48H74O14",
    "brand_names": [
        "Ivermectin",
        "Stromectol",
        "Soolantra",
        "Sklice",
        "Mectizan",
        "Ivomec",
        "Iverscab",
        "Ivecop",
        "Scabo",
        "Ivectin",
        "Ivermactol",
        "Vermact",
        "Iverfast",
        "Medimectin",
        "Iverzine"
    ],
    "category": "Antiparasitic",
    "dosage_forms": [
        "Tablets",
        "Cream",
        "Topical Lotion",
        "Injection"
    ],
    "strengths": [
        "3 mg",
        "6 mg",
        "12 mg",
        "1% Cream"
    ],
    "mechanism_of_action": {
        "site_of_action": "Parasite Nervous System",
        "physiological_mechanism": "Binds to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, causing paralysis and death."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Parasite Nervous System",
            "effect": "Paralysis and elimination of parasites.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Chloride Ion Channel Activation",
        "key_targets": ["Glutamate-Gated Chloride Channels"],
        "related_conditions": ["Onchocerciasis", "Strongyloidiasis", "Scabies"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is ~60%; increased with fatty meals.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to inactive compounds."
        },
        "elimination": "Primarily excreted via feces (~90%)."
    },
    "interactions": {
        "Warfarin": {
            "site_of_interaction": "Liver",
            "mechanism": "May enhance anticoagulant effect of warfarin.",
            "effect": "Increased bleeding risk.",
            "recommendation": "Monitor INR levels and adjust warfarin dosage as necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Fatty meals enhance absorption."],
        "toxins": ["Alcohol (may increase risk of adverse effects)"]
    },
    "effects_on_symptoms": {
        "Parasitic Infections": {
            "site_of_effect": "Parasite Nervous System",
            "mechanism": "Induces paralysis and death of parasites.",
            "direction": "Complete elimination of parasites",
            "magnitude": "Significant",
            "timeframe": "Within 24-48 hours"
        }
    },
    "diagnostic_conditions": {
        "Onchocerciasis": {
            "symptoms_addressed": ["Skin Itching", "Skin Nodules", "Visual Disturbances"],
            "therapeutic_action": "Eliminates microfilariae and reduces symptoms.",
            "optimal_dosage": "150 mcg/kg as a single dose, repeated annually.",
            "response_time": "Within days"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Diarrhea", "Dizziness"],
        "moderate": ["Skin Rash", "Fatigue"],
        "severe": ["Severe Allergic Reactions", "Hypotension"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Complete Blood Count"],
        "frequency": "Periodically during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Albendazole", "Mebendazole"],
    "combination_therapies": {
        "recommended_combinations": ["With doxycycline for certain filarial infections"],
        "cautions": ["Monitor for additive adverse effects"]
    },
    "contraindications": ["Hypersensitivity to ivermectin"],
    "precautions": ["Monitor for signs of neurotoxicity", "Use with caution in patients with hepatic impairment"],
    "side_effects": ["Nausea", "Diarrhea", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Neurological Symptoms", "Hypotension"],
        "treatment": ["Supportive care"]
    },
    "notes": "Ivermectin is marketed under various brand names, including Ivermectin, Stromectol, Soolantra, Sklice, Mectizan, Ivomec, Iverscab, Ivecop, Scabo, Ivectin, Ivermactol, Vermact, Iverfast, Medimectin, and Iverzine. It is a widely used antiparasitic agent effective against a variety of parasitic infections. Regular monitoring is recommended for long-term therapy, especially in patients with hepatic impairment."
},
  {
    "iupac_name": "Methyl 5-(propylthio)-1H-benzimidazol-2-ylcarbamate",
    "chemical_formula": "C12H15N3O2S",
    "brand_names": [
        "Albendazole",
        "Albenza",
        "Zentel",
        "Valbazen",
        "Eskazole",
        "Andazol",
        "Benda",
        "Aldazole",
        "Alworm",
        "Wormnil",
        "Zentozide",
        "Helmal",
        "Sanazole",
        "Vermisol",
        "Bendex"
    ],
    "category": "Antiparasitic",
    "dosage_forms": [
        "Tablets",
        "Chewable Tablets",
        "Oral Suspension"
    ],
    "strengths": [
        "200 mg",
        "400 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Parasite Cytoskeleton",
        "physiological_mechanism": "Binds to beta-tubulin, inhibiting microtubule polymerization and glucose uptake in parasites, leading to energy depletion and death."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Parasite Metabolic Processes",
            "effect": "Inhibits energy production and kills parasites.",
            "timeframe": "Effects observed within hours of administration."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Microtubule Disruption",
        "key_targets": ["Beta-Tubulin"],
        "related_conditions": ["Hydatid Disease", "Neurocysticercosis", "Ascariasis"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is low (~5%); increased with fatty meals.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Converted to active metabolite albendazole sulfoxide."
        },
        "elimination": "Primarily excreted via feces (~90%)."
    },
    "interactions": {
        "Dexamethasone": {
            "site_of_interaction": "Liver",
            "mechanism": "Increases plasma levels of albendazole sulfoxide.",
            "effect": "Enhanced efficacy",
            "recommendation": "Monitor for increased therapeutic effects and potential toxicity."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Fatty meals enhance absorption."],
        "toxins": ["Alcohol (may increase risk of hepatic side effects)"]
    },
    "effects_on_symptoms": {
        "Parasitic Infections": {
            "site_of_effect": "Parasite Metabolic Processes",
            "mechanism": "Disrupts energy production and kills parasites.",
            "direction": "Complete elimination of parasites",
            "magnitude": "Significant",
            "timeframe": "Within days of therapy initiation"
        }
    },
    "diagnostic_conditions": {
        "Neurocysticercosis": {
            "symptoms_addressed": ["Seizures", "Headaches"],
            "therapeutic_action": "Kills larval cysts and reduces symptoms.",
            "optimal_dosage": "15 mg/kg/day in divided doses for 8-30 days.",
            "response_time": "Within 1-2 weeks"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Abdominal Pain", "Dizziness"],
        "moderate": ["Elevated Liver Enzymes", "Fatigue"],
        "severe": ["Hepatotoxicity", "Bone Marrow Suppression"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests", "Complete Blood Count"],
        "frequency": "Every 2 weeks during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Ivermectin", "Mebendazole"],
    "combination_therapies": {
        "recommended_combinations": ["With corticosteroids for neurocysticercosis"],
        "cautions": ["Monitor for additive adverse effects"]
    },
    "contraindications": ["Hypersensitivity to albendazole", "Severe hepatic impairment"],
    "precautions": ["Monitor for signs of hepatotoxicity", "Avoid in pregnancy unless benefits outweigh risks"],
    "side_effects": ["Nausea", "Abdominal Pain", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Hepatic Toxicity", "Neurological Symptoms"],
        "treatment": ["Supportive care"]
    },
    "notes": "Albendazole is marketed under various brand names, including Albendazole, Albenza, Zentel, Valbazen, Eskazole, Andazol, Benda, Aldazole, Alworm, Wormnil, Zentozide, Helmal, Sanazole, Vermisol, and Bendex. It is a broad-spectrum antiparasitic agent used to treat conditions such as neurocysticercosis and hydatid disease. Regular monitoring of liver function and blood counts is essential during prolonged therapy."
},
  
  {
    "iupac_name": "(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid sodium salt",
    "chemical_formula": "C15H10I4NNaO4",
    "brand_names": [
        "Levothyroxine",
        "Synthroid",
        "Eltroxin",
        "Euthyrox",
        "Thyrox",
        "Levoxyl",
        "Unithroid",
        "Eltroxine",
        "Thyronorm",
        "Thyrowel",
        "Levotabs",
        "Thyrofit",
        "Tirosint",
        "Levo-T",
        "Levothyroid"
    ],
    "category": "Thyroid Replacement Hormone",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Oral Solution"
    ],
    "strengths": [
        "25 mcg",
        "50 mcg",
        "75 mcg",
        "100 mcg",
        "125 mcg",
        "150 mcg",
        "175 mcg",
        "200 mcg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Thyroid Hormone Receptors",
        "physiological_mechanism": "Mimics the effects of endogenous thyroxine (T4), influencing protein synthesis, metabolic rate, and growth regulation."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Endocrine System",
            "effect": "Restores normal thyroid hormone levels and metabolic activity.",
            "timeframe": "Steady-state levels reached in 6-8 weeks."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Thyroid Hormone Regulation",
        "key_targets": ["Thyroid Hormone Receptors"],
        "related_conditions": ["Hypothyroidism", "Goiter"]
    },
    "pharmacokinetics": {
        "absorption": "Oral bioavailability is ~60-80%; reduced by certain foods and medications.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["Deiodinases"],
            "notes": "Converted to active T3 in peripheral tissues."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "Calcium Carbonate": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Reduces absorption of levothyroxine.",
            "effect": "Decreased therapeutic effect",
            "recommendation": "Separate dosing by at least 4 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Absorption may be affected by high-fiber foods."],
        "toxins": ["Alcohol (may affect thyroid hormone metabolism)"]
    },
    "effects_on_symptoms": {
        "Hypothyroidism Symptoms": {
            "site_of_effect": "Systemic",
            "mechanism": "Restores normal metabolic activity.",
            "direction": "Improved energy and metabolic function",
            "magnitude": "Significant",
            "timeframe": "Within 2-4 weeks of therapy"
        }
    },
    "diagnostic_conditions": {
        "Hypothyroidism": {
            "symptoms_addressed": ["Fatigue", "Weight Gain", "Cold Intolerance"],
            "therapeutic_action": "Restores thyroid hormone levels to normal.",
            "optimal_dosage": "1.6 mcg/kg/day (adjusted based on TSH levels).",
            "response_time": "2-4 weeks for initial response"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nervousness", "Insomnia"],
        "moderate": ["Palpitations", "Weight Loss"],
        "severe": ["Cardiac Arrhythmias", "Osteoporosis with prolonged use"]
    },
    "long_term_monitoring": {
        "parameters": ["TSH Levels", "Free T4"],
        "frequency": "Every 6-12 months once stable.",
        "clinical_thresholds": {
            "normal_range": {
                "TSH": "0.5-4.5 mIU/L"
            },
            "alert_threshold": {
                "TSH": "<0.1 or >10 mIU/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Supports growth and development."
        }
    },
    "alternative_therapies": ["Liothyronine", "Desiccated Thyroid Extract"],
    "combination_therapies": {
        "recommended_combinations": ["With liothyronine in some patients"],
        "cautions": ["Monitor for signs of hyperthyroidism"]
    },
    "contraindications": ["Untreated adrenal insufficiency", "Thyrotoxicosis"],
    "precautions": ["Monitor for cardiovascular effects in elderly patients", "Adjust dose in pregnancy"],
    "side_effects": ["Headache", "Nervousness", "Insomnia"],
    "overdose_management": {
        "symptoms": ["Hyperthyroidism Symptoms", "Cardiac Arrhythmias"],
        "treatment": ["Beta-blockers for symptomatic relief"]
    },
    "notes": "Levothyroxine is marketed under various brand names, including Levothyroxine, Synthroid, Eltroxin, Euthyrox, Thyrox, Levoxyl, Unithroid, Eltroxine, Thyronorm, Thyrowel, Levotabs, Thyrofit, Tirosint, Levo-T, and Levothyroid. It is used to treat hypothyroidism and other thyroid hormone deficiencies. Regular monitoring of TSH levels is essential to ensure optimal dosing and avoid complications."
},
  
  {
    "iupac_name": "(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol",
    "chemical_formula": "C18H24O2",
    "brand_names": [
        "Estrogen",
        "Estrace",
        "Premarin",
        "Climara",
        "Vivelle-Dot",
        "Estraderm",
        "Divigel",
        "Evamist",
        "Femtrace",
        "Minivelle",
        "Alora",
        "Delestrogen",
        "Menostar",
        "Estragel",
        "Estrofem"
    ],
    "category": "Hormone Replacement Therapy (HRT)",
    "dosage_forms": [
        "Tablets",
        "Patches",
        "Topical Gel",
        "Vaginal Cream",
        "Injection"
    ],
    "strengths": [
        "0.5 mg",
        "1 mg",
        "2 mg",
        "0.025 mg/day (Patch)",
        "0.05 mg/day (Patch)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Estrogen Receptors",
        "physiological_mechanism": "Binds to estrogen receptors in various tissues, modulating gene expression and restoring estrogenic activity in target tissues."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Reproductive System",
            "effect": "Restores hormonal balance and alleviates menopausal symptoms.",
            "timeframe": "Effects observed within 1-2 weeks of initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Estrogen Receptor Modulation",
        "key_targets": ["Estrogen Receptors (ERα and ERβ)"],
        "related_conditions": ["Menopausal Symptoms", "Osteoporosis"]
    },
    "pharmacokinetics": {
        "absorption": "Depends on the route of administration; oral bioavailability is low due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4", "CYP1A2"],
            "notes": "Extensively metabolized to active and inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~90%)."
    },
    "interactions": {
        "Rifampin": {
            "site_of_interaction": "Liver",
            "mechanism": "Induces metabolism of estrogen.",
            "effect": "Reduced therapeutic effect",
            "recommendation": "Monitor hormone levels and adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Grapefruit juice may increase plasma levels."],
        "toxins": ["Alcohol (may worsen hepatic side effects)"]
    },
    "effects_on_symptoms": {
        "Menopausal Symptoms": {
            "site_of_effect": "Systemic",
            "mechanism": "Replenishes estrogen levels, reducing vasomotor and genitourinary symptoms.",
            "direction": "Improved quality of life",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 weeks"
        }
    },
    "diagnostic_conditions": {
        "Menopause": {
            "symptoms_addressed": ["Hot Flashes", "Vaginal Dryness", "Mood Swings"],
            "therapeutic_action": "Alleviates symptoms and prevents long-term complications like osteoporosis.",
            "optimal_dosage": "1 mg daily orally or as directed for transdermal application.",
            "response_time": "1-2 weeks for symptom relief"
        }
    },
    "adverse_effects": {
        "mild": ["Nausea", "Breast Tenderness", "Headache"],
        "moderate": ["Bloating", "Weight Changes"],
        "severe": ["Thromboembolic Events", "Stroke"]
    },
    "long_term_monitoring": {
        "parameters": ["Bone Density", "Lipid Profile", "Liver Function Tests"],
        "frequency": "Every 6-12 months.",
        "clinical_thresholds": {
            "normal_range": {
                "Bone Density": "T-score > -1.0"
            },
            "alert_threshold": {
                "Bone Density": "T-score < -2.5"
            }
        }
    },
    "population_specific": {
        "Elderly": {
            "adjustments": "Lower initial doses recommended.",
            "rationale": "Reduces risk of adverse cardiovascular events."
        }
    },
    "alternative_therapies": ["Selective Estrogen Receptor Modulators (SERMs)", "Phytoestrogens"],
    "combination_therapies": {
        "recommended_combinations": ["With progestins in women with intact uterus"],
        "cautions": ["Monitor for additive thromboembolic risk"]
    },
    "contraindications": ["History of thromboembolic events", "Known or suspected estrogen-dependent cancers"],
    "precautions": ["Monitor for cardiovascular and thromboembolic risks", "Use with caution in hepatic impairment"],
    "side_effects": ["Nausea", "Breast Tenderness", "Headache"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Abdominal Cramps"],
        "treatment": ["Supportive care"]
    },
    "notes": "Estrogen is marketed under various brand names, including Estrogen, Estrace, Premarin, Climara, Vivelle-Dot, Estraderm, Divigel, Evamist, Femtrace, Minivelle, Alora, Delestrogen, Menostar, Estragel, and Estrofem. It is primarily used for hormone replacement therapy to treat menopausal symptoms and prevent osteoporosis. Regular monitoring is advised to ensure safety and efficacy, especially during long-term use."
},
  
  {
    "iupac_name": "(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one",
    "chemical_formula": "C21H30O2",
    "brand_names": [
        "Progesterone",
        "Prometrium",
        "Crinone",
        "Endometrin",
        "Prochieve",
        "Utrogesterone",
        "Cyclogest",
        "Lutigest",
        "Gestone",
        "Progestogel",
        "Lutinus",
        "Progestin",
        "Gestone",
        "Utrogestan",
        "Progeffik"
    ],
    "category": "Hormone Replacement Therapy (HRT)",
    "dosage_forms": [
        "Capsules",
        "Vaginal Gel",
        "Vaginal Insert",
        "Injection",
        "Topical Cream"
    ],
    "strengths": [
        "100 mg",
        "200 mg",
        "25 mg (Injection)",
        "50 mg (Injection)",
        "8% (Gel)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Progesterone Receptors",
        "physiological_mechanism": "Binds to progesterone receptors, influencing gene expression and modulating reproductive and menstrual cycle processes."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Reproductive System",
            "effect": "Supports luteal phase and prepares endometrium for implantation.",
            "timeframe": "Effects observed within hours to days of initiation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Progesterone Receptor Modulation",
        "key_targets": ["Progesterone Receptors"],
        "related_conditions": ["Luteal Phase Deficiency", "Endometrial Hyperplasia"]
    },
    "pharmacokinetics": {
        "absorption": "Bioavailability varies by route; oral absorption is low due to first-pass metabolism.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Extensively metabolized to pregnanediol and other active metabolites."
        },
        "elimination": "Primarily excreted via urine as glucuronide and sulfate conjugates."
    },
    "interactions": {
        "Carbamazepine": {
            "site_of_interaction": "Liver",
            "mechanism": "Induces progesterone metabolism.",
            "effect": "Reduced therapeutic effect",
            "recommendation": "Monitor progesterone levels and adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["Fatty meals enhance oral absorption."],
        "toxins": ["Alcohol (may alter hormonal metabolism)"]
    },
    "effects_on_symptoms": {
        "Luteal Phase Deficiency": {
            "site_of_effect": "Endometrium",
            "mechanism": "Supports implantation and pregnancy maintenance.",
            "direction": "Improved endometrial function",
            "magnitude": "Significant",
            "timeframe": "Within 1-2 cycles of treatment"
        }
    },
    "diagnostic_conditions": {
        "Endometrial Hyperplasia": {
            "symptoms_addressed": ["Irregular Bleeding", "Thickened Endometrium"],
            "therapeutic_action": "Counteracts estrogen-induced hyperplasia.",
            "optimal_dosage": "200 mg daily for 10-14 days per cycle.",
            "response_time": "Within 1-2 cycles"
        }
    },
    "adverse_effects": {
        "mild": ["Fatigue", "Dizziness", "Breast Tenderness"],
        "moderate": ["Nausea", "Bloating"],
        "severe": ["Thromboembolic Events", "Severe Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Endometrial Thickness", "Hormonal Levels"],
        "frequency": "Every 6-12 months during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Endometrial Thickness": "<12 mm"
            },
            "alert_threshold": {
                "Endometrial Thickness": ">15 mm"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Not typically used in pediatric populations.",
            "rationale": "Limited evidence for safety and efficacy."
        }
    },
    "alternative_therapies": ["Synthetic Progestins", "Combined Hormone Therapy"],
    "combination_therapies": {
        "recommended_combinations": ["With estrogen in hormone replacement therapy"],
        "cautions": ["Monitor for additive thromboembolic risk"]
    },
    "contraindications": ["Active thromboembolic disorders", "Known or suspected breast cancer"],
    "precautions": ["Monitor for cardiovascular risks in at-risk populations", "Use cautiously in hepatic impairment"],
    "side_effects": ["Fatigue", "Dizziness", "Breast Tenderness"],
    "overdose_management": {
        "symptoms": ["Nausea", "Vomiting", "Drowsiness"],
        "treatment": ["Supportive care"]
    },
    "notes": "Progesterone is marketed under various brand names, including Progesterone, Prometrium, Crinone, Endometrin, Prochieve, Utrogesterone, Cyclogest, Lutigest, Gestone, Progestogel, Lutinus, Progestin, Gestone, Utrogestan, and Progeffik. It is used in hormone replacement therapy, infertility treatment, and to support pregnancy. Regular monitoring of hormonal levels and endometrial health is essential for safe and effective use."
},
  
  {
    "iupac_name": "2-[(1,1-Dimethylethyl)amino]-1-(4-hydroxy-3-hydroxyphenyl)ethanol",
    "chemical_formula": "C13H21NO3",
    "brand_names": [
        "Albuterol",
        "ProAir HFA",
        "Ventolin HFA",
        "Proventil HFA",
        "AccuNeb",
        "Salamol",
        "Asmol",
        "Airomir",
        "Asthalin",
        "Respolin",
        "Sultanol",
        "Buterol",
        "Asthavent",
        "Salbutamol",
        "Ventmax"
    ],
    "category": "Beta-2 Adrenergic Agonist (Bronchodilator)",
    "dosage_forms": [
        "Inhaler",
        "Nebulizer Solution",
        "Tablets",
        "Oral Syrup"
    ],
    "strengths": [
        "90 mcg (Inhaler)",
        "2.5 mg/3 mL (Nebulizer Solution)",
        "2 mg (Tablets)",
        "4 mg (Tablets)",
        "2 mg/5 mL (Syrup)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-2 Adrenergic Receptors in the Lungs",
        "physiological_mechanism": "Stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle and improved airflow."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Respiratory System",
            "effect": "Relieves bronchospasm and improves airflow.",
            "timeframe": "Onset within 5 minutes of inhalation."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Beta-Adrenergic Signaling Pathway",
        "key_targets": ["Beta-2 Adrenergic Receptors"],
        "related_conditions": ["Asthma", "Chronic Obstructive Pulmonary Disease (COPD)"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed when inhaled or taken orally.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP450"],
            "notes": "Metabolized to inactive sulfate conjugates."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "Beta Blockers": {
            "site_of_interaction": "Beta-2 Receptors",
            "mechanism": "Antagonizes bronchodilatory effects.",
            "effect": "Reduced efficacy",
            "recommendation": "Avoid concurrent use or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may exacerbate side effects like dizziness)"]
    },
    "effects_on_symptoms": {
        "Bronchospasm": {
            "site_of_effect": "Bronchial Smooth Muscle",
            "mechanism": "Relaxes smooth muscle, alleviating symptoms.",
            "direction": "Improved breathing",
            "magnitude": "Significant",
            "timeframe": "Within minutes of administration"
        }
    },
    "diagnostic_conditions": {
        "Asthma": {
            "symptoms_addressed": ["Wheezing", "Shortness of Breath", "Chest Tightness"],
            "therapeutic_action": "Provides rapid relief of acute bronchospasm.",
            "optimal_dosage": "90 mcg via inhaler every 4-6 hours as needed.",
            "response_time": "Within 5-10 minutes"
        }
    },
    "adverse_effects": {
        "mild": ["Tremors", "Nervousness", "Dizziness"],
        "moderate": ["Palpitations", "Increased Heart Rate"],
        "severe": ["Paradoxical Bronchospasm", "Severe Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Pulmonary Function Tests", "Heart Rate"],
        "frequency": "Every 6-12 months during long-term therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": ">120 bpm"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing for nebulizer solution.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Levalbuterol", "Ipratropium"],
    "combination_therapies": {
        "recommended_combinations": ["With inhaled corticosteroids for persistent asthma"],
        "cautions": ["Monitor for additive cardiovascular effects"]
    },
    "contraindications": ["Severe hypersensitivity to albuterol or its components"],
    "precautions": ["Monitor for cardiovascular effects in patients with underlying conditions", "Use cautiously in hyperthyroidism"],
    "side_effects": ["Tremors", "Nervousness", "Dizziness"],
    "overdose_management": {
        "symptoms": ["Severe Tachycardia", "Hypertension"],
        "treatment": ["Beta-blockers for symptomatic relief"]
    },
    "notes": "Albuterol is marketed under various brand names, including Albuterol, ProAir HFA, Ventolin HFA, Proventil HFA, AccuNeb, Salamol, Asmol, Airomir, Asthalin, Respolin, Sultanol, Buterol, Asthavent, Salbutamol, and Ventmax. It is primarily used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Regular monitoring of pulmonary function and cardiovascular health is recommended for long-term use."
},
  
  {
    "iupac_name": "4-Hydroxy-α'-{[6-(4-phenylbutoxy)hexyl]amino}-m-xylene-α,α'-diol",
    "chemical_formula": "C25H37NO4",
    "brand_names": [
        "Salmeterol",
        "Serevent Diskus",
        "Serobid",
        "Ventmax",
        "Solumetrol",
        "Astmerol",
        "Almex",
        "Bronmax",
        "Inhalvent",
        "Airmax",
        "Volmax",
        "Respirovent"
    ],
    "category": "Long-Acting Beta-2 Adrenergic Agonist (LABA)",
    "dosage_forms": [
        "Inhaler",
        "Dry Powder Inhaler (DPI)"
    ],
    "strengths": [
        "50 mcg (DPI)",
        "25 mcg/actuation (MDI)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Beta-2 Adrenergic Receptors in the Lungs",
        "physiological_mechanism": "Stimulates beta-2 adrenergic receptors, leading to prolonged relaxation of bronchial smooth muscle and improved airflow."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Respiratory System",
            "effect": "Maintains bronchodilation and prevents bronchospasm.",
            "timeframe": "Onset within 30-48 minutes, duration up to 12 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Beta-Adrenergic Signaling Pathway",
        "key_targets": ["Beta-2 Adrenergic Receptors"],
        "related_conditions": ["Asthma", "Chronic Obstructive Pulmonary Disease (COPD)"]
    },
    "pharmacokinetics": {
        "absorption": "Well-absorbed in the lungs following inhalation.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4"],
            "notes": "Metabolized to inactive hydroxylated compounds."
        },
        "elimination": "Primarily excreted via feces (~60%)."
    },
    "interactions": {
        "Beta Blockers": {
            "site_of_interaction": "Beta-2 Receptors",
            "mechanism": "Antagonizes bronchodilatory effects.",
            "effect": "Reduced efficacy",
            "recommendation": "Avoid concurrent use or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may exacerbate dizziness or cardiovascular effects)"]
    },
    "effects_on_symptoms": {
        "Chronic Bronchospasm": {
            "site_of_effect": "Bronchial Smooth Muscle",
            "mechanism": "Maintains bronchodilation and prevents recurrent episodes.",
            "direction": "Improved breathing",
            "magnitude": "Significant",
            "timeframe": "Effective for up to 12 hours after administration"
        }
    },
    "diagnostic_conditions": {
        "Asthma": {
            "symptoms_addressed": ["Wheezing", "Shortness of Breath", "Chest Tightness"],
            "therapeutic_action": "Prevents nocturnal and exercise-induced bronchospasm.",
            "optimal_dosage": "50 mcg via DPI every 12 hours.",
            "response_time": "Within 30-48 minutes of administration"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nervousness", "Tremors"],
        "moderate": ["Palpitations", "Increased Heart Rate"],
        "severe": ["Paradoxical Bronchospasm", "QT Prolongation"]
    },
    "long_term_monitoring": {
        "parameters": ["Pulmonary Function Tests", "Heart Rate"],
        "frequency": "Every 6-12 months during long-term therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Heart Rate": "60-100 bpm"
            },
            "alert_threshold": {
                "Heart Rate": ">120 bpm"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use lower doses for children under 12 years.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Formoterol", "Tiotropium"],
    "combination_therapies": {
        "recommended_combinations": ["With inhaled corticosteroids for persistent asthma"],
        "cautions": ["Monitor for additive cardiovascular effects"]
    },
    "contraindications": ["Severe hypersensitivity to salmeterol or its components"],
    "precautions": ["Monitor for cardiovascular effects in patients with underlying conditions", "Use cautiously in hyperthyroidism"],
    "side_effects": ["Headache", "Nervousness", "Tremors"],
    "overdose_management": {
        "symptoms": ["Severe Tachycardia", "Hypertension"],
        "treatment": ["Beta-blockers for symptomatic relief"]
    },
    "notes": "Salmeterol is marketed under various brand names, including Salmeterol, Serevent Diskus, Serobid, Ventmax, Solumetrol, Astmerol, Almex, Bronmax, Inhalvent, Airmax, Volmax, and Respirovent. It is primarily used for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). Regular monitoring of pulmonary function and cardiovascular health is recommended for long-term use."
},
  
  {
    "iupac_name": "(R,E)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid",
    "chemical_formula": "C35H36ClNO3S",
    "brand_names": [
        "Montelukast",
        "Singulair",
        "Monteflo",
        "Montela",
        "Montair",
        "Montek",
        "Lukotas",
        "Montene",
        "Monal",
        "Montelo-10",
        "Monteliv",
        "Moncast",
        "Lukast",
        "Monlek",
        "Leukast"
    ],
    "category": "Leukotriene Receptor Antagonist (LTRA)",
    "dosage_forms": [
        "Tablets",
        "Chewable Tablets",
        "Granules"
    ],
    "strengths": [
        "4 mg (Chewable Tablets)",
        "5 mg (Chewable Tablets)",
        "10 mg (Tablets)",
        "4 mg (Granules)"
    ],
    "mechanism_of_action": {
        "site_of_action": "Leukotriene Receptors in Respiratory Airways",
        "physiological_mechanism": "Blocks leukotriene receptors, reducing inflammation, bronchoconstriction, and mucus production."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Respiratory System",
            "effect": "Reduces airway inflammation and prevents bronchospasm.",
            "timeframe": "Onset within hours, with maximum effect in a few days."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Leukotriene Pathway Inhibition",
        "key_targets": ["CysLT1 Receptors"],
        "related_conditions": ["Asthma", "Allergic Rhinitis"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed after oral administration, bioavailability ~64%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP3A4", "CYP2C9"],
            "notes": "Extensively metabolized into inactive metabolites."
        },
        "elimination": "Primarily excreted via bile (~86%)."
    },
    "interactions": {
        "Phenobarbital": {
            "site_of_interaction": "Liver",
            "mechanism": "Induces metabolism of montelukast.",
            "effect": "Reduced efficacy",
            "recommendation": "Monitor therapeutic response and adjust dosage if necessary."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["No significant nutrient interactions reported."],
        "toxins": ["Alcohol (may increase risk of drowsiness)"]
    },
    "effects_on_symptoms": {
        "Asthma Symptoms": {
            "site_of_effect": "Bronchial Airways",
            "mechanism": "Reduces leukotriene-mediated inflammation and bronchoconstriction.",
            "direction": "Improved airway function",
            "magnitude": "Moderate to significant",
            "timeframe": "Effective within 1-2 days of initiation"
        }
    },
    "diagnostic_conditions": {
        "Allergic Rhinitis": {
            "symptoms_addressed": ["Nasal Congestion", "Sneezing", "Runny Nose"],
            "therapeutic_action": "Reduces symptoms of allergic rhinitis.",
            "optimal_dosage": "10 mg orally once daily in the evening.",
            "response_time": "Within 1-2 days"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Fatigue"],
        "moderate": ["Drowsiness", "Dizziness"],
        "severe": ["Mood Changes", "Severe Allergic Reactions"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "Periodically during long-term therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use age-appropriate dosing.",
            "rationale": "Ensures safe and effective therapy."
        }
    },
    "alternative_therapies": ["Antihistamines", "Inhaled Corticosteroids"],
    "combination_therapies": {
        "recommended_combinations": ["With inhaled corticosteroids for asthma management"],
        "cautions": ["Monitor for additive effects"]
    },
    "contraindications": ["Hypersensitivity to montelukast or its components"],
    "precautions": ["Monitor for neuropsychiatric events", "Use cautiously in hepatic impairment"],
    "side_effects": ["Headache", "Nausea", "Fatigue"],
    "overdose_management": {
        "symptoms": ["Severe Drowsiness", "Abdominal Pain"],
        "treatment": ["Supportive care"]
    },
    "notes": "Montelukast is marketed under various brand names, including Montelukast, Singulair, Monteflo, Montela, Montair, Montek, Lukotas, Montene, Monal, Montelo-10, Monteliv, Moncast, Lukast, Monlek, and Leukast. It is primarily used for managing asthma and allergic rhinitis. Regular monitoring of liver function and attention to neuropsychiatric symptoms is recommended during therapy."
},
  
  {
    "iupac_name": "5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole",
    "chemical_formula": "C17H19N3O3S",
    "brand_names": [
        "Omeprazole",
        "Prilosec",
        "Losec",
        "Omez",
        "Omepraz",
        "Zegerid",
        "Protium",
        "Helicid",
        "Ulcozol",
        "Omecid",
        "Omizac",
        "Omebeta",
        "Protoloc",
        "Omepra",
        "Gasec"
    ],
    "category": "Proton Pump Inhibitor (PPI)",
    "dosage_forms": [
        "Capsules",
        "Tablets",
        "Oral Suspension",
        "Injection"
    ],
    "strengths": [
        "10 mg",
        "20 mg",
        "40 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Parietal Cells in the Stomach",
        "physiological_mechanism": "Inhibits the H+/K+ ATPase enzyme, reducing gastric acid secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Gastrointestinal System",
            "effect": "Reduces gastric acidity, promoting ulcer healing and symptom relief.",
            "timeframe": "Onset within 1 hour, lasting up to 24 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Acid Secretion Inhibition",
        "key_targets": ["H+/K+ ATPase Enzyme"],
        "related_conditions": ["Gastroesophageal Reflux Disease (GERD)", "Peptic Ulcer Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed in the small intestine, bioavailability ~35-40%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Extensively metabolized into inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~77%)."
    },
    "interactions": {
        "Clopidogrel": {
            "site_of_interaction": "Liver",
            "mechanism": "Omeprazole inhibits CYP2C19, reducing clopidogrel activation.",
            "effect": "Reduced antiplatelet effect",
            "recommendation": "Consider alternative PPIs or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["May reduce absorption of vitamin B12 with long-term use."],
        "toxins": ["Alcohol (may exacerbate gastrointestinal irritation)"]
    },
    "effects_on_symptoms": {
        "GERD Symptoms": {
            "site_of_effect": "Stomach and Esophagus",
            "mechanism": "Reduces gastric acid reflux and alleviates heartburn.",
            "direction": "Improved symptom control",
            "magnitude": "Significant",
            "timeframe": "Effective within 1-4 days of initiation"
        }
    },
    "diagnostic_conditions": {
        "Peptic Ulcer Disease": {
            "symptoms_addressed": ["Abdominal Pain", "Nausea", "Bloating"],
            "therapeutic_action": "Promotes ulcer healing by reducing acid secretion.",
            "optimal_dosage": "20-40 mg daily for 4-8 weeks.",
            "response_time": "Symptom relief within a few days"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Diarrhea"],
        "moderate": ["Abdominal Pain", "Flatulence"],
        "severe": ["Hypomagnesemia", "Bone Fractures with prolonged use"]
    },
    "long_term_monitoring": {
        "parameters": ["Magnesium Levels", "Bone Density"],
        "frequency": "Every 6-12 months during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Magnesium Levels": "1.7-2.2 mg/dL"
            },
            "alert_threshold": {
                "Magnesium Levels": "<1.0 mg/dL"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Ranitidine", "Famotidine"],
    "combination_therapies": {
        "recommended_combinations": ["With antibiotics for H. pylori eradication"],
        "cautions": ["Monitor for additive adverse effects"]
    },
    "contraindications": ["Severe hypersensitivity to omeprazole or its components"],
    "precautions": ["Monitor for hypomagnesemia in long-term use", "Use cautiously in hepatic impairment"],
    "side_effects": ["Headache", "Nausea", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Confusion", "Blurred Vision", "Tachycardia"],
        "treatment": ["Supportive care"]
    },
    "notes": "Omeprazole is marketed under various brand names, including Omeprazole, Prilosec, Losec, Omez, Omepraz, Zegerid, Protium, Helicid, Ulcozol, Omecid, Omizac, Omebeta, Protoloc, Omepra, and Gasec. It is used to treat conditions such as GERD, peptic ulcer disease, and Zollinger-Ellison syndrome. Long-term therapy may require monitoring for magnesium levels and bone health."
},
  
  {
    "iupac_name": "N-(2-[(5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl)-N'-methyl-2-nitroethene-1,1-diamine",
    "chemical_formula": "C13H22N4O3S",
    "brand_names": [
        "Ranitidine",
        "Zantac",
        "Acid Reducer",
        "Histac",
        "Zinetac",
        "Rantac",
        "Aciloc",
        "Zantid",
        "Rani 2",
        "Ranit",
        "Gentic",
        "Aciban",
        "Rannex",
        "Gertac",
        "Racid"
    ],
    "category": "H2 Receptor Antagonist",
    "dosage_forms": [
        "Tablets",
        "Syrup",
        "Injection"
    ],
    "strengths": [
        "75 mg",
        "150 mg",
        "300 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "H2 Receptors in Gastric Parietal Cells",
        "physiological_mechanism": "Blocks H2 receptors, reducing gastric acid secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Gastrointestinal System",
            "effect": "Reduces gastric acidity, promoting ulcer healing and symptom relief.",
            "timeframe": "Onset within 30-60 minutes, duration up to 12 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Histamine H2 Receptor Inhibition",
        "key_targets": ["H2 Receptors"],
        "related_conditions": ["Gastroesophageal Reflux Disease (GERD)", "Peptic Ulcer Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed, bioavailability ~50%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": [],
            "notes": "Minimal metabolism; mostly excreted unchanged."
        },
        "elimination": "Primarily excreted via urine (~70%)."
    },
    "interactions": {
        "Ketoconazole": {
            "site_of_interaction": "Gastrointestinal Tract",
            "mechanism": "Increases gastric pH, reducing ketoconazole absorption.",
            "effect": "Decreased efficacy of ketoconazole",
            "recommendation": "Separate administration by at least 2 hours."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["May reduce absorption of calcium and iron with long-term use."],
        "toxins": ["Alcohol (may exacerbate liver toxicity)"]
    },
    "effects_on_symptoms": {
        "GERD Symptoms": {
            "site_of_effect": "Stomach and Esophagus",
            "mechanism": "Reduces gastric acid reflux and alleviates heartburn.",
            "direction": "Improved symptom control",
            "magnitude": "Moderate",
            "timeframe": "Effective within 30-60 minutes"
        }
    },
    "diagnostic_conditions": {
        "Peptic Ulcer Disease": {
            "symptoms_addressed": ["Abdominal Pain", "Nausea", "Bloating"],
            "therapeutic_action": "Promotes ulcer healing by reducing acid secretion.",
            "optimal_dosage": "150 mg twice daily or 300 mg at bedtime for 4-8 weeks.",
            "response_time": "Symptom relief within a few days"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Constipation", "Nausea"],
        "moderate": ["Abdominal Pain", "Dizziness"],
        "severe": ["Hepatotoxicity", "Cardiac Arrhythmias"]
    },
    "long_term_monitoring": {
        "parameters": ["Liver Function Tests"],
        "frequency": "Every 6-12 months during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "ALT": "<40 U/L"
            },
            "alert_threshold": {
                "ALT": ">120 U/L"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective therapy."
        }
    },
    "alternative_therapies": ["Famotidine", "Omeprazole"],
    "combination_therapies": {
        "recommended_combinations": ["With antibiotics for H. pylori eradication"],
        "cautions": ["Monitor for additive adverse effects"]
    },
    "contraindications": ["Severe hypersensitivity to ranitidine or its components"],
    "precautions": ["Monitor for hepatotoxicity in long-term use", "Use cautiously in renal impairment"],
    "side_effects": ["Headache", "Constipation", "Nausea"],
    "overdose_management": {
        "symptoms": ["Confusion", "Vomiting", "Tachycardia"],
        "treatment": ["Supportive care"]
    },
    "notes": "Ranitidine is marketed under various brand names, including Ranitidine, Zantac, Acid Reducer, Histac, Zinetac, Rantac, Aciloc, Zantid, Rani 2, Ranit, Gentic, Aciban, Rannex, Gertac, and Racid. It was widely used to treat GERD, peptic ulcers, and related conditions until concerns about impurities led to its withdrawal in some markets. Regular monitoring may be required for patients using alternatives."
},
  
  {
    "iupac_name": "5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole",
    "chemical_formula": "C17H19N3O3S",
    "brand_names": [
        "Esomeprazole",
        "Nexium",
        "Nexium 24HR",
        "Essocam",
        "Esogast",
        "Sompraz",
        "Esofine",
        "Esomac",
        "Nixium",
        "Esotrex",
        "Espar",
        "Ultes",
        "Prozen",
        "Ezomax",
        "Espride"
    ],
    "category": "Proton Pump Inhibitor (PPI)",
    "dosage_forms": [
        "Tablets",
        "Capsules",
        "Oral Suspension",
        "Injection"
    ],
    "strengths": [
        "20 mg",
        "40 mg"
    ],
    "mechanism_of_action": {
        "site_of_action": "Parietal Cells in the Stomach",
        "physiological_mechanism": "Inhibits the H+/K+ ATPase enzyme, reducing gastric acid secretion."
    },
    "pharmacodynamic_effects": [
        {
            "system": "Gastrointestinal System",
            "effect": "Reduces gastric acidity, promoting ulcer healing and symptom relief.",
            "timeframe": "Onset within 1 hour, lasting up to 24 hours."
        }
    ],
    "molecular_pathways": {
        "pathway_name": "Acid Secretion Inhibition",
        "key_targets": ["H+/K+ ATPase Enzyme"],
        "related_conditions": ["Gastroesophageal Reflux Disease (GERD)", "Peptic Ulcer Disease"]
    },
    "pharmacokinetics": {
        "absorption": "Rapidly absorbed, with peak plasma levels in 1-2 hours. Bioavailability ~64%.",
        "metabolism": {
            "primary_site": "Liver",
            "enzymes": ["CYP2C19", "CYP3A4"],
            "notes": "Extensively metabolized to inactive metabolites."
        },
        "elimination": "Primarily excreted via urine (~80%)."
    },
    "interactions": {
        "Clopidogrel": {
            "site_of_interaction": "Liver",
            "mechanism": "Esomeprazole inhibits CYP2C19, reducing clopidogrel activation.",
            "effect": "Reduced antiplatelet effect",
            "recommendation": "Consider alternative PPIs or monitor closely."
        }
    },
    "molecular_interactions": {
        "nutrient_interactions": ["May reduce absorption of vitamin B12 with long-term use."],
        "toxins": ["Alcohol (may exacerbate gastrointestinal irritation)"]
    },
    "effects_on_symptoms": {
        "GERD Symptoms": {
            "site_of_effect": "Stomach and Esophagus",
            "mechanism": "Reduces gastric acid reflux and alleviates heartburn.",
            "direction": "Improved symptom control",
            "magnitude": "Significant",
            "timeframe": "Effective within 1-4 days of initiation"
        }
    },
    "diagnostic_conditions": {
        "Peptic Ulcer Disease": {
            "symptoms_addressed": ["Abdominal Pain", "Nausea", "Bloating"],
            "therapeutic_action": "Promotes ulcer healing by reducing acid secretion.",
            "optimal_dosage": "20-40 mg daily for 4-8 weeks.",
            "response_time": "Symptom relief within a few days"
        }
    },
    "adverse_effects": {
        "mild": ["Headache", "Nausea", "Diarrhea"],
        "moderate": ["Abdominal Pain", "Flatulence"],
        "severe": ["Hypomagnesemia", "Bone Fractures with prolonged use"]
    },
    "long_term_monitoring": {
        "parameters": ["Magnesium Levels", "Bone Density"],
        "frequency": "Every 6-12 months during prolonged therapy.",
        "clinical_thresholds": {
            "normal_range": {
                "Magnesium Levels": "1.7-2.2 mg/dL"
            },
            "alert_threshold": {
                "Magnesium Levels": "<1.0 mg/dL"
            }
        }
    },
    "population_specific": {
        "Pediatrics": {
            "adjustments": "Use weight-based dosing.",
            "rationale": "Ensures safe and effective plasma levels."
        }
    },
    "alternative_therapies": ["Ranitidine", "Omeprazole"],
    "combination_therapies": {
        "recommended_combinations": ["With antibiotics for H. pylori eradication"],
        "cautions": ["Monitor for additive adverse effects"]
    },
    "contraindications": ["Severe hypersensitivity to esomeprazole or its components"],
    "precautions": ["Monitor for hypomagnesemia in long-term use", "Use cautiously in hepatic impairment"],
    "side_effects": ["Headache", "Nausea", "Diarrhea"],
    "overdose_management": {
        "symptoms": ["Confusion", "Blurred Vision", "Tachycardia"],
        "treatment": ["Supportive care"]
    },
    "notes": "Esomeprazole is marketed under various brand names, including Esomeprazole, Nexium, Nexium 24HR, Essocam, Esogast, Sompraz, Esofine, Esomac, Nixium, Esotrex, Espar, Ultes, Prozen, Ezomax, and Espride. It is used to treat conditions such as GERD, peptic ulcer disease, and Zollinger-Ellison syndrome. Long-term therapy may require monitoring for magnesium levels and bone health."
}
    
 ];

const searchInput = document.getElementById("medication-search");
const suggestionsList = document.getElementById("suggestions");
const selectedMedications = document.getElementById("selected-medications");
const submitButton = document.getElementById("submit-medications");

searchInput.addEventListener("input", () => {
  const query = searchInput.value.toLowerCase();
  suggestionsList.innerHTML = "";

  if (query) {
    const suggestions = [];

    // Gather all matching brand names and sort them
    medications.forEach((med) => {
      med.brand_names
        .filter((name) => name.toLowerCase().includes(query))
        .forEach((brand) =>
          suggestions.push({ brand, category: med.category })
        );
    });

    // Sort suggestions alphabetically by brand name
    suggestions.sort((a, b) => a.brand.localeCompare(b.brand));

    // Display sorted suggestions
    suggestions.forEach(({ brand, category }) => {
      const suggestionItem = document.createElement("li");
      suggestionItem.textContent = brand;
      suggestionItem.addEventListener("click", () =>
        selectMedication(brand, category)
      );
      suggestionsList.appendChild(suggestionItem);
    });
  }
});

function selectMedication(brand, category) {
  const medItem = document.createElement("div");
  medItem.classList.add("medication-item");
  medItem.innerHTML = `
    <span>${brand} (${category})</span>
    <button class="delete-button">Delete</button>
  `;
  medItem
    .querySelector(".delete-button")
    .addEventListener("click", () => medItem.remove());
  selectedMedications.appendChild(medItem);
  suggestionsList.innerHTML = "";
  searchInput.value = "";
}

// Submit Button Event
submitButton.addEventListener("click", () => {
  const meds = [];
  document.querySelectorAll(".medication-item span").forEach((med) => {
    meds.push(med.textContent);
  });

  if (meds.length > 0) {
    console.log("Submitted Medications:", meds);
    alert("Medications submitted successfully!");
    // Handle integration with diagnostics system
  } else {
    alert("Please add at least one medication before submitting.");
  }
});

// Function to toggle visibility of a questionnaire below a diagnostic button
function toggleQuestions(questionnaireId) {
  const questionnaire = document.getElementById(questionnaireId);

  if (questionnaire) {
    const isHidden = questionnaire.classList.contains("hidden");

    // Hide all other questionnaires
    document.querySelectorAll(".question-container").forEach((container) => {
      container.classList.add("hidden");
      container.style.display = "none";
    });

    // Show or hide the clicked questionnaire
    if (isHidden) {
      questionnaire.classList.remove("hidden");
      questionnaire.style.display = "block";
    } else {
      questionnaire.classList.add("hidden");
      questionnaire.style.display = "none";
    }
  }
}







